ACR Meeting Abstracts

ACR Meeting Abstracts

Session » 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM
Abstract Number: 415
1-Year Outcomes from a Novel Physical Therapist-Administered Physical Activity Intervention after Total Knee Replacement: A Pilot Study
9:00AM-11:00AM
Abstract Number: 145
1,25(OH)2D3 and Dexamethasone Additively Suppress Synovial Fibroblast Activation By CCR6+ T-Helper Memory Cells and Enhance the Effect of Tnfα Blockade
9:00AM-11:00AM
Abstract Number: 833
11 Patients with Relapsing Polychondritis Presenting with Severe Airways Disease in One Centre in UK
9:00AM-11:00AM
Abstract Number: 610
4 Years Follow-up of a Cohort of Patients with Rheumatoid Arthritis in Sustained Clinical Remission with Optimization of Biological Therapy
9:00AM-11:00AM
Abstract Number: 476
A Better Understanding of Childhood Sjögren Syndrome: Evaluation of the 2016 Acr/EULAR Classification Criteria for Use in Diagnosing Sjögren Syndrome in Children
9:00AM-11:00AM
Abstract Number: 299
A Comparison of Persistent Versus Limited Frequent Emergency Department (ED) Utilization Among Systemic Lupus Erythematosus (SLE) Patients
9:00AM-11:00AM
Abstract Number: 325
A Comparison of RADAI5 and RAPID3 Disease Measures
9:00AM-11:00AM
Abstract Number: 215
A Decade Earlier- Onset of Symptoms of RA in the Indian (Asian) Cohort Compared to Dutch Cohort: Based on Meteor, a Global Database
9:00AM-11:00AM
Abstract Number: 68
A Genome-Wide Association Study Identifies rs116199914 As an Intergenic Variant Associated with Carotid Intima-Media Thickness in Spanish Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 728
A Higher Activity Index at Initial Renal Biopsy Is Associated with Rapid Progression to Renal Failure in Patients with Refractory Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 61
A Human ACPA Monoclonal Antibody Is Preferably Localized at Inflammatory Gingival Tissue and Activates Osteoclastogenensis in Porphyromonas Gingivalis Infected SKG Mouse
9:00AM-11:00AM
Abstract Number: 177
A Needs Assessment to Inform Rheumatology Curriculum Re-Design for Internal Medicine Residents
9:00AM-11:00AM
Abstract Number: 380
A New Tool to Assess Muscle Strength in Polymyositis and Dermatomyositis: Hand-Held Dynamometry
9:00AM-11:00AM
Abstract Number: 676
A Novel Role for the Psoriatic Arthritis Impact of Disease Questionnaire
9:00AM-11:00AM
Abstract Number: 714
A Predictive Clinical-Immunological Index for Infections Unveils Novel Innate and Adaptive Immunity Abnormalities As Key Risk Factors for Infections in a Cohort of Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 244
A Qualitative Study Mapping the Behaviour Change Techniques Used in a Practice-Based Fibromyalgia Self-Management Programme
9:00AM-11:00AM
Abstract Number: 631
A Self-Determination Theory Based Intervention to Promote Autonomous Motivation for, and Engagement in Physical Activity in Rheumatoid Arthritis: Theoretical Process Evaluation of a Randomised Controlled Trial
9:00AM-11:00AM
Abstract Number: 691
A Service Evaluation of Reporting Standards of Computer Tomography Defined Sacroiliitis Suggestive of Axial Spondyloarthritis in Inflammatory Bowel Disease Patients Imaged for Non-Musculoskeletal Indications
9:00AM-11:00AM
Abstract Number: 194
A Survey on Gout-Related Knowledge Among Internal Medicine Residents
9:00AM-11:00AM
Abstract Number: 195
A Two-Year Educational Initiative to Teach Rheumatology through Social Media: The Rheumatology Image of the Week Project (#RheumIOW)
9:00AM-11:00AM
Abstract Number: 473
A Weighty Diagnosis: Weight Change and Risk Factors in Early Juvenile Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 15
Abnormal ZAP-70 Expression in B Cells: New Potential Role in Tolerance Breakdown
9:00AM-11:00AM
Abstract Number: 797
Absolute Reduction of Peripheral CD4+ Regulatory T Cells in Patients with Systemic Sclerosis and Its Restoration By Short-Term and Low Dose IL-2 Treatment
9:00AM-11:00AM
Abstract Number: 420
Accelerated Knee Osteoarthritis Is Characterized By Destabilizing Meniscal Tears and Pre-Radiographic Structural Disease Burden
9:00AM-11:00AM
Abstract Number: 423
Accelerated Knee Osteoarthritis Is Characterized By Pre-Radiographic Degeneration of the Extensor Mechanism and Cruciate Ligaments: Data from the Osteoarthritis Initiative
9:00AM-11:00AM
Abstract Number: 730
Accrual of Atherosclerotic Vascular Events over 10 Years in a Multicentre Inception SLE Cohort
9:00AM-11:00AM
Abstract Number: 84
ACPA-Positive Risk-RA Subject without Subclinical Arthritis Are in High Risk for Later Arthritis Onset, Especially Carriers of HLA-SE Risk-Gene
9:00AM-11:00AM
Abstract Number: 588
Acr Hybrid Analysis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 672
Activation of NLRP3 Inflammasomes in Peripheral Blood Mononuclear Cells of Patients with Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 81
Additive Effects of Functional Rheumatoid Arthritis (RA) LBH Risk Alleles on LBH Gene Transcription
9:00AM-11:00AM
Abstract Number: 289
Adherence of Etanercept in Iraqi Patients with Rheumatoid Arthritis: One- and Five-Year Data from a Local Registry
9:00AM-11:00AM
Abstract Number: 55
Adipose Derived Stem Cell Suppressed Synovial Inflammation and Repaired Cartilage Destruction in Rheumatoid Arthritis Model Mice
9:00AM-11:00AM
Abstract Number: 475
Adolescents’ Perspectives on Living with Childhood-Onset Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 733
Advanced Chronic Kidney Disease in Lupus Nephritis: Factors Leading to Progression
9:00AM-11:00AM
Abstract Number: 590
Advances in Therapeutic Management with First Biological Therapy in Rheumatoid Arthritis throughout 15 Years
9:00AM-11:00AM
Abstract Number: 269
Adverse Event Reporting Rates and Placebo/Standard-of-Care-Arm American College of Rheumatology Responses Vary By Region in Rheumatoid Arthritis Trials
9:00AM-11:00AM
Abstract Number: 86
Age Dependent Effects of Cholesterol and Smoking on the Risk of Rheumatoid Arthritis in Women – Results from a Nested Case Control Study
9:00AM-11:00AM
Abstract Number: 492
All Site Cancers and Lymphoma Incidence in US Veterans with Rheumatoid Arthritis 2001-2015
9:00AM-11:00AM
Abstract Number: 39
Allogeneic Mesenchymal Stem Cells Derived Extracellular Vesicles As a Superior Immunosuppressant in Murine Arthritis Therapy
9:00AM-11:00AM
Abstract Number: 136
Alpn-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Disease in Multiple Mouse Models of Autoimmunity
9:00AM-11:00AM
Abstract Number: 72
Altered Serologic Responses to Epstein Barr Virus Precede Clinical Disease Development in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 710
An Analysis of Cell-of-Origin in Diffuse Large B-Cell Lymphoma in Systemic Lupus Erythematosus, Including Molecular and Clinical Factors Associated with Survival
9:00AM-11:00AM
Abstract Number: 576
An Analysis of Early Introduction of Adalimumab and Subsequent Bio-Free Condition in the Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 190
An Innovative Pilot Educational Program to Inform Rheumatology Fellows about the Population of the Bronx: Issues Affecting and Resources Available to the Community
9:00AM-11:00AM
Abstract Number: 120
An Orally Available Highly Selective 5-Hydroxytryptamine 2B Receptor Antagonist Ameliorating Pulmonary and Dermal Fibrosis in Preclinical Models of Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 82
Analysis of Intestinal Microbiome Profile of Patients with Established Rheumatoid Arthritis and Healthy Controls
9:00AM-11:00AM
Abstract Number: 522
Analysis of Sequential Development of Pulmonary Lesions in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 651
Analysis of the Different Value of Magnetic Resonance Imaging Changes in the Sacroiliac Joints for a Diagnosis of Axial Spondyloarthritis As Judged By Rheumatologists and Radiologists
9:00AM-11:00AM
Abstract Number: 47
Analysis of the Role of RORγt+Foxp3+ T Regulatory 17 (Tr17) Cells in Murine Autoimmune Arthritis Model
9:00AM-11:00AM
Abstract Number: 480
Analyze Myositis with Ultrasound and Exercise (AMUSE) Kids- Initial Analysis of Longitudinal Data
9:00AM-11:00AM
Abstract Number: 649
Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on a Quick Quantitative CRP Assay Performs Similarly Well to ASDAS Based on Conventional CRP in Patients with Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 612
Anti-Drug Antibodies Detected By Competitive ELISA Can Predict Treatment Failure in Patients Taking Adalimumab
9:00AM-11:00AM
Abstract Number: 4
Anti-Jo1 Positive Myositis Patients Display a Characteristic IgG Fc-Glycan Profile Which Is Further Enhanced in Anti-Jo1 Autoantibodies
9:00AM-11:00AM
Abstract Number: 89
Anti-Nuclear Antibodies (ANA) and Air Pollution: Ultrafine Particles and Ozone
9:00AM-11:00AM
Abstract Number: 726
Anti-Retinoblastoma Protein Antibody Is Protective Against Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 85
Antibodies to Citrullinated Protein Antigens (ACPAs) Induce Adipose Tissue Dysfunction Contributing to the Cardiovascular Disease Risk in Rheumatoid Arthritis. Modulation By Biological Dmards
9:00AM-11:00AM
Abstract Number: 208
Antibodies to Citrullinated Protein Antigens Are Associated with Risk of Cardiovascular Disease in Community-Dwelling Women: The Multi-Ethnic Study of Atherosclerosis
9:00AM-11:00AM
Abstract Number: 114
Antifibrotic Regulation By Response Gene to Complement 32 Protein
9:00AM-11:00AM
Abstract Number: 376
Antisynthetase Syndrome: Prevalence of Serositis in Autoantibody Subsets
9:00AM-11:00AM
Abstract Number: 107
Apolipoprotein L1 Risk Variants, Renal Histopathology, and Prognosis in African American SLE Nephritis Patients: A Cohort Study
9:00AM-11:00AM
Abstract Number: 143
Aquaporin 3 (AQP3) Protein Is Highly Expressed in Psoriatic Plaques and AQP3 Gene Expression Strongly Induced By IL-23 in CD4+ Th17 Cells
9:00AM-11:00AM
Abstract Number: 762
Aquaporin-4 Immunoglobulin G Antibody Positive Neuromyelitis Optica Spectrum Disorder and Systemic Autoimmune Diseases Overlap Syndrome: A Single Center Experience
9:00AM-11:00AM
Abstract Number: 554
Are There Any Associations between ANA Development and Poor Treatment Response to Bdmards in RA Patients?
9:00AM-11:00AM
Abstract Number: 724
Are Traditional Biomarkers of Lupus Associated with Renal Pathology in Lupus Nephritis?
9:00AM-11:00AM
Abstract Number: 257
Argentine Registry of Patients with Fibromyalgia
9:00AM-11:00AM
Abstract Number: 372
Arterial Involvement in Erdheim-Chester Disease: A Retrospective Cohort Study
9:00AM-11:00AM
Abstract Number: 494
Arterial Wall Inflammation Declines after 6 Months of Anti-Inflammatory Therapy with Methotrexate and/or Adalimumab in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 35
Arthritis and Atherosclerosis in KRN Ag7 Mice Involve Distinct Inflammatory Cell Populations and Are Independent of CCR2
9:00AM-11:00AM
Abstract Number: 439
Articular Cartilage from Osteoarthritis Patients Shows Extracellular Matrix Remodeling over the Course of Treatment with Sprifermin (Recombinant human fibroblast growth factor 18)
9:00AM-11:00AM
Abstract Number: 703
Articular Manifestations in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
9:00AM-11:00AM
Abstract Number: 718
Assessing Dyspnea in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 440
Assessing Inappropriate Pain Management in Adults with Hip or Knee Osteoarthritis Treated with Different Opioid Intensity Regimens: Results from a Retrospective Database Analysis
9:00AM-11:00AM
Abstract Number: 156
Assessing the Role of Ascvd Score in Primary Thrombosis Prophylaxis Strategy Among Asymptomatic Antiphospholipid Antibody Carriers
9:00AM-11:00AM
Abstract Number: 315
Assessing the Value of Whole Body Magnetic Resonance Imaging As to Clinical Examination to Predict Remission and Relapse in Early Peripheral Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 825
Assessment of Damage and Prognosis in Patients with Adult IgA Vasculitis: Retrospective Multicentered Cohort Study
9:00AM-11:00AM
Abstract Number: 667
Assessment of Radiographic Sacroiliitis on Antero-Posterior Lumbar Radiographs As Compared to Conventional Pelvic Radiographs in Patients with Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 800
Assessment of Recent Evidence to Support Treatment Recommendations in Patients with SSc-ILD
9:00AM-11:00AM
Abstract Number: 217
Association between Comorbidities and Socioeconomic Status Among Patients with Rheumatoid Arthritis in Korea
9:00AM-11:00AM
Abstract Number: 533
Association between Inflammation and Changes in Kidney Function in Patients with Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 355
Association of HLA-DRB1 Shared Epitope Alleles with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
9:00AM-11:00AM
Abstract Number: 689
Association of Kinesiophobia, Aerobic Exercise, Functional Impairment and Disease Activity of Patients with Rheumatoid Arthritis and Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 744
Association of PCSK9 Serum Levels with Lipid Metabolism Dysregulation, Activity/Damage Scores and Subclinical Atherosclerosis in SLE Patients
9:00AM-11:00AM
Abstract Number: 369
Association of Retroperitoneal Fibrosis with Malignancy and the Pathologic Features of Malignancy with Retroperitoneal Fibrosis
9:00AM-11:00AM
Abstract Number: 531
Association of Rheumatoid Arthritis and Other Autoinmune Diseases
9:00AM-11:00AM
Abstract Number: 71
Association of Shared Epitope and Poor Prognostic Factors in RA
9:00AM-11:00AM
Abstract Number: 258
Association of Sudoscan Values with Disease Duration in Female Patients with Fibromyalgia
9:00AM-11:00AM
Abstract Number: 601
At Which Point and for Which Reasons Are Oral MTX Formulations Switched to Injectable Ones in RA Patients? Combined Results from 3 Independent Observational and Clinical Trials
9:00AM-11:00AM
Abstract Number: 737
Atherogenic Index of Plasma in Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A 10-Year Potential Predictor of Cardiovascular Disease
9:00AM-11:00AM
Abstract Number: 729
Atherosclerotic Vascular Events in SLE – an Evolving Story
9:00AM-11:00AM
Abstract Number: 392
Autoantibody Profile and Clinical Characteristics in Patients with Idiopathic Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 137
Autoantibody-Inducing CD4 T (aiCD4 T) Cells Which Induce Systemic Lupus Erythematosus (SLE) Contain Follicular Helper T Cell in Addition to the Major IL-21-Producing CXCR5-ICOShiPD1hi Population: Self-Organized Criticality Theory As the Cause of SLE
9:00AM-11:00AM
Abstract Number: 180
Back to Bedside Teaching: Completion of a Rheumatology Rotation Significantly Increases Internal Medicine Residents’ Competency and Comfort with Comprehensive Knee Examinations
9:00AM-11:00AM
Abstract Number: 65
Bacteria-Derived Indole Drives Autoimmune Arthritis By Altering B Cell Glycosylation of Autoantibodies
9:00AM-11:00AM
Abstract Number: 111
BAFF Inhibition Attenuates Fibrosis in Bleomycin-Induced Scleroderma Model Via Modulating the Regulatory and Effector B-Cell Balance
9:00AM-11:00AM
Abstract Number: 546
Baricitinib: Early Vs. Delayed Start in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 468
Baseline Features and Outcomes of Pediatric-Onset Discoid Lupus Erythematosus: Interim Data Analysis of a Multicenter Retrospective Cohort Study
9:00AM-11:00AM
Abstract Number: 582
Baseline Power Doppler and Multi-Biomarker Disease Activity Score Predict 12-Week Disease Activity Response to Tofacitinib
9:00AM-11:00AM
Abstract Number: 280
Be Fierce. Take Control.TM an Evidence-Based Digital Lupus Awareness and Education Campaign for Young Minority Women at Risk for Lupus
9:00AM-11:00AM
Abstract Number: 283
Benefits Accrued through the Implementation of Telerheumatology Services
9:00AM-11:00AM
Abstract Number: 240
Bi-Directional Associations between “Too Much Sitting” and Self-Reported Pain in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 550
Biologic Discontinuation in Rheumatoid Arthritis: A Population Based Study 1999-2017
9:00AM-11:00AM
Abstract Number: 93
Biomarkers Associating Endothelial Function in Systemic Lupus Erythematous
9:00AM-11:00AM
Abstract Number: 618
Blood Lymphocytes Subtypes As Biomarkers for Early Identification of Optimal Responders to Anti-TNF Treatment in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 485
Bone Loss in Different Sites over Time in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 661
Bridging the Gap between Symptom Onset and Diagnosis in Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 526
Bronchiectasis in RA Is a Crucial Risk Factor of Hospitalised Pneumonia Associated with Bdmards As Well As Interstitial Lung Disease
9:00AM-11:00AM
Abstract Number: 300
Built-in-Electronic-Medical-Record Disease Activity Calculators and Treat-to-Target in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 288
Burden of Illness of Treating Patients with Pemphigus vulgaris
9:00AM-11:00AM
Abstract Number: 139
Calcium/Calmodulin-Dependent Protein Kinase 4 Promotes GLUT1-Dependent Glycolysis in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 650
Can Disease Activity in Patients with Psoriatic Arthritis be Adequately Assessed By a Modified Disease Activity Index for Psoriatic Arthritis (DAPSA) Based on 28 Joints?
9:00AM-11:00AM
Abstract Number: 740
Can Monocyte Chemo-Attractant Protein-1differentiate Different Histological Classes in Lupus Nephritis?
9:00AM-11:00AM
Abstract Number: 566
Capillary Blood Based Methotrexate Polyglutamate Assay for Monitoring Low Dose Methotrexate Therapy in Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 33
Card9 Is a Critical Regulator of Autoimmune Arthritis in SKG Mice
9:00AM-11:00AM
Abstract Number: 801
Cardiac Autonomic Modulation at Rest and during Orthostatic Stress in Systemic Sclerosis Patients
9:00AM-11:00AM
Abstract Number: 518
Cardiometabolic Risk Factors Impact on the Cardioprotective Effect of Apelin on Systolic and Diastolic Function, in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 764
Cardiovascular Disease in SLE at One Center between 1981 and 2016. a Population-Based Study Highlighting the Importance of Disease Duration and Age at Diagnosis
9:00AM-11:00AM
Abstract Number: 509
Cardiovascular Disease Risk Factors May Negatively Impact Rheumatoid Arthritis Disease Outcomes: Findings from the Ontario Best Practices Research Initiative
9:00AM-11:00AM
Abstract Number: 514
Cardiovascular Risk Management in Seropositive Rheumatoid Arthritis: What Can We Do Better?
9:00AM-11:00AM
Abstract Number: 741
Cardiovascular Risk Re-Classification Using Carotid Ultrasound in Systemic Lupus Erythematosus Patients Is Related to the Damage Produced By the Disease
9:00AM-11:00AM
Abstract Number: 308
Carpal Bones Affectation Frequency in Rheumatoid Arthritis By Magnetic Resonance Imaging
9:00AM-11:00AM
Abstract Number: 490
Catastrophizing in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 62
CCR6+CD4+ T Cells Drive IL-23R Signaling-Dependent Progression of Antigen-Induced Arthritis
9:00AM-11:00AM
Abstract Number: 30
CD21lo Cells Are Increased in Patients with Systemic Sclerosis and May be Associated with Interstitial Lung Disease
9:00AM-11:00AM
Abstract Number: 29
CD70-Mediated CD27 Downregulation Contributed to Regulatory B10 Cell Impairment in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 779
Cerebrospinal Fluid Biomarkers for Diagnosing Neuropsychiatric SLE: A Systematic Review and Meta-Analysis
9:00AM-11:00AM
Abstract Number: 284
Challenges and Barriers to Employment That Persons with Osteoarthritis Face at Work Due to Their Condition
9:00AM-11:00AM
Abstract Number: 568
Change in RF and Anti-CCP Isotype Levels in RA Patients Treated with Anti-TNF, Abatacept, Rituximab or Tocilizumab and Correlation with Clinical and Radiographic Outcomes: Data from a Randomized Trial
9:00AM-11:00AM
Abstract Number: 210
Changes in Alcohol Use in Patients with Rheumatoid Arthritis: Associations with Disease Activity, Health Status, and Mortality
9:00AM-11:00AM
Abstract Number: 584
Changes in CD4+ T and B Cell Profile As Indicator of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 579
Changes in DNA Methylation Identify Response to Treatment with Methotrexate and TNF Inhibitors Among RA Patients
9:00AM-11:00AM
Abstract Number: 685
Changes in Key Laboratory Values with Tofacitinib 5mg BID Treatment in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 553
Channeling to Treatment and Associated Changes in Disease Activity Over 12 Months in Patients With RA Treated With Abatacept Versus Other DMARDs in Real-World Community Practice Settings
9:00AM-11:00AM
Abstract Number: 495
Characteristics of Metabolic Syndrome in Men and Women with Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 597
Characteristics of Patients and Predictors of Composite Disease Activity Scores for Switching to Monotherapy Vs Continuing TNF Inhibitor and Methotrexate Combination Therapy in RA: A Retrospective Analysis of the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry
9:00AM-11:00AM
Abstract Number: 359
Characterization of Lymphoid Cells in Synovial Fluid from Cancer Patients with Immunotherapy-Induced Arthritis
9:00AM-11:00AM
Abstract Number: 153
Chemotaxis of Vδ2 T Cells to the Joints Contributes to the Pathogenesis of Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 529
Chest Computed Tomography Abnormalities in Patients with Rheumatoid Arthritis By Serologic Status
9:00AM-11:00AM
Abstract Number: 673
Chronic Back Pain (CBP) in First Degree Relatives (FDRs) of Patient with Ankylosing Spondylitis (AS): Comparison with the US Population, HLA-B27 Frequency and Persistence of Symptoms over Time
9:00AM-11:00AM
Abstract Number: 73
Circular RNAs Expression Profile in Chinese Rheumatoid Arthritis Patients at Different Disease Activity
9:00AM-11:00AM
Abstract Number: 25
Circulating CD24hiCD38hi Regulatory B-Cells Influence Th17-Cell Responses in Patients with Granulomatosis with Polyangiitis
9:00AM-11:00AM
Abstract Number: 205
Circulating Plasma Metabolites and Risk of Rheumatoid Arthritis in the Nurses Health Study
9:00AM-11:00AM
Abstract Number: 94
Circulating Soluble MICA Is Associated to Lupus Nephritis and to a TLR/IFN-I Signature in T Cells in a Cohort of Adult SLE Patients
9:00AM-11:00AM
Abstract Number: 19
Citrulline-Multispecific B Cell Receptor Clades in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 45
CKD-506, First-in-Class Histone Deacetylase (HDAC) 6 Inhibitor, Ameliorates Rheumatoid Arthritis through Regulation of Inflammation and T Cell Function
9:00AM-11:00AM
Abstract Number: 815
Classic and Atypical Polymyalgia Rheumatica, Are Different Syndromes? Study of 93 Patients with PET/CT from a Single Center
9:00AM-11:00AM
Abstract Number: 788
Clinical and Echocardiographic Associates of All-Cause Mortality and Cardiovascular Outcomes in Patients with Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 607
Clinical and Functional Response to Tofacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from the ORAL Strategy Trial
9:00AM-11:00AM
Abstract Number: 165
Clinical and Immunological Features of Antiphospholipid Syndrome in the Elderly: A Retrospective National Multicenter Study
9:00AM-11:00AM
Abstract Number: 161
Clinical and Laboratory Characteristics of Persistently Antiphospholipid Antibody Positive Patients: Retrospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)
9:00AM-11:00AM
Abstract Number: 569
Clinical and Sociodemographic Characteristics of Patients with Rheumatoid Arthritis (RA) Starting Triple Therapy and a Combination of a TNF Inhibitor and Methotrexate from a Large US Registry
9:00AM-11:00AM
Abstract Number: 506
Clinical and Sonographic Characteristics of Carotid Intima-Media Thickness in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 793
Clinical Associations of Anti-U11/U12 (RNPC-3) Autoantibodies in Patients with Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 731
Clinical Characteristics and Neurophysiological Patterns of Peripheral Neuropathies in Patients with Systemic Lupus Erythematosus: A Single Center Experience
9:00AM-11:00AM
Abstract Number: 469
Clinical Characteristics and Treatment of 25 Children with Systemic Lupus Erythematosus Complicated with Thrombotic Microangiopathy in China
9:00AM-11:00AM
Abstract Number: 834
Clinical Characteristics of IgA Vasculitis in Children and Adults: A Retrospective Cohort Study
9:00AM-11:00AM
Abstract Number: 687
Clinical Characteristics of Spondyloarthritis Patients in Japan in Comparison to Other Regions of the World
9:00AM-11:00AM
Abstract Number: 350
Clinical Correlates of Immune-Related Adverse Events for Patients with Melanoma Treated with Checkpoint Inhibitors and a Noted Significant Difference in Peripheral Lymphocyte Counts
9:00AM-11:00AM
Abstract Number: 524
Clinical Course of Interstitial Lung Disease in Rheumatoid Arthritis Patients in Clinical Practice
9:00AM-11:00AM
Abstract Number: 580
Clinical Effectiveness of Tofacitinib 11mg Once Daily (QD) Versus Tofacitinib 5mg Twice Daily (BID) in the Corrona US RA Registry
9:00AM-11:00AM
Abstract Number: 605
Clinical Outcomes of Golimumab As Second Line TNF Inhibitor Treatment in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis of a Non-Interventional Study in Germany
9:00AM-11:00AM
Abstract Number: 235
Clinical Predictors and Risk of Methotrexate Induced Liver Fibrosis
9:00AM-11:00AM
Abstract Number: 697
Clinical Results of Patients with Peripheral Psoriatic Arthritis Not Receiving Biological Therapy in a Multidisciplinary Unit
9:00AM-11:00AM
Abstract Number: 774
Clinical Variables and Serologic Markers of Disease Activity Do Not Aid in Early Recognition of Patients with Tubulointerstitial Disease Who Have No Significant Renal Impairment at Time of Biopsy
9:00AM-11:00AM
Abstract Number: 396
Clinical, Physiologic, and Radiologic Features Associated with Severe MDA5-Associated Interstitial Lung Disease
9:00AM-11:00AM
Abstract Number: 770
Cognitive Function Trajectories Are Associated with the Depressive Symptoms Trajectories in SLE over Time
9:00AM-11:00AM
Abstract Number: 782
Cognitive Impairment and Health-Related Quality of Life in a Lupus Cohort
9:00AM-11:00AM
Abstract Number: 487
Cognitive Impairment in Rheumatoid Arthritis Patients: A Case-Control Study
9:00AM-11:00AM
Abstract Number: 491
Cognitive Impairment Is Associated with Disease Activity in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 70
Colocalization of Malondialdehyde-Acetaldehyde Adducts (MAA) and Extracellular Matrix Proteins in Joint and Lung Tissues from Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 596
Combination of Intra-Articular Steroid Injection and Tofacitinib More Effective Than Tofacitinib in Rapid Radiographic Progression Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 60
Combined Inhibition of Mechanistic Target of Rapamycin and Glutamine Metabolism Inhibits CD4 T Cell Proliferation and Th17 Differentiation, Facilitates the Expansion of Myeloid-Derived Suppressor Cells, and Synergistically Ameliorates Arthritis in SKG Mice
9:00AM-11:00AM
Abstract Number: 693
Combining Adalimumab with Methotrexate Does Not Improve Long Term Sustainability in Patients with Psoriatic Arthritis. Real World Evidence Report from the Quebec Database Rhumadata®
9:00AM-11:00AM
Abstract Number: 694
Combining Etanercept with Methotrexate Does Not Improve Long Term Sustainability in Patients with Psoriatic Arthritis. Real World Evidence Report from the Quebec Database Rhumadata®
9:00AM-11:00AM
Abstract Number: 604
Combining Observational and Randomized Controlled Trial Data Evidence to Jointly Estimate Remission and Response for Biologic and Non-Biologic Therapies in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis
9:00AM-11:00AM
Abstract Number: 572
Combining Tocilizumab with Methotrexate Improves Sustainability. Real World Evidence Report from Quebec Database Rhumadata®
9:00AM-11:00AM
Abstract Number: 581
Comparative Analysis of Outcomes Among Patients with Rheumatoid Arthritis Initiating Tofacitinib in Combination with Oral MTX Who Discontinue, Interrupt, or Persist with MTX
9:00AM-11:00AM
Abstract Number: 599
Comparative Effectiveness in Pain and HAQ-DI Improvement for Baricitinib Versus Adalimumab, Tocilizumab, and Tofacitinib Monotherapies in Csdmard-Naïve Rheumatoid Arthritis Patients: A Matching-Adjusted Indirect Comparison (MAIC)
9:00AM-11:00AM
Abstract Number: 824
Comparing Childhood- Versus Adult-Onset Polyarteritis Nodosa
9:00AM-11:00AM
Abstract Number: 388
Comparison of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme Α Reductase and Anti-Signal Recognition Particle Necrotising Myopathies: A Single Centre Experience
9:00AM-11:00AM
Abstract Number: 821
Comparison of Aortitis Vs Non-Inflammatory Aortic Aneurysms Among Patients Who Undergo Open Aortic Aneurysm Repair
9:00AM-11:00AM
Abstract Number: 763
Comparison of Clinical Characteristics and Outcome between Isolated and Classic Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 759
Comparison of Length of Stay and Total Hospital Charges for Hospitalizations for Sepsis in Patients with Systemic Lupus Erythematosus: A Study of National Inpatient Sample Database 2010 to 2014
9:00AM-11:00AM
Abstract Number: 56
Comparison of Metabolic Changes in Osteoarthritis and Rheumatoid Arthritis Mouse Models
9:00AM-11:00AM
Abstract Number: 659
Comparison of MRI and Conventional Radiography for Detection of Structural Changes Typical for Spa – Data from the Assessment of Spondyloarthritis International Society Cohort
9:00AM-11:00AM
Abstract Number: 786
Comparison of Nailfold Microvascular Damage in Mixed Connective Tissue Disease Versus Systemic Sclerosis Patients during a Three Year Follow-up
9:00AM-11:00AM
Abstract Number: 414
Comparison of Physical Activity Measures Derived from the Fitbit Flex and the Actigraph GT3x+ in an Employee Population with Chronic Knee Symptoms
9:00AM-11:00AM
Abstract Number: 403
Comparison of Radial Extracorporeal Shock Wave Therapy and Traditional Physiotherapy in Rotator Cuff Calcific Tendinitis Treatment
9:00AM-11:00AM
Abstract Number: 287
Comparison of Real-World Costs between Patients with Rheumatoid Arthritis Treated with Subcutaneously-Administered Biologics Previously Treated with Another Biologic
9:00AM-11:00AM
Abstract Number: 332
Components of Impaired Physical Function and Disability in a Non-Rheumatic Population. Normative Values of the Health Assessment Questionnaire Disability Index
9:00AM-11:00AM
Abstract Number: 16
Comprehensive Antibody Profiling Using High Density Peptide Arrays Reveals Novel Citrullinated Protein Targets in Rheumatoid Arthritis Serum Samples
9:00AM-11:00AM
Abstract Number: 658
Construct Validation of the Screening for Inflammatory Pain in the Lower Back Questionnaire: Data from the Screening in Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Cohort
9:00AM-11:00AM
Abstract Number: 641
Construct Validity of the Swollen and Tender Joint Counts for the Measurement of MSK Disease Activity in Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 751
Coronary Plaque Burden in Patients with Lupus Compared to Healthy Volunteers
9:00AM-11:00AM
Abstract Number: 483
Correlation between Disease Activity and Hip Score in Patients with Rheumatoid Arthritis after Total Hip Arthroplasty
9:00AM-11:00AM
Abstract Number: 785
Correlation between Nailfold Capillary Number and Blood Perfusion in Systemic Lupus Erythematosus Patients
9:00AM-11:00AM
Abstract Number: 547
Corticosteroid Bridging Strategies with Methotrexate Monotherapy in Early Rheumatoid and Undifferentiated Arthritis; A Comparison of Efficacy and Toxicity in 2 Clinical Trials
9:00AM-11:00AM
Abstract Number: 627
Corticosteroid Utilization before and after Initiation of Biologic Dmards between Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 642
Cost of Illness Analysis before and after Initiation of Tumour Necrosis Factor α Inhibitors in Patients with Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 191
Creation of an Immunology Series Video Library in Facilitating Basic Immunology Knowledge Acquisition and Retention Amongst Adult Rheumatology Trainees
9:00AM-11:00AM
Abstract Number: 335
Cross-Cultural Validity of Functional Status Assessment Measures for Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 115
CTLA4-Ig/CD86 Interaction on Cultered Human Fibrocytes and Fibroblasts from Systemic Sclerosis Patients
9:00AM-11:00AM
Abstract Number: 817
Current Diagnostic Delays in Vasculitis and Factors Associated with Time to Diagnosis
9:00AM-11:00AM
Abstract Number: 758
Cutaneous Lupus Erythematosus Patients with a Negative ANA Meeting Acr and/or SLICC Criteria for Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 53
Cyclin-Dependent Kinase 4/6 Inhibitor: A Promising Development Candidate Targeting Synovial Hypertrophy for Rheumatoid Arthritis Treatment
9:00AM-11:00AM
Abstract Number: 772
Cytomegaloviral or Pneumocystis Jiroveci Pneumonia Increases Mortality Rate in Systemic Lupus Erythematosus Patients with Pulmonary Hemorrhage: Evidence from Bronchoalveolar Lavage Fluid Analysis
9:00AM-11:00AM
Abstract Number: 18
Cytoplasmic FOXO1 Identifies Novel Disease-Activity Associated B Cell Subsets in SLE
9:00AM-11:00AM
Abstract Number: 589
DAS28-CRP Versus DAS28-ESR and Thresholds for Disease Activity Category: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 99
DC-Hil+ Myeloid-Derived Suppressor Cells Are Elevated in the Peripheral Blood and Lesional Skin of Cutaneous Lupus Patients
9:00AM-11:00AM
Abstract Number: 78
Decreased B Cell Ataxia-Telangiectasia Mutated Expression and Receptor Diversity Identify a Subset of Rheumatoid Arthritis Patients with Increased Joint Erosion Prevalence
9:00AM-11:00AM
Abstract Number: 176
Deductive Anatomy By Self-Examination. a Novel Method to Reinforce Traditional Teaching of Musculoskeletal Anatomy
9:00AM-11:00AM
Abstract Number: 175
Deductive Anatomy By Self-Examination. Preliminary Evaluation of a Novel Method to Reinforce Knowledge of Musculoskeletal Anatomy at the 2018 Panlar Meeting
9:00AM-11:00AM
Abstract Number: 149
Deep Immune-Profiling of CD4+ T Cells in Behçet’s Disease
9:00AM-11:00AM
Abstract Number: 674
Defining the Therapeutic Target in Psoriatic Arthritis: MDA Versus Dapsa
9:00AM-11:00AM
Abstract Number: 796
Demographic and Clinical Features of Systemic Sclerosis Patients with Anti-U1RNP Antibodies: A European Scleroderma Trials and Research (EUSTAR) Analysis
9:00AM-11:00AM
Abstract Number: 31
Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Regulates Inflammation and Joint Damage in the TNF-Tg Mouse Model
9:00AM-11:00AM
Abstract Number: 90
Deoxyribonuclease 1-like-3 Digests Self-DNA from Dead Cells and Prevents Autoimmunity
9:00AM-11:00AM
Abstract Number: 292
Derivation of a National Rheumatoid Arthritis Cohort in the Veterans Health Administration and Validation with the Veterans Affairs Rheumatoid Arthritis Registry
9:00AM-11:00AM
Abstract Number: 754
Determinants of Major Neurocognitive Disorder (Vascular Dementia) in SLE: The Importance of Treatment Adherence of SLE Disease Activity and Cardiovascular Risk Factors
9:00AM-11:00AM
Abstract Number: 331
Development and Implementation of a Patient-Reported Outcomes Measurement Information System (MyRheum)
9:00AM-11:00AM
Abstract Number: 314
Development and Preliminary Validation of an Omeract Magnetic Resonance Imaging (MRI) Scoring System for Ankle Enthesitis in Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 320
Development of a Magnetic Resonance Imaging Atlas for the Classification of Osteoarthritis of the First Metatarsophalangeal Joint
9:00AM-11:00AM
Abstract Number: 281
Development of an African American Lupus Community-Based Patient and Provider Education Program: Lupus Conversations
9:00AM-11:00AM
Abstract Number: 209
Development of an Algorithm for the Classification of Cardiovascular Comorbidity in Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative
9:00AM-11:00AM
Abstract Number: 184
Development of Focused Musculoskeletal Ultrasound Training for Primary Care Providers to Facilitate the Diagnosis of Gout: Initial Steps in an Educational Needs Assessment
9:00AM-11:00AM
Abstract Number: 163
Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase II Item Reduction Survey
9:00AM-11:00AM
Abstract Number: 816
Development of Thoracic Aortic Aneurysms in Patients with Polymyalgia Rheumatica: Underdiagnosed Giant Cell Arteritis?
9:00AM-11:00AM
Abstract Number: 242
DHEA Deficiency in Fibromyalgia
9:00AM-11:00AM
Abstract Number: 760
Diagnosing SLE Arthritis with Dynamic Diffuse Optical Spectroscopy
9:00AM-11:00AM
Abstract Number: 638
Diagnostic Delay and Associated Factors in Axial Spondyloarthritis across Europe. Results from the European Map of Axial Spondyloarthritis Survey
9:00AM-11:00AM
Abstract Number: 266
Diagnostic Delays and Disparities in Access to Care in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 655
Diagnostic Performance of MRI Lesions in the Sacroiliac Joints According to Updated Assessments in Spondyloarthritis International Society Lesion Definitions: A Central Reader Assessment of MRI Scans from the Assessments in Spondyloarthritis Classification Cohort
9:00AM-11:00AM
Abstract Number: 312
Diagnostic Value of MRI in Non-Radiographic Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 805
Diastolic Dysfunction in Scleroderma: An Investigation into Associated Risk Factors and Impact on Survival
9:00AM-11:00AM
Abstract Number: 64
Dietary Magnesium Modulates the Intestinal Microbiome and T Cell Subsets
9:00AM-11:00AM
Abstract Number: 386
Differences in Body Composition in Myositis Patients and Healthy Controls Are Associated with Disease Activity and Duration, Inflammatory Status, Skeletal Muscle Involvement and Physical Activity
9:00AM-11:00AM
Abstract Number: 709
Differential Characteristics of Lupus Psychosis and Steroid Psychosis
9:00AM-11:00AM
Abstract Number: 407
Digital Disruptive Technology for Rehabilitation Following Elective Surgery for Low Back Pain, Knee and Hip Osteoarthritis: A Systematic Review and Meta-Analysis
9:00AM-11:00AM
Abstract Number: 126
Direct Interaction between Autoreactive B Cells and Endothelial Colony Forming Cells Induces Cytokine Production from B Cells through B Cell Receptor and IL-6-JAK2-STAT3 Signaling Pathway, Suppressing Proliferation of Endothelial Colony Forming Cells in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 229
Disability Status, Mortality, and Leading Causes of Death in Seropositive Rheumatoid Arthritis Patients: A Population-Based Study in Korea
9:00AM-11:00AM
Abstract Number: 698
Discontinuation of Methotrexate or TNF Inhibitors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 37
Discovery of DWP213388, a Potent ITK and BTK Dual Target Inhibitor with Excellent Efficacy, As a Treatment for Autoimmune Diseases
9:00AM-11:00AM
Abstract Number: 447
Discriminating between Central & Peripheral Pain Sensitization Using a Slowly Repeated Evoked Pain Protocol
9:00AM-11:00AM
Abstract Number: 614
Disease Activity One Year after Addition of Bucillamine or Sulfasaladine to Methotrexate in Japanese Patients with Rheumatoid Arthritis : Propensity Score Analysis
9:00AM-11:00AM
Abstract Number: 652
Disease Interception in Psoriasis Patients with Subclinical Joint Inflammation By Interleukin 17 Inhibition with Secukinumab – Data from a Prospective Open Label Study
9:00AM-11:00AM
Abstract Number: 543
Disease Severity Among Bio-Naive RA Patients on Csdmards
9:00AM-11:00AM
Abstract Number: 265
Disparities in Utilization and Direct Costs of Hospitalizations and Emergency Room Visits in SLE: The Georgia Lupus Registry
9:00AM-11:00AM
Abstract Number: 221
Distal Interphalangeal Joint Involvement and Its Association with Disease Activity in Rheumatoid Arthritis (RA): Analysis Based on a Nationwide RA Database in Japan
9:00AM-11:00AM
Abstract Number: 138
Distinct Roles of Tfh2, SLAMF7+ Tfh1 Cells and Th1 Cells in the Pathogenesis of IgG4-RD
9:00AM-11:00AM
Abstract Number: 207
Divergent Patterns of Cardiovascular Risk in Biomarkers of Lipids and Subclinical Myocardial Injury during Increased Inflammation in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 622
DMARD Withdrawal in RA Patients Achieving Therapeutic Response with Certolizumab Pegol Combined with Dmards: Results from a Canadian Randomized Study
9:00AM-11:00AM
Abstract Number: 829
DNA Damage and Repair in Patients with Cryoglobulinemic Vasculitis Treated with Direct Anti-HCV Drugs
9:00AM-11:00AM
Abstract Number: 74
DNA Methylation of the Dual Specificity Protein Phosphatase 22 (DUSP22) Gene Promoter in Plasma of Patients with Seropositive and Seronegative RA
9:00AM-11:00AM
Abstract Number: 646
Do Ethnicity, Degree of Family Relationship, and the Spondyloarthritis Subtype in Affected Relatives Influence the Association between a Positive Family History for Spondyloarthritis and HLA-B27 Carriership? Results from the Worldwide ASAS Cohort
9:00AM-11:00AM
Abstract Number: 313
Do Musculoskeletal Ultrasound and Magnetic Resonance Imaging Identify Synovitis and Tenosynovitis at the Same Joints and Tendons? – a Comparative Study in Patients Presenting with Early Arthritis and Clinically Suspect Arthralgia
9:00AM-11:00AM
Abstract Number: 339
Documenting Bone Health for Veterans with Rheumatoid Arthritis in an Outpatient Academic Clinic
9:00AM-11:00AM
Abstract Number: 337
Does a Best Practice Alert Improve RA Patient Referral to Preventative Cardiology?
9:00AM-11:00AM
Abstract Number: 544
Does Anti-Citrullinated Protein Antibody Status Modify Treatment Effect of Certain Biologic DMARDs?
9:00AM-11:00AM
Abstract Number: 826
Does Anti-Glomerular Basement (anti-GBM) Antibody Positivity Correlate with Relapse in Patients with Anti-GBM Disease?
9:00AM-11:00AM
Abstract Number: 296
Does Care By a Multidisciplinary Team Improve Outcomes in Rheumatoid Arthritis? a Randomized Controlled Study
9:00AM-11:00AM
Abstract Number: 771
Does Cognitive Function Change over-Time in Systemic Lupus Erythematosus?
9:00AM-11:00AM
Abstract Number: 437
Does Reduction in Mechanical Knee Joint Loading Explain the Beneficial Effects of Weight Loss in Overweight or Obese Patients with Knee Osteoarthritis?
9:00AM-11:00AM
Abstract Number: 418
Dose-Response Relationship between Neuromuscular Electrical Stimulation and Muscle Function in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 552
Drug Tolerability and Discontinuation Reasons of 7 Biologics in 4466 Treatment Courses of Rheumatoid Arthritis -the Answer Cohort Study-
9:00AM-11:00AM
Abstract Number: 304
Dynamic MRI in Rheumatoid Arthritis for the Assessment of Synovitis Promoting Cartilage Loss
9:00AM-11:00AM
Abstract Number: 431
Early Pre-Radiographic Structural Pathology Precedes the Onset of Accelerated Knee Osteoarthritis: Data from the Osteoarthritis Initiative
9:00AM-11:00AM
Abstract Number: 471
Early Signs of Diastolic Impairment in Children with Incident Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 477
Early Treatment with Intravenous Pulse Methylprednisolone or Methotrexate Is Associated with Decreased Medication Requirements at 12 and 24 Months in Patients with Juvenile Dermatomyositis: A Propensity Score Analysis
9:00AM-11:00AM
Abstract Number: 600
Early Versus Delayed Treatment in Patients with Rheumatoid Arthritis (RA) in Routine Care at a Single US Academic Center: Better Response According to MDHAQ (MultiDimensional Health Assessment questionnaire) for Patients Starting Treatment in the Initial 6 Months
9:00AM-11:00AM
Abstract Number: 624
Easy Accessibility of Biologics and Its Impact on Disease Activity and Quality of Life in Kuwaiti Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 540
Echocardiographic Abnormalities in Rheumatoid Arthritis Patients Compared to Age, Sex and Traditional Cardiovascular Risk Factors Matched Controls
9:00AM-11:00AM
Abstract Number: 507
Echocardiographic Markers of Right Ventricle Dysfunction in Hispanic Patients with Rheumatoid Arthritis: A Case-Control Study
9:00AM-11:00AM
Abstract Number: 702
Effect of Biologics on Radiographic Progression of Peripheral Joints in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
9:00AM-11:00AM
Abstract Number: 419
Effect of Changes in Physical Activity on Cartilage Degradation in Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 578
Effect of Disease Duration and Other Patient Baseline Characteristics on Outcomes in Tocilizumab-Treated Rheumatoid Arthritis Patients: A Pooled Analysis
9:00AM-11:00AM
Abstract Number: 456
Effect of Local and Systemic CCR2 Blockade on Knee Hyperalgesia in a Mouse Model of Osteoarthritis
9:00AM-11:00AM
Abstract Number: 347
Effectiveness of a Biopsychosocial Exercise Approach in Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 181
Effectiveness of Elective Completion in Enhancing Board Preparedness and Comfort with Diagnosing and Treating Rheumatologic Conditions in a Cohort of Internal Medicine Residents at an Academic Medical Center
9:00AM-11:00AM
Abstract Number: 586
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World DATA from the ST. Gallen and-Aarau RA-Cohort
9:00AM-11:00AM
Abstract Number: 454
Effects of Prolonged Chemogenetic Inhibition of Nociceptors in a Murine Surgical Model of Osteoarthritis
9:00AM-11:00AM
Abstract Number: 517
Effects of Statin-Treatment on Coronary Plaques in Patients with Inflammatory Joint Diseases
9:00AM-11:00AM
Abstract Number: 422
Efficacy and Safety of a Fixed-Dose Combination of Nimesulide/Pantoprazole Compared with Naproxen/Esomeprazole for Pain Relief in Patients with Osteoarticular Diseases and Dyspeptic Symptoms
9:00AM-11:00AM
Abstract Number: 563
Efficacy and Safety of Abatacept in Combination with MTX in Early, MTX-Naïve, Anti-Citrullinated Protein Antibody–Positive Patients with RA: Primary and 1-Year Results from a Phase IIIb Study
9:00AM-11:00AM
Abstract Number: 696
Efficacy and Safety of Novel Targeted Synthetic DMARD and Biological DMARD in Active Psoriatic Arthritis: A Systematic Review, Meta-Analysis, and Network Meta-Analysis
9:00AM-11:00AM
Abstract Number: 620
Efficacy of a Second Tumor Necrosis Factor Inhibitor (TNFi) in the Treatment of Rheumatoid Arthritis (RA)
9:00AM-11:00AM
Abstract Number: 684
Efficacy of Ixekizumab in Different Phenotypes of Patients with Active Psoriatic Arthritis (PsA): Results from the Spirit Trials
9:00AM-11:00AM
Abstract Number: 412
Efficacy of Shoe-Stiffening Inserts for First Metatarsophalangeal Joint Osteoarthritis: Preliminary Findings from the Simple Randomised Controlled Trial
9:00AM-11:00AM
Abstract Number: 425
Efficacy, Safety, and Tolerability of ONO-4474, an Orally Available Pan-Tropomyosin Receptor Kinase Inhibitor, in Japanese Patients with Moderate-to-Severe Osteoarthritis of the Knee: A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Comparative Study
9:00AM-11:00AM
Abstract Number: 777
Electrocardiographic Abnormalities Are Associated with the Occurrence of Strokes in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 333
Electronic Delivery of Patient-Reported Outcome Questionnaires on Tablet PCs at Clinic Visit: A Feasibility Study
9:00AM-11:00AM
Abstract Number: 21
Elevated EPSTI1 Promote B Cells Hyperactivation through NF-Kb Signaling in Patients with Sjögren ’s Syndrome
9:00AM-11:00AM
Abstract Number: 75
Elevated Oxylipin Profile in Autoantibody-Positive Individuals at-Risk of Developing Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 364
Elevated sCD40L As a Predictive Biomarker of Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
9:00AM-11:00AM
Abstract Number: 755
Elevated Serum Procalcitonin at Baseline Correlates with Reduced Survival in Patients with Lupus Myocarditis
9:00AM-11:00AM
Abstract Number: 316
Eligibility Rates in Axial Spondyloarthritis Clinical Trials Based on Imaging Criteria
9:00AM-11:00AM
Abstract Number: 59
Elucidating the Expression and Role of Heparan Sulfate Proteoglycan Editing Sulfatases in Human Rheumatoid Arthritis Synovium and a Rat Adjuvant-Induced Arthritis Model
9:00AM-11:00AM
Abstract Number: 290
Emergency Department (ED) Utilization Among SLE Patients and Controls in the Population-Based Michigan Lupus Epidemiology & Surveillance (MILES) Cohort
9:00AM-11:00AM
Abstract Number: 775
Endomyocardial Biopsies in the Diagnosis of Myocardial Involvement in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 97
Enhanced IFN-α Production By Plasmacytoid Dendritic Cells Is Associated with Increased Toll-like Receptor 7 Retention in the Lysosomes and Exosure to Type I IFN in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 113
Epigenetic Changes in Dermal Fibroblasts By Inhibition of DOT1L Affect Cell Proliferation and Cell Cycle, but Have No Direct Effects on Collagen Deposition in in Vitro and In Vivo models of Fibrosis
9:00AM-11:00AM
Abstract Number: 154
Epigenetic Editing of FOXP3 in Human T Cells Is Sufficient to Induce Overexpression and Create a Regulatory T Cell Phenotype in Vitro
9:00AM-11:00AM
Abstract Number: 806
Estradiol Levels Are Elevated in Older Men with Diffuse Cutaneous SSc and Are Associated with Decreased Survival
9:00AM-11:00AM
Abstract Number: 102
Estrogen Controls the Expression of Serine Arginine-Rich Splicing Factor 1 (SRSF1) in Human T Lymphocytes Via Transcriptional and Post-Transcriptional Mechanisms
9:00AM-11:00AM
Abstract Number: 272
Ethnic Disparities in Lupus Nephritis Outcomes in the Inland Empire: Findings from the Southern California Lupus Registry
9:00AM-11:00AM
Abstract Number: 185
Evaluating Medical Student Confidence and Performance of the Pediatric Musculoskeletal Exam
9:00AM-11:00AM
Abstract Number: 199
Evaluating the Perception Among Rheumatologists of Maintenance of Board Certification Programs in the United States
9:00AM-11:00AM
Abstract Number: 570
Evaluation of CXCL13, sICAM1, MMP-3 and S100A8/A9 As Serum Biomarkers in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab
9:00AM-11:00AM
Abstract Number: 792
Evaluation of Esophageal Dysmotility in Systemic Sclerosis: Clinical VALUE of Computed Tomography
9:00AM-11:00AM
Abstract Number: 591
Evaluation of MRI Ramris Score and Clinical Response in Patients with ACPA Positive Undifferentiated Arthritis Treated with Infliximab Versus Placebo
9:00AM-11:00AM
Abstract Number: 189
Evaluation of Rheumatology Lectures By Clinical Students in a Nigerian Medical School: Learning from the Learners
9:00AM-11:00AM
Abstract Number: 478
Evidence Based Recommendations for Corticosteroid Tapering/Discontinuation in New Onset Juvenile Dermatomyositis Patients: Results from the Paediatric Rheumatology International Trials Organisation
9:00AM-11:00AM
Abstract Number: 112
Evidence for Altered Peroxisome Proliferator Activated Receptor (PPAR) Pathway Activity in a Transgenic Mouse Model of Scleroderma (TβRIIΔk-fib): Analysis of Mouse Skin, Lung and Explanted Cells
9:00AM-11:00AM
Abstract Number: 211
Excess in Prevalence of Functional Disability in Patients with Rheumatoid Arthritis: Does Serologic Status Matter?
9:00AM-11:00AM
Abstract Number: 213
Excessive Risk of Major Cardiovascular Events in Sero-Positive Rheumatoid Arthritis and in Patients with Active Disease
9:00AM-11:00AM
Abstract Number: 577
Expanded Autoantibody Profiles Predict Treatment Response to Biologic Therapy in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 410
Experience of Finding Footwear and Factors Contributing to Footwear Choice in People with Gout
9:00AM-11:00AM
Abstract Number: 134
Exploration of T-Cell Signatures Following TCR Stimulation Using Single Cell RNA-Seq to Inform Treatment Response Studies in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 214
Exploring the Relation between Air Pollution and Disease Activity in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 773
Exploring the Relation between Immunoglobulins Level and Infection Risk in Adult Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 20
Expression and Functions of the Transcription Factors Ikaros and Aiolos in Sjogren’s Syndrome and Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 95
Expression of SLAMF6 and Its Functional Significance in Podocytes of Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 298
Factors Affecting Inpatient Mortality in Hospitalizations for Sepsis with Underlying Systemic Lupus Erythematosus: Data from the National Inpatient Sample 2010-2014
9:00AM-11:00AM
Abstract Number: 246
Factors Associated with Disability in a Prospective Cohort of Complex Regional Pain Syndrome Type 1
9:00AM-11:00AM
Abstract Number: 291
Factors Associated with High-Dose Corticosteroid Use in SLE Patients Post Initiation of SLE Therapy
9:00AM-11:00AM
Abstract Number: 520
Factors Associated with the Developement of Severe Respiratory Infections in Patients with Rheumatoid Arthritis Included in a Vaccination Program
9:00AM-11:00AM
Abstract Number: 405
Feasibility of Enabling Self-Management and Coping with Arthritic Pain Using Exercise (ESCAPE-Pain) Programme for Knee Osteoarthritis in Malaysia
9:00AM-11:00AM
Abstract Number: 452
Features of Peripheral and Central Sensitization and Neuropathic Pain Are Seen in Both Osteoarthritis and Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 10
Fibroblast like Synoviocytes (FLS) Are Capable of Inducing Phenotypical Changes Including Class Switch Recombination (CSR) in Naive B Cells, but Additional Factors Are Required to Trigger Immunoglobulin Secretion
9:00AM-11:00AM
Abstract Number: 253
Fibromyalgia Patients Are Frequently Thought to be Challenging to Treat-Are They?
9:00AM-11:00AM
Abstract Number: 250
Fibromyalgia Patients Do Not Appear to Obsess about Their Symptoms Compared with Other Rheumatic Disease Patients
9:00AM-11:00AM
Abstract Number: 247
Fibromyalgia Patients Often Receive Several Rheumatic Disease Diagnoses
9:00AM-11:00AM
Abstract Number: 657
First Validation of Consensus Definitions for MRI Lesions in the Sacroiliac Joint By the Assessments in Spondyloarthritis International Society MRI Group
9:00AM-11:00AM
Abstract Number: 686
Five-Year Efficacy and Safety of Apremilast Treatment in Subjects with Psa: A Pooled Analysis of the 3 Phase III Studies
9:00AM-11:00AM
Abstract Number: 171
Flow Cytometric Assessment of the Mammalian Target of Rapamycin Pathway Using Antiphospholipid Syndrome As a Disease Model
9:00AM-11:00AM
Abstract Number: 795
Frequency and Clinical Associations of Rare Antibodies in a Large Connective Tissue Disease Cohort
9:00AM-11:00AM
Abstract Number: 270
Gaps in Knowledge about the Ontario Trillium Drug Program
9:00AM-11:00AM
Abstract Number: 790
Gastrointestinal Symptom Burden and Quality of Life in Systemic Sclerosis: Understanding the Role of Diet
9:00AM-11:00AM
Abstract Number: 133
GBR830, a True OX40 Antagonist Antibody with Potent Suppressive Effects on T Cell-Mediated Pathological Responses
9:00AM-11:00AM
Abstract Number: 276
Gender Differences in TNFi Treatment Adherence and Response in As Patients: A Prospective Longitudinal Cohort Study
9:00AM-11:00AM
Abstract Number: 51
Genetic Ablation of Inducible Nitric Oxide Synthase in TNF Transgenic Mice with Inflammatory-Erosive Arthritis Prevents Lymph Node Expansion and Decreases Synovial Infiltrates
9:00AM-11:00AM
Abstract Number: 565
Genetic Polymorphism in Dihydrofolate Reductase Impacts Methotrexate Polyglutamation in Adult Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 100
Glycosphingolipids and Proteins in Urine Exosomes: Potential Biomarkers of Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 608
Half Dose Reduction of Methotrexate in Patient with RA Who Achieved Clinical Remission
9:00AM-11:00AM
Abstract Number: 271
Health Care Disparities for Infectious and Non-Infectious Uveitis in the US
9:00AM-11:00AM
Abstract Number: 275
Health Equity: Access to Rituximab for Patients Comparing Variable Access in a Single Rheumatology Clinic
9:00AM-11:00AM
Abstract Number: 496
Heart Failure Risk Among Patients with Rheumatoid Arthritis: Association with Anti-Rheumatic Drugs
9:00AM-11:00AM
Abstract Number: 736
Herpes Zoster and Disseminated Zoster in Systemic Lupus Erythematosus and Lupus Nephritis: Incidence Rates in Real-World Claims Data
9:00AM-11:00AM
Abstract Number: 769
Herpes Zoster in Systemic Lupus Erythematosus: Prevalence and Risk Factors
9:00AM-11:00AM
Abstract Number: 135
High Dimensional Analysis By Mass Cytometry and RNA-Sequencing Reveals Altered Frequency and Exhausted Features of CD4 T and MAIT Cells in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 148
High Level of CD38 Expression in SLE CD8 T Cells Dictates Decreased Cytotoxicity
9:00AM-11:00AM
Abstract Number: 669
High Prevalence of Axial Spondyloarthritis in Patients with Acute Anterior Uveitis and Chronic Back Pain – Preliminary Results of a Prospective Observational Study
9:00AM-11:00AM
Abstract Number: 243
High Prevalence of Fibromyalgia Among Israel School Teachers
9:00AM-11:00AM
Abstract Number: 712
Higher Prednisolone Dose during Treatment of Tuberculosis Correlates with Mortality during Tuberculosis Treatment in Systemic Lupus Erythematosus Patients: A Retrospective Cohort Study
9:00AM-11:00AM
Abstract Number: 106
Highly Elevated Levels of Anti-Mitochondrial Antibodies in Systemic Lupus Erythematosus and Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 26
Hints for Catecholamine-Driven Autocrine Mechanisms to Regulate Regulatory B Cells
9:00AM-11:00AM
Abstract Number: 44
Histone Deacetylase 1 (HDAC1): A Novel Therapeutic Target in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 297
Hospitalization Rates Among Patients with Polymyalgia Rheumatica: A Population-Based Study from 1995-2017
9:00AM-11:00AM
Abstract Number: 515
How Knowledgeable Are Patients with Rheumatoid Arthritis about Cardiovascular Disease?
9:00AM-11:00AM
Abstract Number: 637
How to Define Remission and Low Disease Activity in Psoriatic Arthritis? an Analysis of 419 Patients with a Double Perspective, Based on Composite Scores and Patients’ and Physicians’ Perspectives
9:00AM-11:00AM
Abstract Number: 545
How to Treat Rheumatoid Arthritis Patients When Methotrexate Has Failed? Results from the Meteor Registry
9:00AM-11:00AM
Abstract Number: 236
Hypogammaglobulinemia and Infection Risk in Patients Treated with Rituximab
9:00AM-11:00AM
Abstract Number: 117
Hypomorphic A20 Expression Modulates Fibrosis Susceptibility: Implications for Systemic Sclerosis?
9:00AM-11:00AM
Abstract Number: 104
Identification of a Gut Pathobiont Immunostimulatory Lipoglycan Antigen Linked to Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 583
Identification of a Protein Profile Useful to Predict Response to Methotrexate in Early Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 794
Identification of an Immunodominant Epitope on Rnpc-3 As a Target of Autoantibodies in Patients with Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 103
Identification of IL-17+ and IL-10+ TCRαβ+ CD4- CD8- double Negative (DN) T Cell Subsets in Lupus-Prone Mice and Patients with SLE and Their Significance in Predicting Renal Involvement
9:00AM-11:00AM
Abstract Number: 811
Identification of Risk Factors for Gastric Antral Vascular Ectasia (GAVE) Among Systemic Sclerosis Patients
9:00AM-11:00AM
Abstract Number: 594
Identification of Tocilizumab Treated RA Patients, Whom Are Not Likely to Show Long-Term Clinical Benefit; Reanalysis of the Biomarker Sub-Study of LITHE
9:00AM-11:00AM
Abstract Number: 681
Identification of Treatment Naïve Patients with Psoriatic Arthritis Who Will Require a TNF Inhibitor
9:00AM-11:00AM
Abstract Number: 157
Identifying Additional Risk Factors Associated with Thrombosis and Pregnancy Morbidity in a Unique Cohort of Antiphospholipid Antibody Positive Chinese Patients
9:00AM-11:00AM
Abstract Number: 116
Identifying Matricellular Protein CYR61 As a Potential Anti-Fibrotic and Pro-Angiogenic Mediator in Scleroderma
9:00AM-11:00AM
Abstract Number: 511
Identifying Vulnerable Plaque in Rheumatoid Arthritis Using Novel Microbubble Contrast-Enhanced Carotid Ultrasonography and Serum Biomarkers of Inflammation and Atherosclerosis
9:00AM-11:00AM
Abstract Number: 40
IFN Regulatory Factor 3 but Not IFN Regulatory Factor 7 Contributes to Bone Erosion in Collagen Induced Arthritis
9:00AM-11:00AM
Abstract Number: 168
IgG Anti-High-Density Lipoproteins Antibodies Discriminate between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients
9:00AM-11:00AM
Abstract Number: 238
IL Inhibitors Therapy in Rheumatic Diseases and the Risk of Malignancies: Systematic Review and Meta-Analysis of Rare Harmful Effects in Randomized Controlled Trials
9:00AM-11:00AM
Abstract Number: 317
Imaging Biomarker Based Patient Stratification: Initial Data and Validation in Four Most Common Knee Arthritic Diseases
9:00AM-11:00AM
Abstract Number: 362
Immune Check Point Inhibitors, Auto-Antibodies, and Immune Adverse Reactions
9:00AM-11:00AM
Abstract Number: 356
Immune Related Adverse Events from Immune Checkpoint Inhibitors: A Retrospective Analysis from 2004-2017 at the University of North Carolina at Chapel Hill
9:00AM-11:00AM
Abstract Number: 353
Immune-Related Adverse Events Associated with Immunotherapy in Solid Organ Tumors. Study of 102 Cases from a Referral Single Center for Last 3 Years
9:00AM-11:00AM
Abstract Number: 363
Immune-Related Adverse Events in Cancer Immunotherapy: How Often Do We See Them?
9:00AM-11:00AM
Abstract Number: 346
Immune-Related Adverse Events: Development of a Pilot Immune-Related Adverse Events Clinic for Expedited and Effective Patient Care
9:00AM-11:00AM
Abstract Number: 822
Immuno-Inflammatory Markers and MR-Angiographic Imaging to Detect Disease Activity in Takayasu Arteritis
9:00AM-11:00AM
Abstract Number: 700
Immunogenicity of Originator and Biosimilar Infliximab: Anti-Drug Antibody Occurence, Cross-Reactivity and Epitope Specificities across Six Diseases. Analyses from a Norwegian Randomized Switching Trial
9:00AM-11:00AM
Abstract Number: 832
Immunoglobuline a Vasculitis: Comparison between Pediatric and Adult Population
9:00AM-11:00AM
Abstract Number: 105
Immunologic Properties of Cutaneous Lupus Erythematosus (CLE) Patients Refractory to Antimalarials Compared to Patients That Respond to Antimalarials
9:00AM-11:00AM
Abstract Number: 196
Immunology and Immunopharmacology at Point of Care: A Quality Improvement Teaching Initiative for Rheumatology Fellows
9:00AM-11:00AM
Abstract Number: 460
Immunomodulatory Medication Use for Youth with Newly-Diagnosed Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 358
Immunophenotypic Analysis of T Cells from Leukemia Patients with Immune Checkpoint Inhibitor-Associated Respiratory Complications
9:00AM-11:00AM
Abstract Number: 433
Impact of Bariatric Surgery on Rheumatic Diseases: A Systematic Review and Meta-Analysis
9:00AM-11:00AM
Abstract Number: 505
Impact of Biological Treatment on Left Ventricular Regional Dysfunction in Rheumatoid Arthritis Patients Determined with Global Circumferential and Longitudinal Strain Values Using Cardiac Magnetic Resonance Imaging
9:00AM-11:00AM
Abstract Number: 192
Impact of Case-Based Simulation Training on the Confidence and Knowledge of Medical Residents to Perform Rheumatologic Procedures
9:00AM-11:00AM
Abstract Number: 732
Impact of Disease Course on Atherosclerotic Vascular Events, Osteoporosis and Osteonecrosis in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 560
Impact of Formulary Copayment Change on Treatment Patterns in Rheumatoid Arthritis Patients on Etanercept
9:00AM-11:00AM
Abstract Number: 323
Impact of Gains in Rheumatoid Arthritis Disease Activity Documentation on Outcomes over Time
9:00AM-11:00AM
Abstract Number: 500
Impact of Inflammation and Biologic Treatments on Generation and Progression to Advanced Calcified Coronary Plaques in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 206
Impact of International Classification of Diseases 10th Revision Codes and Updated Medical Information on an Existing Rheumatoid Arthritis Phenotype Algorithm Using Electronic Medical Data
9:00AM-11:00AM
Abstract Number: 443
Impact of Intra-Articular Steroid Injection on Bone Marrow Lesions in Osteoarthritis of the Hip: An Assessment Using the Outcome Measures in Rheumatology Hip MRI Inflammation Scoring System
9:00AM-11:00AM
Abstract Number: 746
Impact of Nephritis on the Outcomes of SLE Patients Hospitalized with Acute Myocardial Infarction; Insights from the National Inpatient Sample Database
9:00AM-11:00AM
Abstract Number: 665
Impact of Peripheral Manifestations on Patient-Reported Outcomes (PROs) and Treatment in Spondyloarthritis. Data from ASAS-Comospa
9:00AM-11:00AM
Abstract Number: 219
Impact of Rheumatoid Arthritis on Influenza-Related Complications: A Population Based Cohort Study
9:00AM-11:00AM
Abstract Number: 326
Implementation of a Treat-to-Target Quality Improvement Program for Rheumatoid Arthritis Management Using Real-Time Patient Reported Outcome Measures
9:00AM-11:00AM
Abstract Number: 338
Implementation of an Automated Phrase to Increase Awareness of Cardiovascular Risk in Rheumatoid Arthritis Patients in an Urban Fellows Rheumatology Clinic
9:00AM-11:00AM
Abstract Number: 328
Implementation of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Documentation in Systemic Lupus Erythematosus (SLE) Patients at an Academic Medical Center
9:00AM-11:00AM
Abstract Number: 295
Implementing a Staff Tobacco Cessation Protocol Increases Quit Line Referrals in a Community Rheumatology Practice
9:00AM-11:00AM
Abstract Number: 502
Implications of Coronary Artery Calcium Score and Its Change over Time As Markers of Coronary Plaque Vulnerability and Patient Risk in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 592
Improved Response to Etanercept Is Associated with Serum Vitamin D Levels in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 245
Improvement in Fibromyalgia Symptoms and Skin Biopsy Results in Patients with Fibromyalgia and Small Fiber Neuropathy Treated with Intravenous Immune Globulin Infusion( IVIG)
9:00AM-11:00AM
Abstract Number: 197
Improving Clinical Decisions for Gout Management: Effect of Online Case-Based Education
9:00AM-11:00AM
Abstract Number: 466
Improving Pneumococcal Vaccination Rates in Childhood-Onset SLE Patients at a Large Tertiary Care Center: The Path to Creating a More Sustainable Model of Vaccination with the Help of EMR
9:00AM-11:00AM
Abstract Number: 349
Improving the Performance of the Spanish Version of QOL-RA
9:00AM-11:00AM
Abstract Number: 54
In a Macaque Model of RA By Immunization with Citrullinated Peptides, the Valine in the 11 Position of the DRB1 Molecule Has Greater Impacts on T-Cell Response to Citrullinated Peptides Than the 70-74 Position in the Shared Epitope
9:00AM-11:00AM
Abstract Number: 394
In Patients with Suspected Idiopathic Inflammatory Myopathy, Does Pre-Biopsy Musculoskeletal MRI Result in Greater Yield of Diagnostic Biopsy Results? Summary of Data from a 10-Year Single Hospital Audit
9:00AM-11:00AM
Abstract Number: 321
In Rheumatoid Arthritis All Disease Activities Are Not Created Equal
9:00AM-11:00AM
Abstract Number: 48
In Vivo Demonstration of Tmtnf Reverse Signaling: Significance in the Therapeutic Response to Anti-TNF Agents during Murine Arthritis
9:00AM-11:00AM
Abstract Number: 158
Incidence and Prevalence of Antiphospholipid Syndrome in a Health Management Organization (HMO): A 15-Year Study
9:00AM-11:00AM
Abstract Number: 542
Incidence and Prevalence of Interstitial Lung Disease in the US Population and in Patients with RA By Anti-Citrullinated Protein Antibody Status
9:00AM-11:00AM
Abstract Number: 820
Incidence And Seasonal Variation Of Biopsy-Proven Giant Cell Arteritis – Revisited: A 20-Year Population-Based Study From Sweden
9:00AM-11:00AM
Abstract Number: 512
Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases: Prospective Data from an Observational Multicentric Study
9:00AM-11:00AM
Abstract Number: 367
Incidence of Inflammatory Bowel Disease (IBD) Among Patients (Pts) with Other Chronic Inflammatory Diseases (CID) Treated with Interleukin-17a (IL-17a) or Phosphodiesterase 4 (PDE4) Inhibitors
9:00AM-11:00AM
Abstract Number: 273
Incidence of Systemic Lupus Erythematosus By Income: A Nationwide Study
9:00AM-11:00AM
Abstract Number: 722
Increased Blood Pressure Visit-to-Visit Variability in Patients with Systemic Lupus Erythematosus: Association with Inflammation, Comorbidities and Increased Mortality
9:00AM-11:00AM
Abstract Number: 497
Increased Concentration of Large Very Low Density Lipoprotein Particles Associates with Progression of Carotid Atherosclerosis in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 706
Increased Incidence and Prevalance of Resistant Hypertension in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
9:00AM-11:00AM
Abstract Number: 534
Increased Insulin Resistance and Impaired Beta-Cell Function in Patients with Rheumatoid Arthritis: The Role of Glucocorticoid Therapy?
9:00AM-11:00AM
Abstract Number: 230
Increased Prevalence of Coronary Artery Disease in Patients with Chest Pain and Seropositive Rheumatoid Arthritis: An Analysis from a Clinical Computed Tomography-Based Large-Scale Population Cohort
9:00AM-11:00AM
Abstract Number: 727
Increased Risk of Coronary Artery Disease Among Patients with Class III Lupus Nephritis: A Retrospective Study of Patients at the University of North Carolina at Chapel Hill
9:00AM-11:00AM
Abstract Number: 537
Increased Risk of Incident Chronic Kidney Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cohort Studies
9:00AM-11:00AM
Abstract Number: 387
Increased Risk of Malignancy in Elderly Patients with Inflammatory Myositis
9:00AM-11:00AM
Abstract Number: 640
Increasing Rates of Arthroplasty for Psoriatic Arthritis in the United Kingdom between 1995 and 2010
9:00AM-11:00AM
Abstract Number: 14
Individual RA-Derived Monoclonal Anti-Citrullinated Protein Autoantibodies (ACPA) Have Extensive Citrulline Multi-Reactivity Demonstrated By a Large-Scale Protein Array Platform
9:00AM-11:00AM
Abstract Number: 602
Individualised Infliximab Treatment: A Treatment Strategy Based on Therapeutic Drug Monitoring
9:00AM-11:00AM
Abstract Number: 366
Infectious Complications of Immunosuppressive Therapy in Patients with Common Variable Immunodeficiency (CVID) and Inflammatory Arthritis
9:00AM-11:00AM
Abstract Number: 666
Inflammation on MRI of the Sacroiliac Joints Is Highly Associated with Structural Damage in Axial Spondyloarthritis Patients in Clinical Practice: Data from the ASAS and DESIR Cohorts
9:00AM-11:00AM
Abstract Number: 285
Inflammatory Bowel Disease Is Associated with a Substantial Economic Burden in Patients with Psoriatic Arthritis and in Patients with Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 318
Inflammatory Findings Detected By MRI at Entheseal Sites in the Pelvic Girdle of Patients with Polymyalgia Rheumatica Have Potential for a Diagnostic Test
9:00AM-11:00AM
Abstract Number: 812
Inflammatory Stays Inflammatory: A Subgroup of Systemic Sclerosis Characterized By High Morbidity and Inflammatory Resistance to Cyclophosphamide
9:00AM-11:00AM
Abstract Number: 216
Inflectra and Remicade Use and Cost in Canada Under Provincial Drug Plans in 2016
9:00AM-11:00AM
Abstract Number: 611
Influence of Dose Titration of Concomitant Steroid and Methotrexate during Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice Based on the IORRA Cohort
9:00AM-11:00AM
Abstract Number: 644
Influence of Inflammation and Structural Damage on Global Functioning in Patients with Axial Spondyloarthritis – Using the ASAS Health Index in Routine Care
9:00AM-11:00AM
Abstract Number: 140
Inhibition of Cathepsin S Leads to Suppression of SS-a/SS-B Specific T Cells from Patients with Primary Sjøgren Syndrome
9:00AM-11:00AM
Abstract Number: 58
Inhibition of Lipid Phosphatase SHIP1 Expands Myeloid-Derived Suppressor Cells and Attenuates Rheumatoid Arthritis in Mice
9:00AM-11:00AM
Abstract Number: 121
Inhibition of Nuclear Receptor Coactivator 3 Attenuates Fibrosis in Murine Models of Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 128
Inhibition of Prolyl-tRNA Synthetase As a Novel Therapeutic Target for Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 450
Injection Site Reaction Associated with Subcutaneous Biologic Agents and Methotrexate. Analysis from the Rhumadata® Clinical Database and Registry
9:00AM-11:00AM
Abstract Number: 232
Inpatient Mortality in Transition-Aged Youth with Rheumatic Disease: An Analysis of the National Inpatient Sample
9:00AM-11:00AM
Abstract Number: 9
Integration of Cytokine Profiles with Distinct B-Cell Functions Reveals a Specific Micro-Environmental Framework in Autoimmune Diseases
9:00AM-11:00AM
Abstract Number: 3
Interferon-Alpha Disrupts DNA-Specific B Cell Tolerance in 3H9 Mice
9:00AM-11:00AM
Abstract Number: 52
Interferon-Alpha Protects Against Pain and Joint Damages in Experimental Arthritis and Is Associated with Expansion of Highly Suppressive Regulatory T Lymphocytes in Protected Mice and in Tocilizumab-Treated Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 613
Interim Analysis of Baseline Characteristics and Preferences of Administration Route of Rheumatoid Arthritis Patients Who Are Bio-Naïve or Switched between Advanced RA Treatments; A Multicenter, Prospective, Observational Study
9:00AM-11:00AM
Abstract Number: 720
Interkeukin-6 Level in Cerebrospinal Fluid As a Biomarker for Systemic Lupus Erythematosus Patients with Longitudinally Extensive Transverse Myelitis like Neuromyelitis Optica Spectrum Disease
9:00AM-11:00AM
Abstract Number: 404
Interleukin 17A– a Translational Target to Treat Supraspinatus Tendinopathy
9:00AM-11:00AM
Abstract Number: 445
Interleukin-1β Inhibition with Canakinumab Associates with Reduced Rates of Total Hip and Knee Replacement (THR/TKR) and Osteoarthritis (OA) Symptoms: Exploratory Results from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
9:00AM-11:00AM
Abstract Number: 255
Interpretation of Proverbs Compared with the Mental Clutter Scale in Fibromyalgia Patients Demonstrates Intact Intellectual Ability Despite the Symptoms of Fibrofog
9:00AM-11:00AM
Abstract Number: 632
Interpretation of Symptoms Should Take into Account Gender in Psoriatic Arthritis: An Analysis of 451 Patients
9:00AM-11:00AM
Abstract Number: 67
Intestinal Inflammation and Netosis Associate with the Presence of Stool IgA ACPA in Subjects at-Risk for RA
9:00AM-11:00AM
Abstract Number: 50
Intra-Articularly Delivering Lentivirus-Based CRISPR Interference Targeting Long Non-Coding RNA H19 in Synovial Fibroblasts Ameliorates Experimental Arthritis
9:00AM-11:00AM
Abstract Number: 479
Intravenous Immunoglobulin in Combination with Intravenous Methylprednisolone in the Treatment of Calcinosis Associated with Juvenile Dermatomyositis (JDM)
9:00AM-11:00AM
Abstract Number: 305
Introduction and Value of a Shortened Psamris-7 in Psa-Patients before and after Treatment Escalation to Bdmard Using High Resolution MRI
9:00AM-11:00AM
Abstract Number: 204
Investigating Asthma, Allergic Disease, Passive Smoke Exposure, and Risk of Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 639
Is a Primary Good Response to Nsaids Predictive of the Subsequent Response to the First TNF Inhibitor in Patients with Early Axial Spondyloarthritis ?
9:00AM-11:00AM
Abstract Number: 435
Is Frailty Associated with Worse Outcomes after Total Joint Replacements?
9:00AM-11:00AM
Abstract Number: 749
Is Lupus Nephritis Onset Delayed in Older Caucasian Females with Less Aggressive Pathology?
9:00AM-11:00AM
Abstract Number: 241
Is There a Relationship between Takotsubo Cardiomyopathy and Fibromyalgia? Insights from the National Inpatient Sample Database
9:00AM-11:00AM
Abstract Number: 535
Is There Achilles Tendon Damage in Rheumatoid Arthritis Patients?
9:00AM-11:00AM
Abstract Number: 630
Is Treatment Adherence of RA Patients to Injectable MTX Influenced By Previous MTX Route of Administration?
9:00AM-11:00AM
Abstract Number: 17
Kappa-Deleting Recombination Excision Circles (KREC) in B Cells and Serum B Cell Activating Factor (BAFF): Possible Aids in Predicting Juvenile Dermatomyositis Response to Rituximab
9:00AM-11:00AM
Abstract Number: 411
Kinesiophobia and Physical Function Among Adults with Knee Osteoarthritis: Before and after Strength Training Classes
9:00AM-11:00AM
Abstract Number: 551
Leflunomide As a Concomitant DMARD Choice for the Biological Treatment Era of Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 564
Levels of CXCL13 and sICAM1 Correlate with Disease Activity Score in Rheumatoid Arthritis (RA) Patients Treated with Tocilizumab (TCZ)
9:00AM-11:00AM
Abstract Number: 472
Libman Sacks Endocarditis in Pediatric Systemic Lupus Erythematosus: Clinical Features and Complications
9:00AM-11:00AM
Abstract Number: 406
Limiting the Risk of Osteoarthritis after Anterior Cruciate Ligament Injury: Are We Missing the Opportunity to Intervene?
9:00AM-11:00AM
Abstract Number: 510
Lipid Profile and Cardiovascular Risk in Subjects at Risk for Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 527
Long-Term Follow up of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 617
Long-Term Outcome of Rituximab in Rheumatoid Arthritis: Real World Experience
9:00AM-11:00AM
Abstract Number: 748
Long-Term Survival of Renal Transplantation Due to Lupus Nephritis. Comparative Study with Non-Autoimmune Transplantation. Study from a Single Center
9:00AM-11:00AM
Abstract Number: 628
Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Descriptive Data from the Ontario Best-Practice Research Initiative Database
9:00AM-11:00AM
Abstract Number: 574
Longitudinal Efficacy Analysis of Patients with Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Dmards: Response Following Rescue from Baricitinib 2mg to 4mg Once-Daily
9:00AM-11:00AM
Abstract Number: 787
Longitudinal Follow-up of Anti-Topoisomerase I Positive Patients within the Leiden Systemic Sclerosis Cohort – Prognosis Infaust?
9:00AM-11:00AM
Abstract Number: 562
Low Inflammation on Magnetic Resonance Imaging in Patients with Rheumatoid Arthritis That Achieved Sustained Clinical Remission on Adalimumab
9:00AM-11:00AM
Abstract Number: 499
Low Inflammatory Burden and Statin Exposure Inhibit Progression and Induce Regression of Early Coronary Plaques in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 525
Low Interstitial Lung Disease Event Rate in Patients with Rheumatoid Arthritis: Pooled Post Hoc Analysis of Data from the Tofacitinib Clinical Development Program
9:00AM-11:00AM
Abstract Number: 670
Low Rate of Spinal Radiographic Progression over 2 Years in Ankylosing Spondylitis Patients Treated with Secukinumab: A Historical Cohort Comparison
9:00AM-11:00AM
Abstract Number: 343
Low Rates of Immunizations in Cohort of Immunocompromised Patients in an Academic Rheumatology Practice
9:00AM-11:00AM
Abstract Number: 513
Low Serum IGF1 Is Associated with Higher Cardiovascular Morbidity in the Middle-Aged Women with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 474
Lupus Impact Tracker (LIT) As a New Tool in Assessing Patient Reported Outcome in Pediatric Lupus
9:00AM-11:00AM
Abstract Number: 92
Lupus Nephritis Serum Induces Neutrophil Chemotaxis Towards Glomerular Endothelial Cells in Vitro
9:00AM-11:00AM
Abstract Number: 141
Lymphocyte Activation Gene 3 Plasma Level Is Increased and Associated with Progression in Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 88
Lymphocyte DNA Methylation As a Mediator of Genetic Risk in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 124
M10, a Small Fragment of the Hepatocyte Growth Factor Receptor, Attenuates Fibrotic Changes in a Murine Model of Scleroderma Lung Disease and in Human Lung Fibroblasts
9:00AM-11:00AM
Abstract Number: 311
Magnetic Resonance Imaging of the Cervical Spine in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Presenting with Chronic Neck Pain – a Systematic Comparison of Clinical Assessments
9:00AM-11:00AM
Abstract Number: 558
Major Reduction of Ultrasound Detected Synovitis during Subcutaneous Tocilizumab Treatment; Results from a Multicenter 24 Weeks Study of Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 162
Mammalian Target of Rapamycin (mTOR) Pathway Assessment in Antiphospholipid Antibody Positive Patients with Livedo Reticularis/racemosa
9:00AM-11:00AM
Abstract Number: 519
Marginal Structure Modeling of Association between Disease Activity and Hospitalized Infection Among Patients in a Rheumatoid Arthritis Registry
9:00AM-11:00AM
Abstract Number: 808
Mean Number of Nailfold Capillaries Is Associated with Disease Activity at 6 Months Follow-up in Systemic Sclerosis Patients
9:00AM-11:00AM
Abstract Number: 635
Measuring Spinal Mobility over Time in Early Axial Spondyloarthritis: Can We Do It Reliably?
9:00AM-11:00AM
Abstract Number: 203
Meat Consumption and Risk of Rheumatoid Arthritis in Women: A Population-Based Cohort Study
9:00AM-11:00AM
Abstract Number: 828
Medium and Small-Sized Vessel Involvement in Hypereosinophilic Syndrome
9:00AM-11:00AM
Abstract Number: 719
Men and Sexual Function: An Overlooked Issue in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 146
Mesenchymal Stromal Cell Transferred Mitochondria Elicit an Immune Function Reprogramming That Entails T Regulatory Cell Commitment and Clinical Improvement of Graft Vs Host Disease
9:00AM-11:00AM
Abstract Number: 455
Metabolic Syndrome and Trajectories of Pain Severity and Number of Painful Sites in Knee Osteoarthritis: Data from a 10.7-Year Prospective Study
9:00AM-11:00AM
Abstract Number: 704
Metabolomics Analysis of Insulin Resistance in Mild/Inactive Non-Diabetic Systemic Lupus Erythematosus Women
9:00AM-11:00AM
Abstract Number: 122
Metformin Inhibited the Development of Bleomycin-Induced Murine Scleroderma Via Restoring the Balance between Regulatory and Effector T Cells and Suppressing Spleen Germinal Center Formation
9:00AM-11:00AM
Abstract Number: 516
Microalbuminuria in Rheumatoid Arthritis: Investigating the Association with Diffuse Functional and Morphological Alterations of the Retinal Microvasculature, the Dermal Capillary Network and the Coronary Microcirculation
9:00AM-11:00AM
Abstract Number: 34
Microbiome-Drived Aberration of Hematopoietic Stem Cell Development Facilitates Immune Deregulation on the Onset of Collagen-Induced Arthritis in Mice
9:00AM-11:00AM
Abstract Number: 261
Mindfulness Is Associated with Sleep Quality Among Patients with Fibromyalgia
9:00AM-11:00AM
Abstract Number: 127
MiR-3606-3p Inhibits Systemic Sclerosis through Targeting TGF-β Receptor II
9:00AM-11:00AM
Abstract Number: 776
MMP7 and CXCL12: Two Promising Biomarkers in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 742
Moderate to Severe Depression in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 42
Modulation of Autoimmune Arthritis By Protein Tyrosine Phosphatase SHP-1
9:00AM-11:00AM
Abstract Number: 151
Molecular Mechanisms of Pathogenic T Cell Resilience in Human Arthritis
9:00AM-11:00AM
Abstract Number: 22
Monoclonal Anti-Citrullinated Protein Antibodies Generated from RA-Derived B Cells Recognize Amino Acid Motifs Rather Than Specific Proteins
9:00AM-11:00AM
Abstract Number: 365
Monoclonal Gammopathy in Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 125
Monocyte Transcriptome Delineates SSc Patients with Functionally Distinct Patterns of Gene Dysregulation That Persist through Differentiation
9:00AM-11:00AM
Abstract Number: 212
Mortality and Causes of Death in Patients with Inflammatory Arthritis in Hong Kong over 20 Years
9:00AM-11:00AM
Abstract Number: 654
MRI Lesion Definitions in Axial Spondyloarthritis: A Consensus Reappraisal from the Assessments in Spondyloarthritis International Society
9:00AM-11:00AM
Abstract Number: 609
Multi-Biologic Usage in Rheumatoid Arthritis Is Not Infrequent in the Routine Practice
9:00AM-11:00AM
Abstract Number: 381
Muscle Endurance Deficits in Myositis Patients Despite Normal Manual Muscle Testing Scores
9:00AM-11:00AM
Abstract Number: 398
Muscle Function and Health-Related Quality of Life in Patients with Polymyositis and Dermatomyositis
9:00AM-11:00AM
Abstract Number: 399
Musculoskeletal Comorbidities after Total Knee Replacement for Osteoarthritis
9:00AM-11:00AM
Abstract Number: 357
Musculoskeletal Immune-Related Adverse Events with Use of Checkpoint Inhibitors in Malignancy: Experience in Sydney, Australia
9:00AM-11:00AM
Abstract Number: 131
Myofibroblast Cells Expression of CD248 May Contribute to Exacerbate Microvascular Damage during Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 383
Myositis Patients with Anti-U1-RNP and Anti-Ro52 Autoantibodies Are at Risk of Pericarditis, Glomerulonephritis, and Pulmonary Hypertension
9:00AM-11:00AM
Abstract Number: 397
Myositis-Specific Autoantibodies and Their Clinical Associations
9:00AM-11:00AM
Abstract Number: 382
Nailfold Capillary Changes in the Adult Newly Onset-Dermatomyositis: A Prospective Cohort Study
9:00AM-11:00AM
Abstract Number: 374
Nailfold Microangiopathy in Dermatomyositis and Systemic Sclerosis: What Is Different?
9:00AM-11:00AM
Abstract Number: 182
Needs Assessment of a Structured Program for Fellows As Teachers: Rheumatology Program Directors’ Perspective
9:00AM-11:00AM
Abstract Number: 183
Needs Assessment of a Structured Teaching Program for Fellows As Teachers: Rheumatology Fellows’ Perspective
9:00AM-11:00AM
Abstract Number: 701
Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Psoriatic Arthritis Patients without Prior Biologic Treatment
9:00AM-11:00AM
Abstract Number: 457
Neuropathic Pain in Patients with Knee Osteoarthritis (Preliminary Report)
9:00AM-11:00AM
Abstract Number: 766
Neutrophil Extracellular Traps Are a Source of Extracellular High Mobility Group Box-1: Association with Clinical and Histopathological Features in Patients with Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 699
New Onset/Recurrence of Inflammatory Arthralgia/Spondyloarthritis in Patients Treated with Vedolizumab for Intestinal Bowel Disease
9:00AM-11:00AM
Abstract Number: 340
No Improvement in Time to Biopsy and Therapy in Lupus Nephritis Patients over Two Decades
9:00AM-11:00AM
Abstract Number: 831
No More HCV RNA in Serum and Cryoprecipitate in Patients with Persisting HCV-Cryoglobulinemia Vasculitis after Daa-Induced Sustained Virological Response
9:00AM-11:00AM
Abstract Number: 814
NON Diffuse SSc, Peripheral Neuropathy, Concomitant Sjogren Syndrome and ANTI-RNA Polymerase III Represent Risk Factors for the Higher Frequency of Cancer in a Large Single Cohort of Patients with Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 123
Non-Hematopoietic Derived TNF Drives Pulmonary Vasculopathy: A New Model of CTD-Associated Pulmonary Hypertension
9:00AM-11:00AM
Abstract Number: 508
Non-Invasive Evaluation of Left Atrial Pressure in Hispanic Patients with Rheumatoid Arthritis: A Case-Control Study
9:00AM-11:00AM
Abstract Number: 220
Non-Medical Switch to Biosimilars: What Have We Learned?
9:00AM-11:00AM
Abstract Number: 567
Non-Surgical Periodontal Therapy Plus Short-Term Antibiotic Treatment May Improve Clinical Disease Activity: A Pilot Study in Difficult to Treat Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 682
Nonsteroidal Anti-Inflammatory Drug Use and Hypertension in Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 43
Novel Anti-Malarial Drug Derivative Inhibited Anti-Citrullinated Protein/Peptide Antibodies and Rheumatoid Factors Production in Dnaseii/Ifnr Double Knock out Mice
9:00AM-11:00AM
Abstract Number: 132
Novel Therapeutic Peptides Which Target CD206 Inhibit Macrophage Dependent Fibroblast Activation in Scleroderma
9:00AM-11:00AM
Abstract Number: 424
Occult Extractable Synovial Fluid in Inflammatory and Non-Inflammatory Arthritis of the Knee
9:00AM-11:00AM
Abstract Number: 201
Occupational Exposure to Coal and Silica Dust Is Associated with Elevated Risk of Rheumatoid Arthritis in Coal Mining Areas of US
9:00AM-11:00AM
Abstract Number: 461
Ofatumumab Use in Childhood-Onset Systemic Lupus Erythematosus: A Single-Center Experience
9:00AM-11:00AM
Abstract Number: 427
One Year Efficacy and Safety of One or Three Injections of Hylan G-F 20 for Knee Osteoarthritis: A Systematic Literature Review and Meta-Analysis
9:00AM-11:00AM
Abstract Number: 375
Only a Minor Proportion of Individuals with Anti-Aminoacyl-tRNA Synthetase Autoimmunity Presents with the Clinical Picture of “Antisynthetase-Syndrome”
9:00AM-11:00AM
Abstract Number: 342
Optimizing the Dataset to Collect from Patients to Accurately Predict Their Status Prior to the Clinic Visit
9:00AM-11:00AM
Abstract Number: 46
Organic Dust Inhalants Shift Immune Responses and Extracellular Matrix Balance between Synovium and Lung in the Collagen-Induced Arthritis Mouse Model
9:00AM-11:00AM
Abstract Number: 260
Outcome Expectations and Fibromyalgia: Perceived Benefits of Exercise Are Associated with Self-Efficacy and Physical Performance
9:00AM-11:00AM
Abstract Number: 743
Outcome of Stroke in Patients with Systemic Lupus Erythematosus: A Nested Case-Control Study
9:00AM-11:00AM
Abstract Number: 239
Outcomes of Hospitalizations and the Temporal Trends in Mortality from Acute Myocardial Infarction in Patients with RA and FM during 2005 to 2015
9:00AM-11:00AM
Abstract Number: 277
Outcomes of Telemedicine for Rheumatoid Arthritis in the Alaska Native Population
9:00AM-11:00AM
Abstract Number: 11
PAD4-Independent Interaction of ACPA with Nuclear Antigens in Apoptotic Cells and Neutrophil Extracellular Traps (NETs) Defines a Subset of Autoantibodies
9:00AM-11:00AM
Abstract Number: 449
Pain Processing in Chronic Low Back Pain Individuals with or without Sick Leave
9:00AM-11:00AM
Abstract Number: 187
Participant-Reported Effect of an Indigenous Health Continuous Professional Development Education Initiative
9:00AM-11:00AM
Abstract Number: 446
Participation in American Football Is Associated with Increased Risk for Knee Pain and Osteoarthritis: Data from the Osteoarthritis Initiative
9:00AM-11:00AM
Abstract Number: 442
Patient Factors Associated with Gaps in Osteoarthritis Care
9:00AM-11:00AM
Abstract Number: 417
Patient Reported Outcomes Pre and Post Intervention in Older Veterans with Chronic Back Pain
9:00AM-11:00AM
Abstract Number: 723
Patient-Reported Cognitive Screen Does Not Identify Cognitive Sub-Domains: Exploration of the Subscale Structure of the Perceived Deficits Questionnaire in a Systemic Lupus Erythematosus Cohort
9:00AM-11:00AM
Abstract Number: 384
Patients with Anti-Synthetase Syndrome Have a Similar Prevalence and Severity of Interstitial Lung Disease to Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 249
Patients with Fibromyalgia May be Fearful of Developing Dementia Despite Lack of Concrete Evidence of Cognitive Decline
9:00AM-11:00AM
Abstract Number: 267
Patterns of Access to Prescription Medications Among Lupus Cases and Controls in the Population-Based Michigan Lupus Epidemiology & Surveillance (MILES) Cohort
9:00AM-11:00AM
Abstract Number: 619
Patterns of Change of a Second Biological Dmard in a Cohort of Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 319
Patterns of Muscle Oedema, Atrophy and Fatty Replacement in the Idiopathic Inflammatory Myopathies: A Single-Centre Retrospective Review of Magnetic Resonance Imaging Data
9:00AM-11:00AM
Abstract Number: 150
PD-1 Signaling Interferes with OX40L to Alter the Suppressive Function and Proliferation of CD4+ Regulatory T Cells in Lupus Mice
9:00AM-11:00AM
Abstract Number: 188
Pediatric Trainee Confidence and Exposure to Rheumatology
9:00AM-11:00AM
Abstract Number: 463
Percentage of Glomerular Crescents Predicts Renal Outcomes in Childhood-Onset Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 648
Performance of an Online Self-Referral Questionnaire Compared to a Physician-Based Referral Approach to Identify Patients with a High Probability of Axial Spondyloarthritis: Results from the Optiref Study
9:00AM-11:00AM
Abstract Number: 142
Peripheral CD4+CD25+Foxp3+T Regulatory Cells Absolutely Reduce in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 756
Peripheral Neutrophil CD64 Index Combined with Biomarkers Improves the Ability of Diagnosing Bacterial Infection in Patients with SLE
9:00AM-11:00AM
Abstract Number: 548
Persistence in Low Disease Activity or Remission with Etanercept Monotherapy in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
9:00AM-11:00AM
Abstract Number: 118
Pharmacological Inhibition of JAK/STAT Signaling By Tofacitinib Prevents Experimental Organ Fibrosis: Novel Therapy for Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 393
Physical Activity Monitoring Using Wrist-Worn Accelerometer in the Assessment and Follow-up of Patients with Myositis
9:00AM-11:00AM
Abstract Number: 336
Physical Activity Monitors: New Tool to Assess Improvement in Myositis
9:00AM-11:00AM
Abstract Number: 294
Physical Therapists’ Ability to Recognize Inflammatory Arthritis Cases and Awareness of Importance for Their Prompt Referral to Rheumatology
9:00AM-11:00AM
Abstract Number: 155
Polyfunctional Synovial T-Cell Responses and Synovial Invasiveness Repressed By Blockade of Phosphodiesterase 4
9:00AM-11:00AM
Abstract Number: 152
Polymorphonuclear Neutrophils and Regulatory T Lymphocytes (Treg) Cooperate to Sustain Treg Activity in Normal and Arthritic Contexts
9:00AM-11:00AM
Abstract Number: 352
Polymyalgia Rheumatica-like Syndrome from Checkpoint Inhibitor Therapy: Case Series and Systematic Review of the Literature
9:00AM-11:00AM
Abstract Number: 234
Population-Based Estimates of Fatigue Prevalence Among Adults Aged >18 Years with and without Arthritis, United States, 2015-2016
9:00AM-11:00AM
Abstract Number: 750
Positive Remodeling Index and Low Attenuation Non-Calcified Coronary Plaques: Markers of Vulnerable Coronary Plaques in Systemic Lupus?
9:00AM-11:00AM
Abstract Number: 69
Possible Association of Early Inflammatory Arthritis with Viral Outbreaks Such As Influenza: Time Series Analysis of the Canadian Early Inflammatory Arthritis Cohort
9:00AM-11:00AM
Abstract Number: 621
Practical Optimization of Methotrexate Dose Improves Disease Control of Rheumatoid Arthritis Despite Reduction or Discontinuation of Oral Glucocorticoids
9:00AM-11:00AM
Abstract Number: 193
Practice Improvement Using Virtual Online Training: A Novel App-Based Platform to Teach Clinical Reasoning in Rheumatology
9:00AM-11:00AM
Abstract Number: 38
Pre-Clinical Clonally-Expanded aggrecan89-103–Specific CD4+ T Cells Are a Target for Autoimmune Arthritis Prevention
9:00AM-11:00AM
Abstract Number: 80
Prediction of Future Development of Rheumatoid Arthritis in Patients with Seropositive Arthralgia
9:00AM-11:00AM
Abstract Number: 784
Prediction of Hospital-Acquired Bacterial Infections in Patients with SLE
9:00AM-11:00AM
Abstract Number: 170
Predictive Value of Antiphospholipid Antibodies in the Acute Phase of Deep Vein Thrombosis
9:00AM-11:00AM
Abstract Number: 595
Predictive VALUE of CD19 SERUM Levels for LONG TERM Therapeutic Response and Utility As Biomarker for Optimization, in Rheumatoid Arthritis Patients Treated with Rituximab
9:00AM-11:00AM
Abstract Number: 501
Predictors of Change in Coronary Plaque Burden and Composition in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 765
Predictors of End-Stage Renal Disease in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 593
Predictors of Persistence of Biologic Drug Step-Down Strategies in Inflammatory Arthritis: An Observational Study in Clinical Practice up to Seven Years of Follow-up
9:00AM-11:00AM
Abstract Number: 400
Predictors of Response to a Single Intra-Articular Injection of Mannitol-Modified Cross-Linked Hyaluronic Acid (HANOX-M-XL) in Patients with First Metatarsophalangeal Joint Osteoarthritis (hallux rigidus)
9:00AM-11:00AM
Abstract Number: 798
Predominant Fasciitis and Mild Intramuscular Edema on Muscle Magnetic Resonance Imaging in Scleroderma-Associated Myopathy
9:00AM-11:00AM
Abstract Number: 160
Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)
9:00AM-11:00AM
Abstract Number: 725
Preliminary Population-Based Incidence and Prevalence Estimates of Primary Discoid Lupus and Cutaneous Lupus Erythematosus from the Manhattan Lupus Surveillance Program
9:00AM-11:00AM
Abstract Number: 377
Preliminary Validation of Rectus Femoris Muscle Ultrasound in Idiopathic Inflammatory Myopathy Patients
9:00AM-11:00AM
Abstract Number: 402
Preoperative Physical Function Influences on Stair Climbing Ability 1 Month after Total Knee Arthroplasty
9:00AM-11:00AM
Abstract Number: 98
Presence of Apoptotic Microparticle Containing Immune Complexes in Asymptomatic ANA+ Individuals Despite the Absence of Inflammation
9:00AM-11:00AM
Abstract Number: 664
Prevalence and Factors Associated with Peripheral Manifestations in Spondyloarthritis. an Ancillary Analysis of the ASAS-Comospa Study
9:00AM-11:00AM
Abstract Number: 752
Prevalence and Predictors of Peripheral Vascular Disease in a Cohort of Systemic Lupus Erythematosus (SLE) Patients
9:00AM-11:00AM
Abstract Number: 536
Prevalence and Relative Factors for Frailty in Patients with RA from a Prospective Observational Study
9:00AM-11:00AM
Abstract Number: 259
Prevalence of Attention Deficit Hyperactivity Disorder Among Patients with Fibromyalgia
9:00AM-11:00AM
Abstract Number: 705
Prevalence of Cervical Human Papillomavirus Infection in Women with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
9:00AM-11:00AM
Abstract Number: 804
Prevalence of Echocardiographic Abnormalities in Patients with Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 813
Prevalence of Gastroesophageal Disease in Systemic Sclerosis and Its Impact on Lung Disease: Fact or Fiction
9:00AM-11:00AM
Abstract Number: 430
Prevalence of Intra-Articular Mineralization on Knee CT in Persons with or at Risk of Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 541
Prevalence of Sjögren’s Syndrome in Patients with RA Enrolled in a Large Observational US Registry
9:00AM-11:00AM
Abstract Number: 830
Primary Central Nervous System Vasculitis with Tumor-like Presentation
9:00AM-11:00AM
Abstract Number: 470
Pro-Inflammatory High Density Lipoprotein Function Is Associated with Accelerated Carotid Intimal Medial Thickness Progression in Childhood-Onset SLE
9:00AM-11:00AM
Abstract Number: 783
Procalcitonin and CXCL9 As Potential Biomarkers for Pneumonia in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1
Profiling of B-Cell Related Factors and Its Decoy Receptors in Rheumatoid Arthritis: Potential Clues for Patient Stratification
9:00AM-11:00AM
Abstract Number: 453
Profound Changes in the NaV1.8 Nociceptive Innervation of the Murine Knee Joint after Destabilization of the Medial Meniscus
9:00AM-11:00AM
Abstract Number: 169
Prognosis of Patients with Antiphospholipid Syndrome Nephropathy
9:00AM-11:00AM
Abstract Number: 802
Prognostic Significance of Bicaudal D2 Antibodies in Sistemic Sclerosis (SSc) Patients
9:00AM-11:00AM
Abstract Number: 528
Progression in Interstitial Lung Disease – Comparison of Rheumatoid Arthritis with Idiopathic Pulmonary Fibrosis
9:00AM-11:00AM
Abstract Number: 660
Progression of Radiographic Sacroiliitis in Patients with Axial Spondyloarthritis from the Assessment of Spondyloarthritis International Society Cohort on Central Reading – Five-Year Data
9:00AM-11:00AM
Abstract Number: 668
Progression of Unilateral Grade 2 Sacroiliitis in a Psoriatic Arthritis Cohort
9:00AM-11:00AM
Abstract Number: 799
Progressive Lung Fibrosis in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the Eustar Database
9:00AM-11:00AM
Abstract Number: 745
Prolonged Remission and Influence on Damage Accrual and Infection for Patients with Systemic Lupus Erythematosus: A Multi-Center Cohort Study from China
9:00AM-11:00AM
Abstract Number: 12
Protein Phosphatase 2A, a Serine/Threonine Phosphatase, Is Essential for Optimal B Cell Function
9:00AM-11:00AM
Abstract Number: 761
Protein/Creatinin Urinary Index Has Concordance with 24 Hour Urinary Proteinuria in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 348
Psychometric Validation of the Arthritis Helplessness Index in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 252
Publication Bias Regarding Scientific Studies about Fibromyalgia
9:00AM-11:00AM
Abstract Number: 378
Pulmonary Hypertension in Anti-Synthetase Syndrome
9:00AM-11:00AM
Abstract Number: 401
Quality of Systematic Reviews Comparing Conventional Vs. Computer-Assisted Joint Replacement
9:00AM-11:00AM
Abstract Number: 675
Quantitative Ultrasound of the Calcaneus Has a Role to Play in Detecting Low Bone Mineral Density in Axial Spondyloarthropathy Patients
9:00AM-11:00AM
Abstract Number: 530
RA-Voice: Evaluating Laryngeal Involvement in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 263
Racial Disparities in Total Knee Replacement Failure Are Not Explained By Poverty
9:00AM-11:00AM
Abstract Number: 559
Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 662
Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab for up to 3 Years
9:00AM-11:00AM
Abstract Number: 778
Rates of Herpes Zoster Virus Infection in SLE Patients on Immunosuppression
9:00AM-11:00AM
Abstract Number: 231
Rates of Influenza Vaccination in a Cohort of Patients with Rheumatoid Arthritis and Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 459
Readmission Rate within 30 Days of Hospitalization Due to New Onset Lupus Nephritis and Associated Risk Factors: The Importance of Intravenous Pulse Methylprednisolone Therapy
9:00AM-11:00AM
Abstract Number: 688
Real Life Analysis of a Latin America Tertiary Spondyloarthritis Single-Center: High Frequency of Peripheral Involvement and Use of Synthetic Dmard
9:00AM-11:00AM
Abstract Number: 645
Real World Secukinumab Study in Ankylosing Spondylitis and Psoriatic Arthritis – Comorbidities and Extraarticular Manifestations: Incidence and Status throughout a Non-Interventional Study in Germany
9:00AM-11:00AM
Abstract Number: 598
Real-World Experience of Effectiveness and Safety of Certolizumab Pegol for Rheumatoid Arthritis in Japan: Single-Center Retrospective Study
9:00AM-11:00AM
Abstract Number: 629
Real-World Use of Tofacitinib Compared with Tumor Necrosis Factor Inhibitors in a Cohort of 211 Patients with Rheumatoid Arthritis: Data from a Drug-Based Registry Study in Taiwan
9:00AM-11:00AM
Abstract Number: 711
Recurrence of Lupus Nephritis in Renal Transplant Recipients
9:00AM-11:00AM
Abstract Number: 167
Recurrent Thrombosis in Patients with Antiphospholipid Antibodies Following an Initial Venous or Arterial Thromboembolic Event
9:00AM-11:00AM
Abstract Number: 101
Regulation of Monocyte Function By Epstein Barr Virus Interleukin-10 (vIL10) in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 432
Relation of Patellofemoral Joint Alignment, Morphology, and Radiographic Osteoarthritis to Frequent Anterior Knee Pain
9:00AM-11:00AM
Abstract Number: 532
Relationship between Insulin Sensitivity and Beta Cell Secretion in Non-Diabetic Rheumatoid Arthritis Subjects
9:00AM-11:00AM
Abstract Number: 264
Relationships between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 663
Relative Contributions of Improvements in the Psoriasis Area and Severity Index (PASI) and Disease Activity Index for Psoriatic Arthritis (DAPSA) to Improvements in Quality of Life and Function in Patients with Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 164
Reliability of Lupus Anticoagulant and Anti-Phosphatidylserine/Prothrombin Autoantibodies in Antiphosphospholipid Syndrome: A Multicenter Study
9:00AM-11:00AM
Abstract Number: 643
Remission in Psoriatic Arthritis: Definition and Predictors
9:00AM-11:00AM
Abstract Number: 636
Remission/Low Disease Activity Is a Reasonable Treatment Target in Psa: Results from a Routine Care European Cohort of Psa Patients Treated with Ustekinumab or TNF Inhibitors
9:00AM-11:00AM
Abstract Number: 8
Repertoire Studies in Rheumatoid Arthritis Reveal B-Cell Distortions and Baseline Shifts in Unmutated IgG
9:00AM-11:00AM
Abstract Number: 57
Repository Corticotropin Injection (H.P. Acthar® Gel) Inhibits Bone Degradation in Rat Adjuvant-Induced Arthritis Model
9:00AM-11:00AM
Abstract Number: 226
Representation of Elderly People and Women in Rheumatoid Arthritis and Osteoarthritis Trials: A Systematic Review and Meta-Analysis Comparing Clinical Trials with Population-Based Studies
9:00AM-11:00AM
Abstract Number: 354
Rheumatic Complications of Immune Checkpoint Inhibitor Therapy: A Single Center Experience
9:00AM-11:00AM
Abstract Number: 351
Rheumatic Immune-Related Adverse Events in Patients on ANTI-PD-1 Inhibitors: Fasciitis with Myositis Syndrome As a New Rheumatic Complication of Immunotherapy
9:00AM-11:00AM
Abstract Number: 79
Rheumatoid Arthritis (RA)-Associated Autoantibodies Are Present in the Periodontal Exudate of Patients with and without RA
9:00AM-11:00AM
Abstract Number: 484
Rheumatoid Arthritis Patients Have Lower Preoperative Expectations but Greater Clinical Improvement after Total Knee Arthroplasty Compared to Osteoarthritis Patients
9:00AM-11:00AM
Abstract Number: 227
Rheumatoid Arthritis Patients Treated with Abatacept, Rituximab and Tocilizumab in Denmark and Sweden: Risk of Serious Infections
9:00AM-11:00AM
Abstract Number: 87
Rheumatoid Arthritis Patients with Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity
9:00AM-11:00AM
Abstract Number: 603
Rheumatologists Beliefs in the Effectiveness of Other Methotrexate-Based Treatment Approaches May Explain the Low Use of Triple Therapy: A Bayesian Belief Elicitation
9:00AM-11:00AM
Abstract Number: 301
Rheumatology Clinic Staff Needs for Partnering to Improve Blood Pressure and Tobacco Risk Management
9:00AM-11:00AM
Abstract Number: 389
Risk Factors Associated with Mortality in Inflammatory Myositis: An Asian Perspective
9:00AM-11:00AM
Abstract Number: 361
Risk Factors of Immune-Related Adverse Events in Patients Treated with Anti-Programmed Cell Death 1 Antibody Pembrolizumab
9:00AM-11:00AM
Abstract Number: 379
Risk Factors of Venous Thromboembolism in Idiopathic Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 202
Risk of Inflammatory Arthritis Development in the Family Members of Indigenous North American (INA) RA Patients
9:00AM-11:00AM
Abstract Number: 218
Risk of Serious Infection Associated with TNF Inhibitor Versus Triple Therapy in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 224
Risk of Venous Thrombotic Events in Rheumatoid Arthritis Patients Initiating Tofacitinib or Adalimumab
9:00AM-11:00AM
Abstract Number: 370
Rituximab in Idiopathic Retroperitoneal Fibrosis
9:00AM-11:00AM
Abstract Number: 24
Rituximab Induces an Early Re-Assessment of the Immune and Vascular Systems in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 827
Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes and Adverse Events
9:00AM-11:00AM
Abstract Number: 174
Rivaroxaban Versus Warfarin As Secondary Thromboprophylaxis in Patients with Antiphospholipid Syndrome: A Randomized, Multicenter, Open-Label, Clinical Trial
9:00AM-11:00AM
Abstract Number: 7
RNA Sequencing Detection of Gene Dysregulation in B Cells Sorted from Salivary Gland Tissue and from Peripheral Blood Reveals New Pathways Involved in Primary Sjögren’s Syndrome Pathophysiology
9:00AM-11:00AM
Abstract Number: 129
Rnaseq Analysis of Human Skin in Organ Culture Identifies Collagen 22A1 As a TGF-β Early Response Gene
9:00AM-11:00AM
Abstract Number: 6
Ro52/Trim21 Influences Follicular B Cell Homeostasis and Immunoglobulin Production
9:00AM-11:00AM
Abstract Number: 413
S100A8 & S100A9: Alarmin Mediated Inflammation in Tendinopathy
9:00AM-11:00AM
Abstract Number: 791
Safety and Suitability of a Direct Thrombin Inhibitor, Dabigatran Etexilate, in Scleroderma-Associated Interstitial Lung Disease (SSc-ILD) Patients
9:00AM-11:00AM
Abstract Number: 360
Sarcoidosis Induced By Immune Check Point Inhibitors
9:00AM-11:00AM
Abstract Number: 465
Seasonal Variation in Cutaneous Flares for Pediatric Lupus
9:00AM-11:00AM
Abstract Number: 489
Self-Reported Depression in Patients with Rheumatoid Arthritis Is Undertreated and Associated with Poorer Clinical Status and Lower Rates of Remission in Routine Care
9:00AM-11:00AM
Abstract Number: 715
Septic Shock Among Patients with Systemic Lupus Erythematosus: Short and Long-Term Outcome and Cost. Analysis of the French Nationwide Database
9:00AM-11:00AM
Abstract Number: 735
Serum Albumin at One Year Predicts Long-Term Renal Outcome
9:00AM-11:00AM
Abstract Number: 172
Serum Chemokines and miRNA Levels and Its Association with Cumulative Organ Damage in Patients with Antiphospholipid Syndrome: A Bench to Bedside Study
9:00AM-11:00AM
Abstract Number: 341
Setting Treatment Target for Joint Surgery in Lower Limbs in Patients with Long-Standing Rheumatoid Arthritis Based on Multicenter Prospective Cohort Study; Validation and Reliability of Objective Index of Activity Speed (Timed Up and Go test) for Measuring Physical Function
9:00AM-11:00AM
Abstract Number: 390
Severe Axial and Pelvifemoral Muscle Damage in Immune-Mediated Necrotizing Myopathy Evaluated By Whole-Body MRI
9:00AM-11:00AM
Abstract Number: 108
Sex-Specific Expression of CXorf21 Provide Molecular Explanation for the Fundamental Difference in Male and Female Immune Response: An Explanation for Female-Bias SLE Pathogenesis
9:00AM-11:00AM
Abstract Number: 385
Sexual Dysfunction in Female Patients with Idiopathic Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 810
Sexual Dysfunction in Women with Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 13
Shared Genetic Origins Among Anti-Proteinase 3 and Anti-Glomerular Basement Membrane Double-Positive Human Autoantibodies
9:00AM-11:00AM
Abstract Number: 262
Shedding Light on Fibromyalgia: Emotional Regulation Processes and Executive Functions Join Together
9:00AM-11:00AM
Abstract Number: 5
Short Chain Fatty Acid Acetate Induces Regulatory B Cells in Mice and Humans, Which Can Protect Against Arthritis
9:00AM-11:00AM
Abstract Number: 428
Significant Pain Reduction with Oral Methotrexate in Knee Osteoarthritis; Results from a Randomised Controlled Phase III Trial of Treatment Effectiveness
9:00AM-11:00AM
Abstract Number: 606
Similiar Efficacy of Tofacinitib on Disease Activity in Rheumatoid Arthritis Patients with and without Previous Biologicals; Results from the Turkbio Regıstry
9:00AM-11:00AM
Abstract Number: 781
Simultaneous Identification of Two Biomarkers in ACTIVE LUPUS Nephritis: Autophagy in Treg CELLS and Prolactin Receptors in B Lymphocytes
9:00AM-11:00AM
Abstract Number: 77
Single Nucleotide Polymorphism in the Gene Encoding Peptidylarginine Deiminase 4 Correlates with Reduced Neutrophil Extracellular Traps and Anti-Histone Antibodies in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 110
Single-Cell RNA-Seq Analysis of ANA+ Healthy and SLE Patients Show Variations in Activated Stress Response and Regulatory Pathways
9:00AM-11:00AM
Abstract Number: 144
Small Molecule Inhibitor of Bcl-6 Reduces the Tfh Population in Peripheral Blood, Splenic Germinal Center and Ankle Joints in a Collagen-Induced Arthritis Mouse Model of RA
9:00AM-11:00AM
Abstract Number: 345
Snap Crackle Pop: Healing the Cracks in Our Referral Process, Helping Pediatric Rheumatology Patients Get Care Sooner
9:00AM-11:00AM
Abstract Number: 274
Socioeconomic Disparities in Disease Activity in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 716
Soluble CD163 Is a Biomarker Associated with Accelerated Carotid Atheroma in SLE Patients at Otherwise Low Risk for Cardiovascular Disease
9:00AM-11:00AM
Abstract Number: 713
Soluble ST2 and CXCL-10 May Serve As Biomarkers of Diastolic Dysfunction in SLE and Correlate with Disease Activity and Damage
9:00AM-11:00AM
Abstract Number: 683
Spanish Validation of the Gepard Questionnaire for the Detection of Psoriatic Arthritis in Argentinean Patients with Psoriasis
9:00AM-11:00AM
Abstract Number: 768
Spinal Cord Syndromes Associated with Systemic Lupus Erythematous: Differentiating Lupus Myelitis, Neuromyelitis Optica, and Multiple Sclerosis
9:00AM-11:00AM
Abstract Number: 634
Spinal Mobility Measures Allow Discrimination of Subgroups of Different Activity and Severity in Early Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 408
State or Trait: Pain Catastrophizing and Widespread Pain Following TKR and Their Associations with Pain Relief
9:00AM-11:00AM
Abstract Number: 623
Step-Down-Bridge Versus Tight-Step-up Therapy in Patients with Early Rheumatoid Arthritis Lacking Poor Prognostic Factors: An Economic Point of View
9:00AM-11:00AM
Abstract Number: 481
Stepping It up: The Use of Physical Activity Monitors As an Outcome Measure in Juvenile Myositis
9:00AM-11:00AM
Abstract Number: 462
Steroid Use in Pediatric Proliferative Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 677
Structural Damage Characteristics of Patients with Ankylosing Spondylitis in China
9:00AM-11:00AM
Abstract Number: 436
Structural Effects of Intra-Articular Sprifermin in Symptomatic Radiographic Knee Osteoarthritis: A Post-Hoc Analysis of Cartilage Morphology over the 2-Year Treatment-Period of a 5-Year Randomized, Placebo-Controlled, Phase II Study
9:00AM-11:00AM
Abstract Number: 309
Sub-Clinical Disease Activity in the Feet of Patients with Early Rheumatoid Arthritis: What Clinical Assessments Miss
9:00AM-11:00AM
Abstract Number: 707
Subclinical Parameters of Arterial Stiffness and Arteriosclerosis Correlate with QRISK3 in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 690
Subcutaneous Secukinumab Provides Sustained Inhibition of Radiographic Progression in Patients with Active Psoriatic Arthritis: 52-Week Results from a Phase 3 Study
9:00AM-11:00AM
Abstract Number: 573
Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis
9:00AM-11:00AM
Abstract Number: 166
Superior Sensitivity for Detection of Primary Antiphospholipid Syndrome By a 9-Test Panel in Patients with Deep Venous Thrombosis, Pulmonary Embolism, and Stroke or Transient Ischemic Attack
9:00AM-11:00AM
Abstract Number: 616
Supplementation of Methotrexate (MTX) with Ticagrelor Therapy Suppresses Disease Activity in Patients with Moderate to Very Active Ra; Further Evidence That Adenosine and Its Receptors Mediate the Anti-Inflammatory Activity of MTX
9:00AM-11:00AM
Abstract Number: 66
Suppression of Inflammatory Arthritis, in Human Paraoxonase 1 Transgenic Mice, Correlates with Upregulation of the Hepatic Glutathione Pathway and Reduction of Bioactive Lipid Mediators
9:00AM-11:00AM
Abstract Number: 823
Survival of Biopsy Proven Giant Cell Arteritis in Northern Italy: Correlation with Clinical, Laboratory and Histopathological Findings
9:00AM-11:00AM
Abstract Number: 179
Swimming Against the Stream- the Fishbowl Discussion Method As an Interactive Tool for Medical Conferences – Experiences from the 11. European Lupus Meeting
9:00AM-11:00AM
Abstract Number: 322
Swollen Joint Count Vs. RAPID3: Why a Discrepancy in Remission State?
9:00AM-11:00AM
Abstract Number: 368
Synovianalysis Using Leukocyte Esterase Reagent Strips
9:00AM-11:00AM
Abstract Number: 395
Systemic Lupus Erythematosus (SLE) with Inflammatory Myositis
9:00AM-11:00AM
Abstract Number: 32
T Cell-Intrinsic Nod2 Protects Against Th17-Mediated Autoimmune Arthritis in SKG Mice
9:00AM-11:00AM
Abstract Number: 147
T Follicular Helper Cell Phenotype in RA Patients Receiving Rituximab
9:00AM-11:00AM
Abstract Number: 625
Tapering of Biological Antirheumatic Drugs in Rheumatoid Arthritis Patients Is Achievable and Cost Effective in Daily Clinical Practice: DATA from the Brussels UCL RA Cohort
9:00AM-11:00AM
Abstract Number: 119
Targeting Dysregulated CD38/NAD+ Homeostasis Mitigates Multiple Organ Fibrosis
9:00AM-11:00AM
Abstract Number: 41
TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Improves Bone Strength in Mouse Model for Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 293
Temporal Trends and Factors Associated with Bisphosphonate Drug Holidays
9:00AM-11:00AM
Abstract Number: 307
Tenosynovitis on MRI of Bilateral Hands and Its Concordance with Joint Swelling/Tenderness in Patients with Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 186
The Accuracy and Potential Impact of a Diagnostic Decision Support System in Rare Disease Cases
9:00AM-11:00AM
Abstract Number: 416
The Association of Biomechanical Change and Pain Catastrophizing with the Chronic Low Back Pain
9:00AM-11:00AM
Abstract Number: 426
The Association of Dietary Patterns with Knee Symptoms and MRI Detected Structures in Patients with Knee Osteoarthritis (OA)
9:00AM-11:00AM
Abstract Number: 482
The Association of Short-Term Ultraviolet Radiation Exposure and Calcinosis in Juvenile Dermatomyositis in the Childhood Arthritis & Rheumatology Research Alliance Registry
9:00AM-11:00AM
Abstract Number: 717
The Burden of Chronic Kidney Disease in Systemic Lupus Erythematosus (SLE): A Nationwide Epidemiologic Study
9:00AM-11:00AM
Abstract Number: 721
The Burden of Renal Arteriosclerosis in Lupus Nephritis: A Cohort Study Examining Prevalence and Predictors of Renal Arteriosclerosis
9:00AM-11:00AM
Abstract Number: 626
The Comparative Effectiveness of Cycling Tumor Necrosis Factor Inhibitor (TNFi) Versus Swapping to a Nontnfi on Patient-Reported Functional Ability of Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 615
The Comparative Observational Study about Efficacy, Safety and Adherence between Tocilizumab and Infliximab in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 373
The Effect of an Intensive Controlled 6-Moth Exercise Program with Subsequent 6-Month Follow-up Period in Patients with Idiopathic Inflammatory Myopathies – Preliminary Data
9:00AM-11:00AM
Abstract Number: 223
The Effect of Concomitant Diabetes on RA-Related Outcomes: Results from the Acr’s RISE Registry
9:00AM-11:00AM
Abstract Number: 633
The Effect of Guselkumab on Dactylitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 278
The Effect of Patient, Prescriber and Region on the Initiation of First Biologic for Rheumatoid Arthritis: A Longitudinal Population Study
9:00AM-11:00AM
Abstract Number: 268
The Effect of Renaming Gout to Urate Crystal Arthritis on Illness and Treatment Perceptions in Māori (the Indigenous People of Aotearoa/New Zealand)
9:00AM-11:00AM
Abstract Number: 256
The Effectiveness of Medications for Fibromyalgia Based on Patient Experiences
9:00AM-11:00AM
Abstract Number: 807
The Effects of DNA Methylation on Differential Expression in Dermal Fibroblasts from African-American Patients with Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 173
The Efficacy of Treatment with Low Dose Aspirin and Low Molecular Weight Heparin in Pregnant Women with Criteria Anti-Phospholipid Antibodies
9:00AM-11:00AM
Abstract Number: 486
The Electrophysiologic and Sonographic Evaluation of Peripheral Nerves in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 248
The Emotional Quotient in Fibromyalgia Patients Is Similar to Rheumatic Disease Controls
9:00AM-11:00AM
Abstract Number: 451
The Frequency of Neuropathic Pain in Patients with Low Back Pain and the Relationship with Demographic Characteristics: A Cross-Sectional Study
9:00AM-11:00AM
Abstract Number: 159
The Frequency of Screening and Prevalence of Antiphospholipid Antibodies in the General Population
9:00AM-11:00AM
Abstract Number: 178
The Impact of a Novel Immune Related Adverse Event Tumor Board on Interprofessional Clinical Confidence and Collaboration
9:00AM-11:00AM
Abstract Number: 330
The IMPACT of a Referral Algorithm for Axial Spondyloarthritis: Four Month Follow-up in Patient Reported Outcomes
9:00AM-11:00AM
Abstract Number: 557
The Impact of Comedication with Conventional Synthetic Dmards on Drug Retention and Clinical Effectiveness of Tofacitinib, Anti–Tumor Necrosis Factor Therapy and Biologics with an Alternative Mode of Action in Patients with Rheumatoid Arthritis. a Cohort Study
9:00AM-11:00AM
Abstract Number: 2
The Influence of Abatacept on Human B Cell Functions
9:00AM-11:00AM
Abstract Number: 747
The Influence of Depression on Clinical Features of Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 96
The Liver X Receptor Modulates Inflammatory Cytokines Based on Lxrα Polymorphism in Monocyte-Derived Macrophages and Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 464
The Long Term Outcomes in Chinese Children Diagnosed with Systemic Lupus Erythematosus and Biopsy Proven Lupus Nephritis – a 18-Year Cohort
9:00AM-11:00AM
Abstract Number: 254
The Lumbar Spine Is Straight in Fibromyalgia Patients
9:00AM-11:00AM
Abstract Number: 521
The Lung in an English Cohort of Rheumatoid Arthritis Patients – an Overview of Different Types of Involvement and Treatment
9:00AM-11:00AM
Abstract Number: 809
The Lymphangiogenetic Factors VEGF-C, CCL21 and Ang-2 Are Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 708
The Montreal Cognitive Assessment Test. a Useful Tool in Screening of Cognitive Impairment in Patients with Systemic Lupus Erythematosusshort Title: Cognitive Impairment in SLE
9:00AM-11:00AM
Abstract Number: 327
The Patient Global Assessment and Common Composite Disease Activity Measures Vary Minimally When Patients Reflect on Their Arthritis or Their Global Health: Results from the Canadian Early Arthritis Cohort Study
9:00AM-11:00AM
Abstract Number: 36
The Pleiotropic Effects of TAM Signaling on Inflammatory Arthritis in Mice Using Kbxn Serum Transfer Induced Arthritis
9:00AM-11:00AM
Abstract Number: 429
The Potential Clinical Relevance of Imaging Biomarker Data from Short-Term Interventional Trials in Osteoarthritis: A Comparison of the Cathepsin K Inhibitor Miv-711 Phase 2a MRI Knee Joint Data and KL-Matched 5577 Knee Control Data from the Osteoarthritis Initiative
9:00AM-11:00AM
Abstract Number: 441
The Presence of Neuropathic Pain Does Not Influence the Response to Hyaluronic Acid (HA) in Patients with Knee Osteoarthritis but HA Injections Modify Pain Phenotype
9:00AM-11:00AM
Abstract Number: 523
The Prevalence and Clinical Characteristics of Rheumatoid Arthritis with Interstitial Lung Disease in the San Joaquin Valley of Central California
9:00AM-11:00AM
Abstract Number: 467
The Prevalence and Clinical Features of Co-Occurring Autoimmunity in Children with Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry
9:00AM-11:00AM
Abstract Number: 286
The Prevalence and Treatment Patterns of Women of Childbearing Age with Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 789
The Relationship between YKL-40 and Vascular Endothelial Growth Factor in Angiogenesis in Systemic Sclerosis Patients
9:00AM-11:00AM
Abstract Number: 28
The Rho Kinase Family Member, ROCK2, Promotes Germinal Center Responses and Is Required for Optimal Humoral Immunity
9:00AM-11:00AM
Abstract Number: 83
The Risk of Developing Rheumatoid Arthritis Based on HLA-DQ Genotypes
9:00AM-11:00AM
Abstract Number: 237
The Risk of Serious and Opportunistic Infections in Rheumatologic Patients on Interleukin Inhibitors: A Systematic Review and Meta-Analysis
9:00AM-11:00AM
Abstract Number: 130
The Role of Cofilin, an Actin Associated Protein, in Activation of Systemic Sclerosis Vascular Smooth Muscle Cells
9:00AM-11:00AM
Abstract Number: 585
The Role of Genetic Polymorphisms on the Response to Methotrexate Variations Among Rheumatoid Arthritis Patients in Saudi Arabia
9:00AM-11:00AM
Abstract Number: 306
The Role of Inflammation in the Evolution of MRI Erosions in the Feet of Patients with Early RA
9:00AM-11:00AM
Abstract Number: 734
The Role of Micro-RNA 142-3p Expression in Lupus Nephritis in an Egyptian Cohort
9:00AM-11:00AM
Abstract Number: 587
The Superiority of a Treat to Target Strategy over Conventional Treatment with Fixed Csdmard and Corticosteroids: A Multi-Centre Randomized Controlled Trial in RA Patients with Inadequate Response to Conventional Synthetic Dmards, and a New Therapy with Certolizumab Pegol
9:00AM-11:00AM
Abstract Number: 310
The Trajectory of Grade 1 Erosions in the Feet of Patients with Early RA
9:00AM-11:00AM
Abstract Number: 198
The Utility of a Coloring Book As an Adjunct Tool to Teach Musculoskeletal Sonoanatomy: A Pragmatic Randomized Control Trial
9:00AM-11:00AM
Abstract Number: 282
The Utility of Positive ANA Referrals at the University of Chicago
9:00AM-11:00AM
Abstract Number: 303
The Value of the Simplified Ramris-5 in Early RA Patients Under Methotrexate Therapy Using High Field MRI
9:00AM-11:00AM
Abstract Number: 371
Therapeutic Efficacy and Safety of Iguratimod in Treating Mild IgG4-Related Diseases
9:00AM-11:00AM
Abstract Number: 324
Three Health It Interventions Increased Documentation of RA Disease Activity Scores in an Academic Rheumatology Clinic: Results from an Interrupted Time Series Study
9:00AM-11:00AM
Abstract Number: 555
Three Year Outcomes of Patients with Elderly-Onset Rheumatoid Arthritis Treated with a Therapeutic Strategy Targeting Low Disease Activity, and Impact of Adverse Events on Physical Function
9:00AM-11:00AM
Abstract Number: 539
Thyroid Function in Early Versus Established Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 575
Time to Discontinuation of Biologic Therapy By Mechanism of Action in Rheumatoid Arthritis: Results from a Rheumatoid Arthritis Cohort
9:00AM-11:00AM
Abstract Number: 448
Tizanidine, a Frequently Used Muscle Relaxant, Is Associated with Severe Hypotension: Role of Cytochrome P450 1A2 Inhibition in Routine Clinical Practice
9:00AM-11:00AM
Abstract Number: 692
TNF Inhibitor Dose Tapering in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis
9:00AM-11:00AM
Abstract Number: 233
TNF Inhibitors: Prevalence of Use and Predictors of Treatment Non-Persistence in the 2011-2016 Medicare Population
9:00AM-11:00AM
Abstract Number: 63
TNF-α Blockade Incompletely Reverses Inflammatory Pulmonary Pathology in the TNF-Transgenic Mouse Model of Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 767
Tobacco and Systemic Lupus Erythematosus Relationships: Pay Attention to the Retina!
9:00AM-11:00AM
Abstract Number: 49
Tofacitinib Facilitates the Expansion of Myeloid-Dirived Suppressor Cells and Ameliorates Interstitial Lung Disease in SKG Mice
9:00AM-11:00AM
Abstract Number: 27
Top-Down Proteomics Coupled with Antibody Sequencing from Single B Cells Reveals a Monoclonal Anti-Sm Clone Present in the Serum of an SLE Patient over Three Years
9:00AM-11:00AM
Abstract Number: 444
Trajectories of Sport or Recreational Activities over Eight Years and Associated Factors in Persons at Risk for Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 803
Treating Interstitial Lung Disease and Skin Involvement in Systemic Sclerosis with Oral Versus Intravenous Cyclophosphamide: Preliminary Efficacy and Safety Data from 2 Randomized Clinical Trials and 1 Registry
9:00AM-11:00AM
Abstract Number: 556
Treatment Initiation and Duration in DMARD Naïve Rheumatoid Arthritis Patients: Analysis of US Health Plan Claims
9:00AM-11:00AM
Abstract Number: 23
Treatment with Immune Checkpoint Inhibitors and the Development of Autoantibodies
9:00AM-11:00AM
Abstract Number: 434
Trends in Procedure Type, Patient Characteristics, and Outcomes Among Persons with Knee Osteoarthritis Undergoing Bariatric Surgery, 2005-2014
9:00AM-11:00AM
Abstract Number: 498
Trends in the Incidence of Cardiovascular Diseases in Patients with Rheumatoid Arthritis in Spain: A National Observational Cohort Study of Hospital Discharges
9:00AM-11:00AM
Abstract Number: 493
Trends in the Incidence of SOLID Tumors in Patients with Rheumatoid Arthritis in Spain. a National Observational Cohort Study
9:00AM-11:00AM
Abstract Number: 695
Tumor Necrosis Factor Inhibitor Persistence and Reasons for Discontinuation in US Veterans with Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 738
Two Clinical Phenotypes of Chinese SLE-PAH Patients
9:00AM-11:00AM
Abstract Number: 538
Type 1 Diabetes in RA: Comparison with Type 2 and Its Association with RA Severity and Treatment
9:00AM-11:00AM
Abstract Number: 91
Type I IFN Production Is Induced By Non-Haematopoietic Tissue Cells but Not Plasmacytoid Dendritic Cells in Preclinical Autoimmunity and SLE
9:00AM-11:00AM
Abstract Number: 561
U-Act-Early Trial 3 Years Follow-up: Radiographic Joint Damage and Use of Bdmards over 5 Years in Early RA Patients Treated-to-Target with Strategies Initiating Tocilizumab, Methotrexate or Their Combination
9:00AM-11:00AM
Abstract Number: 225
U.S. Trends in Hospitalization Rates and Causes and in-Hospital Mortality in Rheumatoid Arthritis Patients, 2000-2014
9:00AM-11:00AM
Abstract Number: 678
Ultrasonographic Evaluation of Achilles Tendon in Early Axial Spondyloarthropathy: Is There Any Difference between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthropathy?
9:00AM-11:00AM
Abstract Number: 679
Ultrasonographic Research of the Relationship between Nail Disorders and Peripheral Arthritis or Enthesitis in Patients with Psoriasis and Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 109
Unique miRNA Signatures Detected in Extracellular Vesicles from Patients with Systemic Lupus Erythematous
9:00AM-11:00AM
Abstract Number: 409
Unique Skeletal Muscle Relaxant Tolperisone in a Crossover Driving Simulation Study: No Evidence of Sedation Compared to Cyclobenzaprine and Placebo
9:00AM-11:00AM
Abstract Number: 571
United States Rheumatology Practice-Based Real-World Evidence of Methotrexate Utilization and Response to Therapy in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab
9:00AM-11:00AM
Abstract Number: 680
Unmet Needs in the Treatment of Ankylosing Spondylitis. a Long-Term Observational Study from a Single University Center
9:00AM-11:00AM
Abstract Number: 549
Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry
9:00AM-11:00AM
Abstract Number: 757
Urinary Galectin-3 Binding Protein As a Novel Biomarker of Renal Disease Activity in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 739
Urine and Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Differentially Correlates with Renal and Non-Renal Systemic Lupus Erythematosus (SLE): A Prospective, Case-Control Study
9:00AM-11:00AM
Abstract Number: 780
Urine Metabolomic Profile in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 334
Use of Handheld Device to Enhance Patient Reported Outcome Measure Data Collection in an Academic Rheumatology Practice
9:00AM-11:00AM
Abstract Number: 329
Use of Inter-Professional Collaboration to Improve Adherence to American College of Rheumatology Recommendations for Use of Disease Activity Measures
9:00AM-11:00AM
Abstract Number: 344
Use of Lean Six-Sigma Methodologies to Improve Pneumococcal Vaccination Rates Among Immunocompromised Veterans with Rheumatologic Diseases: A Quality Improvement Project
9:00AM-11:00AM
Abstract Number: 819
Use of Takayasu Arteritis Damage Score (TADS) to Measure Damage in Takayasu Arteritis
9:00AM-11:00AM
Abstract Number: 251
Using the Stroop Word Naming Test and the Mental Clutter Scale in Fibromyalgia Patients to Evaluate the Symptoms of Fibrofog. in Office Testing of Cognitive Complaints
9:00AM-11:00AM
Abstract Number: 647
Validation of a New Electronic Spinal Mobility Index for Patients with Axial Spondyloarthritis Based on Inertial Motion Unit (IMU) Sensors
9:00AM-11:00AM
Abstract Number: 653
Validation of Assessments in Spondyloarthritis International Society MRI Lesion Definitions in Axial Spondyloarthritis: Data from the Echography in Spondyloarthritis Cohort
9:00AM-11:00AM
Abstract Number: 458
Validation of the 2012 Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria Compared to the 1997 Acr Criteria and 2017 Candidate Weighted Criteria for Lupus in Pediatric Patients
9:00AM-11:00AM
Abstract Number: 200
Validation of the Ers-RA Risk Score in a Dutch Population
9:00AM-11:00AM
Abstract Number: 671
Validation of the Rexspa (Reductive X-Ray Score for Psoriatic Arthritis) in an Argentinean Cohort of Patients with Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 302
Validity and Responsiveness of Inflammation and Joint Damage Scores Based on the Omeract Rheumatoid Arthritis MRI Scoring System
9:00AM-11:00AM
Abstract Number: 279
Variations and Disparities in Healthcare Teams Among Individuals with Lupus
9:00AM-11:00AM
Abstract Number: 504
Views of Primary Care Physicians and Rheumatologists Regarding Screening and Management of Hyperlipidemia Among Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 222
Viral Exposures As a Risk Factor for Rheumatoid Arthritis: Summarizing the Evidence
9:00AM-11:00AM
Abstract Number: 818
Visual Involvement in Giant Cell Arteritis: A Prospective Multi Center Study
9:00AM-11:00AM
Abstract Number: 503
Waist Circumference Based Abdominal Obesity Versus Body Mass Index in Rheumatoid Arthritis: Influence on the Risk of Diabetes and Cardiovascular Disease
9:00AM-11:00AM
Abstract Number: 438
What Characterizes Osteoarthritis: Ultrasound-Detected Inflammation but Not Osteophytes Is More Common in Hand Osteoarthritis Than in Painless Bony Enlargements
9:00AM-11:00AM
Abstract Number: 421
What Do Patients with Osteoarthritis Think of Their Preoperative Education before Total Hip Replacement Surgery:Qualitative Study
9:00AM-11:00AM
Abstract Number: 656
What Is the Level of Agreement between Local and Central Readers in the Detection of Active and Structural MRI Lesions Typical of Axial Spondyloarthritis? Data from the Assessments in Spondyloarthritis Classification Cohort Study
9:00AM-11:00AM
Abstract Number: 76
Whole Blood Targeted Bisulfite Pyrosequencing Identifies Differentially Methylated Regions within Major Histocompatibility Complex (MHC) of Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 228
Widespread Chronic Use of Proton-Pump Inhibitors and Potential for Drug-Drug Interactions in Rheumatoid Arthritis and Lupus Patients
9:00AM-11:00AM
Abstract Number: 753
Young SLE Patients Have Higher Coronary Artery Calcium Scores Compared with Population Controls
11:00AM-12:30PM
Abstract Number: 838
Efficacy and Safety of Combined Immunosuppressive Therapy with High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Disease Accompanied By Anti-MDA5-Positive Dermatomyositis -a Multicenter Prospective Study –
11:00AM-12:30PM
Abstract Number: 837
Efficacy of High-Dose Versus Standard-Dose Influenza Vaccine in Seropositive Rheumatoid Arthritis Patients
11:00AM-12:30PM
Abstract Number: 839
Fibromyalgia Is Identified in Routine Care on Indices Derived from an MDHAQ (MultiDimensional Health Assessment Questionnaire) with Robust Agreement with 2011 Revised Fibromyalgia Criteria Questionnaire
11:00AM-12:30PM
Abstract Number: 836
Genetic Risk Score Prediction in Ankylosing Spondylitis
12:00PM-2:00PM
Abstract Number: PP08
Communication, Support, and Advocacy Lead to Improved Health and Quality of Life
12:00PM-2:00PM
Abstract Number: PP09
Improved Quality of Life and Decreased Symptoms of Lupus with Diet, Exercise, and Functional Medicine
12:00PM-2:00PM
Abstract Number: PP04
Improved Quality of Life with Patient Engagement in Research
12:00PM-2:00PM
Abstract Number: PP05
Integrative Approach to Treatment of an Adult with Juvenile Rheumatoid Arthritis
12:00PM-2:00PM
Abstract Number: PP06
Learning to Self-Advocate in the Transition from Pediatric to Adult Lupus Care
12:00PM-2:00PM
Abstract Number: PP12
Living a Full Life with A.S. Through Adaptations
12:00PM-2:00PM
Abstract Number: PP03
Managing OsteoArthritis Pain with Daily Meditation
12:00PM-2:00PM
Abstract Number: PP01
Physician, Patient, Person. Success in Balancing Multiple Roles Takes Support
12:00PM-2:00PM
Abstract Number: PP07
Strengthening My Resiliency: How My Interprofessional Healthcare Team and I Improved My Management of Lupus
12:00PM-2:00PM
Abstract Number: PP13
Support Groups and Patient Centred Care; Making a Difference in the Lives of People with Autoimmune and Rheumatic Conditions in Ghana
12:00PM-2:00PM
Abstract Number: PP02
Sustained Weight Loss Managed by Multiple Medical Specialists
12:00PM-2:00PM
Abstract Number: PP11
The Road Less Traveled– Nontraditional Approaches to Increased Patient Adherence and Positive Outcomes
12:00PM-2:00PM
Abstract Number: PP10
Using a Mobile App to Facilitate Patient-Doctor Discussions to Make Informed Decisions Regarding ‘Painsomnia’
2:30PM-4:00PM
Abstract Number: 891
A Phase 3, Randomized, Controlled Trial Comparing Upadacitinib Monotherapy to MTX Monotherapy in MTX-Naïve Patients with Active Rheumatoid Arthritis
2:30PM-4:00PM
Abstract Number: 890
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate
2:30PM-4:00PM
Abstract Number: 848
A2A Adenosine Receptor Stimulation Switches TGF-β Signaling to Promote Chondrocyte Proliferation and Cartilage Regeneration
2:30PM-4:00PM
Abstract Number: 900
Abatacept Vs. Placebo in Early Diffuse Cutaneous Systemic Sclerosis— Results of a Phase 2 Investigator Initiated, Double-Blind, Placebo-Controlled, Multicenter, Randomized Controlled Trial Study
2:30PM-4:00PM
Abstract Number: 862
Addressing the Pediatric Rheumatology Workforce Shortage: Results from the American College of Rheumatology Annual Pediatric Residents Program
2:30PM-4:00PM
Abstract Number: 857
An Interactive Rheumatology Curriculum for Interprofessional Teams Using a Novel Mobile App
2:30PM-4:00PM
Abstract Number: 867
An MRI Guided Treat-to-Target Strategy in Rheumatoid Arthritis Patients in Clinical Remission Improved MRI Inflammation but Not Damage Progression – Results from the Imagine-RA Randomized Controlled Trial
2:30PM-4:00PM
Abstract Number: 875
Anti-Calreticulin Antibody – a Novel Antibody in Patients with Idiopathic Inflammatory Myopathies and Its Association with Malignancy
2:30PM-4:00PM
Abstract Number: 852
Antigenic Property of Prothrombin/HLA-DR Complex on Procoagulant Cells in Patients with Antiphospholipid Syndrome
2:30PM-4:00PM
Abstract Number: 912
Association of Adiposity Measures in Childhood and Adulthood with Knee Cartilage Thickness, Volume and Bone Area in Young Adults
2:30PM-4:00PM
Abstract Number: 881
Association of Comorbidities with DAS28 Disease Status and Remission in Race/Ethnic Groups with Rheumatoid Arthritis
2:30PM-4:00PM
Abstract Number: 895
Associations of Statin Usage with Disease Activity in Ankylosing Spondylitis
2:30PM-4:00PM
Abstract Number: 847
Basic Calcium Phosphate Crystals Induce Osteoarthritis-Associated Changes in Chondrocyte Phenotype through Activation of Calcium/Calmodulin Kinase 2
2:30PM-4:00PM
Abstract Number: 894
Cancer Risk in Ankylosing Spondylitis in United States Medicare Beneficiaries: Detection of a Chronic Non Steroidal Anti-Inflammatory Drug Use Signature
2:30PM-4:00PM
Abstract Number: 846
CD14 Deficiency Dampens Osteoclastogenesis and Alters Bone Remodeling in a Murine Model of Osteoarthritis
2:30PM-4:00PM
Abstract Number: 901
Changes in Quantitative Scleroderma Lung CT Measures in Patients Treated with Cyclophosphamide or  Transplantation
2:30PM-4:00PM
Abstract Number: 899
Changes in the Systemic Sclerosis Molecular Signatures after Myeloablation Followed By Autologous Hematopoietic Stem Cell Transplantation and Their Clinical Correlates
2:30PM-4:00PM
Abstract Number: 907
Characterization of Preferential Recognition of a Chimeric Recombinant Proteinase 3 Variant By Anti-Neutrophil Cytoplasmic Antibodies
2:30PM-4:00PM
Abstract Number: 863
Combining Cardiac Magnetic Resonance and Right Heart Catheterization to Evaluate Right Ventricular Function for the Prognosis Prediction in Patients with Connective Tissue Diseases and Pulmonary Hypertension
2:30PM-4:00PM
Abstract Number: 849
Constructing a Macrophage Infiltration Timeline in a Murine Model of Osteoarthritis
2:30PM-4:00PM
Abstract Number: 861
Critical Appraisal Self-Efficacy and Learning Behavior in Rheumatology Trainees
2:30PM-4:00PM
Abstract Number: 906
Defining the Gut Microbiome in Patients with ANCA-Associated Vasculitis
2:30PM-4:00PM
Abstract Number: 911
Demographic and Clinical Characteristics Reflect Differences in Osteoarthritis Phenotypes of the Lumbar Spine: The Johnston County Osteoarthritis Project
2:30PM-4:00PM
Abstract Number: 876
Dermatomyositis Skin Shares Type I Interferon Overlap with Cutaneous Lupus but Displays Many Unique Expression Changes That May Serve As Biomarkers for Skin Disease
2:30PM-4:00PM
Abstract Number: 844
Differential Roles of Tnfα-TNFR1 and Tnfα-TNFR2 in the Differentiation and Function of Induced CD4+Foxp3+ Treg Cells in Autoimmune Diseases
2:30PM-4:00PM
Abstract Number: 908
Early Prediction of Long-Term Evolutionary Profiles of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss) Based on Baseline and Follow-up Characteristics
2:30PM-4:00PM
Abstract Number: 886
Efficacy and Safety of Switching from Adalimumab to Baricitinib: Long-Term Data from Phase 3 Extension Study in Patients with Rheumatoid Arthritis
2:30PM-4:00PM
Abstract Number: 887
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Dmards
2:30PM-4:00PM
Abstract Number: 888
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Methotrexate
2:30PM-4:00PM
Abstract Number: 898
Efficacy and Safety of Tocilizumab for the Treatment of Systemic Sclerosis: Results from a Phase 3 Randomized Controlled  Trial
2:30PM-4:00PM
Abstract Number: 860
Efficacy of a Web-Based Module to Educate Internal Medicine Housestaff on Gout
2:30PM-4:00PM
Abstract Number: 853
Enhanced Type I Interferon Gene Signature in Primary Antiphospholipid Syndrome: Association with Earlier Disease Onset and Preeclampsia
2:30PM-4:00PM
Abstract Number: 892
Establishing the Minimal Clinically Important Difference (MCID) for the Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)
2:30PM-4:00PM
Abstract Number: 871
Estimates of Diet Quality Explain Less Variability in Serum Urate Levels Than Genetic Factors
2:30PM-4:00PM
Abstract Number: 883
Evaluation of Fracture Risk and Osteoporosis in Males with Rheumatoid Arthritis
2:30PM-4:00PM
Abstract Number: 869
Failure to Reach Serum Urate Target Is Associated with Elevated Mortality in Gout
2:30PM-4:00PM
Abstract Number: 854
First and Recurrent Thrombosis Risk after 1897 Patient-Years of Follow-up: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)
2:30PM-4:00PM
Abstract Number: 873
General Safety of Febuxostat and Allopurinol in a Cardiovascular Outcomes Study in Patients with Gout
2:30PM-4:00PM
Abstract Number: 885
Herpes Zoster in Tofacitinib Users with and without Concomitant Methotrexate and Glucocorticoids
2:30PM-4:00PM
Abstract Number: 893
Identification of Axial Spondyloarthritis Patients in a Large Dataset: The Development and Validation of Novel Methods
2:30PM-4:00PM
Abstract Number: 878
IFN Level Assessed By Ultrasensitive Detection Technology in Myositis Patient: A Promising Biomarker of Disease Activity in Dermatomyositis and Anti-Synthetase Syndrome
2:30PM-4:00PM
Abstract Number: 855
IgG Antiphospholipid Antibodies, -a Common but Neglected Finding in Patients with Myocardial Infarction
2:30PM-4:00PM
Abstract Number: 879
IL-31 Protein Expression in Lesional Skin Correlates with Itch in Dermatomyositis
2:30PM-4:00PM
Abstract Number: 910
In Diagnostic Prevalence and Treatment Patterns of Male and Female Ankylosing Spondylitis Patients in the United States, 2006-2016
2:30PM-4:00PM
Abstract Number: 914
Increased Adverse Childhood Experiences in Children with Arthritis: An Analysis of the National Survey of Children’s Health
2:30PM-4:00PM
Abstract Number: 856
Integrated mRNA and microRNA Transcriptomes of Monocytes from Antiphospholipid Syndrome Patients Identifies Molecular Networks Related to Their Atherothrombotic Status. Modulatory Effects of In Vivo Ubiquinol Supplementation
2:30PM-4:00PM
Abstract Number: 851
Integrin Mac-1 Potentiates Neutrophil Adhesion and NET Release in Antiphospholipid Syndrome
2:30PM-4:00PM
Abstract Number: 842
Interleukin 17 Receptor D (IL-17RD) Is Regulated By Pro-Inflammatory Cytokines and Plays a Role in the Development of Collagen-Induced Arthritis
2:30PM-4:00PM
Abstract Number: 868
International Multi-Reader Validation of the Outcome Measures in Rheumatology Hip MRI Scoring System (OMERACT HIMRISS) for Bone Marrow Lesions in Osteoarthritis
2:30PM-4:00PM
Abstract Number: 872
Is the Serum Uric Acid Therapeutic Target Protective of Chronic Kidney Disease, Cardiovascular Disease, and Mortality for Patients with Gout? a Longitudinal Study
2:30PM-4:00PM
Abstract Number: 843
Localization of the Voltage-Gated Sodium Channel 1.7 in Peripheral Monocytes Contributes to Activation of BAFF Signaling in Monocytes of Patients with Primary Sjögren’s Syndrome
2:30PM-4:00PM
Abstract Number: 850
Long Term Efficacy of Cartilage Repair Induced By scSOX9 in Situ with Bone Marrow-Derived Mesenchymal Stem Cells
2:30PM-4:00PM
Abstract Number: 904
Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Results of the Four-Year Study of Rituximab in ANCA-Associated Vasculitis Registry
2:30PM-4:00PM
Abstract Number: 902
Longitudinal Trends in Clinical Disease Features after Myeloablative Autologous Stem-Cell Transplantation or Cyclophosphamide in Severe Scleroderma
2:30PM-4:00PM
Abstract Number: 858
Measuring Cognitive Load during Arthrocentesis Training: Our Initial Experience
2:30PM-4:00PM
Abstract Number: 845
New Insights in Lupus Dermatitis: Differential Regulation and Roles of Tissue-Resident Dendritic Cell Subsets in the Pathogenesis of Autoimmune Skin Inflammation
2:30PM-4:00PM
Abstract Number: 870
Patient-Reported Burden of Gout in 2017 from the United States
2:30PM-4:00PM
Abstract Number: 866
Patterns of Monosodium Urate Deposition on Dual-Energy CT in Gout Patients on Urate-Lowering Therapy
2:30PM-4:00PM
Abstract Number: 896
Pharmacogenomics Study of Predicting Response of TNF Blocker and Medical Image Progression in Chinese Han Ankylosing Spondylitis Population
2:30PM-4:00PM
Abstract Number: 882
Predictors of Chronic Kidney Disease in US Veterans with Rheumatoid Arthritis
2:30PM-4:00PM
Abstract Number: 897
Prevalence of Inflammatory and Chronic Changes Suggestive of Axial Spondyloarthritis in Magnetic Resonance Images of the Axial Skeleton in Individuals < 45 Years in the General Populationas Part of a Large Community Study (SHIP)
2:30PM-4:00PM
Abstract Number: 874
Preventing a Large Majority of Incident Gout Cases By Modifying Key Risk Factors: Findings from a Prospective Cohort of 44,629 Men over 26 Years
2:30PM-4:00PM
Abstract Number: 884
Rheumatoid Arthritis Disease Activity Predicting Incident Clinically-Apparent Interstitial Lung Disease: A Prospective Cohort Study
2:30PM-4:00PM
Abstract Number: 903
Riociguat in Patients with Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study (RISE-SSc)
2:30PM-4:00PM
Abstract Number: 913
Risk Factors for Knee Pain Exacerbation on Walking: A within-Person Knee-Matched Study
2:30PM-4:00PM
Abstract Number: 880
Serum Cytokine and Chemokine Concentrations Predict Incident Cancer in US Veterans with Rheumatoid Arthritis
2:30PM-4:00PM
Abstract Number: 905
Serum Interleukin-6 Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
2:30PM-4:00PM
Abstract Number: 877
Serum Krebs Von Den Lungen-6 Is a Useful Biomarker for Assessing Activity of Myositis-Associated Interstitial Lung Disease
2:30PM-4:00PM
Abstract Number: 865
Structural and Microstructural Intraarticular Bone Changes at the Metacarpal Heads in Patients with Psoriatic Arthritis Compared to Controls: A HR-pQCT Study
2:30PM-4:00PM
Abstract Number: 909
Temporal Trends of ANCA-Associated Vasculitis Comorbidities: Results from a National, Longitudinal, Matched-Cohort Study
2:30PM-4:00PM
Abstract Number: 915
The Association between Structural and Symptomatic Progression in Knee Osteoarthritis
2:30PM-4:00PM
Abstract Number: 840
The CCL21/CCR7 Axis Drives Vascular, Inflammatory and Destructive Remodeling in Rheumatoid Arthritis
2:30PM-4:00PM
Abstract Number: 864
The Diagnostic Utility of the Relation between MRI Bone Marrow Edema and Other Types of MRI Lesions in the Sacroiliac Joints in Axial Spondyloarthritis
2:30PM-4:00PM
Abstract Number: 841
TNFR2 Inactivation Reduces Psoriatic Inflammation in Mice Via Down-Regulating Dendritic Cell Expansion and Inhibiting IL-23/IL-17 Pathways
2:30PM-4:00PM
Abstract Number: 889
Upadacitinib As Monotherapy: A Phase 3 Randomized Controlled Double-Blind Study in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
2:30PM-4:00PM
Abstract Number: 859
Using Online Simulation of Pediatric Musculoskeletal Cases to Evaluate How Knowledge of Costs Affects Diagnostic Workup
4:30PM-6:00PM
Abstract Number: 924
10X Genomics-Based Single-Cell RNA-Seq and Low Input RNA-Seq Identify a Transcriptional Landscape Supporting Interferon in the Pathogenesis of Autoimmune-Associated Congenital Heart Block
4:30PM-6:00PM
Abstract Number: 919
A Machine Learning Classifier for Assigning Individual Patients with Systemic Sclerosis to Intrinsic Molecular Subsets
4:30PM-6:00PM
Abstract Number: 954
A New Way to Think about Composite Magnetic Resonance Imaging Scores to Measure Osteoarthritis Severity and Progression
4:30PM-6:00PM
Abstract Number: 918
A Novel Familial RELA Truncation Is Associated with Behçet’s-like Mucocutaneous Ulceration Syndrome
4:30PM-6:00PM
Abstract Number: 971
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept or Placebo on Standard of Care in Patients with Active Class III or IV Lupus Nephritis
4:30PM-6:00PM
Abstract Number: 925
Abortive Viral Infection Becomes Macrophage Activation Syndrome in Mice with Chronically Elevated Interleukin-18: Evidence for Synergy with Cytotoxic Impairment
4:30PM-6:00PM
Abstract Number: 975
Alteration of Vascular Inflammatory Markers in SLE By Anifrolumab in the Phase IIb Muse Study
4:30PM-6:00PM
Abstract Number: 972
An Anti-CD28 Domain Antibody, Lulizumab, in Systemic Lupus Erythematosus: Results of a Phase II Study
4:30PM-6:00PM
Abstract Number: 922
Anakinra Treatment Prevents Myocardial Mechanical Dysfunction and Inhibits Histologic Evidence of Myocardial Inflammation in the Mouse Model of Kawasaki Disease
4:30PM-6:00PM
Abstract Number: 970
Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
4:30PM-6:00PM
Abstract Number: 957
Biomechanical Therapy for Osteoarthritis of the Knee: A Randomized Controlled Trial
4:30PM-6:00PM
Abstract Number: 956
Bone Mineral Density Is a Causal Risk Factor for Knee and Hip Osteoarthritis: A Population-Based and Mendelian Randomization Study in the UK Biobank
4:30PM-6:00PM
Abstract Number: 941
Causal Inference Methods for the Effect of Rheumatoid Arthritis on Mortality Independent of Lifestyle and Clinical Factors before and after RA Diagnosis
4:30PM-6:00PM
Abstract Number: 966
Central Triage Clinic for Psoriatic Arthritis – Performance of Triage Methods
4:30PM-6:00PM
Abstract Number: 947
Clinical Characteristics and Outcome after Treatment of a National Cohort of PCR-Positive Lyme Arthritis
4:30PM-6:00PM
Abstract Number: 965
Defining Cutoffs Corresponding to Low Levels of Disease Activity in Psoriatic Arthritis, Using the Patient-Reported Psoriatic Arthritis Impact of Disease Questionnaire (PsAID12). an Analysis of 436 Patients
4:30PM-6:00PM
Abstract Number: 938
Dermal Lymphatic Dysfunction and Photosensitivity in the MRL/Lpr Lupus Model
4:30PM-6:00PM
Abstract Number: 948
Effects of Antiretroviral Therapy with Tenofovir and Other Antiretroviral Drugs on the Inflammatory State and Bone Remodeling on Newly Diagnosed HIV-Patients at Basal and 3 Months after Starting Treatment
4:30PM-6:00PM
Abstract Number: 952
Effusion-Synovitis and Infrapatellar Fat Pad Edema Differentiate Accelerated Knee Osteoarthritis: Data from the Osteoarthritis Initiative
4:30PM-6:00PM
Abstract Number: 953
Evaluating MRI-Detected Knee Inflammation Prior to Total Knee Replacement As a Predictive Biomarker of Clinically Important Pain Reduction Two Years Later
4:30PM-6:00PM
Abstract Number: 937
Evidence of a Common Microglial Signature in Models of ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’
4:30PM-6:00PM
Abstract Number: 932
Fibroblasts Senescence Is Observed in Rheumatoid and Osteoarthritic Synovial Tissues and Triggers a Pro-Inflammatory Program Ex Vivo
4:30PM-6:00PM
Abstract Number: 944
Gout: A Potential Risk Factor for Uveitis in the Older Adults?
4:30PM-6:00PM
Abstract Number: 967
Health Care Utilization for Musculoskeletal Issues during the Pre-Diagnosis Period in Psoriatic Arthritis – a Population-Based Study
4:30PM-6:00PM
Abstract Number: 934
HIV Protease Inhibitors Cure Lupus-Prone Mice and Prevent T Helper 17 Cell-Driven Inflammation By Inhibiting CD95-Non-Apoptotic Signaling Pathway
4:30PM-6:00PM
Abstract Number: 951
IFN-Gamma Production in Lyme Arthritis Synovial Tissue Promotes Differentiation of Fibroblast-like Synoviocytes into Inflammatory Effector Cells
4:30PM-6:00PM
Abstract Number: 940
Inactivated Influenza Vaccine Prevents Respiratory Infections and Improves All-Cause and Cause-Specific Mortality in Immunosuppressed People with Autoimmune Rheumatic Diseases: Propensity Score Adjusted Cohort Study Using Data from Clinical Practice Research Datalink
4:30PM-6:00PM
Abstract Number: 933
Inflammation in the Hippocampus Affects Insulin-like Growth Factor-1 Receptor Signaling and Contributes to Neurological Sequelae in Rheumatoid Arthritis
4:30PM-6:00PM
Abstract Number: 916
Integrative Analysis of Multi-Omics Data in an Ethnically Diverse Lupus Cohort Identifies Distinct Molecular Subtypes of SLE
4:30PM-6:00PM
Abstract Number: 930
Joint Location-Specific IL6 and JAK-STAT Signaling in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS)
4:30PM-6:00PM
Abstract Number: 974
Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis: A Prospective, Multicenter, Randomized, Open-Label Clinical Trial
4:30PM-6:00PM
Abstract Number: 980
Long-Term Outcome of Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis:Results of 18-Year Follow-up in the Population-Based Nordic JIA Cohort
4:30PM-6:00PM
Abstract Number: 949
Long-Term Rheumatic and Musculoskeletal Disorders Associated to Ebola Virus Infection
4:30PM-6:00PM
Abstract Number: 963
Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program
4:30PM-6:00PM
Abstract Number: 973
Low-Dose IL-2 Combined with Rapamycin Efficiently Promoted Disease Remission and Recovered the Balance of Th17/Regulatory T Cells in Patients with Refractory Systemic Lupus Erythematosus
4:30PM-6:00PM
Abstract Number: 955
Lower Limb Muscle Strength and Protection Against Functional Decline and Structural Worsening in Knee Osteoarthritis
4:30PM-6:00PM
Abstract Number: 921
Multi-Omics Analysis Identifies a Gene Signature Associated with the Clinical Response to Anti-TNF Therapy in Rheumatoid Arthritis
4:30PM-6:00PM
Abstract Number: 935
Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Lipocalin-2
4:30PM-6:00PM
Abstract Number: 923
Neutrophils from Children with Systemic JIA Exhibit Persistent Proinflammatory Activation Despite Long-Standing Clinically Inactive Disease
4:30PM-6:00PM
Abstract Number: 981
New Consensus on an Updated Core Domain Set for Clinical Trials in Juvenile Idiopathic Arthritis
4:30PM-6:00PM
Abstract Number: 977
Nurse Led Safe Switching from Original Reference Product Infliximab to Biosimalar in Patients with Juvenile Idiopathic Arthritis and Uveitis – a Single Centre Experience Including Baseline and Post Switch Infliximab Levels and Antibodies
4:30PM-6:00PM
Abstract Number: 969
Obstetric Outcomes in Women with Psoriatic Arthritis: Results from Nationwide Inpatient Sample Database 2003-2011
4:30PM-6:00PM
Abstract Number: 945
Pain, Functional Limitations and Physical Activity Participation Trajectories in Patients with Symptomatic Knee and Hip Osteoarthritis: A Multi-Trajectory Analysis
4:30PM-6:00PM
Abstract Number: 931
Patients with Seropositive Rheumatoid Arthritis Who Do Not Mount a CRP Response When They Have Synovitis Are Immunologically Distinct and Are Poorly Served By Current Management Strategies
4:30PM-6:00PM
Abstract Number: 964
Psoriatic Arthritis Impact of Disease (PsAID12) Was Provisionally Endorsed at Omeract 2018 As Core Instrument to Measure Psoriatic Arthritis-Specific Health-Related Quality of Life in Randomized Controlled Trials and Longitudinal Observational Studies
4:30PM-6:00PM
Abstract Number: 939
Rab4A Protects from Lupus Nephritis By Limiting Germinal Center Formation and Pro-Inflammatory Expression of GLUT1 and Integrin By Renal Epithelial Cells
4:30PM-6:00PM
Abstract Number: 920
Rheumatoid Arthritis Patient-Specific Therapeutic Target Identification Using Integrative Epigenetic Profiling
4:30PM-6:00PM
Abstract Number: 943
Risk of Prostate Cancer in US Veterans with Rheumatoid Arthritis
4:30PM-6:00PM
Abstract Number: 942
Risk of Serious Infections in Tocilizumab Versus TNF Inhibitor Initiators in Patients with RA: A Multi-Database Cohort Study
4:30PM-6:00PM
Abstract Number: 962
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis
4:30PM-6:00PM
Abstract Number: 936
Selective Deficiency of Serine Arginine-Rich Splicing Factor 1 (SRSF1) in T Lymphocytes Leads to mTORC1 Activation, Treg Dysfunction and Systemic Autoimmune Disease
4:30PM-6:00PM
Abstract Number: 946
Short-Term Safety of Fractional-Dose Yellow Fever Vaccination in Autoimmune Rheumatic Diseases and Kinetics of White Blood Cells
4:30PM-6:00PM
Abstract Number: 928
Single Cell RNA-Sequencing of Rheumatoid Synovial Fibroblasts Reveals a Disease-Associated Spatial Gradient Modulated By Inductive Notch Signaling
4:30PM-6:00PM
Abstract Number: 979
Stopping Medicines for Inactive Juvenile Idiopathic Arthritis: What Do Patients and Families Consider?
4:30PM-6:00PM
Abstract Number: 961
The Association of Biologic Drug-Levels with Infection Risk: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
4:30PM-6:00PM
Abstract Number: 959
The Prevalence of Methotrexate Associated Hepatotoxicity in a Multi-Hospital Health System
4:30PM-6:00PM
Abstract Number: 927
The Reprogramming of Regulatory T Cells to a Th17 Phenotype in Systemic Juvenile Idiopathic Arthritis
4:30PM-6:00PM
Abstract Number: 960
The Risk of Gastrointestinal Perforations Associated with Biologic Disease-Modifying Anti-Rheumatic Drugs Used in Rheumatoid Arthritis: A Nationwide Swedish Cohort Study
4:30PM-6:00PM
Abstract Number: 958
Tocilizumab and the Risk for Cardiovascular Disease Events Among Rheumatoid Arthritis Patients: A Direct Comparison in Real World Setting
4:30PM-6:00PM
Abstract Number: 929
Transcriptional Profiling of the Subcutaneous Rheumatoid Nodule: An Insight into Pathogenic Mechanisms and Cellular Content
4:30PM-6:00PM
Abstract Number: 976
Transitioning from Paediatric to Adult Health Services: Development of an Integrated Programme Incorporating Patient and Provider Values
4:30PM-6:00PM
Abstract Number: 978
Treat-to-Target Study for Improved Outcome in Polyarticular Juvenile Idiopathic Arthritis
4:30PM-6:00PM
Abstract Number: 926
Truncating Mutations in SAMD9L Cause an Early-Onset Immune-Dysregulatory Syndrome of Neutrophilic Panniculitis, Interstitial Lung Disease and Cytopenias
4:30PM-6:00PM
Abstract Number: 917
Type 1 Interferon Levels Correlates with Age of Diagnosis and Ethnicity in Systemic Lupus Erythematous
4:30PM-6:00PM
Abstract Number: 950
Ultrasonographic Examinations Show Highly Prevalent Abnormalities of Hamstring Tendons in Lyme Arthritis Patients
4:30PM-6:00PM
Abstract Number: 968
What Is the Impact of Imaging on Diagnostic Ascertainment of Patients Presenting with Undiagnosed Back Pain in Routine Practice and the Impact of Central Reading? Data from the Screening in Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Cohort
9:00AM-11:00AM
Abstract Number: 1489
“Continuous Reduction” in Serum RF Titers Predicts Low Disease Activity and Good Therapeutic Response in RA Patients Treated with TNF Inhibitors, but Does Not Relate to Clinical Outcomes during ABT Treatment
9:00AM-11:00AM
Abstract Number: 1152
“Doctor, a Storm Is Coming and My Joints Hurt”: Evaluating Associations between Weather Changes and Arthritis Symptoms
9:00AM-11:00AM
Abstract Number: 1758
A 24 Month Analysis of Rituximab Safety and Efficacy in Eosinophilic Granulomatosis with Polyangiitis
9:00AM-11:00AM
Abstract Number: 1155
A Collaborative Cardio-Rheumatology Clinic for Primary Prevention of Cardiovascular Diseases – a Descriptive Study
9:00AM-11:00AM
Abstract Number: 1034
A Conplastic Mice Model of Aging Reveals That Mitochondrial DNA Variation Influences the Process of Joint Deterioration
9:00AM-11:00AM
Abstract Number: 1256
A Customized Health Information Technology Effectively Identifies and Directs Bone Health Services in Rural Veterans with Osteoporosis Risk Factors
9:00AM-11:00AM
Abstract Number: 1785
A Data-Driven Approach to Guide Physicians When Considering the Differential Diagnosis of IgG4-Related Disease
9:00AM-11:00AM
Abstract Number: 1800
A Declining Trend in Frequency of Secondary Amyloidosis in Behçet’s Syndrome
9:00AM-11:00AM
Abstract Number: 1359
A Machine Learning Approach to Knee OA Phenotyping: The Johnston County Osteoarthritis Project
9:00AM-11:00AM
Abstract Number: 983
A MAPK Activated Kinase 2 Inhibitor Attenuates Inflammatory and Destructive Arthritis in Human Ex Vivo Models
9:00AM-11:00AM
Abstract Number: 1311
A Multidisciplinary Cohort of Patients with Interstitial Pneumonia with Autoimmune Features
9:00AM-11:00AM
Abstract Number: 1427
A New Model of Care for Pediatric Rheumatology in Ontario: Preliminary Results from Pilot Telemedicine Clinics Utilizing Advanced Clinician Practitioners in Arthritis Care
9:00AM-11:00AM
Abstract Number: 1343
A Novel Autoantibody Against DNA Damage Binding Protein-1 in Idiopathic Inflammatory Myopathy
9:00AM-11:00AM
Abstract Number: 1027
A Novel IL-1 Mediated Autoinflammatory Disease Caused By a Specific Gain-of-Function Mutation in Dysferlin
9:00AM-11:00AM
Abstract Number: 1296
A Novel Potent and Selective Urate Transporter 1 Inhibitor, NC-2700, with pH-Raising Effect on Low Urinary pH
9:00AM-11:00AM
Abstract Number: 1299
A Novel Recombinant Oral Urate Oxidase (UrOx) Alln-346 Reduces Severe Hyperuricemia and Normalizes Hyperuricosuria in Nephropathic Urox Knockout (UrOxKO) Mice
9:00AM-11:00AM
Abstract Number: 1365
A Phase IIa Study of Anti-GM-CSF Antibody GSK3196165 in Subjects with Inflammatory Hand Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1277
A Prospective Study Examining the Prevalence of CT Erosions in the Feet and Ankles of Patients with Gout Treated with Allopurinol
9:00AM-11:00AM
Abstract Number: 1243
A Quality Improvement Initiative to Increase Adherence to Hydroxychloroquine Dosing Guidelines at an Academic Medical Center
9:00AM-11:00AM
Abstract Number: 1429
A Quality Update: Improved Transfer Time Among Rheumatology Patients Transferring from Pediatric to Adult Care at an Academic Medical Center
9:00AM-11:00AM
Abstract Number: 1730
A Role for Duplex Ultrasound of Hand Arteries in the Assessment of the Vasculopathy Associated to Systemic Sclerosis-like Diseases
9:00AM-11:00AM
Abstract Number: 1347
A Semi-Quantitative Whole Body Magnetic Resonance Imaging Assessment Tool to Define Musculoskeletal Abnormalities in Patients with Idiopathic Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 1412
A Systematic Literature Review of Efficacy and Safety of Current Therapies for the Treatment of Hyperimmunoglobulinemia D Syndrome and TNF Receptor-Associated Periodic Syndrome
9:00AM-11:00AM
Abstract Number: 1105
Abatacept Is Effective in Experimental Digestive and Lung Tissue Fibrosis
9:00AM-11:00AM
Abstract Number: 1266
ABCG2 rs2231142 Q141K and Oxypurinol Concentration in People with Gout Receiving Allopurinol
9:00AM-11:00AM
Abstract Number: 1766
Abdominal Adipose Tissue Predicts Incident Major Cardiovascular Events in Systemic Necrotizing Vasculitis Patients: Data from a Prospective Cohort Study on 120 Patients
9:00AM-11:00AM
Abstract Number: 1032
Aberrant Sarcoplasmic Expression of the Alarmin ‘High Mobility Group Box Protein 1” (HMGB1) in Patients with Idiopathic Inflammatory Myopathy
9:00AM-11:00AM
Abstract Number: 1333
Abnormal Function of High Density Lipoproteins in Idiopathic Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 1465
Absolute Number of Regulatory T Cells Decreased While Osteopontin Increased in Peripheral Blood of New Onset Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1607
Achievement of Cdapsa Low Disease Activity or Remission Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psa in Subjects Treated with Apremilast
9:00AM-11:00AM
Abstract Number: 1179
Achieving Important Improvement in WOMAC Pain and Function By Three Months Post-Surgery Influences Satisfaction 1 Year Following Total Knee Replacement (TKR)
9:00AM-11:00AM
Abstract Number: 1655
Achieving Remission in Psoriatic Arthritis By Early Initiation of TNF Inhibition: A Double-Blind, Randomized, Placebo-Controlled Trial of Golimumab + Methotrexate Versus Placebo + Methotrexate
9:00AM-11:00AM
Abstract Number: 1157
Acknowledged Biostatistical Help and the Quality of Statistical Analyses in Randomized Controlled Trials in Rheumatology
9:00AM-11:00AM
Abstract Number: 1320
Activity Tracker Bracelets Captures Familial Mediterranean Fever Attacks and Their Impact on Daily Physical Activities
9:00AM-11:00AM
Abstract Number: 1618
Adipose Tissue Inflammation in Psoriatic Arthritis: Overexpression of a Wide Array of Inflammatory Mediators and Associations with Disease and Treatment Characteristics
9:00AM-11:00AM
Abstract Number: 1424
After 24 Months Observation Period the Patients Related Outcomes Improve Significantly in the Juvenile Scleroderma Inceptions Cohorte
9:00AM-11:00AM
Abstract Number: 1044
Alendronate-CGS21680 Conjugates Prevent Bone Erosion in a Murine Osteolysis Model
9:00AM-11:00AM
Abstract Number: 1732
Alterations of Body Composition in Patients with Systemic Scleroderma Are Associated with Disease Activity, Physical Activity and Serum Levels of Inflammatory Cytokines
9:00AM-11:00AM
Abstract Number: 1466
Altered Count of NK Cells and Non-Classical Monocyte Subpopulation in the Pre-Clinical Phase of Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1553
An Analysis of Real-World Data on the Safety of Etanercept in Elderly Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1372
An Analysis of the Quality and Readability of Online Osteoarthritis Information with Historical Comparison
9:00AM-11:00AM
Abstract Number: 1757
An Economic Systematic Literature Review of Eosinophilic Granulomatosis with Polyangiitis
9:00AM-11:00AM
Abstract Number: 1028
An Entheseal Innate Immune Cell Biological Basis for Differential Efficacy of PDE4 and IL-23 Pathway Blockade between Psoriatic Disease and Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1250
An Evaluation of Utilization Patterns and Appropriateness of Laboratory Tests Among New Referrals to Rheumatologists: Choosing Unwisely!
9:00AM-11:00AM
Abstract Number: 1790
An Unmet Need for Oral Ulcer Activity in Patients with Behcet’s Disease: A Multi-National Study
9:00AM-11:00AM
Abstract Number: 1797
An Update on Pulmonary Artery Involvement in Behcet’s Syndrome: More Pulmonary Artery Thrombotic Disease and a Better Outcome
9:00AM-11:00AM
Abstract Number: 1295
Anakinra Is More Effective at Reducing Pain from Acute Crystal Induced Arthritis When Compared to Conventional Therapy: A Retrospective Review at a Tertiary Care Center
9:00AM-11:00AM
Abstract Number: 1324
Anakinra Treatment in Refractory Cases of Adult-Onset Still Disease: Case Series
9:00AM-11:00AM
Abstract Number: 1815
Aneurysmal Lesions in Behcet’s Disease: A Report of 69 Cases from a Single Center
9:00AM-11:00AM
Abstract Number: 1340
Anti-Aminoacyl-tRNA-Synthetase Antibodies Which Are Positive By ELISA but Negative By RNA-Immunoprecipitation Suggest Different Antigen Recognition and Clinical Relevance Different from Typical Anti-Synthetase Syndrome
9:00AM-11:00AM
Abstract Number: 1551
Anti-Drug Antibodies to Certolizumab Pegol Are Assiciated with Low Drug Levels and Reduced Clinical Response at 3 Months in Patients with Inflammatory Joint Diseases
9:00AM-11:00AM
Abstract Number: 1001
Anti-Fractalkine Monoclonal Antibody Dislodges Intravascular Monocytes Involved in Exacerbation of Synovial Inflammation in Collagen-Induced Arthritis Model
9:00AM-11:00AM
Abstract Number: 995
Anti-Fractalkine Monoclonal Antibody Inhibits Joint Destruction through Suppression of Osteoclast Precursor Migration and Induces Synovial Cell Death in Collagen-Induced Arthritis Model Mice
9:00AM-11:00AM
Abstract Number: 1521
Anti-IL-6 Therapy Modulates Leptin in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1346
Anti-NT5c1A Autoantibodies As Biomarkers in Inclusion Body Myositis
9:00AM-11:00AM
Abstract Number: 1344
Anti-Splicing Factor Proline/Glutamine-Richautoantibodies Rarely Co-Exist with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies in a Cohort of Dermatomyositis Patients from the United States
9:00AM-11:00AM
Abstract Number: 1219
Antibiotic Resistance Trends Among Bacteria Causing Septic Arthritis at One Medical Center between 2002-2016
9:00AM-11:00AM
Abstract Number: 1108
Antibody Repertoire Dynamics in Systemic Sclerosis after Myeloablative Autologous Hematopoietic Stem-Cell Transplantation or Cyclophosphamide Treatment
9:00AM-11:00AM
Abstract Number: 1691
Application of the Doris Algorithm for the Definition of Disease Remission and Its Relation with Damage Accrual over a 2-Year Period in a Cohort of Italian Patients with Systemic Lupus Erythematosus Classified According to Clinical Disease Patterns
9:00AM-11:00AM
Abstract Number: 1379
Appraisal of the Educational Needs in Patients with Osteoarthritis Using the Educational Needs Assessment Tool Questionnaire
9:00AM-11:00AM
Abstract Number: 1772
Apremilast in Refractory Oral and/or Genital Ulcers in Behçet’s Disease. Multicenter Study of 37 Cases
9:00AM-11:00AM
Abstract Number: 1481
Are ACPA Associated with More Bone Loss over Time in Patients with RA?
9:00AM-11:00AM
Abstract Number: 1188
Are Residents Choosing Wisely? Analysis of Adherence to Recommendations of Ordering Anti-Nuclear Antibody Testing in an Internal Medicine Residency Primary Care Clinic
9:00AM-11:00AM
Abstract Number: 1065
Artesunate Can Synergize with Methotrexate on Inhibiting Migration and Invasion of Fibroblast-like Synoviocytes from Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1622
ASAS Consensus on Spanish Nomenclature for Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1399
Assessing a Conceptual Framework of Quality of Life in a Cutaneous Lupus Erythematosus Population
9:00AM-11:00AM
Abstract Number: 1366
Assessment of Health-Related Quality of Life in a 52-Week, Phase 2, Randomized, Controlled Trial of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for Treatment of Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1627
Assessment of Myocardial Dysfunction Using Speckle Tracking Echocardiography in Patients with Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1803
Assessment of Severity and Risk Factors of Post-Thrombotic Syndrome in Vascular Behçet Disease: Muticentered Retrospective Study
9:00AM-11:00AM
Abstract Number: 1268
Assessment of the Persistence of Crystals Under Polarised Light Microscopy in Stored Synovial Fluid Samples
9:00AM-11:00AM
Abstract Number: 1405
Assessment of the Psychometric Properties of Patient-Reported Outcomes of Depression in SLE
9:00AM-11:00AM
Abstract Number: 1501
Assessment of Treatment Response Using the Multi-Biomarker Disease Activity Score in Rheumatoid Arthritis Patients Initiating Methotrexate
9:00AM-11:00AM
Abstract Number: 1410
Assessment of Work Outcomes with Truncation from Job Loss in an Arthritis Randomized Clinical Trial
9:00AM-11:00AM
Abstract Number: 1087
Association between Cigarette Smoking and Systemic Lupus Erythematosus – a Bayesian Multivariate Meta-Analysis of Case-Control and Cohort Studies
9:00AM-11:00AM
Abstract Number: 1169
Association between Depressive Symptom Subtypes and Disease Severity in Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1457
Association between Disease Activity and Radiographic Progression in the Current Treat-to-Target Paradigm of Rheumatoid Arthritis: Real World Data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry
9:00AM-11:00AM
Abstract Number: 1125
Association between Hyperuricemia and Metabolic Syndrome with or without Obesity: Results from the 2016 Korea National Health and Nutrition Examination Survey
9:00AM-11:00AM
Abstract Number: 1288
Association between Musculoskeletal Ultrasonography and Bone Remodeling Markers and the Role of Ultrasonography on Monitoring Treatment Responsiveness in Patients with Gout and Hyperuricemia
9:00AM-11:00AM
Abstract Number: 1281
Association of HFE Genotypes with Clinical Severity in Patients with Definite Calcium Pyrophosphate Arthritis
9:00AM-11:00AM
Abstract Number: 1625
Association of HLA-B Type and Sacroiliitis in Patients with Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1345
Association of HLA-DRB1*0301 with Antisynthetase Syndrome in Spanish Patients
9:00AM-11:00AM
Abstract Number: 1161
Association of Knee Ligament and/or Meniscal Injury with Radiographic Knee Osteoarthritis in Military Officers
9:00AM-11:00AM
Abstract Number: 1136
Association of Mitochondrial DNA Haplotypes with Symptomatic Hand and Thumb Based Osteoarthritis and Hand OA Progression
9:00AM-11:00AM
Abstract Number: 1145
Association of Niacin Intake with Osteoporosis. the Cardiovascular Health Study
9:00AM-11:00AM
Abstract Number: 1381
Association of Omeract Core Domains of Pain and Function with Patient Satisfaction after Total Joint Replacement
9:00AM-11:00AM
Abstract Number: 1056
Association of Paraoxonase 1 Gene Polymorphisms and Enzyme Activity with Progression of Carotid Atherosclerosis in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1734
Association of Short-Term Longitudinal Changes in Clinical and Physiologic Variables with Overall Survival in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
9:00AM-11:00AM
Abstract Number: 1081
Associations between Daily Alcohol Intake and SLE-Related Cytokines and Chemokines U.S. Female Nurses without SLE
9:00AM-11:00AM
Abstract Number: 1509
Associations between Perceived Stress and Joint Signs in an Anti-Cyclic Citrullinated Peptide Antibody Positive at-Risk Population
9:00AM-11:00AM
Abstract Number: 1752
Asthma in Eosinophilic Granulomatosis with Polyangiitis Treated with Rituximab
9:00AM-11:00AM
Abstract Number: 1355
Asymptomatic Hyperuricemia Is Associated with Increased Prevalence of Symptomatic Knee Osteoarthritis: Data from Third National Health and Nutrition Examination Survey
9:00AM-11:00AM
Abstract Number: 1596
Atherosclerotic Cardiovascular Disease in Psoriatic Arthritis: Evaluation of Risk Factor Management and Use of Aspirin and Statin for Prevention in a Primary Care Setting
9:00AM-11:00AM
Abstract Number: 1274
Atmospheric Temperature and the Incidence of Gout Flare: Data from the Korea Meteorological Association and National Health Insurance Service
9:00AM-11:00AM
Abstract Number: 1713
Attainment of Low Disease Activity and Remission in SLE Patients Who Started with High Disease Activity in the Atacicept Phase IIb Address II Study and Its Long-Term Extension
9:00AM-11:00AM
Abstract Number: 1314
Autoantibodies and Clinical Outcomes in Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases
9:00AM-11:00AM
Abstract Number: 1307
Autoantibodies in Idiopathic Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features – a Prospective Study
9:00AM-11:00AM
Abstract Number: 1574
Autoantibodies Present in Saliva from Sjogren’s Syndrome and Non-Sjogren’s Sicca Patients Are Not Detectible in Serum
9:00AM-11:00AM
Abstract Number: 1699
Autoantibodies to M-Phase Phosphoprotein I (MPP-1: KIF20B) in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1341
Autoantibodies to Mi-2 Alpha and Mi-2 Beta in Patients with Myositis
9:00AM-11:00AM
Abstract Number: 1423
Autoantibody Testing in Pediatric Localized Scleroderma (LS)
9:00AM-11:00AM
Abstract Number: 1017
Autoantigen Pentraxin-3 Is an Inflammatory Cytokine Storms Suppressor By Switching Monocytes Pyroptosis to Apoptosis in a Complement-Dependent Manner in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1026
Autoinflammatory Diseases, Particularly SAVI and Candle, Are Driven By Chronically Active Type I Interferons
9:00AM-11:00AM
Abstract Number: 1075
Automated Multiparameter Microscopy and Image Analysis: Next Generation Synovial Tissue Histology
9:00AM-11:00AM
Abstract Number: 1353
Autophagy Marker LC3 Accumulates in Immune-Mediated Necrotizing Myopathy Muscle Fibres
9:00AM-11:00AM
Abstract Number: 1057
Autophagy Promotes Citrullination of Vimentin and Its Interaction with Major Histocompatibility Complex Class II in Synovial Fibroblasts
9:00AM-11:00AM
Abstract Number: 1568
Azathioprine and Mycophenolate for Management of Sjögren’s Syndrome-Related Interstitial Lung Disease: A Retrospective Cohort Study
9:00AM-11:00AM
Abstract Number: 1561
B Lymphocyte Depletion Therapy with Rituximab in Primary Sjögren’s Syndrome: Indications , Effectiveness and Ultrasonographic Response
9:00AM-11:00AM
Abstract Number: 1518
Baricitinib and Tofacitinib in Real Life – Does Obesity Impact Response to Janus Kinase Inhibitor Therapy in Rheumatoid Arthritis?
9:00AM-11:00AM
Abstract Number: 1526
Baseline Characteristics and Outcomes in Patients with Anemia in Clinical Studies of Tofacitinib
9:00AM-11:00AM
Abstract Number: 1495
Baseline Characteristics of Methotrexate Inadequate Responder Patients with RA Who Achieved Low Disease Activity with Tofacitinib Monotherapy
9:00AM-11:00AM
Abstract Number: 1802
Behcet’s Disease in the Southwestern United States
9:00AM-11:00AM
Abstract Number: 1459
Bone Erosion Volume Changes Measured By HR-pQCT at 3-Months after Initiation of Anti-TNF Treatment Predicted Erosion Volume Changes at 1-Year in RA
9:00AM-11:00AM
Abstract Number: 1597
Bone Mineral Density and Serum Biomarkers of Bone Turnover in Ankylosing Spondylitis Patients Treated with Secukinumab: 2-Year Data from the Pivotal Phase 3 Study
9:00AM-11:00AM
Abstract Number: 1755
Burden of Illness Associated with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States
9:00AM-11:00AM
Abstract Number: 1283
Calcium Pyrophosphate Crystal Deposition in a Cohort of 48 Patients with Gitelman Syndrome
9:00AM-11:00AM
Abstract Number: 1139
Can Body Composition Explain the Sex Disparity in Risk of Osteoarthritis?
9:00AM-11:00AM
Abstract Number: 1258
Can Patients Enter Medical History Data By Self-Report Directly into an Electronic Medical Record (EMR)? “Private Medical History” (PMH) Software for Physician Report in EMR Format and Patient Storage to Correct and Update Medical History for Any EMR
9:00AM-11:00AM
Abstract Number: 1164
Canadians’ Views about Using Big Data in Health Research from a National Online Survey: A Partnership of Patient-Consumers and Researchers
9:00AM-11:00AM
Abstract Number: 1325
Canakinumab Treatment in Adult-Onset Still’s Disease: Case Series
9:00AM-11:00AM
Abstract Number: 1589
Cardiac Biomarkers and Carotid Atherosclerosis and Its Progression in Psoriatic Disease
9:00AM-11:00AM
Abstract Number: 1185
Cause and Rate of Hospitalization of Lupus Patients
9:00AM-11:00AM
Abstract Number: 1140
Cause-Specific Mortality in Knee, Hip and Hand Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1111
CBS004, a Novel Monoclonal Antibody Against Bdca-2 Inhibits TLR-Induced Activation of Human pDC in Vitro and In Vivo. a Novel Therapeutic Target for Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 987
CCL11 Is Involved in Cell Migration in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1090
Cell-Free Mitochondrial DNA As a Novel Biomarker in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1765
Cerebrospinal Fluid Biomarker of Disease Activity: Significance in ANCA-Related Hypertrophic Pachymeningitis
9:00AM-11:00AM
Abstract Number: 1688
Changes in Heart Rate Variability Reflect Clinical Improvement and Flare in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1083
Changes of Innate Lymphoid Cells in Peripheral Blood of Patients with Systemic Lupus Erythematosus and Its Correlations with Clinical Markers
9:00AM-11:00AM
Abstract Number: 1388
Characteristics and Symptom Severity in 21,101 Patients Reporting Systemic Lupus Erythematous in the Patientslikeme Online Health Community
9:00AM-11:00AM
Abstract Number: 1812
Characterization and Prevalence of Morbus Behçet in Switzerland
9:00AM-11:00AM
Abstract Number: 1110
Characterization of CD20+ T Cells in Patients with Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1117
Characterization of the Esophageal Microbiome in Patients with Systemic Sclerosis (SSc)
9:00AM-11:00AM
Abstract Number: 1068
Characterization of the Role of Endocannabinoid System Using Jwh-133, a Selective Cannabinoid CB2 Receptor Agonist, in IL-1β-Induced Inflammation in Human Rheumatoid Arthritis Synovial Fibroblasts
9:00AM-11:00AM
Abstract Number: 1215
Characterizing Changes in the Median Nerve during Hand Grip Using Dynamic Sonographic Imaging
9:00AM-11:00AM
Abstract Number: 1763
Characterizing the Gut and Plasma Metabolomes in Patients with ANCA-Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 1121
Characterizing the T Cell Receptor Repertoire in Patients with Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1130
Chronic Risk Factors for Recurrent Gout Flares Among Established Gout Patients: A Prospective Cohort Analysis
9:00AM-11:00AM
Abstract Number: 1554
Cigarette Smoking Does Not Affect Treatment Response to Tofacitinib in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1782
Cigarette Smoking Is a Risk Factor for IgG4-Related Disease
9:00AM-11:00AM
Abstract Number: 1013
Circulating Hybrid M1/M2 Monocytes/Macrophages in Systemic Sclerosis Patients with Lung Involvement
9:00AM-11:00AM
Abstract Number: 1474
Circulating Transfer RNA-Derived Small RNAs Are Altered in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1754
Clinical and Economic Characteristics of Patients Diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome) in the United States
9:00AM-11:00AM
Abstract Number: 1321
Clinical and Genetic Analysis of the Patients Mimicking Familial Mediterranean Fever
9:00AM-11:00AM
Abstract Number: 1306
Clinical Characteristics and Treatment Patterns in Patients with Interstitial Pneumonia with Autoimmune Features (IPAF)
9:00AM-11:00AM
Abstract Number: 1809
Clinical Characteristics of Older Age-Onset Behçet Syndrome Patients
9:00AM-11:00AM
Abstract Number: 1582
Clinical Correlations and Expression Pattern of the Autoimmunity Susceptibility Factor Diora-1 in Primary Sjögren’s Syndrome
9:00AM-11:00AM
Abstract Number: 1207
Clinical Evaluation Correlates Poorly with Ultrasound and Magnetic Resonance Imaging of Joints and Entheses in Early Peripheral Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1807
Clinical Features and Disease Course of Neurologic Involvement in Behcet’s Disease
9:00AM-11:00AM
Abstract Number: 1313
Clinical Features and Timing of Studies in Interstitial Lung Disease with Autoimmune Disease Features: Do Autoantibody Panels Improve Diagnostic Yields and/or Increase Costs?
9:00AM-11:00AM
Abstract Number: 1645
Clinical Features of Axial Spondyloarthritis Patients Diagnosed in Secondary Versus a Tertiary Hospital
9:00AM-11:00AM
Abstract Number: 1448
Clinical Impact of Articular Ultrasound in Diagnosis and Follow-up of Patients with Polyarthritis
9:00AM-11:00AM
Abstract Number: 1493
Clinical Predictor Factors Associated with Sustained Disease Activity Among Patients with Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1450
Clinical Radiology Reports Are Unreliable for Assessment of Radiographic Structural Progression in US Veterans with Rheumatoid Arthritis Initiating Tumor Necrosis Factor Inhibitor Therapy
9:00AM-11:00AM
Abstract Number: 1776
Clinical Significance of Allergy in IgG4-Related Disease
9:00AM-11:00AM
Abstract Number: 1704
Clinical SLE Disease Activity Index Score of Zero May be a More Pragmatic Outcome Measure in SLE Studies
9:00AM-11:00AM
Abstract Number: 1570
Clinical Utility of a Second Minor Salivary Gland Biopsy in Patients with Suspected Sjögren’s Syndrome: A Retrospective Cohort Study
9:00AM-11:00AM
Abstract Number: 1318
Clinical Utility of Ultrasonography (US) in Diagnosing and Monitoring Disease Activity of Relapsing Polychondritis (RP) and Comparison of Cartilaginous US Findings between RP, Repeated Trauma and Healthy Subjects
9:00AM-11:00AM
Abstract Number: 1649
Cohort Identification of Axial Spondyloarthritis in a Large Healthcare Dataset: Current and Future Methods
9:00AM-11:00AM
Abstract Number: 1329
Combination of Methotrexate and Leflunomide in Refractory Chronic Adult Onset Still’s Disease: Case Series and Literature Review
9:00AM-11:00AM
Abstract Number: 1452
Combination of Ultrasound Power Doppler-Verified Synovitis and Seropositivity Accurately Identifies Patients with Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1089
Commensal Gut Bacteria of Anti-Ro Positive Mothers of Children with Neonatal Lupus in Aggregate Resemble Healthy Subjects without Overt Dysbiosis of Abundance of Microorganisms
9:00AM-11:00AM
Abstract Number: 1565
Comorbidity Burden in Primary Sjögren’s Syndrome: A Long-Term Observation in Clinical Practice
9:00AM-11:00AM
Abstract Number: 1098
Comparative Analysis of the Total Proteome of the Skin Lesions from Cutaneous Lupus Erythematosus (CLE) and Dermatomyositis (DM)
9:00AM-11:00AM
Abstract Number: 1174
Comparative Cost per Response for Four Clinical Outcomes of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1615
Comparative Risk of Atrial Fibrillation and Cardiovascular Events between TNF-Inhibitors and Ustekinumab in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study
9:00AM-11:00AM
Abstract Number: 1534
Comparative Risk of Diabetes Mellitus in Rheumatoid Arthritis Patients Treated with Different Biologics- a Cohort Study
9:00AM-11:00AM
Abstract Number: 1375
Comparative Safety of Flavocoxid (Limbrel) Versus Nsaids Among Osteoarthritis Patients
9:00AM-11:00AM
Abstract Number: 1773
Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis Due to Behçet’s Disease. National Multicenter Study of 177 Cases
9:00AM-11:00AM
Abstract Number: 1285
Comparision of Urate Burden in Well and Poorly Controlled Gout Patients: A Dual-Energy CT Study
9:00AM-11:00AM
Abstract Number: 1549
Comparison of Adverse Events and Survival of Treatment in Patients with Rheumatoid Arthritis Receiving Combined Treatment of Methotrexate and Leflunomide Versus Those Receiving Biological Therapy
9:00AM-11:00AM
Abstract Number: 1186
Comparison of Biologic Discontinuation in Patients with Elderly-Onset Vs Younger-Onset Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1778
Comparison of Clinical and Angiographic Features of Arterial Involvement in Takayasu’s Arteritis and Behcet’s Disease
9:00AM-11:00AM
Abstract Number: 1483
Comparison of Clinical Features of Seronegative and Seropositive Early Rheumatoid Arthritis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients
9:00AM-11:00AM
Abstract Number: 1151
Comparison of Methodologic Approaches to Maximize the Validity of Fitbit Device Data for Arthritis-Related Research Purposes
9:00AM-11:00AM
Abstract Number: 1033
Comparison of Oral Administration of Diacerein, Intra-Articular Injection of Diacerein Solution, and Intra-Articular Injection of Diacerein-Loaded Nanoparticle in Osteoarthritis Rat Model
9:00AM-11:00AM
Abstract Number: 1322
Comparison of Serum Hepcidin and Calprotectin Levels in Patients with Familial Mediterranean Fever (FMF) and Healthy Subjects
9:00AM-11:00AM
Abstract Number: 1214
Comparison of Ultrasound Features of Major Salivary Glands in Sarcoidosis, Amyloidosis, and Sjögren’s Syndrome
9:00AM-11:00AM
Abstract Number: 1380
Complications Following Total Hip Arthroplasty in Inflammatory Versus Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1043
Computational Analysis of Potential Self-Antigens in Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1667
Confirmatory Factor Analysis of the Patient-Reported Perceived Deficits Questionnaire in Systemic Lupus Erythematosus: Cautions for Use of Subscales
9:00AM-11:00AM
Abstract Number: 1073
Connective Tissue Growth Factor Associates with Angiogenesis through Notch-1 Activation in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1193
Consensus Statements on Scanning Conventions and Documentation in Musculoskeletal Ultrasound
9:00AM-11:00AM
Abstract Number: 1668
Construction and Validation of a Frailty Index As a Novel Health Measure in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1149
Contemporary Prevalence of Gout and Hyperuricemia in the United States (National Health and Nutrition Examination Survey [NHANES] 2015-2016) and Decadal Trends (NHANES 2007-2016)
9:00AM-11:00AM
Abstract Number: 1249
Contraception Compliance in Patients with Rheumatological Diseases on Disease Modifying Antirheumatic and Cytotoxic Drugs
9:00AM-11:00AM
Abstract Number: 1211
Contribution of Ultrasonography Examination in Symptomatic Radiographic Knee OA
9:00AM-11:00AM
Abstract Number: 1354
Correlates of Neuropathic Pain in Knee Osteoarthritis: The Modified Paindetect Questionnaire and the Osteoarthritis Initiative
9:00AM-11:00AM
Abstract Number: 1663
Correlation between Biologics and Bath Ankylosing Spondylitis Metrology Index within the First 12 Months of Treatment in Patients with Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1453
Correlation between Clinical and Ultrasonographic Remission? the Effect of Non-Inflammatory Patient-Based Factors on Different Remission Definitions
9:00AM-11:00AM
Abstract Number: 1487
Correlation between Cytokine Levels and Power-Doppler Ultrasound Activity Is BMI Dependent, and Different in ACPA Positive and ACPA Negative RA with Wrist Arthritis
9:00AM-11:00AM
Abstract Number: 1682
Correlation between SLE Specific and Generic Health Related Quality of Life Surveys, and Their Association with Patient Global Rating of Change and Lupus Low Disease Activity State: A Longitudinal Study
9:00AM-11:00AM
Abstract Number: 1395
Could the Shortening of the Electronic Osteoarthritis Knee and Hip Quality of Life (OAKHQOL) Questionnaire Improve Its Metric Properties?
9:00AM-11:00AM
Abstract Number: 991
Critical Role of Interleukin-1α (IL-1α) in IL-1β-Induced Inflammatory Responses: Cooperation with NF-κBp65 in Transcriptional Regulation
9:00AM-11:00AM
Abstract Number: 1530
CRP Changes during Bacterial Infections in Baricitinib-Treated Patients with RA
9:00AM-11:00AM
Abstract Number: 1613
Dactylitis in Early Spondyloarthritis. Baseline Data from a Prospective French National Cohort
9:00AM-11:00AM
Abstract Number: 1392
Decreased Injection Site Pain Associated with New Etanercept Formulation in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1447
Decreased Lymphatic Drainage in the Hands of Flaring RA Patients As Measured By Indocyanine Green Clearance Via Real Time Near Infrared Imaging
9:00AM-11:00AM
Abstract Number: 1598
Depression and Anxiety Reduce Probability of Achieving a State of Minimal Disease Activity in Patients with Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1389
Depression and the Patient Reported Outcomes Measurement Information System in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1660
Depression Has a Greater Impact on Psoriatic Arthritis Than Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1510
Depression Is a Major Driver of Functional Capacity in Patients with Rheumatoid Arthritis Regardless of Disease Activity
9:00AM-11:00AM
Abstract Number: 1738
Detect Outperforms Echocardiography Based Screening Guidelines for Early Detection of Systemic Sclerosis Associated Pulmonary Arterial Hypertension
9:00AM-11:00AM
Abstract Number: 1370
Detection of an Autoantibody Profile to Characterize Patients with Early (Pre-symptomatic) Knee Osteoarthritis: Data from the Osteoarthritis Initiative
9:00AM-11:00AM
Abstract Number: 1052
Detection of Precursors of RANK- Osteoclast-like Cells (Olcs) in Peripheral Blood and Olcs in Bone Tissue from Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 1263
Develop a Master Algorithm for Drug Withdraw Strategy in Reduction of Adverse Events – a Machine Learning Model from the Smart System of Disease Management (SSDM)
9:00AM-11:00AM
Abstract Number: 1037
Develop an in Vitro Model to Test the Different Behavior of mtDNA in OA and Healthy Patients, Based on Mitochondrial Activity and Metabolic Response
9:00AM-11:00AM
Abstract Number: 1261
Development a Core Domain Set to Assess Shared Decision Making Interventions in Rheumatology: An OMERACT White Paper to Facilitate Endorsement
9:00AM-11:00AM
Abstract Number: 1394
Development and Pilot of a Patient Satisfaction Scale in Rheumatology
9:00AM-11:00AM
Abstract Number: 1042
Development of a Neo-Epitope Specific Assay for Serological Assessment of Type X Collagen Degradation and Its Potential Diagnostic Value for Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1455
Development of a Predictive Model of Radiological Damage in Patients with Rheumatoid Arthritis Based on Artificial Intelligence
9:00AM-11:00AM
Abstract Number: 999
Development of an Affimab Engineered to Simultaneously Target IL-6 and Tnfα for Therapeutic Use in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1706
Development of an Online Lupus Self-Management Program Based on the Transtheoretical Model of Change
9:00AM-11:00AM
Abstract Number: 1559
Development of Lymphoma in Patients with Sjogren’s Syndrome
9:00AM-11:00AM
Abstract Number: 1368
Diabetes Mellitus Is Not a Risk Factor for Knee Osteoarthritis, a Systematic Review and Meta-Analysis
9:00AM-11:00AM
Abstract Number: 1229
Diagnosing Prosthetic Joint Infections in Patients with Inflammatory Arthritis
9:00AM-11:00AM
Abstract Number: 1735
Diagnostic Accuracy of MR Angiography in a Cohort with Systemic Sclerosis Compared to Other Rheumatic Diseases with Acral Hypoperfusion
9:00AM-11:00AM
Abstract Number: 1569
Diagnostic Performance of Labial Salivary Gland Biosy, Serological and Clinical Data in Sjogrens Syndrome. in Argentinian Multicenter
9:00AM-11:00AM
Abstract Number: 1441
Diagnostic Performances of Antibodies Against Carbamylated Proteins in US Based Populations with Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 1310
Diagnostic Utility of Myositis Antibodies in Patients with Interstitial Lung Disease and Suspected Underlying Connective Tissue Disease
9:00AM-11:00AM
Abstract Number: 1132
Diet Modification for Gout Patients: Effects on Gout Attacks and Risk Factors for Metabolic Syndrome
9:00AM-11:00AM
Abstract Number: 1695
Differences between Early and Adult-Onset Systemic Lupus Erythematosus in Cohort of Argentinian Patients
9:00AM-11:00AM
Abstract Number: 1407
Differences in the Measurement Properties of the Patient-Reported Outcomes Measurement Information System Physical Function Short-Form 10a Among Racial/Ethnic Minorities with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1035
Different Cartilage-Bone Unit in Patients with Primary Osteoarthritis and Secondary Osteoarthritis Caused By Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1442
Differential Chemical Isotope Labeling Liquid Chromatography Mass Spectrometry and a Universal Metabolome Standard Reveals a Metabolome Profile with Consistent Accuracy for Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1059
Differentially-Utilized Transcription Factors and Enhancers in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes
9:00AM-11:00AM
Abstract Number: 1602
Disease Characteristics, Quality of Life, and Work Productivity By Enthesitis Sites: Real-World Data from the US Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
9:00AM-11:00AM
Abstract Number: 1670
Disease Course Patterns in Systemic Lupus Erythematosus: Impact on Long-Term Outcomes
9:00AM-11:00AM
Abstract Number: 1741
Disease Duration and Autoantibodies Predict Distinct Skin Score Trajectories in Diffuse Cutaneous Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1742
Disease-Specific Autoantibodies Associate with Remarkably Different Risk of Development of Significant Lung Fibrosis in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1046
Distinct Balance of TNF-α/IL-10 in Circulating and Infiltrating CD163+ Macrophages between Rapidly and Slowly Progressive Symptomatic Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1014
Distinct Macrophage Phenotype and Bioenergetic Profiles in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1074
Distinct Metabolic Profile in the Urine of Rheumatoid Arthritis Patients:a Possible Link to Arthritis Phenotypes
9:00AM-11:00AM
Abstract Number: 1113
Distinct Pathways in Anti-RNP-Associated Pulmonary Hypertension and Anti-RNP-Associated Raynaud’s Phenomenon
9:00AM-11:00AM
Abstract Number: 1520
DMARD Hepatotoxicity in Rheumatoid Arthritis and Its Association with the Surrogates of Metabolic Syndrome
9:00AM-11:00AM
Abstract Number: 1463
Do Anti-Citrullinated Protein Antibodies and Anti-Sjögren’s-Syndrome-Related Antigen a Double Positive Patients with Secondary Sjögren’s Syndrome and RA Have Higher Joint Disease Activity?
9:00AM-11:00AM
Abstract Number: 1630
Do Symptoms of Depression and Anxiety Influence Treatment Response and Long-Term Physical Health Outcomes in Ankylosing Spondylitis?
9:00AM-11:00AM
Abstract Number: 1326
Does Testing for SAA Is More Beneficial Than CRP for the Follow-up of Patients with Familial Mediterranean Fever ?
9:00AM-11:00AM
Abstract Number: 1112
Downregulated Expression of Interferon Regulatory Factor 8 in Circulating Monocytes Exhibits Pro-Fibrotic Phenotype in Patients with Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1058
Doxycycline Directly Scavenges Reactive Oxygen Species and Inhibits the Formation of Malondialdehyde-Acetaldehyde-Protein Adducts – a Novel Mechanism of Action for an Old Drug
9:00AM-11:00AM
Abstract Number: 1259
Driving Performance and Safety in Rheumatoid Arthritis: A Systematic Review
9:00AM-11:00AM
Abstract Number: 1275
Dual-Energy CT for the Diagnosis of Gout: A Prospective Study in Patients with No Prior History of Gout
9:00AM-11:00AM
Abstract Number: 1084
Dysfunction of the DNASE1L3 Pathway and Antigen Accumulation in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 1330
Dyskeratotic Cells in Persistent Pruritic Skin Lesions Are Apoptotic and Associated with High Levels of Serum IL-18, and Possibly Predict the Outcomes in Adult-Onset Still’s Disease
9:00AM-11:00AM
Abstract Number: 1471
ECV304 Cells Self-Citrullinate Proteins Targeted By Anti-Citrullinated Protein/Peptide Autoantibodies from Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 1276
Effect of Colchicine on Diabetes Incidence Among Gout Patients in a Veterans’ Affairs Population
9:00AM-11:00AM
Abstract Number: 1525
Effect of JAK-Inhibitor Versus Bdmards on Quality of Life in Rheumatoid Arthritis : A Meta Analysis of Randomized Controlled Trials
9:00AM-11:00AM
Abstract Number: 1226
Effect of New Method for Pre-Administration Assessment of Intravenous Biologics on Infections in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1724
Effectiveness and Safety of Rituximab for the Treatment of Refractory Systemic Sclerosis Associated Calcinosis: A Case Series
9:00AM-11:00AM
Abstract Number: 1740
Effectiveness and Safety of Tocilizumab for the Treatment of Refractory Systemic Sclerosis Associated Interstitial Lung Disease: A Case Series
9:00AM-11:00AM
Abstract Number: 1490
Effects of Biologic Drugs on Prognosis of Rheumatoid Arthritis Among Patients with Poor Glycated Hemoglobic A1c (HbA1c) Control
9:00AM-11:00AM
Abstract Number: 1400
Effects of Childhood-Onset SLE on Academic Achievements and Employment in Adult Life
9:00AM-11:00AM
Abstract Number: 1036
Effects of Three Potential Anabolic Disease-Modifying Osteoarthritis Drugs – Sprifermin, Insulin-like Growth Factor 1 and Bone Morphogenetic Protein 7 – on Matrix Production and the Phenotype of Articular Chondrocytes
9:00AM-11:00AM
Abstract Number: 1291
Efficacy and Safety of Anakinra in Congestive Heart Failure Patients, Including Lvad, with Acute Gouty Arthritis: A Retrospective Study of 36 Patients at an Academic Medical Center
9:00AM-11:00AM
Abstract Number: 1769
Efficacy and Safety of Biomimic Rituximab in Granulomatosis with Polyangiitis – Experience from a Single Tertiary Care Centre in India
9:00AM-11:00AM
Abstract Number: 1546
Efficacy and Safety of Corticosteroids in Rheumatoid Arthritis: Systematic Literature Review and Practical Recommendations
9:00AM-11:00AM
Abstract Number: 1811
Efficacy and Safety of Interferon α2a As an Add-on Treatment for Refractory Behcet’s Uveitis
9:00AM-11:00AM
Abstract Number: 1791
Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome in a Phase III Study: A Prespecified Analysis By Baseline Patient Demographics and Disease Characteristics
9:00AM-11:00AM
Abstract Number: 1745
Efficacy of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss) Treatments According to the Type of Manifestations Based on Analysis of 376 Patients
9:00AM-11:00AM
Abstract Number: 1513
Efficacy of Etanercept By Body Mass Index in Women and Men with Rheumatoid Arthritis: A Post Hoc Analysis of Three Randomized Trials
9:00AM-11:00AM
Abstract Number: 1367
Efficacy of Intra-Articular Cntx-4975 for Knee OA Pain Varies with Radiographic Presence of OA in the Opposite Knee
9:00AM-11:00AM
Abstract Number: 1308
Efficacy of Rituximab for Connective Tissue Disease (CTD) Associated Interstitial Lung Disease (ILD):a Single Center Study of 47 Patients
9:00AM-11:00AM
Abstract Number: 1475
Eicosanoid Mediators of Systemic Inflammation and Arthritis in the Elderly
9:00AM-11:00AM
Abstract Number: 1255
Elevated Serum Globulin Gap As a Reliable and Cost-Savings Marker of Inflammation in Patients with Systemic Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 1350
Elevated Serum Levels of Soluble CD146 and CD146 Autoantibody in Patients with Polymyositis/Dermatomyositis
9:00AM-11:00AM
Abstract Number: 1499
Elevated Serum MMP-3 in Remission Predicts Relapsed in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 993
Elucidating the Role of the Lymphatic System in the Pathogenesis of Psoriasis and Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1415
Emapalumab, an Anti-Interferon Gamma Monoclonal Antibody in Two Patients with NLRC4-Related Disease and Severe Hemophagocytic Lymphohistiocytosis (HLH)
9:00AM-11:00AM
Abstract Number: 1409
Empowerment in Hispanic Rheumatoid Arthritis Patients: A Validation Study
9:00AM-11:00AM
Abstract Number: 1094
Endogenous Ifnβ Production Is Required for Efficient BCR Crosslinking and Survival of SLE B Cells
9:00AM-11:00AM
Abstract Number: 1432
Engaging Patients and Parents to Improve Mental Health for Youth with Rheumatologic Disease
9:00AM-11:00AM
Abstract Number: 1535
Enhancing Patient Ability to Process and Use Information about Medication Risks and Benefits
9:00AM-11:00AM
Abstract Number: 1196
Entheseal Involvement in Asymptomatic Healthy Subjects: Prevalence and Distribution of the Ultrasound Elementary Lesions of Enthesitis, with a Particular Focus on Those Indicating “Active” Inflammation
9:00AM-11:00AM
Abstract Number: 1759
Eosinophilic Granulomatosis with Polyangiitis: A Monocentric Cohort Analysis of Manifestations and Relapses of ANCA-Positive and ANCA-Negative Patients
9:00AM-11:00AM
Abstract Number: 1124
Epidemiological Characteristics of Inpatient Admissions for Acute Inflammatory Gout Arthropathy and Factors Affecting Length of Stay: A National Level Study
9:00AM-11:00AM
Abstract Number: 1651
Epidemiology of Depression and Anxiety in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis
9:00AM-11:00AM
Abstract Number: 992
Epigallocatechin-3-Gallate (EGCG) Suppresses Systemic Inflammation By Inhibiting IL-6-Induced STAT3 Activation in Cultured Hepatocytes and in Liver Tissue of Adjuvant-Induced Arthritis (AIA) Rats
9:00AM-11:00AM
Abstract Number: 1403
Estimates of Minimally Important Differences and Patient Acceptable Symptom State in Five Patient-Reported Outcomes Measurement Information System Short-Forms Among Individuals with SLE
9:00AM-11:00AM
Abstract Number: 1153
EULAR ‘Points to Consider’ for the Conduction of Workforce Requirement Studies in Rheumatology
9:00AM-11:00AM
Abstract Number: 1278
Evaluating a Causal Role of Mitochondrial Variation in the Development of Gout
9:00AM-11:00AM
Abstract Number: 1382
Evaluating Results of an Interferon-γ Release Assay in Patients with Autoimmune Skin Disease on Hydroxychloroquine
9:00AM-11:00AM
Abstract Number: 1421
Evaluating the Validity of SIX-Minute Walk Test in Juvenile Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1716
Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis in a Phase II Trial of Abatacept Vs. Placebo
9:00AM-11:00AM
Abstract Number: 1677
Evaluation of Erythrocyte Sedimentation Rate As a Marker of Disease Activity in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1323
Evaluation of Prolidase and HIF-1α Levels in Patients with Familial Mediterranean Fever (FMF)
9:00AM-11:00AM
Abstract Number: 1761
Evaluation of the Functional Activity of Endothelial Progenitor Cells in Patients with ANCA-Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 1584
Evaluation of the Performance of the 2016 American College of Rheumatology-European League Against Rheumatism (Acr-Eular) Classification Criteria for Primary Sjogren`S Syndrome in Different Centers of Argentina
9:00AM-11:00AM
Abstract Number: 1383
Examining Cutaneous Disease Activity As an Outcome Measure for Clinical Trials in Dermatomyositis
9:00AM-11:00AM
Abstract Number: 1578
Exercise Increases Aerobic Capacity in Primary Sjögren´s Syndrome: A Randomized Controlled Trial
9:00AM-11:00AM
Abstract Number: 1204
Experience Matters in Ultrasound Assessment of Gout
9:00AM-11:00AM
Abstract Number: 1176
Experiences of Urban First Nations and Métis Patients Accessing and Navigating the Health System for Inflammatory Arthritis Care
9:00AM-11:00AM
Abstract Number: 1717
Expert Consensus on the Screening, Treatment, and Management of Patients with Systemic Sclerosis-Interstitial Lung Disease, and the Potential Role of Anti-Fibrotics in a Treatment Paradigm for Systemic Sclerosis-Interstitial Lung Disease: A Delphi Consensus Study
9:00AM-11:00AM
Abstract Number: 1689
Explaining the Discrepancy between Physician and Patient-Reported Measures of Disease Activity in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1545
Exploring the Effects of Depressive Symptoms on the Efficacy of Sarilumab and Improvements in Health-Related Quality of Life
9:00AM-11:00AM
Abstract Number: 1586
Expression of JAK Proteins and Autophagy Markers in Sjögren’s Syndrome Patients
9:00AM-11:00AM
Abstract Number: 1107
Expression Quantitative Trait Loci -eQTL- Analysis in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1418
External Validation of the Autoinflammatory Disease Activity Index (AIDAI) in Patients with Colchicine-Resistant FMF, Hids/Mkd, and TRAPS: Results from a Pivotal, Phase 3 Trial of Canakinumab
9:00AM-11:00AM
Abstract Number: 1593
Extra-Articular Manifestations, Neoplasms and Cardiovascular Events in a Series of Spondyloarthritis from a Single Center
9:00AM-11:00AM
Abstract Number: 1101
Extracellular Vesicle-Mediated Delivery of EBV SMALL RNA (EBER1) Activates LUPUS Nephritis Related Antiviral Immunity in Tubular Epithelial CELLS VIA TLR3
9:00AM-11:00AM
Abstract Number: 1335
Extracellular Vesicles Induce Pro-Inflammatory Cytokines in Dermatomyositis
9:00AM-11:00AM
Abstract Number: 1801
Factors Associated with Damage Progression in Behçet’s Syndrome Uveitis
9:00AM-11:00AM
Abstract Number: 1478
Factors Associated with Disability and Health-Related Quality of Life in Biologic-Treated Patients with Rheumatoid Arthritis in Persistent Moderate Disease Activity
9:00AM-11:00AM
Abstract Number: 1396
Factors Associated with Specific Quality of Life Evolution in SLE Patients: A French Prospective Longitudinal Multicenter Study
9:00AM-11:00AM
Abstract Number: 1133
Factors for Opioids Use in the Early Treatment Options for the Knee Osteoarthritis Patients
9:00AM-11:00AM
Abstract Number: 1777
Factors Related to Deterioration of IgG4-Related Disease in Untreated Patients with IgG4-Related Disease
9:00AM-11:00AM
Abstract Number: 1661
Factors That May be Associated with Uveitis in Patients with Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1319
Familial Mediterranean Fever Related Damage Assessed By Auto-Inflammatory Disease Damage Index (ADDI) and Associated Factors with Damage
9:00AM-11:00AM
Abstract Number: 1159
Fat Mass Is Associated with Musculoskeletal Pain in Women : A Three-Year Longitudinal Study
9:00AM-11:00AM
Abstract Number: 1393
Fatigue in Men and Women with Psoriatic Arthritis: An International Qualitative Study
9:00AM-11:00AM
Abstract Number: 1387
Fatigue in Patients with Rheumatoid Arthritis As Compared to Different Groups of Cancer Patients
9:00AM-11:00AM
Abstract Number: 1664
Fatigue Measurements in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1548
Favorable Effect of Hydroxychloroquine in Patients with Rheumatoid Arthritis and Diabetes or Impaired Glucose Control
9:00AM-11:00AM
Abstract Number: 1786
Favourable Response to Rituximab for the Treatment of IgG4-Related Disease: Long-Term Follow-up of 10 Patients Resistant to Glucocorticoids and Immunosuppressives
9:00AM-11:00AM
Abstract Number: 1725
Fecal Microbiota Transplantation in Patients with Systemic Sclerosis- a Pilot Study
9:00AM-11:00AM
Abstract Number: 1462
Fibrin Deposition and Neutrophil Infiltration of Rheumatoid Arthritis Synovium Are Associated with Duration of Morning Stiffness
9:00AM-11:00AM
Abstract Number: 1072
Fibrin-Triggered Chondrosynovial Adhesion As a Novel Mechanism of Cartilage Damage in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1029
Fibroblast-like Synoviocytes As Immune Effectors in the Pathogenesis of Synovial Lesion in Antibiotic-Refractory Lyme Arthritis
9:00AM-11:00AM
Abstract Number: 1201
Finger Extensor Tendon Involvement Is Frequent in Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1357
Flexion Contractures Are Associated with Worse Pain, Stiffness, and Function in Patients with Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1240
Foot Osteomyelitis in Inflammatory Rheumatic Diseases: A Retrospective Observational Study
9:00AM-11:00AM
Abstract Number: 1633
Fragility Fractures in Psoriatic Arthritis Patients: A Matched-Control Study
9:00AM-11:00AM
Abstract Number: 1703
Fragmented Qrs in Patients with Systemic Lupus Erythematosus: Relation to the Disease Activity: A Cross-Sectional Study
9:00AM-11:00AM
Abstract Number: 1537
Frequency and Duration of Early Non-Serious Adverse Events in Rheumatoid Arthritis Patients Treated with Tofacitinib 5 Mg Twice Daily As Monotherapy and Combination Therapy
9:00AM-11:00AM
Abstract Number: 1592
Frequency and Pattern of the Uveitis in Spondyloarthritis with Biological Therapy
9:00AM-11:00AM
Abstract Number: 1636
Frequency and Specificity of MRI Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis and Non-Specific Back Pain: First Analysis of MRI Scans from the Assessments in Spondyloarthritis International Society Classification Cohort
9:00AM-11:00AM
Abstract Number: 1166
Friend or Foe: Does Walking at Higher Intensities Increase or Decrease the Risk of Total Knee Arthroplasty over Five Years?
9:00AM-11:00AM
Abstract Number: 986
Fucosylated Tumor Necrosis Factor α Is Expressed in Rheumatoid Arthritis Synovial Tissues and Is Involved in Monocyte Adhesion
9:00AM-11:00AM
Abstract Number: 1336
Functional, Radiographic and Serologic Correlates of Anti-SSA52 Kd – Associated Interstitial Lung Disease
9:00AM-11:00AM
Abstract Number: 1760
Fungal Composition of the Nasal Mucosa in Patients with Granulomatosis with Polyangiitis
9:00AM-11:00AM
Abstract Number: 1603
Gender-Specific Differences in Chinese Patients with Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 1109
Gene Expressions of TMEM176A and TMEM176B Were Prominent at the Stage of Subclinical Pulmonary Vascular Disease in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1119
Genetic Signatures from RNA Sequencing of Pediatric Localized Scleroderma (LS) Skin
9:00AM-11:00AM
Abstract Number: 1135
Genome-Wide Meta-Analysis Identified Two Novel Variants Associated with Hallux Valgus
9:00AM-11:00AM
Abstract Number: 1714
Global Consensus Building and Prioritization of Major Challenges in Lupus Diagnosis, Care, Treatment and Research
9:00AM-11:00AM
Abstract Number: 1386
Golimumab Improves Work Productivity and Activity As Well As Quality of Life in Patients with Rheumatoid Arthritis (RA), Psoriasis Arthritis (PsA) and Axial Spondyloarthritis (axSpA): Interim Results from a Non-Interventional Study in Austria (Go Active)
9:00AM-11:00AM
Abstract Number: 1147
Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): 1-Year Results from a Non- Interventional Trial in Germany
9:00AM-11:00AM
Abstract Number: 1126
Gout and Chronic Pain in Older Adults: A Medicare Claims Study
9:00AM-11:00AM
Abstract Number: 1298
Gout and the Risk of Parkinson’s Disease in Older Adults: A Study of U.S. Medicare Data
9:00AM-11:00AM
Abstract Number: 990
Guanylate Binding Protein 5 (GBP5) Inhibits Rheumatoid Arthritis Synovial Fibroblast Mediated Inflammation and Tissue Destruction
9:00AM-11:00AM
Abstract Number: 1251
Guideline Adherence for Perioperative Use of Immunosuppressive Medications in Patients with Rheumatologic Disease
9:00AM-11:00AM
Abstract Number: 1676
Health Related Quality of Life over Time in a Multi-Ethnic Cohort of Patients with Systemic Lupus Erythematosus and Correlation with Disease Activity and Organ Damage
9:00AM-11:00AM
Abstract Number: 1384
Health-Related Quality of Life in Patients with Ankylosing Spondylitis in the United States
9:00AM-11:00AM
Abstract Number: 1417
Hemophagocytic Lymphohistiocytosis (HLH) Mimickers: CXCL9 As a Potential Biomarker Distinguishing HLH from Other Hyperferritinemic Syndromes
9:00AM-11:00AM
Abstract Number: 1224
High Rates of Conversion and Reversion of Tuberculosis Screening Assays in Rheumatic Patients during Long Term Biologic Treatment
9:00AM-11:00AM
Abstract Number: 1719
High-Throughput Quantitative Histology in Systemic Sclerosis Skin Disease Using Computer Vision
9:00AM-11:00AM
Abstract Number: 1280
Higher Body Fat Percentage in Non-Obese Late-Onset Gout Patients
9:00AM-11:00AM
Abstract Number: 1720
Higher Neutrophil Count Predicts More Severe Skin/Lung Disease and Increased Mortality in Early Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1621
Higher Serum Uric Acid Levels Protect Against Osteoporosis in Patients with Axial Spondyloarthropathy
9:00AM-11:00AM
Abstract Number: 1292
HLA-B*58:01 Genotype and the Risk of Allopurinol-Associated Severe Cutaneous Adverse Reactions in a Predominately Black or African American Population with Advanced Chronic Kidney Disease
9:00AM-11:00AM
Abstract Number: 1435
Hormonal Contraception Use and Capacity to Self-Screen for Contraindications Among Adolescents in a Pediatric Rheumatology Clinic
9:00AM-11:00AM
Abstract Number: 1611
Hospitalizations for Serious Infections in Psoriatic Arthritis Patients: Data from the National Inpatient Sample 2000-2014
9:00AM-11:00AM
Abstract Number: 1177
How Are Patients with Chronic Musculoskeletal Pain Conditions Being Managed Initially in the U.S.?
9:00AM-11:00AM
Abstract Number: 1678
How Consistently Do Publications Define SLE? a Systematic Review
9:00AM-11:00AM
Abstract Number: 1556
How Phenotype of the Small Fibre Neuropathy in Primary Sjögren Syndrome Differs from Others Causes of Small Fibre Neuropathy ?
9:00AM-11:00AM
Abstract Number: 1787
How to Better Diagnose IgG4 Related Disease: a Single-Center Based Experience
9:00AM-11:00AM
Abstract Number: 1051
Hoxd Genes Regulate Arthritis-Relevant Pathways
9:00AM-11:00AM
Abstract Number: 1244
Hydroxychloroquine Quality Improvement Project at UF Health Jacksonville Rheumatology Clinics
9:00AM-11:00AM
Abstract Number: 1181
Hydroxychloroquine: Do We All See Eye to Eye? a Single-Site Analysis of Hydroxychloroquine Dosing Compared to 2016 American Academy of Ophthalmology Guidelines
9:00AM-11:00AM
Abstract Number: 1629
Hyperlipoproteinemia (a) in Patients with Spondyloarthritis. Results of the CARMA Study
9:00AM-11:00AM
Abstract Number: 1080
Hypomethylation of STAT1 and HLA-DRB1 in CD8+ T Cells Is Associated with Type-I Interferon-Dependent HLA-DRB1 Overexpression and Activation of Autologous CD4+ T Cells in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1669
iC3b/C3 Ratios More Strongly Correlate with SLE Disease Activity in African-Americans Compared to Whites
9:00AM-11:00AM
Abstract Number: 1064
Identification of a Panel of Circulating Proteins Associated to Synovial Pathotypes in Early Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 1077
Identification of Biomarkers Involved in the Resolution Phase of Inflammation: Specialized Pro-Resolving Mediator Receptors Expression in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1488
Identification of Joint Locations That Are Poor Prognostic in an Early Seropositive Erosive RA Cohort
9:00AM-11:00AM
Abstract Number: 1293
Identification of New and Rare Variants in ABCG2, SLC22A1 and ALDH16A1 Genes in Crystal-Proven Early-Onset Gout
9:00AM-11:00AM
Abstract Number: 1048
Identification of Novel Molecules with Senolytic and Autophagy Activity As Osteoarthritis Therapeutics
9:00AM-11:00AM
Abstract Number: 1118
Identification of Transcriptional Regulatory Networks in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1095
IFN Gene Expression Correlates with Frequency of Circulating Switched Memory B-Cells in Patients with Incomplete Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1775
IgG4-Related Disease, Clinical Series on Chilean Patients
9:00AM-11:00AM
Abstract Number: 985
IL-6 and TNF-a Cooperate to Modulate Cell Cycle of RA-FLS Via Cyclin Dependent Kinase 6
9:00AM-11:00AM
Abstract Number: 1685
IL2 Decrease Is Associated to ANTI-DNA Positivity in Systemic LUPUS Erythematous Patients
9:00AM-11:00AM
Abstract Number: 1092
Immune Complex-Driven Neutrophil Activation and BAFF Production Promote B Cell Activation and Autoantibody Production in Human SLE
9:00AM-11:00AM
Abstract Number: 1289
Immunosuppressant Use and Gout in the Prevalent Solid Organ Transplant Population
9:00AM-11:00AM
Abstract Number: 1187
Impact of a Nurse-Led Program of Patient Self-Assessment and Self-Management Axial Spondyloarthritis: Results of a Prospective, Multicentre, Randomized, Controlled Trial
9:00AM-11:00AM
Abstract Number: 1601
Impact of Clinical Specialty Setting and Geographic Regions on Disease Management in Patients with Psoriatic Arthritis: Results from a Cross-Sectional Observational Study in the United States
9:00AM-11:00AM
Abstract Number: 1514
Impact of Comorbidity Burden and Obesity on the Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1638
Impact of Extra-Articular Manifestations on Patient-Reported Outcomes in Ankylosing Spondylitis and Psoriatic Arthritis: Interim Results from the Complete Studies
9:00AM-11:00AM
Abstract Number: 1696
Impact of Hurricane Maria on a Cohort of Systemic Lupus Erythematosus Patients from Puerto Rico
9:00AM-11:00AM
Abstract Number: 1532
Impact of Immunogenicity on Clinical Efficacy and Administration Related Reaction in TNF Inhibitors: A Pooled-Analysis from Three Biosimilar Studies in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1746
Impact of Interstitial Lung Disease on the Long-Term Survival in 76 Japanese Patients with Microscopic Polyangiitis
9:00AM-11:00AM
Abstract Number: 1422
Impact of Juvenile Localized Scleroderma on Longitudinal Quality of Life
9:00AM-11:00AM
Abstract Number: 1547
Impact of Obesity on Drug Survival of Tofacitinib in Patients with Rheumatoid Arthritis: Analysis from the Turkbio Registry
9:00AM-11:00AM
Abstract Number: 1390
Impact of Psoriatic Arthritis from the Patient’s Perspective in the Context of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire: An Online Global Survey
9:00AM-11:00AM
Abstract Number: 1458
Impact of the Joint Presence of Erosions and ACPA on Rheumatoid Arthritis Disease Activity over Time: Results from the Meteor Registry
9:00AM-11:00AM
Abstract Number: 1604
Impact of Time to Minimal Disease Activity and Quality of Life One Year after Diagnosis of Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1021
Impact of TLR7 Ligation in RA Pathology
9:00AM-11:00AM
Abstract Number: 1128
Impact of Urate-Lowering Therapy on the Risk of Cardiovascular Events and All-Cause Mortality Among Individuals with Gout
9:00AM-11:00AM
Abstract Number: 1476
Implication of CXCL5 (Epithelial neutrophil-activating peptide 78) in the Development of Insulin Resistance in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1644
Improvement in Morning Stiffness in Subjects with Psa Is Associated with Improvements in Pain, Physical Function, and Patient Global Response to Treatment
9:00AM-11:00AM
Abstract Number: 1654
Improvement of Cytological Grade and Tear Production in Ankylosing Spondylitis Patients Under Anti-TNF Therapy: A Long-Term Follow-up
9:00AM-11:00AM
Abstract Number: 1550
Improvement of HbA1c in Patients with Rheumatoid Arthritis and Diabetes Type 2 during Treatment with Tocilizumab
9:00AM-11:00AM
Abstract Number: 1351
In Situ Dendritic Cell Characterization in Idiopathic Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 982
In the Presence of IL-18, IL-10 but Not IL-6 Induces IFN-γ Production and the Surface Expression of TRAIL on NK Cells
9:00AM-11:00AM
Abstract Number: 1115
In Vivo Assessment of Prevention of Lung Fibrosis Using the Pan-PPAR Agonist Lanifibranor in the Tβriiδk-Fib Mouse Model of Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1736
Incidence and Risk Factors for Gangrene in Patients with Systemic Sclerosis from the Eustar Cohort
9:00AM-11:00AM
Abstract Number: 1234
Incidence of Conversion of Screening Tests for M. Tuberculosis (PPD, GIF-release assay) in a Metropolitan Cohort of Patients Treated with TNF-α Inhibitors
9:00AM-11:00AM
Abstract Number: 1486
Incidence of Subclinical Signs of Inflammation in Patients with New Onset of Non-Specific Musculoskeletal Symptoms and Anti-Citrullinated Peptide Positivity: First Interims Analysis of the Panora Trial
9:00AM-11:00AM
Abstract Number: 1631
Incidence of Uveitis in Patients with Spondyloarthritis: The Impact of Biologics Era.a Multicenter Study Using Data from International ASAS-Comospa Study
9:00AM-11:00AM
Abstract Number: 1808
Increased Frequency of Obstructive Sleep Apnea Syndrome in Behcet’s Syndrome Patients with Vena Cava Superior Thrombosis
9:00AM-11:00AM
Abstract Number: 1729
Increased Risk of Valvular Heart Disease in Patients with Systemic Sclerosis: Results from a Population-Based Cohort (1980-2016)
9:00AM-11:00AM
Abstract Number: 1690
Increased Sensitivity Οf Τhe New (2017) Αnd Τhe 2012 SLICC As Compared Τo Τhe Acr 1997 Classification Criteria Ιn Early Systemic Lupus Erythematosus (SLE): The 2017 Αnd 2012 Criteria May Classify Non-Overlapping Subgroups Οf Patients
9:00AM-11:00AM
Abstract Number: 1799
Increased Vein Wall Thickness in Behçet’s Syndrome
9:00AM-11:00AM
Abstract Number: 1356
Increasing Oral Doses of GLPG1972 Administered Daily for 29 Days Show a Strong Target Engagement in Patients with Knee and/or Hip OA
9:00AM-11:00AM
Abstract Number: 1610
Incremental Benefits to Quality of Life Associated with Achieving Higher Levels of American College of Rheumatology Response and Skin Clearance in Patients with Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1227
Indicator Opportunistic Infections after Biological Treatment in Rheumatoid Arthritis, 10 Years Follow up in Clinical Practice
9:00AM-11:00AM
Abstract Number: 1208
Indicators for Active Musculoskeletal Ultrasound Findings of Psoriatic Arthritis Vary on Each Body Part
9:00AM-11:00AM
Abstract Number: 1516
Infection Events in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim All-Case Post-Marketing Surveillance
9:00AM-11:00AM
Abstract Number: 1398
Inflammatory Arthritis DMARD Adverse Effects Are Pervasive and Can Greatly Impact Quality of Life and Work and Social Roles: Initial Results from the Omeract Safety Working Group
9:00AM-11:00AM
Abstract Number: 1617
Influence of Disease Activity in the Physical Activity of Psoriatic Arthritis Patients
9:00AM-11:00AM
Abstract Number: 1269
Influence of Diuretic-Response Sodium Transporter Genes on Renal Uric Acid Handling in Response to Frusemide
9:00AM-11:00AM
Abstract Number: 1282
Influence of Renal Function on the Velocity of Tophus Resolution and Achievement of Disease Remission in Patients with Chronic Refractory Gout Treated with Pegloticase
9:00AM-11:00AM
Abstract Number: 1010
Inhibition of Bruton’s Tyrosine Kinase (BTK) Prevents Inflammatory Macrophage Differentiation: A Potential Role in RA and SLE
9:00AM-11:00AM
Abstract Number: 1012
Inhibition of Inflammation and Oxidative Stress in Systemic Sclerosis (SSc) Macrophages
9:00AM-11:00AM
Abstract Number: 1284
Initial Pegloticase Serum Levels Predict Persistent Responsiveness in Patients with Chronic Refractory Gout
9:00AM-11:00AM
Abstract Number: 1294
Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegadricase) with Svp-Rapamycin Enables Sustained Reduction of Acute Gout Flares
9:00AM-11:00AM
Abstract Number: 1810
Initial Visit Symptoms in Probable Behçet’s Predictive of ISG Criteria Behçet’s: Data from New York and Amsterdam Cohorts
9:00AM-11:00AM
Abstract Number: 1693
Innate, Adaptive, and TNF-Superfamily Immune Pathways Inform a Lupus Disease Activity Immune Index That Characterizes Disease Activity in SLE
9:00AM-11:00AM
Abstract Number: 1623
Insight into the Quality of Life of Patients with Ankylosing Spondylitis: Real-World Data from a US-Based Life Impact Survey
9:00AM-11:00AM
Abstract Number: 1517
Integrated Safety Analysis across Phase 3 Clinical Studies Including the Controlled and Uncontrolled Periods for Intravenous Golimumab in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 1723
Intensified B-Cell Depletion Therapy in Progressive Systemic Sclerosis Patients: 24 Months Follow-up
9:00AM-11:00AM
Abstract Number: 1814
Interferon-Alpha for the Management of Lower Extremity Deep Vein Thrombosis in Behcet’s Syndrome: A Case Series
9:00AM-11:00AM
Abstract Number: 1662
Interplay Among Inflammation, Adipokines and Endothelial Dysfunction in Patients with Psoriatic Arthritis. Relationship with Cardiovascular and Metabolic Comorbidities. Modulation By Apremilast
9:00AM-11:00AM
Abstract Number: 1751
Interstitial Lung Disease during ANCA-Associated Vasculitis: A Poor-Prognosis Factor
9:00AM-11:00AM
Abstract Number: 1753
Interstitial Lung Disease in ANCA-Associated Vasculitis Defines a Unique Subgroup of Patients at High Risk for Respiratory Death: A Cluster Analysis
9:00AM-11:00AM
Abstract Number: 1748
Interstitial Lung Disease in ANCA-Positive Vasculitis Patients
9:00AM-11:00AM
Abstract Number: 1312
Interstitial Pneumonia with Autoimmune Features (IPAF)-Nsip: Hurdles to Reclassification of Overlapping Ilds
9:00AM-11:00AM
Abstract Number: 1309
Interstitial Pneumonia with Autoimmune Features: Is It Frequent?
9:00AM-11:00AM
Abstract Number: 1558
Intravenous Immunoglobulin Efficacy for Primary Sjögren’s Syndrome Associated Small Fiber Neuropathy
9:00AM-11:00AM
Abstract Number: 1230
Invasive Fungal Infection with Cryptococcal Meningitis in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1019
Involvement of Mast Cells in the Pathogenesis of Sjögren’s Syndrome By Induction of Tissue Fibrosis Via Fibroblast Collagen Synthesis
9:00AM-11:00AM
Abstract Number: 1020
Involvement of Toll-like-Receptor-9 Pathway on Natural Killer Cells in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1482
Is 14.3.3η a Predictor of Development of Rheumatoid Arthritis in Patients with Early Undifferentiated Arthritis?
9:00AM-11:00AM
Abstract Number: 1168
Is a Change in Physical Activity Associated with a Change in Health-Related Quality of Life after Total Knee Replacement?
9:00AM-11:00AM
Abstract Number: 1656
Is a Positive Family History of Spondyloarthritis Relevant for Diagnosing Axial Spondyloarthritis Once HLA-B27 Status Is Known? Data from the ASAS, DESIR, and SPACE Cohorts
9:00AM-11:00AM
Abstract Number: 1628
Is Axial Psoriatic Arthritis Distinct from Ankylosing Spondylitis with and without Concomitant Psoriasis?
9:00AM-11:00AM
Abstract Number: 1591
Is Enthesitis a Marker of Disease Severity in Early Psoriatic Arthritis?
9:00AM-11:00AM
Abstract Number: 1779
Is the Number of IgG4+ Plasma Cells Observed By Immunostaining Important Beyond Its Diagnostic Utility in IgG4-Related Disease?
9:00AM-11:00AM
Abstract Number: 1401
Is There a Specific Effect of Jak-Inhibitors on Pain and Fatigue in Rheumatoid Arthritis?
9:00AM-11:00AM
Abstract Number: 1235
Isoniazid Monotherapy As a Prophylaxis for Tuberculosis in Patients with Rheumatic Diseases Exposed to Prolonged, High-Dose Glucocorticoids
9:00AM-11:00AM
Abstract Number: 1397
Item Responses to Disease-Specific Quality of Life Questionnaires in the 18 Months Following a Flare in SLE: An Item Response Theory Analysis of a French Prospective Longitudinal Multicenter Study
9:00AM-11:00AM
Abstract Number: 1315
Japanese Relapsing Polychondritis Patients with Airway Involvement Were Mutually Exclusive with Those with Ear Involvement in the Clinical Characteristics
9:00AM-11:00AM
Abstract Number: 1768
Kidney Involvement, Poor Performance Status, and Higher Cumulative Dose of Glucocorticoid Are the Risk Factors of the Discontinuation of Immunosuppressant in Patients with Antineutrophil Cytoplasmic Antibody Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 1431
Kikuchi-Fujimoto Disease: A Retrospective Analysis of 23 Pediatric Cases from a US Center
9:00AM-11:00AM
Abstract Number: 1377
Knee Osteoarthritis Symptom Duration Is Associated with Conditioned Pain Modulation and Vibration Perception Threshold Impairment
9:00AM-11:00AM
Abstract Number: 1671
Laboratory Investigation Results Influence Physician’s Global Assessment of Disease Activity in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1270
Lack of Association of Comorbidities with Ultrasonographic Urate Deposition in Asymptomatic Hyperuricemia
9:00AM-11:00AM
Abstract Number: 1581
Lack of Specificity in Testing for Murine Tissue Specific Autoantibodies for the Diagnosis of Sjogren’s Syndrome
9:00AM-11:00AM
Abstract Number: 1562
Large Granular Lymphocyte Proliferations in Primary Sjögren’s Syndrome: An Iatrogenic Manifestation
9:00AM-11:00AM
Abstract Number: 1620
Lateral DXA More Effective in Detecting Osteoporosis Than Conventional DXA in Axial Spondyloarthropathy
9:00AM-11:00AM
Abstract Number: 1798
Leg Ulcers in Behçet’s Syndrome: An Observational Survey in 24 Patients
9:00AM-11:00AM
Abstract Number: 1454
Levels of 14-3-3eta Are an Independent Predictor of Long-Term Radiographic Erosive Progression and of Short-Term Rapid Radiographic Erosive Progression in Patients with Inflammatory Polyarthritis
9:00AM-11:00AM
Abstract Number: 1062
Linking Systemic Angiogenic Markers to Synovial Vascularization in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1253
Lipid Screening and Treatment Patterns Among Patients with Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 1594
Liver Enzyme Elevation in Patients with Ankylosing Spondylitis Treated with TNF Inhibitor: A Single-Center Historical Cohort Study
9:00AM-11:00AM
Abstract Number: 1419
Long-Term Outcome of 50 Patients with Linear Scleroderma Treated with  Methotrexate
9:00AM-11:00AM
Abstract Number: 1747
Long-Term Outcomes of Patients with Nonsevere Eosinophilic Granulomatosis with Polyangiitis Given Azathioprine and Glucocorticoids for Remission Induction
9:00AM-11:00AM
Abstract Number: 1749
Long-Term Renal Outcome in Pulmonary-Limited Microscopic Polyangiitis
9:00AM-11:00AM
Abstract Number: 1411
Long-Term Safety of Different Doses of Canakinumab (<2, 2–<4, and 4–<8 mg/kg) in Patients Aged <4–≥65 Years: Results from the β-Confident Registry
9:00AM-11:00AM
Abstract Number: 1771
Long-Term Survival of Renal Transplantation in Rapidly Progressive Glomerulonephritis (RPGN). Study of 43 Cases from a Single Center
9:00AM-11:00AM
Abstract Number: 1529
Long-Term, Real-World Safety of Adalimumab in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1406
Longitudinal Construct Validity of the Psaid Individual Items: Can We Eliminate Other Questionnaires If Using the Psaid?
9:00AM-11:00AM
Abstract Number: 1665
Longitudinal Stratification of Gene Expression Reveals Three SLE Groups of Disease Activity Progression
9:00AM-11:00AM
Abstract Number: 1334
Low Density Granulocytes As Biomarkers of Disease Activity and Damage in Patients with Idiopathic Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 1352
Low Density Granulocytes in Idiopathic Inflammatory Myopathy
9:00AM-11:00AM
Abstract Number: 1086
Low-Dose IL-2 Combined with Rapamycin Efficiently Promotes Remission of Refractory Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1583
Low-Dose IL-2 Promotes the Proliferation of Peripheral Regulatory T Cells in Primary Sjogren’s Syndrome to Restore Its Balances with Pro-Inflammatory Lymphocytes
9:00AM-11:00AM
Abstract Number: 1675
Lupus Impact Tracker Responds to Changes in Low Disease Activity and Remission Outcomes in a Large Spanish Lupus Registry Cohort
9:00AM-11:00AM
Abstract Number: 1674
Lupus Impact Tracker Validation in a Large European Spanish Lupus Registry Cohort
9:00AM-11:00AM
Abstract Number: 1701
Lupus Low Disease Activity State: Predicting Organ Damage Accrual and Cardiovascular Risk in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1122
Lymphocyte Immunophenotypes at Randomization on the Scleroderma: Cyclophosphamide or Transplantation Trial: Comparison of Treatment Naïve and DMARD Treated Participants with Healthy Controls
9:00AM-11:00AM
Abstract Number: 1007
Macrophage Mediators of Autoimmune Valvular Carditis and Fibrosis
9:00AM-11:00AM
Abstract Number: 1362
Magnetic Resonance Imaging Features Can Classify Adults Who Will Develop Accelerated Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1524
Malignancies and Serious Infections in Randomized Controlled Trials of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
9:00AM-11:00AM
Abstract Number: 1515
Malignancy in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim Analysis of All-Case Post-Marketing Surveillance
9:00AM-11:00AM
Abstract Number: 1595
Malignancy in Psoriatic Disease
9:00AM-11:00AM
Abstract Number: 1104
Mass Cytometry Analysis Detects Dysregulated T Cell Complement Responses in Diffuse Cutaneous Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1536
Mean Platelet Volume Changes with Baricitinib Indicate Reduced New Platelet Production in Baricitinib-Treated Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 1469
Measurement of Anti-Amyloid β Autoantibodies in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1173
Measuring the Advanced Clinician Practitioner in Arthritis Care (ACPAC) Program Trained Extended Role Practitioner (ERP) Workforce in Canada: A Profile of Practice Settings, Roles and Participation in Models of Arthritis Care in Canada
9:00AM-11:00AM
Abstract Number: 1590
Metabolomics Profile Predicts Carotid Atherosclerosis Progression in Psoriatic Disease
9:00AM-11:00AM
Abstract Number: 1245
Methotrexate Quality Improvement Project at UF Health Jacksonville Rheumatology Clinics
9:00AM-11:00AM
Abstract Number: 1492
Methotrexate Response in Early Rheumatoid Arthritis Predicted Using a Somamer Proteomic Assay
9:00AM-11:00AM
Abstract Number: 1449
Microwave Radiometry As a Novel Additional Method for Rheumatoid Arthritis Disease Activity Assessment: A Prospective Single-Center Study
9:00AM-11:00AM
Abstract Number: 1468
Minor Salivary Gland Biopsy: Its Importance in Rheumatoid Arthritis and Secondary Sjögren’s Syndrom
9:00AM-11:00AM
Abstract Number: 1025
MiR-146a a Key Player in Bone Metabolism
9:00AM-11:00AM
Abstract Number: 1264
Modeling the Costs and Outcomes Associated with Treatment Sequences, with and without Tofacitinib, for Moderately to Severely Active Psoriatic Arthritis in the US
9:00AM-11:00AM
Abstract Number: 1538
Moderate Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1009
Monocytes Membrane TNF Expression and Anti-TNF Treatment in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1171
Mortality Among Those with OA: Time-Varying Effects of Socioeconomic Measures
9:00AM-11:00AM
Abstract Number: 1331
Moving from Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody to Anti-Melanoma Differentiation-Associated Gene 5 Syndrome
9:00AM-11:00AM
Abstract Number: 1445
MRI Bone Erosions in RA Patients Relatives with Clinically Suspicious Arthralgia
9:00AM-11:00AM
Abstract Number: 1789
Mucocutaneous Activity Index As a Patient-Reported Outcome Measure in Behcet’s Disease: A Multi-Center Study from Turkey
9:00AM-11:00AM
Abstract Number: 1102
Multi-Organ RNA-Sequencing of Patients with Systemic Sclerosis (SSc) Finds That Intrinsic Subsets Are Conserved across Organ Systems
9:00AM-11:00AM
Abstract Number: 1737
Multiplexed Autoantibody Profiles in a Systemic Sclerosis Clinical Trial Comparing Autologous Hematopoietic Stem Cell Transplantation and Cyclophosphamide
9:00AM-11:00AM
Abstract Number: 1652
Musculoskeletal Involvement in Inflammatory Bowel Disease’S Patients: A Mono Centric Experience
9:00AM-11:00AM
Abstract Number: 1205
Musculoskeletal Ultrasound and Conventional Radiography Evaluation of the Hip in Patients with Calcium Pyrophosphate Deposition Disease
9:00AM-11:00AM
Abstract Number: 1337
Myocardial Fatty Acid Metabolism and Perfusion Mismatch in Scintigraphy Predicts Worse Prognosis in Clinically Amyopathic Dermatomyositis
9:00AM-11:00AM
Abstract Number: 1612
Myocardial Infarctions Among Ankylosing Spondylitis Patients in a Large US Insurance Database
9:00AM-11:00AM
Abstract Number: 1339
Myositis Specific Anti-Histidyl tRNA Synthetase (HisRS) Autoantibodies Display High Reactivity Against Hisrs Conformational Epitopes and Associate with Lung and Joint Involvement
9:00AM-11:00AM
Abstract Number: 1342
Myositis Specific Antibodies Measured Using a Novel Particle Based Multi-Analyte Assay Resemble Myositis Subsets By Principle Component Analysis
9:00AM-11:00AM
Abstract Number: 1085
Natural Gingerols Inhibit Neutrophil Extracellular Trap Release Elicited By Lupus Autoantibodies
9:00AM-11:00AM
Abstract Number: 996
Neutralizing Effect of Anti-Infliximab Antibodies on Infliximab-Stimulated Human Coronary Artery Endothelial Cells
9:00AM-11:00AM
Abstract Number: 1456
Neutrophil Activation Is Associated with Disease Activity and Predicts Development of Erosive Disease and Extra Articular Manifestations in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1003
Neutrophil Response to Ultraviolet Light in Normal and Lupus Conditions
9:00AM-11:00AM
Abstract Number: 1795
New Major Organ Involvement Is Lower in Young Male Behçet’s Patients Compared to Retrospective Series: Five-Year Results of a Prospective Cohort
9:00AM-11:00AM
Abstract Number: 1464
Newer Generation Cyclic Citrullinated Peptide (CCP) 3.1 Assay in the Diagnosis of Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1552
No Effect of Concomitant Glucocorticoid Therapy on Efficacy and Safety of Tocilizumab Monotherapy Found in Rheumatoid Arthritis Clinical Trials
9:00AM-11:00AM
Abstract Number: 1813
Non-Aphthous Beginning As an Independent Risk Factor for the Course of Behçet’s Disease
9:00AM-11:00AM
Abstract Number: 1160
Non-Elderly Adults Who Have Never Seen a Health-Care Provider for Chronic Joint Symptoms- Updated Results from National Health Interview Survey 2015
9:00AM-11:00AM
Abstract Number: 1069
Non-Receptor Protein Tyrosine Phosphatase 14 (PTPN14) Promotes YAP-Dependent Tgfbeta Signaling in RA FLS
9:00AM-11:00AM
Abstract Number: 1767
Occurrence and Etiology of Gastrointestinal Perforation in Patients with Vasculitis
9:00AM-11:00AM
Abstract Number: 1491
Oestrogen Levels and the Outcome of Leflunomide Treatment in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1099
Ongoing DNA Damage, Chromatin Deregulation and Defective DNA Damage Response in Systemic Autoimmune Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 1302
Opioid Analgesic Use in Acute Gout Patients Discharged from the Hospital
9:00AM-11:00AM
Abstract Number: 1049
Optical Biomarkers for the Early Diagnosis of Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1444
Optimization of Ultrasonographic Examination for the Diagnosis of Erosive Rheumatoid Arthritis Versus Erosive Osteoarthritis with Radiography Considered As Gold Standard
9:00AM-11:00AM
Abstract Number: 1804
Optimization Protocol for Adalimumab Treatment in Refractory Uveitis Due to Behçet’s Disease
9:00AM-11:00AM
Abstract Number: 1031
Orally Administered Cherry Juice Inhibits Localized Nfκb Activity and Histopathological Infiltrates in a Murine Model of Gout
9:00AM-11:00AM
Abstract Number: 1301
Organic Anion Transport Inhibitors Suppress Chondrocyte Pyrophosphate Production
9:00AM-11:00AM
Abstract Number: 1239
Organisms Associated with Prosthetic Joint Septic Arthritis over the Past Two Decades: Data from a Single Tertiary Medical Center Located in the Northeastern United States
9:00AM-11:00AM
Abstract Number: 1523
Pain Is Improved in Around 50% of Patients and Fatigue in 40% of Patients with Rheumatoid Arthritis Treated with Sarilumab in the Target, Mobility and Monarch Trials
9:00AM-11:00AM
Abstract Number: 1428
Parental Involvement and Adolescents/Young Adults Self-Management during the Transition Period: A Cross-Sectional Survey in Childhood Onset Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 1030
Parenteral Injection of Human Adipose-Derived Mesenchymal Stem Cells Attenuates Inflammation in an Acute Model of Gouty Arthritis
9:00AM-11:00AM
Abstract Number: 1587
Pathogenic Role of Interleukin 27 in the Nonobese Diabetic Mouse Model of Sjögren Syndrome
9:00AM-11:00AM
Abstract Number: 1519
Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years
9:00AM-11:00AM
Abstract Number: 1391
Patient-Acceptable Symptom State in Psoriatic Arthritis: Prevalence and Associated Factors in Real Clinical Practice
9:00AM-11:00AM
Abstract Number: 1722
Patient-Level Factors Associated with Hospital Readmission Among Patients with Systemic Sclerosis Associated Pulmonary Hypertension
9:00AM-11:00AM
Abstract Number: 1434
Patient-Proxy Agreement on Health-Related Quality of Life in Juvenile Fibromyalgia Syndrome
9:00AM-11:00AM
Abstract Number: 1178
Patients’ and Healthcare Professionals’ Resource Preferences for a Knowledge Translation Toolkit for Hip and Knee Replacement Rehabilitation
9:00AM-11:00AM
Abstract Number: 1619
Patterns and Outcomes on As Patients Disease Activity Using Smart System of Disease Management (SSDM): Analysis of T2T Pattern Shift and the Correlation between Disease Activity and Mental Health
9:00AM-11:00AM
Abstract Number: 1163
Patterns of Depressive Symptoms before and after Surgery for Hip, Knee and Lumbar Spine Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1154
Patterns of Opioid Use and Patient Characteristics before Total Hip and Knee Replacement
9:00AM-11:00AM
Abstract Number: 1461
Peptidylarginine Deiminase-4 Antibodies Are Not Associated with Worse RA Activity, Symptoms or Impacts
9:00AM-11:00AM
Abstract Number: 1599
Performance of Referral Strategies for Spondyloarthritis: A Population-Based Nationwide Study
9:00AM-11:00AM
Abstract Number: 1473
Performance of the Meso Scale Multiplex Platform in the Assessment of Serum Cytokines / Chemokines in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1681
Performance of the Proposed American College of Rheumatology / European League Against Rheumatism 2017 Classification Criteria for SLE in Adult and Juvenile Systemic Lupus Erythematosus and Other Anti-Nuclear Antibody Related Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 1143
Periodontal Disease Is Associated with an Increased Risk of Ankylosing Spondylitis: A Systematic Review and Meta-Analysis
9:00AM-11:00AM
Abstract Number: 1082
Peripheral Blood CD11c+ CD21- Age-Associated B Cells (ABCs) in Human Systemic Lupus Erythematosus Are Associated with Innate Type III Interferon and Disease Activity
9:00AM-11:00AM
Abstract Number: 1236
Peripheral-Blood B-Cell Subset Disturbances in Whipple’s Disease
9:00AM-11:00AM
Abstract Number: 1209
Peritenon Extensor Tendon Inflammation, Synovitis and Enthesopathy in Psoriastic Arthritis: What Is the Connection?
9:00AM-11:00AM
Abstract Number: 1580
Persistent Serological Activity in Primary Sjögren’s Syndrome
9:00AM-11:00AM
Abstract Number: 1247
Pharmacist-Managed Titration of Urate-Lowering Therapy to Streamline Gout Management
9:00AM-11:00AM
Abstract Number: 1050
Pharmacokinetic and pharmacodynamic modelling of the novel anti-ADAMTS-5 nanobody M6495 using the neo-epitope ARGS as a biomarker
9:00AM-11:00AM
Abstract Number: 1728
Pharmacokinetics of Cyclophosphamide in Scleroderma Treated By Cyclophosphamide Versus Transplantation
9:00AM-11:00AM
Abstract Number: 1414
Pharmacovigilance of Biologics for Systemic Juvenile Idiopathic Arthritis Patients By the German Biologics Registry
9:00AM-11:00AM
Abstract Number: 1076
Phospholipase C-eta2, As a C2 Domain-Containing Protein, Regulate Aggressiveness of Fibroblast‐like Synoviocytes and Ameliorate Arthritis in Experimental Animal Models of Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1006
Physical Activity at Lower Intensities Reduces Localized IL-1b in a Murine Model of Gout By Systemically Down-Regulating TLR2 Expression on Circulating Neutrophils and Suppressing CXCL1 Expression
9:00AM-11:00AM
Abstract Number: 1002
Pkcα Deficiency Protected Mice from UVB Induced-Skin Inflammation through Attenuation of Neutrophil Netosis
9:00AM-11:00AM
Abstract Number: 1762
Plasma iC3b Level As a Biomarker of Disease Relapse in ANCA-Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 1079
Plasma Metabolomic Analysis Combined with Transcriptome Data Has Revealed the Importance of Amino Acids Homeostasis in SLE Pathogenesis
9:00AM-11:00AM
Abstract Number: 1460
Plasma Mir-146a-5p Associates with Beneficial Body Composition and Plasma Metabolic Profiles in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1123
Plasmacytoid Dendritic Cells in Bronchoalveolar Lavage Correlate with Pulmonary Artery Diameter and Infiltrate Perivascular Areas in the Lungs from Patients with Systemic Sclerosis Associated Pulmonary Hypertension
9:00AM-11:00AM
Abstract Number: 1023
Plasmacytoid Dendritic Cells That Infiltrate the Lungs Produce Profibrotic Cytokines and Chemokines in Bleomycin-Induced Model of Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 994
Platelet Derived Growth Factor Receptors (PDGFRs) and Their Implication in Inflammatory Arthritis
9:00AM-11:00AM
Abstract Number: 1241
Pneumococcal Vaccination Quality Improvement Initiative within a Rheumatology Clinic at an Academic Medical Center
9:00AM-11:00AM
Abstract Number: 1710
Polypharmacy in Older Adults with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1672
Poor Sleep Quality Predicts Worsening SLE Disease Activity
9:00AM-11:00AM
Abstract Number: 1246
Practices of Hydroxychloroquine Dosing Based on the American Association of Ophthalmology (AAO) 2016 Recommendations: A Single Center Experience
9:00AM-11:00AM
Abstract Number: 1502
Predicting Response to Methotrexate Therapy in New-Onset RA: No Value of Adding Protein Biomarkers to Clinical Predictors
9:00AM-11:00AM
Abstract Number: 1137
Prediction Models for Poor Function Outcomes over 10 Years in Persons at High Risk for Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1788
Predictive Factors for Work-Day Loss in a Multi-Center Study in Behcet’s Disease: Indirect Costs for Healthcare
9:00AM-11:00AM
Abstract Number: 1271
Predictive Factors of Increased Vascular Stiffness in Patient with Gout and Hyperuricemia
9:00AM-11:00AM
Abstract Number: 1361
Predictive Modeling of Therapeutic Response in Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1373
Predictive Probabilities Are Superior in Communicating the Clinical Relevance of Cartilage Thickness As an Imaging Biomarker of Knee Osteoarthritis Progression
9:00AM-11:00AM
Abstract Number: 1507
Predictors of Fatigue and Persistent Fatigue in Early Rheumatoid Arthritis: A Longitudinal Observational Study
9:00AM-11:00AM
Abstract Number: 1260
Predictors of Hospitalization Due to Acute Gout: A Retrospective Cohort Study
9:00AM-11:00AM
Abstract Number: 1494
Predictors of Persistence to Methotrexate Treatment in RA – Assessment of Different Modelling Approaches
9:00AM-11:00AM
Abstract Number: 1436
Pregnancy Outcomes in Partners of DMARD Exposed Men with Juvenile Idiopathic Arthritis – an Observational Study
9:00AM-11:00AM
Abstract Number: 1472
Preliminary Analysis of Genetic Variants in the Immune System Related to the Body Mass Index in Early Arthritis Patients
9:00AM-11:00AM
Abstract Number: 1008
Presence of a Specific Defect in M2 Polarization of Blood Monocytes from Patients with Rheumatoid Arthritis, Associated with Increased microRNA-155
9:00AM-11:00AM
Abstract Number: 1286
Pretreatment and Coadministration with Methotrexate Improved Durability of Pegloticase (Krystexxa) Response: A Prospective, Proof-of-Concept, Case Series
9:00AM-11:00AM
Abstract Number: 1566
Prevalence and Prognosis of Interstitial Lung Disease in a Large Cohort of Chinese Primary Sjögren’s Syndrome Patients
9:00AM-11:00AM
Abstract Number: 1605
Prevalence of Anterior Uveitis in Patients with Spondyloarthropathy in a Single US Academic Center: A Retrospective Study from Routine Care
9:00AM-11:00AM
Abstract Number: 1614
Prevalence of Sonographic Enthesitis in Patients with Psoriasis without Arthritis and Its Association Risk Factors of Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1646
Prevalence of Spondyloarthritis in Patients with Anterior Uveitis
9:00AM-11:00AM
Abstract Number: 1129
Prevalence, Incidence, Determinants, and Impacts of Depression and Anxiety in Gout: A Systematic Review
9:00AM-11:00AM
Abstract Number: 1585
Primary Sjögren’s Syndrome Stratification Based on the Severity of Patient-Reported Fatigue
9:00AM-11:00AM
Abstract Number: 1497
PRISM-RA: A Personalized Medicine Test That Accurately Predicts Rheumatoid Arthritis Patients Who Will Not Respond Adequately to Tumor Necrosis Factor Inhibitors
9:00AM-11:00AM
Abstract Number: 1158
Privacy-Preserving Linkage between the Arthritispower Registry and Commercial Payer Claims Data to Support Comparative Effectiveness and Outcomes Research
9:00AM-11:00AM
Abstract Number: 1088
Pro-Inflammatory and Regulatory Soluble Mediator Pathways Vary between African American and European American SLE Patients
9:00AM-11:00AM
Abstract Number: 1480
Prognosis of Pneumonia in Rheumatoid Arthritis Patient: An Analysis of Using a Nationwide Administrative Database
9:00AM-11:00AM
Abstract Number: 1744
Prognostic Value of Right Heart Involvement in Systemic Sclerosis:Not Only Pulmonary Arterial Hypertension
9:00AM-11:00AM
Abstract Number: 1363
Progression of Pain, Stiffness, Function Changes, and Ultrasound Detected Synovitis and Osteophyte Formation in Patients with Hand Osteoarthritis over Three Years
9:00AM-11:00AM
Abstract Number: 1707
Prolactin and Dehydroepiandrosterone Sulfate in Women with Active Systemic Lupus Erythematosus of Recent Onset Versus Chronic Inactive  Patients
9:00AM-11:00AM
Abstract Number: 1684
Prolonged Remission/Low Disease Activity State Is Associated with a Better Health-Related Quality
9:00AM-11:00AM
Abstract Number: 1727
Prospective Confirmation of Potential Link between Proton Pump Inhibitor Exposure and Calcinosis in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1420
Prospective Validation of Cone Beam Computed Tomography for the Assessment of Disease Progression in Linear Scleroderma of the Face
9:00AM-11:00AM
Abstract Number: 1071
Protective Role of the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Rs2495477 Polymorphism in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1114
Proteomic Aptamer Analysis Reveals a Distinct Profile of Very Early Systemic Sclerosis (SSc) Patients at Risk for Progression Toward Definite SSc
9:00AM-11:00AM
Abstract Number: 1332
Proteomic Discovery Analysis Identifies Unique Proteins and Pathways Correlating with Different Clinical Activity and Damage Measures in Juvenile Dermatomyositis (JDM)
9:00AM-11:00AM
Abstract Number: 1643
Psa Impact of Disease Questionnaire Scores Are Correlated with Disease Activity, As Measured By Cdapsa in Patients with Psa
9:00AM-11:00AM
Abstract Number: 1653
Psychological Distress in Patients with Axial Spondyloarthritis in Europe. Results from the European Map of Axial Spondyloarthritis Survey
9:00AM-11:00AM
Abstract Number: 1600
Psychometric Properties of the Assessment of Spa International Society Health Index in Patients with Active As/Radiographic Axial Spa in a Phase 3 Clinical Study
9:00AM-11:00AM
Abstract Number: 1138
Public Health Impact of Physical Inactivity in the Knee OA Population in the US
9:00AM-11:00AM
Abstract Number: 1231
Pyogenic Vertebral Osteomyelitis: Outcome Variables Analysis in a 116 Patients Cohort at a Tertiary Hospital during the Last 8 YEARS
9:00AM-11:00AM
Abstract Number: 1254
QI Project: Inpatient Practices in Ordering Fluorescent Anti-Nuclear Antibodies (F-ANA) and ANA Subserologies in a City Hospital in an Underserved Community
9:00AM-11:00AM
Abstract Number: 1272
Quality of Gout Management in a Rheumatology Clinic Using a Provider-Pharmacist Team-Based Approach
9:00AM-11:00AM
Abstract Number: 1555
Quality of Life of Rheumatoid Arthritis Patients Treated with Biologics
9:00AM-11:00AM
Abstract Number: 1348
Quantitative High Throughput Screening of Small Molecules to Inhibit Interferon-Stimulated Major Histocompatibility Complex Class I in Myositis Muscle
9:00AM-11:00AM
Abstract Number: 1721
Racial Differences in SSc Disease Presentation: A Cross-Sectional European Scleroderma Trials and Research Group Study
9:00AM-11:00AM
Abstract Number: 1542
Real-World Data from a Post-Approval Safety Surveillance Study of Tofacitinib Vs Biologic Dmards and Conventional Synthetic Dmards: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
9:00AM-11:00AM
Abstract Number: 1624
Real-World Insight into the Disease Burden and Treatment of Spondyloarthritis from a US-Based Life Impact Survey
9:00AM-11:00AM
Abstract Number: 1328
Recurrent Pericarditis: A Challenge in Autoinflammatory Disease Clinic and the Role of Anakinra
9:00AM-11:00AM
Abstract Number: 1223
Reduced Antibody Titers Against Pertussis in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 984
Reduced Expression of CX3CR1 in Peripheral CD14++CD16+monocytes Is a Novel Feature of Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1512
Reduction in Power Doppler Ultrasound Score with Tocilizumab Treatment Associates with Improvement in the Protective Profile of HDL in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 989
Reduction of Serum IL17F and IL22 By IL23p19 Blockade with Guselkumab Is Associated with Improvement in Joint Symptoms in Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1004
Reevaluating Citrullination and Peptidylarginine Deiminases in Neutrophil Extracellular Trap-like Structures
9:00AM-11:00AM
Abstract Number: 1697
Refractory Lupus Patients: How Frequent Do We See Them in the 21st Century?
9:00AM-11:00AM
Abstract Number: 1616
Region-Specific Differences in Clinical Presentation of Patients with Axial Spondyloarthritis – Results from a Large Multinational Cohort Study
9:00AM-11:00AM
Abstract Number: 1005
Regulation of Neutrophil Activation in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 988
Regulatory T Cells with Skewed Responses and Propionate-Producing Gut Bacteria Increased Simultaneously in Patients with Relapsing Polychondritis
9:00AM-11:00AM
Abstract Number: 1508
Relationship between BMI and Lower Limb Dysfunction in Japanese Female Patients with Rheumatoid Arthritis (the data from NinJa registry)
9:00AM-11:00AM
Abstract Number: 1279
Relative Insufficiency of Renal Uric Acid Excretion in Gout Patients with Obesity Leads to High Serum and Glomerular Filtration Load of Uric Acid
9:00AM-11:00AM
Abstract Number: 1700
Remission and Low Disease Activity State Prevent Hospitalizations and Emergency Room Visits in Systemic Lupus Erythematosus Patients
9:00AM-11:00AM
Abstract Number: 1430
Research Priorities for Addressing Mental Health Needs of Pediatric Patients with Rheumatologic Disease
9:00AM-11:00AM
Abstract Number: 1316
Respiratory Involvement in Relapsing Polychondritis – a Single Centre Study
9:00AM-11:00AM
Abstract Number: 1404
Responsiveness of Promis (Patient Reported Outcomes Measurement Information System) Measures in a Multi-Racial, Multi-Ethnic Systemic Lupus Erythematosus (SLE) Cohort
9:00AM-11:00AM
Abstract Number: 1165
Restless Sleep Trajectories over 8 Years: Data from the Osteoarthritis Initiative
9:00AM-11:00AM
Abstract Number: 1781
Retrospective Analysis of IgG4-RD Patient Population at the Cleveland Clinic between 2007-2017
9:00AM-11:00AM
Abstract Number: 1796
Retrospective Analysis of Initial Presentation Findings of Behcet’s Syndrome throughout 4 Decades
9:00AM-11:00AM
Abstract Number: 1248
Revisit an Old Question: Should Glucose-6-Phosphate Dehydrogenase Level be Checked in Patients with Rheumatic Diseases Prior to Initiating Certain Drugs?
9:00AM-11:00AM
Abstract Number: 1467
Rheumatoid Arthritis Activity Monitoring and Multiplex Biomarker Verification By Tageted Proteomics
9:00AM-11:00AM
Abstract Number: 1015
Rheumatoid Arthritis Peripheral CD14+ Monocytes Are Hyper-Inflammatory, Hyper-Glycolytic and Retain a Memory Bias Toward M1 Macrophages
9:00AM-11:00AM
Abstract Number: 1503
Rheumatoid Factor Positivity Is Related with Higher Discontinuation Rate of Tumor Necrosis Factor Inhibitor Therapy Due to Adverse Event and Insufficient Response in Rheumatoid Arthritis: A Multiple Imputation Method for COX Proportional Hazard Model
9:00AM-11:00AM
Abstract Number: 1750
Rheumatoid Factor Titer Is Inversely Correlated with ANCA Titer and Relates to Characteristic Manifestations in Patients with Eosinophilic Granulomatosis with Polyangiitis
9:00AM-11:00AM
Abstract Number: 1242
Rheumatologists Participating in the RISE Registry Succeeded in the First Year of the Merit-Based Incentive Payment System (MIPS)
9:00AM-11:00AM
Abstract Number: 1588
Risk of Cancer in Patients with Psoriasis/Psoriatic Arthritis: A Population-Based Study in the Province of British Columbia
9:00AM-11:00AM
Abstract Number: 1297
Risk of Dementia in Patients with Gout and the Impact of Urate-Lowering Therapies: A Large Population-Based Cohort Study
9:00AM-11:00AM
Abstract Number: 1144
Risk of Osteoporotic Fractures in Patients with Rheumatoid Arthritis and End Stage Renal Disease. Findings from the Usrds Database
9:00AM-11:00AM
Abstract Number: 1563
Risk of Overall Malignancies in Korean Patients with Primary Sjögren Syndrome
9:00AM-11:00AM
Abstract Number: 1305
Risk of Progression of Interstitial Lung Disease with Autoimmune Features to a Systemic Autoimmune Rheumatic Disease
9:00AM-11:00AM
Abstract Number: 1127
Risk of Stroke Among Patients with Gout in Taiwan: A Nationwide Population Study
9:00AM-11:00AM
Abstract Number: 1116
Risk of Systemic Sclerosis According to Charge of the HLA-DRβ1 Third Hypervariable Region
9:00AM-11:00AM
Abstract Number: 1416
Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 1304
Rituximab in Connective Tissue Disease – Associated Interstitial Lung Disease
9:00AM-11:00AM
Abstract Number: 1233
Rituximab Safety in Patients with Rheumatoid Arthritis. an Eleven-Year Follow-up Observational Study
9:00AM-11:00AM
Abstract Number: 1303
Rituximab Versus Mycophenolate Mofetil in Interstitial Lung Disease Secondary to Connective Tissue Disease
9:00AM-11:00AM
Abstract Number: 1571
RNA Sequencing Detection of Gene Dysregulation in Epithelial Cells Sorted from Salivary Gland Tissue Reveals Interesting Pathways Involved in Primary Sjögren’s Syndrome Pathophysiology
9:00AM-11:00AM
Abstract Number: 1349
Rnaseq of Peripheral Blood Mononuclear Cells from Juvenile Dermatomyositis, Necrotizing Myopathy and Controls Are an Aid in Diagnosis
9:00AM-11:00AM
Abstract Number: 1063
Role of Mitochondrial-Bound HK2 in Rheumatoid Arthritis Fibroblast-like Synoviocytes
9:00AM-11:00AM
Abstract Number: 1686
Rule-Based Algorithm Using Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria to Identify Patients with Systemic Lupus Erythematosus (SLE) from Electronic Health Record (EHR) Data
9:00AM-11:00AM
Abstract Number: 1470
Russell Bodies and Serological Status in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1715
Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
9:00AM-11:00AM
Abstract Number: 1539
Safety of Methotrexate and Leflunomide Combination Therapy in the Treatment of Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1413
Safety of Tocilizumab in Patients Aged <2 Years with Active Systemic Juvenile Idiopathic Arthritis Treated for One Year
9:00AM-11:00AM
Abstract Number: 1573
Salivary Dysbiosis Correlates with Clinical Status of Anti-Ro Positive Mothers of Children with Neonatal Lupus
9:00AM-11:00AM
Abstract Number: 1572
Salivary Flow Rates and Oral Health Related Quality of Life Are Associated with Ultrasonographic Scoring of the Major Salivary Glands in Sjogren Syndrome
9:00AM-11:00AM
Abstract Number: 1783
Salivary Gland Disease in IgG4-Related Disease Is Associated with Allergic Histories
9:00AM-11:00AM
Abstract Number: 1225
Screening for Acquired Latent Tuberculosis in Patients with Rheumatoid Arthritis(RA) on Anti-Tnfα Therapy (TNF-I) in Southern California
9:00AM-11:00AM
Abstract Number: 1252
Screening for Tuberculosis before Initiating TNF Inhibitors: How Well Do We Do? a Nationwide Experience
9:00AM-11:00AM
Abstract Number: 1189
Secukinumab Versus Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis from Korean Perspective
9:00AM-11:00AM
Abstract Number: 1091
Serine Arginine-Rich Splicing Factor 1 (SRSF1) Is Essential for T Lymphocyte Homeostasis and Decreased Levels of SRSF1 Correlate with Lymphopenia in SLE Patients
9:00AM-11:00AM
Abstract Number: 1637
Serious Infections Among Psoriatic Arthritis Patients Taking TNF Inhibitors Versus Non-TNF Biologics: A Systematic Review and Network Meta-Analysis
9:00AM-11:00AM
Abstract Number: 1093
Serologic Evidence Linking Epstein Barr Virus Reactivation, Heightened Interferon Pathway Activation and Increased Disease Activity in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1221
Serologic Screening for Coccidioidomycosis Among Medicare Beneficiaries with Rheumatic Diseases on Biologic Response Modifiers, Corticosteroids, and Dmards
9:00AM-11:00AM
Abstract Number: 1070
Seroreactivity Against Recombinant Citrullinated Myosin Is Associated with Measures of Diastolic Dysfunction in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1477
Serum Autoantibody Multi-Analyte Testing in Rheumatoid Arthritis Can Reduce Avoidable Costs Associated from False Positive Results. a Simulation Study in the United States of America
9:00AM-11:00AM
Abstract Number: 1680
Serum Calprotectin in Systemic Lupus Erythematosus: Is It a Good Activity Biomarker?
9:00AM-11:00AM
Abstract Number: 1708
Serum Complement Regulatory Proteins and Disease Activity of Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1784
Serum IgG4 Test Characteristics: Immunonephelometry Versus Liquid Chromatography Tandem Mass Spectrometry
9:00AM-11:00AM
Abstract Number: 1743
Serum Markers Potentially Associated with PAH in Systemic Sclerosis; A Targeted Screening Approach
9:00AM-11:00AM
Abstract Number: 1061
Serum Metabolomic Profiling Predicts Synovial Gene Expression in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1498
Serum MMP-3 More Than 155ng/Ml at Baseline Predicts One-Year Radiographic Progression in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1564
Severe, Life-Threatening Phenotype of Primary Sjögren Syndrome: Clinical Characterization and Outcomes in 1580 Patients (GEAS-SS Registry)
9:00AM-11:00AM
Abstract Number: 1496
Sex Differences in the Achievement of Clinical Remission and Low MRI Synovitis Scores in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1170
Sex-Specific Associations between Systemic Inflammatory Cytokines and Osteoarthritis Knee Pain
9:00AM-11:00AM
Abstract Number: 1726
Sexual Dysfunction in Systemic Sclerosis Female Patients
9:00AM-11:00AM
Abstract Number: 1780
Shear Wave Elastography in the Evaluation of Submandibular Gland Characteristics in IgG4-Related Disease
9:00AM-11:00AM
Abstract Number: 1733
Should We Perform Exercise Echocardiogram As a Screening Test for Pulmonary Arterial Hypertension (PAH) for All Systemic Sclerosis (SSc) Patients?
9:00AM-11:00AM
Abstract Number: 1106
Signal Transducer and Activator of Transcription 3 (STAT3) Activation in Peripheral Blood Mononuclear Cells of Systemic Sclerosis Patients: Correlation with Disease Specific Manifestations
9:00AM-11:00AM
Abstract Number: 1047
Signaling at Adenosine A2A Receptor (A2aR) in Osteoblasts; Crosstalk with Wnt/ β-Catenin Signaling Pathway
9:00AM-11:00AM
Abstract Number: 1257
Simple and Cost-Effective Intervention Doubled the Rate of Osteoporosis Screening in High Risk Rheumatology Patients
9:00AM-11:00AM
Abstract Number: 1213
Simplified Salivary Gland Ultrasonography for Sjögren Syndrome and Sicca Symptoms: Experience from a Single Medical Center in Taiwan
9:00AM-11:00AM
Abstract Number: 1533
Simulating Population Disability Outcomes for Alternative Treatment Pathways in Patients with Active Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1067
Simulating the Pathogenesis of Arthritis in Vitro By Developing a Human-Based Multicomponent 3D Joint Model
9:00AM-11:00AM
Abstract Number: 1579
Sjögren’s Syndrome Is Associated with Reduced Sex Hormone Exposure: A Case-Control Study
9:00AM-11:00AM
Abstract Number: 1718
Skin Gene Expression Profiling Predicts Longitudinal Modified Rodnan Skin Score Change
9:00AM-11:00AM
Abstract Number: 1648
Smoking Status in Patients with Psoriasis and Psoriatic Arthritis: An Irish Perspective
9:00AM-11:00AM
Abstract Number: 1576
Soluble Semaphorin 4D/CD100 Is Increased in the Saliva of Sjögren’s Syndrome
9:00AM-11:00AM
Abstract Number: 1577
Soluble Siglec-5 Is a Novel Salivary Biomarker for Primary Sjogren’s Syndrome
9:00AM-11:00AM
Abstract Number: 1134
Some Is Better Than None: Minimum Physical Activity Threshold to Prevent Disability in Older Adults with Lower Extremity Joint Symptoms
9:00AM-11:00AM
Abstract Number: 1210
Sonographic Appearance of Inflammatory Myopathies: Increased Muscle Echointensity and Qualitative Changes
9:00AM-11:00AM
Abstract Number: 1641
Spa-Net: A Disease-Specific Integrated Ehealth System and Quality Registry for Spondyloarthritis in Daily Practice in the Netherlands
9:00AM-11:00AM
Abstract Number: 1097
Spatial-Time Cluster Analysis of SLE Disease Activity
9:00AM-11:00AM
Abstract Number: 1806
Spinal Cord Involvement in Behcet’s Disease- Experience of a Vasculitis Centre at Silk Road
9:00AM-11:00AM
Abstract Number: 1228
Spine Immobilization and Neurological Complications in Vertebral Osteomyelitis: Results from a Multicenter Prospective Observational Study
9:00AM-11:00AM
Abstract Number: 1078
Standardization of Synovial Biopsies Procedures across Centers: A Consensus Initiative Using a Delphi Survey
9:00AM-11:00AM
Abstract Number: 1162
Standing Balance and Walking Time Among Older Adults with and without Joint Hypermobility: The Johnston County Osteoarthritis Project
9:00AM-11:00AM
Abstract Number: 1805
Strong Association of HLA-DRB1*0901 with Japanese Patients with Chronic Progressive Neuro-Behçet’s Disease
9:00AM-11:00AM
Abstract Number: 1120
Strong HLA and Novel Non-HLA Associations Identified By Auto-Antibody Subset Analysis of African Americans with Scleroderma from the Genome Research in African American Scleroderma Patients Cohort
9:00AM-11:00AM
Abstract Number: 1287
Strong Impact of Dysfunctional Variants of ABCG2 on Hyperuricemia and Gout in Children and Adolescents
9:00AM-11:00AM
Abstract Number: 1054
Study of the Metabolic Effect of MSCs on Their Chondroprotective and Regenerative Properties: Modulating Their Metabolism to Improve Their Therapeutic Potential for the Treatment of Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1650
Subclinical Atheromatosis and Estimation of Cardiovascular Risk in Patients with Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1770
Subglottic Stenosis and Endobronchial Disease in Granulomatosis with Polyangiitis
9:00AM-11:00AM
Abstract Number: 1385
Subjective Well-Being Among Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 1222
Suboptimal Immunization Coverage Among Rheumatology Patients in Routine Clinical Care
9:00AM-11:00AM
Abstract Number: 1212
Superiority of Musculoskeletal Ultrasound (MSUS) over Clinical Examination Regarding Detection of Arthritis in Patients with Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1000
Surface Adenosine Monophosphate Deaminase 2 As a Novel Regulator Modifying Ectonucleotidase-Driven Generation of Anti-Inflammatory Extracellular Adenosine
9:00AM-11:00AM
Abstract Number: 1485
Survivin Measurements Improve Prediction of Rheumatoid Arthritis Among Patients with Unexplained Arthralgia
9:00AM-11:00AM
Abstract Number: 1659
Sustained Improvements in Physical Function, Quality of Life, and Work Productivity after Ixekizumab Therapy in Patients with Active Psoriatic Arthritis: 3-Year Results
9:00AM-11:00AM
Abstract Number: 1172
Symptoms Compatible with Osteoarthritis and Self-Reported Osteoarthritis in the Population: Findings from the Canadian Longitudinal Study on Aging
9:00AM-11:00AM
Abstract Number: 1218
Synovial Fluid Culture: Comparison of Two Culture Methods
9:00AM-11:00AM
Abstract Number: 1232
Synovial Fluid Profile in Neutropenic Patients with Septic Arthritis
9:00AM-11:00AM
Abstract Number: 1053
Synovial Inflammation Identifies Patients Clusters in Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1506
Synovial Tissue Histopathology Findings in EARLY RA. Is It Usefull? Analysis of the Belgian CAP48 Cohort
9:00AM-11:00AM
Abstract Number: 1756
Systematic Review of the Clinical Effectiveness of Treatments in Eosinophilic Granulomatosis with Polyangiitis
9:00AM-11:00AM
Abstract Number: 1642
Systematic Screening of Comorbidities Improves Vaccination Rates, Skin Cancer Screening and Vitamin D Supplementation in Patients with Axial Spondyloarthritis: Results of a Prospective, Controlled ,One Year Randomised Trial
9:00AM-11:00AM
Abstract Number: 1371
Systemic Exposure of Triamcinolone Acetonide Following Bilateral Injection of Extended-Release Triamcinolone Acetonide and Standard Triamcinolone in Patients with Bilateral Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1290
Systemic Inflammation and Atherosclerosis in Patients with Gout. Results from the NOR-Gout Study
9:00AM-11:00AM
Abstract Number: 1687
Systemic Lupus Flares Based on BILAG and Sledai Rules Are Inconsistent, but May be Better Understood Using Visual Analogue Scales
9:00AM-11:00AM
Abstract Number: 1103
Systemic Sclerosis Has a Distinct Serum Protein Profile That Correlates with Its Clinical Manifestations
9:00AM-11:00AM
Abstract Number: 1440
Systemic Sclerosis in Pediatric Patients: An Epidemiological Study in a Large Insured Population in the US
9:00AM-11:00AM
Abstract Number: 1039
Tenofovir Induces Osteopenia and Dipyridamole, an Inhibitor of the Ent-1 Nucleoside Transporter, Reverses the Osteopenic Effect of Tenofovir In Vivo
9:00AM-11:00AM
Abstract Number: 1038
Tenofovir, a Nucleoside Analog Reverse Transcriptase Inhibitor for Treatment of HIV, Promotes Osteoclast Differentiation and Decreases Osteoblast Formation By a Mechanism Depending on ATP Release and Adenosine
9:00AM-11:00AM
Abstract Number: 1202
Tenosynovial Aspiration By Ultrasound Guidance: Even Small Volumes Can Have a Big Impact
9:00AM-11:00AM
Abstract Number: 1203
Tenosynovitis Detected By Ultrasound Predicts Arthritis Onset in Individuals at Risk of Developing Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1606
The 66/68 Joint Count for the Measurement of MSK Disease Activity/Peripheral Joint Activity in Psa: A Grappa-Omeract Working Group Initiative
9:00AM-11:00AM
Abstract Number: 1041
The Anti-Adamts-5 Nanobody®, M6495, Protects Against Cartilage Breakdown in Cartilage and Synovial Joint Tissue Explant Models
9:00AM-11:00AM
Abstract Number: 1267
The Association between Clinically Suspect Arthralgia and Adipokines in Obese Patients
9:00AM-11:00AM
Abstract Number: 1698
The Association between Periodontitis and the Disease Activity of Systemic Lupus Erythematosus: A Cross-Sectional Study
9:00AM-11:00AM
Abstract Number: 1575
The Association between Salivary Gland Ultrasonography and Clinical Manifestation in Patients with Early Primary Sjögren’s Syndrome
9:00AM-11:00AM
Abstract Number: 1358
The Association of Microbial Translocation and WOMAC Function in Patients with Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1146
The Association of Raas Inhibitor Use with Osteoporosis. Findings from the Women’s Health Initiative
9:00AM-11:00AM
Abstract Number: 1265
The Challenges of Managing Gout in Primary Care: Results of a Best Practice Audit
9:00AM-11:00AM
Abstract Number: 1197
The Characteristics of the Distribution of Normal Feeding Vessels between Young and Elderly Adults in Wrist Joints of Healthy Volunteers Depicted By Ultrasound (MSKUS)
9:00AM-11:00AM
Abstract Number: 1045
The Coll2-1 Peptide of Collagen Type II: A New Actor of Synovitis in Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1626
The Disease Expression in Familial and Sporadic Axial Spondyloarthritis Patients
9:00AM-11:00AM
Abstract Number: 1182
The Disproportionate High Risk of Re-Fracture after Osteoporotic Treatment in Patients with Autoimmune Diseases
9:00AM-11:00AM
Abstract Number: 1016
The Distinct Profile of Ly6clo Monocytes in the Murine Joint Compared with Those in Circulation Suggests a Unique Role in Inflammatory Arthritis
9:00AM-11:00AM
Abstract Number: 1183
The Distribution of Insurance in a Population-Based Cohort of SLE: Georgians Organized Against Lupus Cohort, 2012-2016
9:00AM-11:00AM
Abstract Number: 1180
The Economic Burden of Systemic Lupus Erythematosus (SLE) within a Commercially-Insured Population in the United States Stratified By Disease Severity
9:00AM-11:00AM
Abstract Number: 1238
The Effect of Antibiotic Therapy on Positive Culture Results Among Patients with Prosthetic Joint Septic Arthritis
9:00AM-11:00AM
Abstract Number: 1327
The Effect of Etoposide on Inducing Remission in Refractory Adult-Onset Still’s Disease: A Retrospective, Single-Center Study
9:00AM-11:00AM
Abstract Number: 1657
The Effect of Guselkumab on Enthesitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1148
The Effects of Physical Activity on Bone Density of High School Girls: A Prospective Study
9:00AM-11:00AM
Abstract Number: 997
The Effects of the Jak-Stat Signal Pathway Inhibition on Collagen Biosynthesis in Fibroblast Cell Culture
9:00AM-11:00AM
Abstract Number: 1543
The Efficacy, Safety and Adherence of Biologicbiological Disease-Modifying Anti Rheumatic Drugs, Infliximab, Tocilizumab and Abatacept, in Elderly Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1195
The Evaluation of the Small Enthesis of the Hands By Ultrasound: A Study on Healthy Subjects
9:00AM-11:00AM
Abstract Number: 1100
The Frequencies and Molecular Profiles of CD16+ Monocyte Subsets in Patients with Systemic Lupus Erythematosus, Primary Antiphospholipid Syndrome, and Antiphospholipid Syndrome with Lupus, Identify Specific Clinical Features of These Diseases
9:00AM-11:00AM
Abstract Number: 1634
The Impact of Comorbidities on Physical Function in Patients with Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics. Results of a National Study
9:00AM-11:00AM
Abstract Number: 1220
The Impact of Gender on the Clinical Presentation, Management and Outcomes of Patients with Native Joint Septic Arthritis
9:00AM-11:00AM
Abstract Number: 1192
The Impact of Participation in an Adalimumab (Humira) Patient Support Program on the Onset and Management of Disease Flares
9:00AM-11:00AM
Abstract Number: 1191
The Importance of Quantitative Assessment of Joint/Organ Damage and Patient Distress in Addition to Inflammatory Activity in Routine Clinical Care
9:00AM-11:00AM
Abstract Number: 1262
The Importance of Standardization of Musculoskeletal Procedures Performed in an Academic Rheumatology Clinic
9:00AM-11:00AM
Abstract Number: 1609
The Incidence Rate of Spondyloarthritis in Slovenia
9:00AM-11:00AM
Abstract Number: 1369
The Influence of Hand Osteoarthritis on Bone Microstructure and Biomechanical Properties of Radial Bone
9:00AM-11:00AM
Abstract Number: 1694
The Lupus Severity Index Accurately Identifies Patients with Severe SLE in a Multi-Ethnic Cohort
9:00AM-11:00AM
Abstract Number: 1500
The Multi-Biomarker Disease Activity Score Tracks Response to Rituximab Treatment in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 1793
The Omeract Core Domain Set for Clinical Trials in Behçet’s Syndrome
9:00AM-11:00AM
Abstract Number: 1376
The Omeract-Oarsi Core Set of Outcome Domains to Measure in Clinical Trials for People with Hip and/or Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1446
The Optimal Joint Set for Ultrasound Assessment of Synovitis in RA: Results from the Rasch Measurement Model
9:00AM-11:00AM
Abstract Number: 1194
The Physiological Changes of the Enthesis in Response to Age, Body Mass Index and Physical Activity: An Ultrasound Study in Healthy People
9:00AM-11:00AM
Abstract Number: 1505
The Point-of-Care Ichroma Anti-CCP Test Showed a Competitive Measurement Accuracy, in Comparison to the Conventional Automated Tests
9:00AM-11:00AM
Abstract Number: 1040
The Potential Role of Choline Kinase Alpha in Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1150
The Potential Uses of an Infodemiology Approach for Health-Care Services in Rheumatology
9:00AM-11:00AM
Abstract Number: 1479
The Predictive Utility of Anti-Cyclic Citrullinated Peptide Antibodies to Diagnose Rheumatoid Arthritis in Patients with Hepatitis C and Polyarthralgias
9:00AM-11:00AM
Abstract Number: 1131
The Prevalence and Incidence of Gout, Its Associated Comorbidities and Treatment Pattern: An Epidemiological Study from Germany
9:00AM-11:00AM
Abstract Number: 1511
The Relationship between Lipid Profile Changes and Inflammation across the Phase 3 Sarilumab Rheumatoid Arthritis (RA) Developmental Program
9:00AM-11:00AM
Abstract Number: 1374
The Relationship between Loneliness and Osteoarthritis in US Adults from a Nationally Representative Survey
9:00AM-11:00AM
Abstract Number: 1300
The Relationship between Metabolic Syndrome Severity and the Risk of Mortality in Gout Patients: A Population Based Study
9:00AM-11:00AM
Abstract Number: 1774
The Relationship between Serum Cholinesterase, Dickkopf-1 and Number of Organ Involvement in Japanese Patients with IgG4-Related Disease
9:00AM-11:00AM
Abstract Number: 1402
The Relationship of Pain, Fatigue and Emotional Distress with Quality of Life in Juvenile Myositis
9:00AM-11:00AM
Abstract Number: 1567
The Risk Factors and Prognosis of Interstitial Lung Disease Associated with Primary Sjogren’s Syndrome: A Multi-Center Cohort Study
9:00AM-11:00AM
Abstract Number: 1167
The Role of Fear-Avoidance Model on Pain and Disability in Knee Osteoarthritis Patients
9:00AM-11:00AM
Abstract Number: 1433
The Role of Patient and Parental Resilience in Amplified Musculoskeletal Pain Syndrome
9:00AM-11:00AM
Abstract Number: 1360
The Role of Personality in Patients with Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1541
The Safety Profile of Iguratimod in Real Clinical Practice: Analysis of 491 Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1055
The TLR-4 Inhibitor 6-Shogaol As a Treatment in Osteoarthritis Trough the Modulation of Chondrocyte Hypertrophy and Matrix Calcification
9:00AM-11:00AM
Abstract Number: 1199
The Use of Musculoskeletal Ultrasound to Assess Remission in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1666
The Use of Patient-Reported Outcome Measures to Assess Clinical Features of Fibromyalgia in SLE
9:00AM-11:00AM
Abstract Number: 1764
The Utility of Serum Angiopoietin-1 and Angiopoietin-2 in Patients with Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 1426
The Utilization of S100 Proteins Testing in Pediatric Rheumatology Patients in a Tertiary Care Institution and Implications for Care
9:00AM-11:00AM
Abstract Number: 1451
The Value of Adding MRI to a Clinical Treat-to-Target Strategy in Rheumatoid Arthritis Patients in Clinical Remission: Clinical and Radiographic Outcomes from the Imagine-RA Randomized Controlled Trial
9:00AM-11:00AM
Abstract Number: 1608
The Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients with Psoriatic Disease
9:00AM-11:00AM
Abstract Number: 1522
Time Dependent Effect of Biologic Therapy on Overall Survival in Patients with Rheumatoid Arthritis and Cancer
9:00AM-11:00AM
Abstract Number: 1011
Tissue Resident Macrophages Establish a Niche That Limits Monocyte to Macrophage Differentiation in Synovial Tissue during Homeostasis
9:00AM-11:00AM
Abstract Number: 1022
TNF-α Regulates Plasmacytoid Dendritic Cells By Suppressing IFN-α Production and Enhancing Th1 and Th17 Cell Differentiation
9:00AM-11:00AM
Abstract Number: 1216
To Study the Frequency of Persistent Arthritis, in Patients with Chikungunya Fever, in a Tertiary Health Care Center
9:00AM-11:00AM
Abstract Number: 1066
Tocilizumab Effect on Serum Angiogenic Factors in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 1018
Tofacitinib Impairs Monocyte-Derived Dendritic Cell Differentiation in Rheumatoid Arthritis and Psoriatic Arthritis.
9:00AM-11:00AM
Abstract Number: 1527
Tofacitinib Improves Left Ventricular Mass and Cardiac Output in Rheumatoid Arthritis Patients with Chronic Heart Failure
9:00AM-11:00AM
Abstract Number: 1544
Tofacitinib Safety and Efficacy in the Treatment of Rheumatoid Arthritis in a Central/Eastern European Subpopulation
9:00AM-11:00AM
Abstract Number: 1531
Tofacitinib Show Similar Retention When Used with and without Methotrexate. Analysis from the Rhumadata® Clinical Database and Registry
9:00AM-11:00AM
Abstract Number: 1317
Tracheomalacia in Coventry in UK
9:00AM-11:00AM
Abstract Number: 1141
Trajectories of Extensive Sitting and Associated Predictors in Persons at High Risk for Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 1705
Trajectory Analysis of Combined Disease Activity and Physical Component Summary Scale in an Inception Cohort of Adults with Systemic Lupus Erythematosus: Latent Classes Inform Different Patterns
9:00AM-11:00AM
Abstract Number: 998
Transcription Factor Fli-1 Impacts Renal IL-17 Expression in Adult MRL/Lpr Mouse Despite Similar Interstitial Immune Cell Infiltration into the Kidney
9:00AM-11:00AM
Abstract Number: 1438
Treatment and Response of Down Syndrome Arthropathy
9:00AM-11:00AM
Abstract Number: 1364
Treatment of Knee Osteoarthritis with SM04690 Improved WOMAC A1 “Pain on Walking” – Results from a 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor
9:00AM-11:00AM
Abstract Number: 1217
Trend of Frequency and Outcome of Reactive Arthritis in Japanese Patients with Bladder Cancer Following Intravesical BCG Therapy over the Last 20 Years
9:00AM-11:00AM
Abstract Number: 1142
Trend of Lymphoma Incidence in US Veterans with Rheumatoid Arthritis Vs Osteoarthritis: 2002-2017
9:00AM-11:00AM
Abstract Number: 1443
Ultrasonographic Criteria for the Diagnosis of Erosive Rheumatoid Arthritis Disease Using Osteoarthritic Patients As Controls Compared to Validated Radiographic Criteria
9:00AM-11:00AM
Abstract Number: 1632
Ultrasonographic Evaluation of the Enthesis in Patients Affected By Entheropatic Spondiloarthritis. Focus on Distal Enthesis of the Patellar Tendon
9:00AM-11:00AM
Abstract Number: 1206
Ultrasonographic Involvement of the Anterior Chest Wall,a Five Years Follow up
9:00AM-11:00AM
Abstract Number: 1198
Ultrasound-Detected Joint Erosions in Rheumatoid Arthritis: What Every Sonographer Should Know
9:00AM-11:00AM
Abstract Number: 1096
Unexpected Association between Health-Related Quality of Life and the Blood Interferon Modular Transcriptional Signatures in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1200
Unilateral Ultrasound Scoring Methods for Synovitis in Rheumatoid Arthritis: An Agreement Study Exploring the Most Inflammatory Active Side
9:00AM-11:00AM
Abstract Number: 1528
Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)
9:00AM-11:00AM
Abstract Number: 1024
Unique Pattern of Lectin Pathway Complement Protein Levels in Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1425
Update from the Juvenile Scleroderma Inception Cohort
9:00AM-11:00AM
Abstract Number: 1190
Use of Biologic Drugs and Adverse Events in Patients with Rheumatic Disease: DATA from the Mexican Biologics Registry
9:00AM-11:00AM
Abstract Number: 1437
Use,Safety and Efficacy of Thalidomide from a Tertiary Level Pediatric Rheumatology Centre in India
9:00AM-11:00AM
Abstract Number: 1560
Usefulness of 18F-FDG Positron Emission Tomography for Lymphoma Diagnosis in Patients with Primary Sjögren’S Syndrome
9:00AM-11:00AM
Abstract Number: 1679
Usefulness of Cardiac Screening in Patients with Systemic Lupus Erythematosus and Anti-Ro Positive Antibodies
9:00AM-11:00AM
Abstract Number: 1692
Using ICD-10-CM Codes to Identify Patients with Systemic Lupus Erythematosus in the Electronic Health Record
9:00AM-11:00AM
Abstract Number: 1408
Using Patient Reported Outcomes at Point of Care in Immune Mediated Diseases: Minimal Clinically Important Differences
9:00AM-11:00AM
Abstract Number: 1504
Utility of Serial ACPA Measurements in Rheumatoid Arthritis: Results of a Prospective Cohort Study
9:00AM-11:00AM
Abstract Number: 1702
Utility of the Avise Connective Tissue Disease Test in Predicting Lupus Diagnosis and Progression of Disease
9:00AM-11:00AM
Abstract Number: 1711
Utility of the Lupus Low Disease Activity State (LLDAS) in Discriminating Responders in the BLISS-52 and BLISS-76 Phase 3 Trials of Intravenous Belimumab in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 1709
Utilization of Complementary and Integrative Medicine Among Lupus Patients:a Patient Centered Analysis of Perceived Effectiveness and Preference
9:00AM-11:00AM
Abstract Number: 1639
Uveitis As First Symptom in Patients with Spondyloarthritis. Data from the Spanish Registry Regisponser
9:00AM-11:00AM
Abstract Number: 1647
Uveitis, the Most Faithful Partner of Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1673
Validation and Evaluation of the Spanish Version of the Systemic LUPUS Activity Questionnaire in an Argentine Population
9:00AM-11:00AM
Abstract Number: 1378
Validation of a Spanish Version of the Functional Index for Hand Osteoarthritis (FIHOA)
9:00AM-11:00AM
Abstract Number: 1540
Validation of Hepatic Fibrosis Markers in People with Rheumatoid Arthritis on Methotrexate
9:00AM-11:00AM
Abstract Number: 1712
Validation of Proposed EULAR/Acr SLE Classification Criteria Versus SLICC SLE Classification Criteria
9:00AM-11:00AM
Abstract Number: 1338
Validation of the Diagnostic Accuracy of Myositis-Related Antibodies in a Large Patient-Cohort
9:00AM-11:00AM
Abstract Number: 1635
Validity of Patient-Reported Outcomes Measurement Information System Measures in Ankylosing Spondylitis Patients
9:00AM-11:00AM
Abstract Number: 1484
Value of Anti-RA33 Isotypes in an European Rheumatoid Arthritis Patient Cohort
9:00AM-11:00AM
Abstract Number: 1683
Variation in HEp-2 Antinuclear Antibody (ANA) Titer Is Strongly Associated with the ANA Kit Manufacturer
9:00AM-11:00AM
Abstract Number: 1060
Variation in the Synovial Fluid Metabolome According to Disease Activity in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1794
Venous Vessel Wall Thickness in Lower Extremity Is Increased in Male Behcet’s Disease Patients
9:00AM-11:00AM
Abstract Number: 1731
Vertebral Fracture Prevalence and Measurement of the Scanographic Bone Attenuation Coefficient on CT-Scan in 70 Patients with Systemic Scleroderma
9:00AM-11:00AM
Abstract Number: 1557
Visualization of Dorsal Root Ganglionitis with Three-Tesla Magnetic Resonance Neurography in Sensory Ataxic Neuropathy Associated with Sjögren’s Syndrome
9:00AM-11:00AM
Abstract Number: 1273
What Did Patients from the US Think about Their Gout in 2017?
9:00AM-11:00AM
Abstract Number: 1739
What Do Patient Reported Outcomes for Routine Monitoring of Gastrointestinal Tract Symptoms in a Systemic Sclerosis Center Tell Us about Clinical Features of Potential Small Intestinal Bacterial Overgrowth?
9:00AM-11:00AM
Abstract Number: 1237
What Is the Value of Synovial Biopsies for the Diagnosis of Septic Arthritis?
9:00AM-11:00AM
Abstract Number: 1658
Which Factors Influence the Diagnostic Delay in Patients with Axial Spondyloarthritis?
9:00AM-11:00AM
Abstract Number: 1640
Work Disability in Psoriatic Arthritis Patients
9:00AM-11:00AM
Abstract Number: 1156
Work Productivity and Activity Impairment in Patients with Rotator Cuff Tendinopathy
9:00AM-11:00AM
Abstract Number: 1792
Work Productivity Is Impaired in Patients with Behcet’s Syndrome
9:00AM-11:00AM
Abstract Number: 1439
Yellow Fever Vaccination in Brazil: Short-Term Safety in Pediatric Autoimmune Rheumatic Diseases
11:00AM-12:30PM
Abstract Number: 1821
Filgotinib, an Oral, Selective Janus Kinase 1 Inhibitor, Is Effective in Psoriatic Arthritis Patients with an Inadequate Response to Conventional Disease-Modifying Anti-Rheumatic Drugs: Results from a Randomized, Placebo-Controlled, Phase 2 Study
11:00AM-12:30PM
Abstract Number: 1816
Five-Year Outcome of Operative and Nonoperative Management of Meniscal Tear in the Presence of Osteoarthritic Changes
11:00AM-12:30PM
Abstract Number: 1818
Greater BMD Gains with Denosumab Vs Risedronate in Glucocorticoid-Treated Subjects: Results from the Final 24-Month Analysis of a Randomized, Double-Blind, Double-Dummy Study
11:00AM-12:30PM
Abstract Number: 1817
MicroRNA-128 Impairs Cartilage Integrity and Deteriorates Osteoarthritis Pathogenesis through Deregulating Chondrocyte Autophagy
11:00AM-12:30PM
Abstract Number: 1819
MUC5B promoter Variant rs35705950 Is a Risk Factor for Rheumatoid Arthritis – Interstitial Lung Disease
11:00AM-12:30PM
Abstract Number: 1820
Myeloablative Autologous Hematopoietic Stem Cell Transplantation for Severe Scleroderma: Long-Term Outcomes 6-11 Years after Entry on a Randomized Study Comparing Transplantation and Cyclophosphamide
2:30PM-4:00PM
Abstract Number: 1871
A High Cardiovascular Biomarker Panel Risk Score Is Associated with Increased 10-Year Risk of Cardiovascular Events and Death in SLE
2:30PM-4:00PM
Abstract Number: 1850
A Population Based Study of High School Academic Outcomes in Individuals with Childhood-Onset Chronic Rheumatic Diseases in Manitoba, Canada
2:30PM-4:00PM
Abstract Number: 1873
Age- and Cause-Specific Standardized Mortality Ratio of Systemic Lupus Erythematosus Patients in Ontario, Canada over 43 Years (1971-2013)
2:30PM-4:00PM
Abstract Number: 1858
An Assay Panel Combining Anti-Protein Arginine Deiminase 4 with Rheumatoid Factor Isotypes Distinguishes Anti-Citrullinated Peptide Antibody Negative Rheumatoid Arthritis
2:30PM-4:00PM
Abstract Number: 1863
Anti-Cyclic Citrullinated Protein Antibody at Multiple Cutoff Levels and in Combination with Rheumatoid Factor IgM and Serum Calprotectin Is Highly Specific for the Development of Rheumatoid Arthritis within 3 Years
2:30PM-4:00PM
Abstract Number: 1839
Association of Diet Quality with Overall Fibromyalgia Impact, and Psychosocial and Quality of Life Outcomes in Women with Fibromyalgia
2:30PM-4:00PM
Abstract Number: 1880
Cardiovascular (CV) Risk Factors and Atherosclerotic CV Events Among Incident Cases of Systemic Sclerosis: Results from a Population Based Cohort (1980-2016)
2:30PM-4:00PM
Abstract Number: 1848
Cardiovascular Risk Factors in Adults with Juvenile Idiopathic Arthritis in Sustained Remission
2:30PM-4:00PM
Abstract Number: 1882
Characteristics and Treatment Outcomes of Takayasu Arteritis in a Nationwide, Retrospective Cohort Study in Japan
2:30PM-4:00PM
Abstract Number: 1884
Clinical Features and Outcome of Patients with Polyarteritis Nodosa – a Global Collaborative Study
2:30PM-4:00PM
Abstract Number: 1841
Current Rheumatology Fellows Experiences with Health Disparities and Disparity Education: A Qualitative Study
2:30PM-4:00PM
Abstract Number: 1845
Defining and Examining Retention in Care in an Urban Lupus Cohort
2:30PM-4:00PM
Abstract Number: 1860
Development and Validation of a Microrna Panel to Differentiate between Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Control Subjects
2:30PM-4:00PM
Abstract Number: 1835
Diagnosis of Fibromyalgia: Disagreement between Fibromyalgia Criteria and Clinician-Based Fibromyalgia Diagnosis in a University Clinic
2:30PM-4:00PM
Abstract Number: 1881
Discovery and Validation of Novel Disease Subsets in 806 Patients with Takayasu’s Arteritis across Four International Cohorts
2:30PM-4:00PM
Abstract Number: 1840
Disease Activity in Rheumatoid Arthritis Patients Is Influenced By Countries’ Socioeconomics: Results from the Meteor Registry
2:30PM-4:00PM
Abstract Number: 1867
Drug Retention and Response Rates of TNFi Treatment in 21,470 Patients with Axial Spondyloarthritis Treated in Clinical Practice– Pooled Data from the Eurospa Research Network Collaboration
2:30PM-4:00PM
Abstract Number: 1868
Efficacy and Safety Outcomes in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the First 52-Week Randomized Placebo-Controlled Study (NCT02552212)
2:30PM-4:00PM
Abstract Number: 1855
Erythrocyte Bound C4d in the Presence of Adverse Pregnancy Outcome Events in Pregnant Women with Systemic Lupus Erythematosus
2:30PM-4:00PM
Abstract Number: 1862
Exploring the Lipid Paradox Theory in Rheumatoid Arthritis: Very Low Circulating Low-Density Lipoprotein Concentration Levels Are Associated with Pro-Atherogenic Biomarkers
2:30PM-4:00PM
Abstract Number: 1836
Fibromyalgia Diagnosis and Biased Assessment: Sex, Prevalence, Biology and Bias
2:30PM-4:00PM
Abstract Number: 1838
Fibromyalgia, Beyond the 2016 Establishment. an Analysis of Novel Symptom Clusters for Differentiating Fibromyalgia from Other Chronic Pain Disorders
2:30PM-4:00PM
Abstract Number: 1826
From Cancer to Autoimmunity : A New Model of Rheumatoid Arthritis Emerging from a Constitutional Genetic Approach Used in Low Penetrance Cancers
2:30PM-4:00PM
Abstract Number: 1827
Genetic Ablation of Phd Finger Protein 19 Gene Promotes Autoimmune Arthritis in Mice
2:30PM-4:00PM
Abstract Number: 1828
Gut-Joint T Cell Trafficking in a Model of Bacteria-Driven Murine IBD-Spa
2:30PM-4:00PM
Abstract Number: 1878
Immunosuppression in Diffuse Systemic Sclerosis Improves Outcomes Using a Novel Composite Response Index
2:30PM-4:00PM
Abstract Number: 1842
Implementation of an African American Popular Opinion Leader Model to Address Disparities in Lupus Knowledge and Care
2:30PM-4:00PM
Abstract Number: 1843
Improving Access to Rheumatology Care for High-Risk Lupus Patients Can Help Decrease Hospitalizations
2:30PM-4:00PM
Abstract Number: 1866
Incidence of Inflammatory Bowel Disease Among Patients Treated with Ixekizumab: An Update on Adjudicated Data from an Integrated Database of Patients with Psoriasis and Psoriatic Arthritis
2:30PM-4:00PM
Abstract Number: 1883
Infections Are Associated With Increased Risk of Giant Cell Arteritis – a Population-Based Case-Control Study From Southern Sweden
2:30PM-4:00PM
Abstract Number: 1875
Influence of Setting an Upper Limit of the Modified Rodnan Skin Score As an Inclusion Criterion in Systemic Sclerosis Clinical Trials on the Ratio of Skin Fibrosis Progression Vs. Improvement – an Analysis of the Genisos Cohort
2:30PM-4:00PM
Abstract Number: 1831
Intestinal Inflammatory Regulation in Murine and Human Spondyloarthropathy Requires High-Affinity T Cell Receptor-Zeta Chain-Associated Protein (ZAP)70-Mediated Runt-Related Transcription Factor (Runx)3 Activity
2:30PM-4:00PM
Abstract Number: 1865
Ixekizumab Significantly Improves Self-Reported Overall Functioning and Health in Patients with Active As/Radiographic Axial Spa Naive to Biologic DMARD Therapy: 16‑Week Results of a Phase 3 Randomized, Active and Placebo-Controlled Trial
2:30PM-4:00PM
Abstract Number: 1864
Ixekizumab Significantly Improves Signs, Symptoms, and Spinal Inflammation of Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 16-Week Results of a Phase 3 Randomized, Active and Placebo-Controlled Trial
2:30PM-4:00PM
Abstract Number: 1861
Lipid Screening in Medicare Beneficiaries with Rheumatoid Arthritis
2:30PM-4:00PM
Abstract Number: 1885
Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger’s disease): A Multicenter Study of 224 Patients
2:30PM-4:00PM
Abstract Number: 1890
Longitudinal Deep Learning on Electronic Health Record Data to Predict Future Rheumatoid Arthritis Disease Activity
2:30PM-4:00PM
Abstract Number: 1823
Loss of Synovial Tissue Resident Macrophages Permits Monocyte to Macrophage Differentiation and Inflammation in Hupo Mice
2:30PM-4:00PM
Abstract Number: 1856
Low Aspirin Use and High Prevalence of Preeclampsia Risk Factors Among Pregnant Women in a Multi-National SLE Inception Cohort
2:30PM-4:00PM
Abstract Number: 1857
Low Molecular Weight Heparin and Aspirin Combination Therapy Modulates Th1/Th2 Cell Imbalance in Pregnant Patients with Antiphospholipid Antibody-Associated Recurrent Pregnancy Loss
2:30PM-4:00PM
Abstract Number: 1876
Machine Learning Classification of Peripheral Blood Gene Expression Identifies a Subset of Patients with Systemic Sclerosis Most Likely to Show Clinical Improvement in Response to Hematopoietic Stem Cell Transplant
2:30PM-4:00PM
Abstract Number: 1846
Menarchal Status at Diagnosis and Final Height in Females with Childhood-Onset Systemic Lupus Erythematosus
2:30PM-4:00PM
Abstract Number: 1824
Osteoclast Derived-Autotaxin, a Distinguishing Factor for Inflammatory Bone Loss
2:30PM-4:00PM
Abstract Number: 1853
Paternal Use of Methotrexate (MTX) and Congenital Malformations – a Systematic Review and Meta-Analysis
2:30PM-4:00PM
Abstract Number: 1892
Patient and Health System Characteristics Associated with Receipt of Disease Modifying Anti-Rheumatic Drugs in a National VA Sample
2:30PM-4:00PM
Abstract Number: 1891
Patterns of Biosimilar Use in the Rheumatology Informatics System for Effectiveness (RISE) Registry
2:30PM-4:00PM
Abstract Number: 1889
Patterns of Glucocorticoid Use and Provider-Level Variation in a Commercially Insured Incident Rheumatoid Arthritis Population
2:30PM-4:00PM
Abstract Number: 1829
Perturbations of the Gut Fungal and Bacterial Microbiome with Biologic Therapy in Spondyloarthritis
2:30PM-4:00PM
Abstract Number: 1870
Phase 2 Trial of Induction Therapy with Anti-CD20 (Rituximab) Followed By Maintenance Therapy with Anti-BAFF (Belimumab) in Patients with Active Lupus Nephritis
2:30PM-4:00PM
Abstract Number: 1886
Phenotypic Subgroups in IgG4-Related Disease – a Cluster Analysis
2:30PM-4:00PM
Abstract Number: 1851
Physical Function Trajectories in Children with Juvenile Myositis
2:30PM-4:00PM
Abstract Number: 1887
Practice Variation in Prescriptions of Non-TNFi Biologics and Tofacitinib: Data from the Rheumatology Informatics System for Effectiveness (RISE) Registry
2:30PM-4:00PM
Abstract Number: 1852
Pregnancy in Lupus: 17-Year U.S. Nationwide Trend in Obstetric and Maternal Outcomes
2:30PM-4:00PM
Abstract Number: 1832
Proteomic and Transcriptomic Profiling of Cells in Ankylosing Spondylitis Patients Identifies a Novel, Synovial-Resident CD8+ T Cell
2:30PM-4:00PM
Abstract Number: 1844
Racial Disparities and Accelerated SLE Mortality from a Population-Based Registry: The Georgia Lupus Registry
2:30PM-4:00PM
Abstract Number: 1874
Remission and Low Disease Activity State Are Protective of Intermediate and Long-Term Outcomes in SLE Patients. Data from a Multi-Ethnic, Multi-Center US Cohort
2:30PM-4:00PM
Abstract Number: 1849
Remission Status after 18 Years of Follow-up in the Population-Based Nordic Juvenile Idiopathic Arthritis (JIA) Cohort
2:30PM-4:00PM
Abstract Number: 1825
Rheumatoid Arthritis Associated Haploinsufficiency in PTPN2 Enhances Severity of IL-17 Mediated Autoimmune Arthritis
2:30PM-4:00PM
Abstract Number: 1822
RNA-Sequencing of Mouse and Human Synovial Fibroblasts Reveals Fibroblast Subset-Specific Responses to Inflammation
2:30PM-4:00PM
Abstract Number: 1830
Role of BMP2 in Entheseal Bone Formation in Inflammatory Arthritis
2:30PM-4:00PM
Abstract Number: 1872
Safety and Efficacy of Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells in Patients with Systemic Lupus Erythematosus: Results of an Open-Label Phase I Study
2:30PM-4:00PM
Abstract Number: 1847
Screening Youth with Lupus for Depression and Anxiety in Pediatric Rheumatology Clinics
2:30PM-4:00PM
Abstract Number: 1888
SLE Among the Leading Causes of Years of Potential Life Lost in Young Women: Population-Based Study, 2000-2015
2:30PM-4:00PM
Abstract Number: 1854
SLE Flares during and after Pregnancy Are Mild and Occur at Similar Rates
2:30PM-4:00PM
Abstract Number: 1834
Sleep Apnea and Fibromyalgia: Data from the Cleveland Clinic Fibromyalgia Registry
2:30PM-4:00PM
Abstract Number: 1877
Specific Pneumoproteins Predict Progression of Interstitial Lung Disease in Systemic Sclerosis Patients Undergoing Treatment with Immunosuppression
2:30PM-4:00PM
Abstract Number: 1869
Sustained Improvements in Signs and Symptoms of Active Ankylosing Spondylitis and Reassuring Safety with Secukinumab 300mg: 3-Year Results from a Phase 3 Study
2:30PM-4:00PM
Abstract Number: 1879
The Effects of Riociguat on Raynaud’s Phenomenon and Digital Ulcers in Patients with Diffuse Systemic Sclerosis: Results from the Phase IIb RISE-SSc Study
2:30PM-4:00PM
Abstract Number: 1859
The Prognostic Value of Autoantibody Isotypes for Predicting Therapeutic Responses to Methotrexate in Patients with Rheumatoid Arthritis
2:30PM-4:00PM
Abstract Number: 1833
The Vδ2 Subset of Γδt-Cells Are Present at Healthy Human Enthesis and Have Transcriptional and Functional Characteristics Consistent with a Capacity for IL- 17A Production in Response to IL-23
2:30PM-4:00PM
Abstract Number: 1837
Validity of the Cognitive Index of the Symptom Severity Scale (SSS-Cog) in Assessing Cognitive Impairment in Fibromyalgia Patients
4:30PM-6:00PM
Abstract Number: 1938
A Phase IIb Dose-Ranging Study of Anti-GM-CSF with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate
4:30PM-6:00PM
Abstract Number: 1936
A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy, Safety and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis
4:30PM-6:00PM
Abstract Number: 1906
Abdominal Obesity and Risk of Developing Rheumatoid Arthritis in Women
4:30PM-6:00PM
Abstract Number: 1931
Abundance of Plasma Microbial Small RNAs Are Predictive of Improvement in Disease Activity after DMARD Initiation for Rheumatoid Arthritis
4:30PM-6:00PM
Abstract Number: 1941
Altered Cognitive Function in Systemic Lupus Erythematosus and Associations with Inflammation and Functional Brain Changes
4:30PM-6:00PM
Abstract Number: 1942
Anti-NMDA Receptor Antibodies in Systemic Lupus Erythematosus Associate with Decreased White Matter Integrity and Impaired Spatial Memory
4:30PM-6:00PM
Abstract Number: 1943
Apolipoprotein L1 Risk Variants Associate with Poor Renal Outcomes, Damage Accrual, and Death: A Prospective Ghanaian SLE Cohort
4:30PM-6:00PM
Abstract Number: 1908
Bariatric Surgery Does Not Affect the Incidence of Rheumatoid Arthritis in Obese Subjects
4:30PM-6:00PM
Abstract Number: 1894
Baricitinib-Associated Changes in Type l Interferon Gene Signature during a 24-Week Phase-2 Clinical SLE Trial
4:30PM-6:00PM
Abstract Number: 1948
Beliefs and Preferences for Reducing Sedentary Time in Those with Current or Past Knee Symptoms
4:30PM-6:00PM
Abstract Number: 1915
Big Data Analysis of Autoimmune Diseases Induced By Cancer Immunotherapies: Identifying Pharmacological Patterns of Organ-Specific Involvement
4:30PM-6:00PM
Abstract Number: 1946
Changing the Conversation about Pain: Development and Testing of an Interprofessional Pain CME Applicable for Rheumatologists and Rheumatology Health Professionals
4:30PM-6:00PM
Abstract Number: 1922
Characterization of the Pharmacology and Pharmacokinetics of Cntx-4975, a High-Purity, Synthetic Trans-Capsaicin in Clinical Development for the Treatment of Moderate to Severe OA Knee Pain
4:30PM-6:00PM
Abstract Number: 1956
Cohort Effects in Back Pain: The Effect of Changes in Life-Style and Co-Occurring Conditions
4:30PM-6:00PM
Abstract Number: 1932
Complications Following Total Knee Arthroplasty in Inflammatory Versus Osteoarthritis
4:30PM-6:00PM
Abstract Number: 1918
Defining Pain That Does Not Interfere with Activities Among Rheumatoid Arthritis (RA) Patients
4:30PM-6:00PM
Abstract Number: 1947
Do Changes in Pain Sensitization and Depressive Symptoms Mediate the Effect of Extreme Weight Loss on Knee Pain Improvement?
4:30PM-6:00PM
Abstract Number: 1927
Do Remission and Low Disease Activity State Go Hand in Hand with Patient’s Perception of Disease Burden and Quality of Life in Systemic Lupus Erythematosus?
4:30PM-6:00PM
Abstract Number: 1944
Does Renin Angiotensin System Blockade in Addition to Immunosuppressive Therapy Improve Proteinuria in Acute Lupus Nephritis?
4:30PM-6:00PM
Abstract Number: 1899
Down-Regulation of RNA Processing Protein CFIm25 Amplifies Skin Fibrosis By up-Regulating Pro-Fibrotic Transcripts/Proteins in Systemic Sclerosis
4:30PM-6:00PM
Abstract Number: 1945
Early Prediction of Long-Term Renal Outcomes in Lupus Nephritis Using Hazard Index Equations
4:30PM-6:00PM
Abstract Number: 1926
Effects of Social Networking on Chronic Disease Management in Rheumatoid Arthritis
4:30PM-6:00PM
Abstract Number: 1952
Experimental Tendinopathy Treatment with SM04755, a Topical Small Molecule Inhibitor of the Wnt Pathway
4:30PM-6:00PM
Abstract Number: 1954
Factors Associated with Overweight or Obesity in Athletes 5 Years after Anterior Cruciate Ligament Injury
4:30PM-6:00PM
Abstract Number: 1900
FGFR3/ FGF9 Regulates the Activity of Profibrotic Cytokine and Growth Factor Pathways to Drive Fibroblast Activation and Tissue Fibrosis in Systemic Sclerosis
4:30PM-6:00PM
Abstract Number: 1925
Goal Concordance in Rheumatoid Arthritis: Beyond Pain Reduction, Is There Agreement?
4:30PM-6:00PM
Abstract Number: 1907
High Serum Adiponectin Associates with the Incidence of Rheumatoid Arthritis in Obese Subjects
4:30PM-6:00PM
Abstract Number: 1930
Histologic and Transcriptional Evidence of Subclinical Synovial Inflammation in Rheumatoid Arthritis Patients in Clinical Remission
4:30PM-6:00PM
Abstract Number: 1933
Histological Features and Tissue-Macrophage Phenotype of Synovial Biopsies Identify RA Patients in Sustained Remission at Risk of Disease Flare after Treatment Tapering or Discontinuation
4:30PM-6:00PM
Abstract Number: 1909
Impact and Timing of Smoking Cessation on Reducing Risk for Seropositive Rheumatoid Arthritis Among Women
4:30PM-6:00PM
Abstract Number: 1910
Impact of Cyclic Citrullinated Peptide Autoantibody Level on Progression to Rheumatoid Arthritis Among CCP-Positive Patients without RA in a Clinical Setting
4:30PM-6:00PM
Abstract Number: 1949
Implementation of a Health Diary for Patients with Fibromyalgia
4:30PM-6:00PM
Abstract Number: 1919
Individual Short-Acting Opioids and the Risk of Opioid-Related Adverse Events in Adolescents
4:30PM-6:00PM
Abstract Number: 1893
Indoleamine-2,3-Dioxygenase in Murine and Human Systemic Lupus Erythematosus
4:30PM-6:00PM
Abstract Number: 1920
Is There Objective Evidence of Neuropathy in Knee Osteoarthritis Based on Clinical Evaluation?
4:30PM-6:00PM
Abstract Number: 1937
Low-Dose IL-2 Restored Reduced Regulatory T Cells in Patients with Rheumatoid Arthritis
4:30PM-6:00PM
Abstract Number: 1905
Lower Education Level Is Associated with Higher Risk of Developing Rheumatoid Arthritis
4:30PM-6:00PM
Abstract Number: 1896
Lupus Keratinocytes Exhibit Skewed Interferon Responses and Dysregulation of a Novel Regulator of Interferon Signaling
4:30PM-6:00PM
Abstract Number: 1913
Management of Ventricular Tachycardia and Cardiomyopathy in the Rheumatologist World: A Retrospective Review of Diagnostic Tools and Treatment Decisions for Cardiac Sarcoidosis
4:30PM-6:00PM
Abstract Number: 1895
Marked Immune Cell Subset Changes in Refractory Lupus Patients in a Phase I Trial of Allogenic Mesenchymal Stem Cells
4:30PM-6:00PM
Abstract Number: 1934
microRNA Targeting IL-33 Gene As Biomarker to Predict Subclinical Atherosclerosis in Patients with Early Rheumatoid Arthritis
4:30PM-6:00PM
Abstract Number: 1924
Mitigating Medication Risk Aversion in the Confident Treatment Decisions for Living with Rheumatoid Arthritis Trial
4:30PM-6:00PM
Abstract Number: 1903
Molecular Analysis of a Skin Equivalent Tissue Culture Model System of Systemic Sclerosis Using RNA Sequencing, Epigenetic Assays, Histology, and Immunoassays
4:30PM-6:00PM
Abstract Number: 1935
Multiple Dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP5094, an Anti-Alpha9 Integrin Monoclonal Antibody, in Patients with Rheumatoid Arthritis on Methotrexate
4:30PM-6:00PM
Abstract Number: 1916
Neutrophil-to-Lymphocyte Ratio Prospectively Predicts the Development of Rheumatic Immune-Related Adverse Events from PD-1 Inhibitor Therapy
4:30PM-6:00PM
Abstract Number: 1904
Orphan Nuclear Receptor Rorα Is a Key Regulator of Tgfβ- and WNT-Signaling in Fibrotic Diseases
4:30PM-6:00PM
Abstract Number: 1902
Pathogenic and Therapeutic Modulation of Activating Epigenetic Memory at a Novel Enhancer for TGFβ2 in Systemic Sclerosis
4:30PM-6:00PM
Abstract Number: 1928
Patient-Physician Communication about Medication Costs in Rheumatoid Arthritis
4:30PM-6:00PM
Abstract Number: 1957
Peri-Operative Glycemic Evaluation Prior to Total Joint Replacement in Patients with and without Diabetes
4:30PM-6:00PM
Abstract Number: 1917
Physician Opioid Prescribing Patterns and Risk for Chronic Opioid Use Among Rheumatoid Arthritis Patients
4:30PM-6:00PM
Abstract Number: 1955
Race Is Associated with Discharge Disposition after Total Knee Arthroplasty (TKA), Which Is Associated with 90-Day Readmission Rate
4:30PM-6:00PM
Abstract Number: 1953
Randomized Trial on Exercise at Late-Stage after Total Knee Replacement
4:30PM-6:00PM
Abstract Number: 1901
Reduced SPAG17 Expression Links Dysfunctional Cilia, Morphogen Signaling Activation and Multiple Organ Fibrosis: Novel Target for Systemic Sclerosis
4:30PM-6:00PM
Abstract Number: 1940
Reductions in Absolute Neutrophil Count (ANC) with Sarilumab Resulting in Dose Delays or Dose Decreases: Effects on Efficacy and Safety
4:30PM-6:00PM
Abstract Number: 1921
Relation of Sensitization and Conditioned Pain Modulation to Post-Knee Replacement Pain
4:30PM-6:00PM
Abstract Number: 1914
Rheumatic Syndromes Associated with Immune-Checkpoint Inhibitors: A Single-Center Cohort of 61 Patients
4:30PM-6:00PM
Abstract Number: 1950
Self-Reported Depression and Anxiety Among US Adults Aged 18-44 Years with Arthritis, National Health Interview Survey 2014-2016
4:30PM-6:00PM
Abstract Number: 1897
Single Cell RNA Expression in Lupus Nephritis Comparing African-American and Caucasian Patients Identifies Differential Expression of Interferon Pathway
4:30PM-6:00PM
Abstract Number: 1939
Sirolimus Treatment in Patients with Refractory Rheumatoid Arthritis: A Double-Arm, Open-Label, phase1/2 Trail
4:30PM-6:00PM
Abstract Number: 1951
The Effect and Psychosocial Impact of a Longstanding Telephone Peer Counseling Service on Volunteers with Systemic Lupus Erythematosus
4:30PM-6:00PM
Abstract Number: 1911
The Expanding Clinical Spectrum of Patients with Deficiency of Adenosine Deaminase 2 (DADA2)
4:30PM-6:00PM
Abstract Number: 1929
The Neutrophil-Lymphocyte Ratio in Newly Diagnosed Rheumatoid Arthritis and Its Ability to Predict Treatment Failure
4:30PM-6:00PM
Abstract Number: 1923
Treating Rheumatoid Arthritis to Target: Is Low Disease Activity Good Enough?
4:30PM-6:00PM
Abstract Number: 1912
Treatment of Cardiac Sarcoidosis: A Comparative Study of Steroids Alone Versus Steroids Associated with Immunosuppressive Drugs
4:30PM-6:00PM
Abstract Number: 1898
Type I Interferon-Induced Proteins May Facilitate the Occurrence of Long QT Syndrome (LQTS) in Parallel with Anti-Ro/SSA and Anti-Ro52/TRIM21 Antibody Levels in Patients with Systemic Lupus Erythematous (SLE): A Bench to Bedside Approach
9:00AM-11:00AM
Abstract Number: 2349
“I Was Prepared for the Other Side Effects; I Wasn’t Prepared for This One.”: A Qualitative Study of the Patients’ Experience of Inflammatory Arthritis Due to Immune Checkpoint Inhibitor Therapy for Cancer
9:00AM-11:00AM
Abstract Number: 2720
30-Day Hospital Readmission for Granulomatosis with Polyangiitis: Analysis from National Readmission Database
9:00AM-11:00AM
Abstract Number: 2086
4-Phenylbutyric Acid Mediates Therapeutic Effect in Systemic Lupus Erythematosus: Observations in an Experimental Murine Lupus Model
9:00AM-11:00AM
Abstract Number: 2171
A 5-Year National Trend in Acute Myocardial Infarctionamong Hospitalized Patients with Psoriatic Arthritis: Data from National Inpatient Sample
9:00AM-11:00AM
Abstract Number: 2757
A Comparison of Pharmacokinetic and Pharmacodynamic Outcomes of Tocilizumab Treatment in Giant Cell Arteritis after Subcutaneous and Intravenous Dosing
9:00AM-11:00AM
Abstract Number: 2152
A Comparison of the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics Classification (SLICC) Criteria to Detect Patients with Systemic Lupus Erythematosus (SLE) in Electronic Health Record (EHR) Data
9:00AM-11:00AM
Abstract Number: 2439
A Description of Contraception Practices in the Ohio State University Lupus Cohort
9:00AM-11:00AM
Abstract Number: 2508
A First-in-Man Bioelectronic Therapy for Biologic-Refractory Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2341
A Link between Quality of Patient–Rheumatologist Communication and Patient Healthcare Needs in Psoriatic Arthritis: An Online Survey of US-Based Patients and Rheumatologists
9:00AM-11:00AM
Abstract Number: 2762
A Longer or Bilateral Temporal Artery Biopsy (TAB) Is More Likely to Yield a Positive Result for Giant Cell Arteritis (GCA) in the Veterans Health Administration (VHA) Database Cohort
9:00AM-11:00AM
Abstract Number: 2146
A Meta-Analysis of the Prevalence and Risk Factors for Retinal Toxicity in Rheumatologic Patients on Hydroxychloroquine Therapy
9:00AM-11:00AM
Abstract Number: 1981
A Molecular Bayesian Network for Rheumatoid Arthritis Reveals Multiple Candidate Key Regulators for Disease Severity
9:00AM-11:00AM
Abstract Number: 2504
A More Time Under Remission Impacts in a Better Health-Related Quality of Life in Rheumatoid Arthritis Mestizo Population
9:00AM-11:00AM
Abstract Number: 2756
A Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice in Treatmet with Tocilizumab Compared with Giacta Trial
9:00AM-11:00AM
Abstract Number: 2528
A Multicenter Study Assessing the Efficacy and Safety of Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: Preliminary Interim Data from the Open-Label Treatment Period
9:00AM-11:00AM
Abstract Number: 2716
A New Score to Predict Digital Ulcers Combining Clinical Data, Imaging and Patient History in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 2009
A Novel Role of ZCCHC6 in the Regulation of MMP13 in Experimental Osteoarthritis in Mice
9:00AM-11:00AM
Abstract Number: 2342
A Pan-Canadian Study of Factors Associated with Perceived Doctor-Patient Communication in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2510
A Phase IIa Mechanistic Study of Anti-GM-CSF (GSK3196165) with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate
9:00AM-11:00AM
Abstract Number: 2738
A Randomized Phase 3 Trial Evaluating the Safety and Efficacy of Avacopan in Patients with New or Relapsing Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 2521
A Randomized, Double-Blind Phase III Study Comparing the Efficacy, Safety and Immunogenicity of PF-06438179/GP1111 (Ixifi™), an Infliximab Biosimilar, and Infliximab Reference Product (Remicade®) in Patients with Moderate to Severe Active RA: Results from Week 54 to Week 78
9:00AM-11:00AM
Abstract Number: 1989
A Regulatory Role of ANTXR1 in RANKL-Induced Osteoclast Differentiation and Function
9:00AM-11:00AM
Abstract Number: 2127
A Role of Vascular Cell Adhesion Molecule 1 and Activated Leukocyte Cell Adhesion Molecule in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 2769
A Single Center Experience of Temporal Artery Biopsies Performed in 30 African American Patients
9:00AM-11:00AM
Abstract Number: 2039
A Survey of Blood and Synovial Tissue Myeloid Cells in RA Patients By Transcriptional Profiling
9:00AM-11:00AM
Abstract Number: 2677
A Systematic Review Examining the Association between Organ Damage and Health-Related Quality of Life in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2228
A Validated Script Concordance Test Demonstrates Interdisciplinary Differences in Clinical Decision-Making When Using Allopurinol to Treat Gout in Chronic Kidney Disease
9:00AM-11:00AM
Abstract Number: 2308
Abaloparatide for Risk Reduction of Nonvertebral and Vertebral Fractures in Postmenopausal Women with Osteoporosis: A Network Meta-Analysis
9:00AM-11:00AM
Abstract Number: 2554
Abatacept without Methotrexate in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of a Phase III, Randomized Study
9:00AM-11:00AM
Abstract Number: 2064
Aberrant Distribution and Function of Plasmacytoid Dendritic Cells in Patients with Ankylosing Spondylitis Are Associated with Unfolded Protein Response
9:00AM-11:00AM
Abstract Number: 1999
Aberrant Expression of the GluN2B N-Methyl D-Aspartate Receptor Subunit in Osteoarthritic Chondrocytes Causes Disease-Associated Changes in Chondrocyte Phenotype through Altered Expression of Core Components of the Chondrocyte Circadian Clock
9:00AM-11:00AM
Abstract Number: 2367
Acceptance Rate and Sociological Factors Involved in the Switch from Originator to Biosimilar Etanercept (SB4)
9:00AM-11:00AM
Abstract Number: 2183
Access to Prescription Drugs in Canada: Results from an Online Survey
9:00AM-11:00AM
Abstract Number: 2402
Acoustic Emissions Generated By the Temporomandibular Joint of Patients with Juvenile Idiopathic Arthritis and Their Implication on Patient Assessment and Screening: A Pilot Study
9:00AM-11:00AM
Abstract Number: 2070
Activated Tendon Stromal Cells Drive a Type 17 Immune Response Via CCL20: A Potential Role in the Pathogenesis of Enthesitis in Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 2233
Activation and Deficiency of Circulating Mucosal-Associated Invariant T Cells in Patients with Gouty Arthritis
9:00AM-11:00AM
Abstract Number: 2109
Activation of T Follicular Helper Cells through Epigenetic Regulation By STAT1 and STAT4 in Lupus Patients
9:00AM-11:00AM
Abstract Number: 2680
Activation Towards Health Self-Management in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2199
Active Disease and Follow up 18f-FDG-PET/CT in Patients with Giant Cell Arteritis. Which Treatment Is More Likely to Achieve Remission?
9:00AM-11:00AM
Abstract Number: 2571
Adalimumab Serum Concentration Fails to Predict Achievement of Sustained Remission or Absence of Flare for Patients with Non-Radiographic Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1986
Adalimumab:TNF Complexes Are Cleared More Efficiently By Human Osteoclasts Than Those with Etanercept through Fcg-Receptor Binding and Internalization
9:00AM-11:00AM
Abstract Number: 1996
Adenosine A2A Receptor (A2AR) Stimulation Enhances Mitochondrial Metabolism and Mitigates Reactive Oxygen Species-Mediated Mitochondrial Injury
9:00AM-11:00AM
Abstract Number: 2001
Adenosine A2A Receptor Stimulation Regulates Autophagy in Chondrocytes
9:00AM-11:00AM
Abstract Number: 1997
Adenosine A2A Receptors Maintain Chondrocyte and Cartilage Homeostasis By Maintaining Expression of Anti-Inflammatory Regulators (Nur-77) and Suppressing Expression of Pro-Inflammatory Mediators
9:00AM-11:00AM
Abstract Number: 2036
Adenosine Receptors Expression As Predictor of Response to Methotrexate Therapy in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2427
Adequate Vaccine Response According to the Italian Schedule Among the Offspring of Women Affected By Rheumatoid Arthritis and Treated throughout Pregnancy By Certolizumab Pegol: Case Series
9:00AM-11:00AM
Abstract Number: 2319
Adherence to Guideline Recommendations for Screening and Treatment of Glucocorticoid Induced Osteoporosis in Patients with Rheumatoid Arthritis on Long Term Glucocorticoid Therapy at a Tertiary Care Center
9:00AM-11:00AM
Abstract Number: 2675
Age-Related Metabolic Changes Underlie Pro-Inflammatory Lineage Specification and Contribute to Therapeutic Responsiveness to Mechanistic Target of Rapamycin Blockade in SLE
9:00AM-11:00AM
Abstract Number: 2132
All-Cause Mortality, Hospitalization, and Systemic Lupus Erythematosus (SLE) Related Complications in 2011-2015 Medicare Beneficiaries with SLE
9:00AM-11:00AM
Abstract Number: 2057
Alterations of the Splicing Machinery in Leukocyte Subsets of Rheumatoid Arthritis Patients Modulate Their Inflammatory, Autoimmune and Atherothrombotic Profiles
9:00AM-11:00AM
Abstract Number: 2231
An Ancestral-Specific Interaction of TRIM46 with a Past-History of Smoking May Influence Gout Risk
9:00AM-11:00AM
Abstract Number: 2184
An Economic Evaluation on the Impact of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using Complement C4d Activation Products in a Multivariate Assay Panel (MAP)
9:00AM-11:00AM
Abstract Number: 1982
An Integrative Rheumatoid Arthritis Network for Elucidating Molecular Mechanisms Underlying RA Severity
9:00AM-11:00AM
Abstract Number: 2123
Analysis of Lupus Synovitis Gene Expression Reveals Dysregulation of Pathogenic Pathways Activated within Infiltrating Immune Cells
9:00AM-11:00AM
Abstract Number: 2437
Analysis of Occurrence of Small for Gestational Age Infants in Women with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2461
Analysis of Severe Adverse Drug Reactions to Disease Modifying Drugs in an Inception Rheumatoid Arthritis Cohort
9:00AM-11:00AM
Abstract Number: 2476
Analysis of the Disease Activity and Functional Measures of Young Patients with Rheumatoid Arthritis Undergoing Total Joint Arthroplasty By Using the Database of Nation-Wide Observational Cohort
9:00AM-11:00AM
Abstract Number: 2106
Angiotensin-Converting Enzyme Inhibitors Prevent Spatial Memory Impairment in a Mouse Model of Neuropsychiatric Lupus through LAIR1-Mediated Inhibition of Microglial Activation
9:00AM-11:00AM
Abstract Number: 2394
Anti-Adalimumab Antibodies Kinetics: An Early Guide for Juvenile Idiopathic Arthritis (JIA) Switching
9:00AM-11:00AM
Abstract Number: 2576
Anti-Drug Antibodies, Efficacy, and Impact of Concomitant Methotrexate in Ixekizumab-Treated Patients with Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 2010
Anti-Endothelial Cell Antibodies in Pediatric Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 2268
Anti-IL6-Receptor Tocilizumab in Graves’ Orbitopathy. Multicenter Study of 46 Patients
9:00AM-11:00AM
Abstract Number: 2656
Apremilast As Treatment of Refractory Skin Lupus Lesions
9:00AM-11:00AM
Abstract Number: 2392
Are Single Nucleotide Polymorphisms in Methotrexate Transporter Proteins Associated with Methotrexate Intolerance in Juvenile Idiopathic Arthritis?
9:00AM-11:00AM
Abstract Number: 2669
Assessing the Need for Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis in SLE Patients on Immunosuppression
9:00AM-11:00AM
Abstract Number: 2149
Assessing the Prevalence of Localized Scleroderma in Childhood Using Dministrative Claims Data from the United States
9:00AM-11:00AM
Abstract Number: 2355
Assessment of Barriers to Exercise Participation in Patients with  RA
9:00AM-11:00AM
Abstract Number: 2657
Assessment of Habitual Physical Activity and Performance during Maximal Exercise Test in Systemic Lupus Erythematosus Patients
9:00AM-11:00AM
Abstract Number: 2531
Assessment of Pain Relief with Baricitinib By Treatment History in Patients with Refractory Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2388
Assessment of Treatment Responses, with Special Reference to Remission Using Juvenile Arthritis Disease Activity Score (JADAS), in the Different Categories of Juvenile Idiopathic  Arthritis
9:00AM-11:00AM
Abstract Number: 2500
Association between Anti-Citrullinated Protein Antibody Status, Erosive Disease and Healthcare Resource Utilization in Patients with RA
9:00AM-11:00AM
Abstract Number: 2457
Association between Biologic Dmards and Weight Change in Patients with Inflammatory Arthritis
9:00AM-11:00AM
Abstract Number: 2689
Association between Small Vessel Disease and Arterial Stiffness in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 2015
Association of Anti-Ro52 Autoantibodies with Interstitial Lung Disease and More Severe Disease Manifestations in Juvenile Idiopathic Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 2569
Association of Enthesitis with Achievement of Normal Quality of Life and Clinical Response in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Adalimumab
9:00AM-11:00AM
Abstract Number: 1961
Association of GTF2I Region Polymorphism with Systemic Lupus Erythematosus and Systemic Sclerosis, but Not with ANCA-Associated Vasculitis and Polymyositis/Dermatomyositis, in a Japanese Population
9:00AM-11:00AM
Abstract Number: 1965
Association of HLA Class II Alleles with Relapse and Interstitial Lung Disease in Myeloperoxidsae (MPO) -ANCA Positive Vasculitis in a Japanese Population
9:00AM-11:00AM
Abstract Number: 2140
Association of Hydroxychloroquine Use and Incident Atrial Fibrillation in Rheumatoid Arthritis: A Retrospective Study
9:00AM-11:00AM
Abstract Number: 2670
Association of Hydroxychloroquine Use and Incident Atrial Fibrillation in Systemic Lupus Erythematosus: A Retrospective Study
9:00AM-11:00AM
Abstract Number: 2310
Association of Moderate/Severe Vertebral Fractures with Reduced Trabecular Volumetric Bone Density in Older Women and Reduced Areal Femoral Neck Bone Density in Older Men from Community: A Cross-Sectional Study (SPAH)
9:00AM-11:00AM
Abstract Number: 2150
Association of Poverty Income Ratio with Physical Functioning in a Cohort of Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2110
Association of Systemic Lupus Erythematosus (SLE) Genetic Susceptibility Loci with Lupus Nephritis in Children and Adults with SLE
9:00AM-11:00AM
Abstract Number: 2119
Association of the Variant Form of rs17408553 at Human Leukocyte Antigen-C Supports Evidence That Hypo-Responsive Natural Killer Cells Adversely Influence the Course of Nephritis
9:00AM-11:00AM
Abstract Number: 2147
Associations between Current Cigarette Smoking and SLE-Related Cytokine and Chemokine Biomarkers Among U.S. Female Nurses without SLE
9:00AM-11:00AM
Abstract Number: 2642
Atacicept Dose Rationale for a Phase 3 Study in Patients with High Disease Activity and Auto-Antibody Positive SLE
9:00AM-11:00AM
Abstract Number: 2203
Atherosclerotic Inflammation in Rheumatoid Arthritis Patients: A Post-Hoc Study Using Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography
9:00AM-11:00AM
Abstract Number: 2353
Attitudes and Beliefs Regarding Methotrexate in Patients with Rheumatoid Arthritis: Results from Australian Rheumatology Association Database
9:00AM-11:00AM
Abstract Number: 2351
Attitudes Toward Telehealth Video Conferencing Among Patients with Rheumatic Disease
9:00AM-11:00AM
Abstract Number: 2159
Autoimmune Diseases in Catalonia: A Population Based Study Using a Public Big Data Program
9:00AM-11:00AM
Abstract Number: 2275
Autoimmune Encephalitis with Concomitant Systemic Rheumatologic Auto-Antibodies
9:00AM-11:00AM
Abstract Number: 1998
Autophagy-Related Molecules Detected in Blood and Cartilage Are Biomarkers of Joint Damage in OA
9:00AM-11:00AM
Abstract Number: 2418
Awareness of Fertility and Contraception Issues Among Women with Rheumatologic Diseases
9:00AM-11:00AM
Abstract Number: 2050
B and T Cell Phenotypes of First Degree Relatives of RA Patients in an Indigenous North American Cohort
9:00AM-11:00AM
Abstract Number: 2124
Bacterial Biofilm Product Curli/Edna Induces NETs and Serum Anti-Curli/Edna Levels Correlate with Bacteriuria and Lupus Activity
9:00AM-11:00AM
Abstract Number: 2588
Baseline Pain Severity As a Predictor of Pain Improvement Following Treatment with Tofacitinib in Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1975
Behcet’s Disease Lies in the “B” Holder. New Associations in Disease Susceptibility and Manifestations
9:00AM-11:00AM
Abstract Number: 2072
Beneficial Effect of Combination Therapy of Etanercept with Non-Steroidal Anti-Inflammatory Drugs Compared to Etanercept Monotherapy in a Spondyloarthritis Animal Model
9:00AM-11:00AM
Abstract Number: 2537
Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)
9:00AM-11:00AM
Abstract Number: 2511
Benepali Switches in Clinical Practice – a Positive Single Centre Experience
9:00AM-11:00AM
Abstract Number: 2522
Biosimilar BI 695501 and Adalimumab Reference Product (RP) Have Similar Efficacy and Safety in Patients (pts) with Moderately-to-Severely Active Rheumatoid Arthritis (RA): Long-Term Results from a Phase IIIb Extension Study (VOLTAIRE®-RAext)
9:00AM-11:00AM
Abstract Number: 2154
Biosimilar Infliximab Treated-Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in France: Characteristics and Clinical Outcomes
9:00AM-11:00AM
Abstract Number: 2384
Biosimilar Use in Young Adults with Juvenile Idiopathic Arthritis in Germany
9:00AM-11:00AM
Abstract Number: 2431
Birth Outcomes and Disease Activity during Pregnancy in a Prospective Cohort of Women with Psoriatic Arthritis and Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 2423
Births to Women with Systemic Lupus Erythematosus Can be Identified Accurately in the Electronic Health Record
9:00AM-11:00AM
Abstract Number: 2424
Bisphosphonates during Pregnancy: A Systematic Review Sayanika Kaur MD Fellow Drexel Rheumatology, Mojdeh Khaamesi MD Resident Internal Medicine Arundathi Jayatilleke MD Program Director Drexel Rheumatology
9:00AM-11:00AM
Abstract Number: 2065
Blockade of the JAK/STAT Pathway Inhibits Inflammation and Bone Formation in Two Murine Models of Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 2377
Body Image in Rheumatic Diseases: A Systematic Review
9:00AM-11:00AM
Abstract Number: 2399
Bone Density, Structure and Strength in Canadian Children and Youth with Juvenile Idiopathic Arthritis: The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)
9:00AM-11:00AM
Abstract Number: 2639
Bone Mineral Density Is Not Associated with Osteoporotic Fractures in Premenopausal Women and Men < 50 Years Old with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2259
BONE Sarcoidosis: A French Case Control Study
9:00AM-11:00AM
Abstract Number: 2701
Botulinum Toxin in the Management of Raynaud’s Phenomenon
9:00AM-11:00AM
Abstract Number: 2099
Bruton’s Tyrosine Kinase (BTK) Inhibition Modulates Multiple Cell Types Instrumental in the Pathogenesis of Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 2173
Budget Impact of Etanercept Versus Adalimumab for Treatment of Rheumatoid Arthritis in Biologic-Naïve Patients in the United Kingdom
9:00AM-11:00AM
Abstract Number: 2251
Calcific Tendonitis of the Rotator Cuff: Do We Need Steroid Injection after Ultrasound Guided Percutaneous Lavage? Results of a 12-Months Double-Blind Randomized Controlled Study
9:00AM-11:00AM
Abstract Number: 2026
Calcium Crystal-Mediated Netosis in Juvenile Dermatomyositis and Anti-RNP+ Overlap Syndrome with Skin Involvement
9:00AM-11:00AM
Abstract Number: 2229
Can We Predict Inadequate Response to Allopurinol Dose Escalation? Analysis of a Randomized Controlled Trial
9:00AM-11:00AM
Abstract Number: 2741
Candidate Biomarkers in ANCA-Associated Vasculitis Identified Using a Proteomic Approach
9:00AM-11:00AM
Abstract Number: 2253
Cardiovascular Disease, Other Purported Risk Factors, and Allopurinol-Associated Severe Cutaneous Adverse Reactions: A General Population-Based Cohort Study
9:00AM-11:00AM
Abstract Number: 2242
Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease
9:00AM-11:00AM
Abstract Number: 2329
Carotid Atherosclerosis Is Associated with Compromised Volumetric Bone Mineral Density and Microarchitecture in Patients with Inflammatory Arthritis
9:00AM-11:00AM
Abstract Number: 2122
CD38 over-Expression in CD8 Positive Cells Defines a Group of Patients with SLE Prone to Infections
9:00AM-11:00AM
Abstract Number: 2120
CD47- Signal Regulatory Protein Alpha Interaction Potentiates Proinflammatory Response in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2610
Certolizumab Pegol Serum Levels ≥20 Mg/L Are Associated with Treatment Response in Patients with Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 2513
Change in Disease Activity after Switching Etanercept (originator) to Biosimilar (Benepali) Is Associated with Active Disease at Baseline
9:00AM-11:00AM
Abstract Number: 2175
Change in Frequency of Arthroplasty Surgery in Rheumatoid Arthritis: A 13-Year Population Health Study
9:00AM-11:00AM
Abstract Number: 2662
Changes in Blood Pressure and Proteinuria at One Year in Two Lupus Nephritis Clinical Trials
9:00AM-11:00AM
Abstract Number: 2586
Changes in Lymphocytes and Lymphocyte Subsets in Tofacitinib-Treated Patients with Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 2544
Changes of CD4-(CD8+) Regulatory T Cells in Rheumatoid Arthritis Patients and during Interleukin-2 Therapy
9:00AM-11:00AM
Abstract Number: 2488
Characteristics of Difficult-to-Treat Rheumatoid Arthritis: Results of an International Survey
9:00AM-11:00AM
Abstract Number: 2317
Characterization of Paget´s Disease of Bone Patients from the South of Portugal (Algarve and Alentejo) – Clinical and Genetic Aspects
9:00AM-11:00AM
Abstract Number: 2465
Characterizing Palindromic Symptoms in Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort Study
9:00AM-11:00AM
Abstract Number: 2398
Children with Enthesitis Have Worse Quality of Life, Function, and Pain, Irrespective of Their Juvenile Arthritis Category
9:00AM-11:00AM
Abstract Number: 2003
Chondrocyte Size in Articular Cartilage As a Marker of Osteoarthritis Severity
9:00AM-11:00AM
Abstract Number: 2056
Citrullination Is Not a Determinant in the Lack of Tolerance to Peptidylarginine Deiminase 2 and 4 in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2295
Classification of Idiopathic Inflammatory Myopathies: Assessment of 123 Patients According to 2017 Acr/EULAR Criteria Followed up By a Single Center from Turkey
9:00AM-11:00AM
Abstract Number: 2749
Clinical and Anatomical Correlation in Patients with Polymyalgia Rheumatica By 18F-FDG PET/TC. Study of 75 Patients from a Single Referral Center
9:00AM-11:00AM
Abstract Number: 2740
Clinical and Laboratory Characteristics of ANCA-Associated Vasculitis in Pediatric and Young Adult Patients: A Retrospective Review
9:00AM-11:00AM
Abstract Number: 2745
Clinical and Serological Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab or Abatacept As Steroid-Sparing Agents
9:00AM-11:00AM
Abstract Number: 2725
Clinical Characteristics and Long-Term Follow-up of 382 Microscopic Polyangiitis Patients
9:00AM-11:00AM
Abstract Number: 2731
Clinical Characteristics and Outcomes of ANCA-Vasculitides Associated Renal Disease in a Multi-Ethnic Population from a County Hospital
9:00AM-11:00AM
Abstract Number: 2589
Clinical Characteristics and Treatment Profile of Patients with Psoriatic Arthritis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
9:00AM-11:00AM
Abstract Number: 2217
Clinical Characteristics of Early Onset Gout in Outpatient Setting
9:00AM-11:00AM
Abstract Number: L10
Clinical Efficacy of Leflunomide/Hydroxychloroquine Combination Therapy in Patients with Primary Sjogren’s Syndrome: Results of a Placebo-Controlled Double-Blind Randomized Clinical Trial
9:00AM-11:00AM
Abstract Number: 2659
Clinical Features, Damage Accrual and Survival in Patients with Familial Systemic Lupus Erythematosus (SLE): Data from a Multiethnic, Multinational Latin American Lupus Cohort
9:00AM-11:00AM
Abstract Number: 2760
Clinical Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice
9:00AM-11:00AM
Abstract Number: 2406
Clinical Presentation, Management and Long Term Outcome of Pars Planitis (PP), Panuveitis (PU) and Vogt–Koyanagi–Harada Disease (VKH) in Children and Adolescents
9:00AM-11:00AM
Abstract Number: 2158
Clinical Significance of Anti-Ro52 Antibody in Chinese Patients with Connective Tissue Diseases: A Single-Center Experience
9:00AM-11:00AM
Abstract Number: 2204
Clinical Utility of a Multi-Energy Spectral CT in Crystal Arthritis
9:00AM-11:00AM
Abstract Number: 2600
Clinically Meaningful Improvement in Health-Related Quality of Life and the Association with Disease Activity in Psoriatic Arthritis after Treatment with Guselkumab: Results from a Randomized Placebo-Controlled Phase II Clinical Trial
9:00AM-11:00AM
Abstract Number: 2567
Clinically Meaningful Improvement in Skin and Nail Psoriasis in Bio-Naïve Active Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Results through Week 24 from a Phase 3 Study
9:00AM-11:00AM
Abstract Number: 2464
Clinimetric and Drug Use Differences in Colombian Patients with Early and Established Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2277
Colchicine: An Effective Treatment Option for Unclassified Autoinflammatory Diseases in Children
9:00AM-11:00AM
Abstract Number: 2635
Combined Panel of Nine Tests Has the Greatest Sensitivity but the Lowest Specificity to Detect Antiphospholipid Antibody Syndrome in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2768
Comorbidity Accrual and Mortality in an Inception Cohort of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Single-Center, Observational Long-Term Study
9:00AM-11:00AM
Abstract Number: 2133
Comparative Disease Burden of Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Data from the Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
9:00AM-11:00AM
Abstract Number: 2060
Comparative Histologic and Molecular Analysis of Synovial Tissue in Early Treatment-Naïve Psoriatic and Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: L09
Comparative Risk of Venous Thromboembolism with Tofacitinib Versus Tumor Necrosis Factor Inhibitors: A Cohort Study of Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 2581
Comparing Treatment Patterns of Non-Radiographic Axial Spondyloarthritis Patients in the United States and Europe
9:00AM-11:00AM
Abstract Number: 2754
Comparison between Tocilizumab Prescribed As Monotherapy Versus Combined with Conventional Immunosuppressant Agents in Giant Cell Arteritis Patients
9:00AM-11:00AM
Abstract Number: 2244
Comparison of an Interactive Voice Response (IVR) to Smart Phone App to Determine Patient Preference for Reporting Gout Flares
9:00AM-11:00AM
Abstract Number: 2024
Comparison of B and T Cell Subsets, Cytokine Expression and Synovial Pathology in Down’s Arthritis (DA) and Juvenile Idiopathic Arthritis (JIA)
9:00AM-11:00AM
Abstract Number: 2663
Comparison of Clinical and Laboratory Profiles in 3575 Systemic Lupus Erythematosus Patients with and without Sjögren’s Syndrome: Data from the Spanish Society for Rheumatology Lupus Registry
9:00AM-11:00AM
Abstract Number: 2711
Comparison of Gastric Antral Vascular Ectasia Associated with Systemic Sclerosis with That Associated with Other Diseases: Are There Differences?
9:00AM-11:00AM
Abstract Number: 2647
Comparison of Low-Dose Intravenous Cyclophosphamide with Oral Mycophenolate Mofetil in the Treatment of Lupus Nephritis: Long Term Follow-up Data
9:00AM-11:00AM
Abstract Number: 2487
Comparison of QOL Evaluation Using EQ-5D-3L and EQ-5D-5L in Japanese RA Patients: A Study Using the IORRA Cohort
9:00AM-11:00AM
Abstract Number: 2485
Comparison of Risk for Infection-Related Hospitalization and Associated Costs of Biologic Experienced Rheumatoid Arthritis Patients Treated with Abatacept Versus Other Targeted Disease Modifying Antirheumatic Drugs
9:00AM-11:00AM
Abstract Number: 2408
Comparison of the Tear Cytokine and Chemokine Profile of Children with JIA and JIA-Associated Uveitis
9:00AM-11:00AM
Abstract Number: 2718
Comparison of Various ANCA Detection Methods in Predominantly MPO ANCA-Associated Vasculitis Cohort
9:00AM-11:00AM
Abstract Number: 2630
Complement C4d Split Products in Combination with Lupus Anticoagulant and Low Complement Associate with Thrombosis in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2300
Compliance with Screening and Supplementation Guidelines for Glucocorticoid-Induced Osteoporosis, How Bad Did We Do This Time?
9:00AM-11:00AM
Abstract Number: 1980
Comprehensive Association Analysis between Rare and Common ABCG2 Variants and Gout Susceptibility
9:00AM-11:00AM
Abstract Number: 2222
Construct Validity of Provisional Remission Criteria for Gout: A Dual Energy CT Study
9:00AM-11:00AM
Abstract Number: 2236
Contemporary Comorbidity Burden of Gout and Hyperuricemia in the US during the Past Decade (National Health And Nutrition Examination Survey [NHANES] 2007-2016)
9:00AM-11:00AM
Abstract Number: 2653
Contraceptive Documentation in Systemic Lupus Erythematosus Patients at a Safety Net Hospital
9:00AM-11:00AM
Abstract Number: 2709
Conversion of Normal Mean Pulmonary Arterial Pressure to Pulmonary Hypertension in Systemic Sclerosis – a Longitudinal Observational Study
9:00AM-11:00AM
Abstract Number: 2525
Correlation Analysis between Sirukumab Exposure and Selected Safety Events Following Subcutaneous Administration Using Pooled Phase 3 Data in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2428
Correlation between Antibodies to the Phosphotidylserine/Prothrombin Complex (aPS/PT) and Anti-β2glycoprotein-1-Domain 1 (anti-β2GP1-D1) and Vascular Thrombosis (VT) and/or Pregnancy Morbidity (PM)
9:00AM-11:00AM
Abstract Number: 2448
Correlation between Long-Term Low-Dose Steroid Administration and Reactivation of Hepatitis B Virus in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2624
Cost-Effectiveness of Swapping Strategy for Established Psoriatic Arthritis and Immediate Versus Standard Swapping Strategy for Early Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 2278
Cryopyrinopathy across Generations: Longterm Disease Outcome
9:00AM-11:00AM
Abstract Number: 2037
CTLA4 Signaling Down-Regulates Fcγ Receptor I Expression on Circulating Monocytes: A Potential Mechanism of Action of Abatacept for RA
9:00AM-11:00AM
Abstract Number: 2328
Current Factors Associated with Insufficient Vitamin D Status in Patients with Osteoporosis
9:00AM-11:00AM
Abstract Number: 2708
Current Management of Early Diffuse Cutaneous Systemic Sclerosis in US Scleroderma Centers
9:00AM-11:00AM
Abstract Number: 2771
Current Practice of Cardiovascular Risk Assessment in Giant Cell Arteritis: A Single Center Study
9:00AM-11:00AM
Abstract Number: 2426
Defining a Standardized Core Data Set for Pregnancy Registers in Rheumatic Diseases – an European Approach
9:00AM-11:00AM
Abstract Number: 2182
Defining Alendronate Drug Holidays and Re-Initiation in US Medicare Data
9:00AM-11:00AM
Abstract Number: 2258
Defining Characteristics of Patients with Overlap between Sarcoidosis and Connective Tissue Diseases
9:00AM-11:00AM
Abstract Number: 2703
Delay in Initiation of Therapy Predicts Worse Outcomes in Scleroderma Renal Crisis
9:00AM-11:00AM
Abstract Number: 2590
Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
9:00AM-11:00AM
Abstract Number: 2207
Detecting Hand Joint Ankylosis in Radiographic Images Using Deep Learning: A Step in Development of Automatic Radiographic Scoring System for Bone Destruction
9:00AM-11:00AM
Abstract Number: 1967
Detection of Association of Long Noncoding RNA ATP6V0E2-AS1 Single Nucleotide Polymorphism with Susceptibility to Myeloperoxidase-ANCA Associated Vasculitis Based on Transcriptome Analysis
9:00AM-11:00AM
Abstract Number: 2216
Detection of Left Ventricular Regional Function in Primary Sjögren’s Syndrome Patients without Cardiac Symptons, As Assessed By Feature Tracking Cardiac Magnetic Resonance Imaging
9:00AM-11:00AM
Abstract Number: 2496
Determination of the Minimally Important Difference for Interpreting the RA Multi-Biomarker Disease Activity Test Score: Impact of Diurnal and Daily Biomarker Variation on Scores Adjusted for Age, Sex and Adiposity
9:00AM-11:00AM
Abstract Number: 2410
Determining the Need for Fatigue Management Resources for Young Adults with Rheumatic Disease
9:00AM-11:00AM
Abstract Number: 2194
Develop a New Platform for Post-Marketing Vigilance Though Smart System of Disease Management (SSDM) Mobiles Tools: A Real World Cohort Study of RA Patients from China
9:00AM-11:00AM
Abstract Number: 2298
Developing a Classification Criteria for Cutaneous Dermatomyositis Utilizing the Delphi Technique
9:00AM-11:00AM
Abstract Number: 2181
Development and Feasibility of a Web-Based Data Capture System to Collect Uniform Comprehensive Post-Total Knee Replacement Physical Therapy Intervention Data for Both Clinical and Research Purposes
9:00AM-11:00AM
Abstract Number: 2671
Development and First-in-Human Characterization of an ICOSL and BAFF Bispecific Inhibitor AMG 570 for SLE Treatment
9:00AM-11:00AM
Abstract Number: 2474
Development of a Crosswalk for FACIT-10 (Psychometric Work)
9:00AM-11:00AM
Abstract Number: 2141
Development of a Pediatric Glucocorticoid Toxicity Index
9:00AM-11:00AM
Abstract Number: 2514
Development of a Subcutaneous Formulation of CT-P13 (Infliximab): Maintenance Subcutaneous Administration May Elicit Lower Immunogenicity Compared to Intravenous Treatment
9:00AM-11:00AM
Abstract Number: 2155
Diagnosis of Systemic Sclerosis in the United Kingdom: An Observational Study Using the Clinical Practice Research Datalink
9:00AM-11:00AM
Abstract Number: 2773
Diagnostic and Therapeutic Management of a Suspected Case of GCA: An Opinion Survey
9:00AM-11:00AM
Abstract Number: 2321
Dickkopf-1 Serum Levels in Patients with Systemic Sclerosis and Correlation with Trabecular Bone Score
9:00AM-11:00AM
Abstract Number: 2180
Differences in Longitudinal Disease Activity Measures between Research Cohort and Non-Cohort Participants with Rheumatoid Arthritis Using Electronic Health Record Data
9:00AM-11:00AM
Abstract Number: 2023
Different Patterns of Interferon-Response-Gene Expression May Elucidate Different Pathomechanisms That Drive IFN-Response-Gene Activation in Patients with Presumed IFN-Mediated Autoinflammatory Diseases
9:00AM-11:00AM
Abstract Number: 2673
Different Risk Profiles for Development of Steroid-Related and Steroid-Unrelated Damage in Early Diagnosed SLE: Results from the Italian Multicenter Early Lupus Project Inception Cohort
9:00AM-11:00AM
Abstract Number: 2263
Differentiated Phenotypes at Diagnosis of Sarcoidosis According to the Scadding Classification: Analysis in 1230 Patients
9:00AM-11:00AM
Abstract Number: 2185
Direct Medical Costs for Medicare Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2706
Discriminant Validity and Reliability of World Scleroderma Foundation (WSF) Definition of Skin Ulcers in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 2501
Disease Activity Is the Major Discriminator When Defining Refractory Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2633
Disease Activity, Organ Damage and Patient-Reported Outcome Measures in Swedish Patients with Recent-Onset SLE
9:00AM-11:00AM
Abstract Number: 2646
Disparities in Antimalarial Prescribing for Systemic Lupus Erythematous Nephritis Using a Real-World, Electronic Health Record
9:00AM-11:00AM
Abstract Number: 2478
Do Age and Education Influence the Disease Activity Score? an Explorative Analysis in the Norwegian Register of Dmards
9:00AM-11:00AM
Abstract Number: 2409
Do Children with Juvenile Idiopathic Arthritis Play an Active Role in Their Treatment Adherence? First Results of the Rumaji Study
9:00AM-11:00AM
Abstract Number: 2108
Dock8-Positive CD4 T Cell As Autoantibody-Inducing CD4 T (aiCD4 T) Cell That Causes Systemic Lupus Erythematosus (SLE): Proof of Concept of Self-Organized Criticality Theory As a Cause of SLE
9:00AM-11:00AM
Abstract Number: 2200
Does an 18f-FDG-PET/CT in Patients with Giant Cell Arteritis in Clinical Remission Make Sense?
9:00AM-11:00AM
Abstract Number: 2605
Drug Retention and Response Rates of TNFi Treatment in 13,170 Patients with Psoriatic Arthritis Treated in Routine Care – Pooled Data from the Eurospa Research Network Collaboration
9:00AM-11:00AM
Abstract Number: 2618
Drug Survival of Non TNF Inhibitors Bdmards in Psoriatic Arthritis (Ustekinumab/Secukinumab) : A Real-Word Multicentric Cohort of 161 Patients
9:00AM-11:00AM
Abstract Number: 2002
Dynamic Compression of Articular Cartilage Explants Increases Formation and Decreases Degradation of Type II Collagen
9:00AM-11:00AM
Abstract Number: 2777
Dynamics in Peripheral Blood Cell Counts in Giant Cell Arteritis before Treatment, during Treatment and in Treatment-Free Remission
9:00AM-11:00AM
Abstract Number: 1974
Dynamics of Transcriptional Signatures from Synovial Macrophage Subsets during Acute and Chronic Murine Models of Inflammatory Arthritis
9:00AM-11:00AM
Abstract Number: 2079
Dysbiosis of Gut Microbiomes in Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 2067
Dysbiosis-Dependent Inflammasomes Activation Drives Innate Immune Responses in Ankylosing Spondylitis Patients
9:00AM-11:00AM
Abstract Number: 2081
Dysregulated MiR-125a Promotes Joint Angiogenesis in Psoriatic Arthritis through Altered Bioenergetics
9:00AM-11:00AM
Abstract Number: 2031
Dysregulated NK Cell PLC
9:00AM-11:00AM
Abstract Number: 2607
Early Achievement of ASDAS-Major Improvement in Patients with Ankylosing Spondylitis Treated with TNF-α Blockers Is Associated with a Prominent Longterm Improvement in Metrologic Indices
9:00AM-11:00AM
Abstract Number: 2063
Early Injection of TNF Inhibitor Prevents Spinal Inflammation and Deformity in Curdlan-Induced Spondyloarthritis Animal Model
9:00AM-11:00AM
Abstract Number: 2469
Early Referral and Flare´s Control Prevent Orthopaedic and Hand Surgery Indication in a Dynamic Cohort of Hispanic Early Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 2096
Ectonucleotidase CD73 Suppresses Autoantibody Production and Arterial Vasculopathy in Murine Lupus
9:00AM-11:00AM
Abstract Number: 2035
Effect of Baricitinib on Joint-Related Biomarkers in Patients with Moderate-to-Severe Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2484
Effect of Biologic Agents on Synovial Tissues from Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2540
Effect of Buccal Hygiene on the Systemic Activity of Patients with Rheumatoid Arthritis: A Randomized Clinical Trial
9:00AM-11:00AM
Abstract Number: 1988
Effect of Different Fucoidans on Pathological Pathways Activated in Osteoarthritic Chondrocytes and Synoviocytes
9:00AM-11:00AM
Abstract Number: 2759
Effect of Specific Treatments on Clinical, Serologic, and Imaging Assessments of Disease Activity in Large-Vessel Vasculitis
9:00AM-11:00AM
Abstract Number: 2619
Effect of Statins on CRP Elevation in Patients with Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 2160
Effect of the Metabolic Syndrome on Incident Vascular Events and Mortality in Four Rheumatic Diseases: An 8-Year Longitudinal Analysis
9:00AM-11:00AM
Abstract Number: 2311
Effect of TNF Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients Receiving Bisphosphonate
9:00AM-11:00AM
Abstract Number: 2524
Effect of Upadacitinib on Pain and Morning Stiffness in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs
9:00AM-11:00AM
Abstract Number: 2004
Effective Inhibition of Metalloproteases By a Viscosupplement Based on a Hyaluronic Acid Amide (HYADD®4)
9:00AM-11:00AM
Abstract Number: 2347
Effectiveness of Shared Decision Making in Systemic Lupus Erythematosus Patients at OSU
9:00AM-11:00AM
Abstract Number: 2032
Effector T Helper Cell Differentiation and Cytokine Secretion Are Increased in Young Children with Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 2210
Effects of Anti-Citrullinated Peptide Antibody (ACPA) on Bone Microstructure in Rheumatoid Arthritis: A HR-pQCT Study
9:00AM-11:00AM
Abstract Number: 2751
Effects of Baseline Prednisone Dose on Remission and Disease Flare in Patients with Giant Cell Arteritis Treated with Tocilizumab in a Phase 3 Randomized Controlled Trial
9:00AM-11:00AM
Abstract Number: 2058
Effects of Fatty Acid Supplementation in Modulation of Gut Microbiome and T-Regulatory Cells in Health and Psoriatic Disease
9:00AM-11:00AM
Abstract Number: L03
Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee
9:00AM-11:00AM
Abstract Number: 2462
Efficacy and Safety in the Middle-LONG Period of Rituximab in the Treatment of Diffuse Interstitial Pulmonary Disease Associated with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2563
Efficacy and Safety of a Potent and Highly Selective Oral Tyrosine Kinase 2 Inhibitor, BMS-986165, in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase II, Randomized, Placebo-Controlled Trial
9:00AM-11:00AM
Abstract Number: 2559
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: Two-Year Follow-up from a Phase 3 Study
9:00AM-11:00AM
Abstract Number: L12
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Prior Inadequate Response or Intolerance to 1 or 2 Tumor Necrosis Factor Inhibitors
9:00AM-11:00AM
Abstract Number: 2558
Efficacy and Safety Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the 48-Week Run-in Part of a Withdrawal Study (NCT02505542)
9:00AM-11:00AM
Abstract Number: 2598
Efficacy of Anti-Tumor Necrosis Factor (TNF) Alpha Therapy, in Patients with Spondylarthritis in the University Center of Rouen in France, Divived to the Berlin Algorithm Modified By the Assessement Spondylarthritis Group: A Ten Years Retrospective Study
9:00AM-11:00AM
Abstract Number: 2560
Efficacy of Guselkumab in Psoriasis Patients with Self-Reported Psoriatic Arthritis with Involvement of the Scalp, Nails, Hands, and Feet: A Pooled Analysis from 2 Pivotal Phase 3 Psoriasis Studies
9:00AM-11:00AM
Abstract Number: 2520
Efficacy of the Reference Biologic Agents in Two Different Types of Randomized Clinical Trials: 1/ the Ones Comparing Their Efficacy Vs. Placebo and 2/ the Ones Comparing Their Efficacy Vs. Biosimilar in Rheumatoid Arthritis: A Systematic Review of Literature and Meta-Analysis
9:00AM-11:00AM
Abstract Number: 2603
Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders
9:00AM-11:00AM
Abstract Number: 2623
Efficacy of TNF Inhibitors and Predictive Factors of Clinical Presentation in Patients with Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 2557
Efficacy of Ustekinumab on Spondylitis-Associated Endpoints in TNF-Naïve Active Psoriatic Arthritis Patients with Physician-Reported Spondylitis
9:00AM-11:00AM
Abstract Number: 2650
Efficacy, Safety, and Predictor of Response to Belimumab in a Large Nationwide Cohort Study of Patients with Active Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2697
Elevated Serum Interleukin-34 Levels Are Correlated with Interstitial Lung Disease in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1987
Elucidation of the Function of Dendritic Cell-Specific Transmembrane Protein (DCSTAMP) in Osteoclast Differentiation
9:00AM-11:00AM
Abstract Number: 2346
Emerging Ethical Issues in Physical Activity Monitoring of Persons Living with Arthritis: A Qualitative Evidence Synthesis
9:00AM-11:00AM
Abstract Number: 2652
Engaging the Cholinergic Anti-Inflammatory Pathway By Stimulating the Vagus Nerve Reduces Pain and Fatigue in Patients with SLE
9:00AM-11:00AM
Abstract Number: 2144
Epidemiological Characterisitics of Psoriatric Arthritis: A Nationwide Study of Inpatient Hospitalisations in 2014
9:00AM-11:00AM
Abstract Number: 1964
Epigenetic Changes of Energy Metabolism-Related Genes in Rheumatoid Arthritis Fibroblast-like Synoviocytes
9:00AM-11:00AM
Abstract Number: 2083
Epistasis between HLA-B27 and ERAP1 Affects Gut Microbial Dysbiosis and Arthritis in Experimental Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 1968
eQTL Analysis of More Than 1000 Human Blood Samples Reveals Shared and Unique Signals across Seven Systemic Autoimmune Diseases : The Precisesads Project
9:00AM-11:00AM
Abstract Number: 2082
ERAP1 Deficiency Partially Relieves HLA-B27-Induced ER Stress and IL-23 Expression, but Does Not Restore Dendritic Cell Function in Experimental Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 2316
Errors and Discrepancies in DXA Scans in Imaging Centers in Ecuador
9:00AM-11:00AM
Abstract Number: L11
Etanercept and Methotrexate As Monotherapy or in Combination in Patients with Psoriatic Arthritis: A Phase 3, Double-Blind, Randomized Controlled Study
9:00AM-11:00AM
Abstract Number: 2783
EULAR Task Force Recommendations for a Minimum Core Set of Parameters to be Collected in Giant Cell Arteritis Registries and Databases
9:00AM-11:00AM
Abstract Number: 2389
Evaluating Disease Activity Outcomes for Juvenile Idiopathic Arthritis across the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN)
9:00AM-11:00AM
Abstract Number: 2412
Evaluating Gaps in Reproductive Health Knowledge Among Women with Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 2198
Evaluation of 18F-Fluorodeoxyglucose PET-CT Score at Baseline on the Therapeutic Response to Prednisone in Polymyalgia Rheumatica: A Retrospective Study
9:00AM-11:00AM
Abstract Number: 2201
Evaluation of 18f-Fluorodeoxyglucose Positron Emission Tomography/ Magnetic Resonance Imaging (18F-FDG PET/MRI) in C Protein-Induced Myositis Model in Mice
9:00AM-11:00AM
Abstract Number: 1993
Evaluation of Cartilage Degeneration and Osteoarthritis Pain on Female and Male Mouse Model of Osteoarthritis
9:00AM-11:00AM
Abstract Number: 2215
Evaluation of Left Ventricular Systolic and Diastolic Myocardial Function in Patients with Ankylosing Spondylitis By Speckle-Tracking Echocardiography
9:00AM-11:00AM
Abstract Number: 2712
Evaluation of Longitudinal Outcomes in Scleroderma Patients with Negative Immunofluorescent Anti-Nuclear Antibodies
9:00AM-11:00AM
Abstract Number: 2022
Evidence of Inflammation Amplification By Interleukin-6 and Interleukin-17A in Synovial Compartment of Juvenile Idiopathic Arthritis – Enthesitis Related Arthritis
9:00AM-11:00AM
Abstract Number: 2602
Evolution of Patient Characteristics in the Era of Biological Treatment of Psoriatic Arthritis: 18-Year Belgian Experience from Leuven Spondyloarthritis Biologics Cohort (BioSPAR)
9:00AM-11:00AM
Abstract Number: 2350
Examining Ethnic Differences in Osteoarthritis (OA) Patients’ Knowledge and Attitudes Regarding Prescription Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
9:00AM-11:00AM
Abstract Number: 2094
Examining T Cell Exhaustion in Murine Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2363
Examining Workplace Supports in the Context of RA Disease Activity
9:00AM-11:00AM
Abstract Number: 1960
Exome Sequencing Reveals Rare Recessive Mutations in Multiple Genes Including FAS, RAD51B, and ISG15 in a Single Family with Lupus and Suggests a Unique Genetic Model
9:00AM-11:00AM
Abstract Number: 2343
Exploring Decision Making Needs about Pain Management Among Adolescents with Juvenile Idiopathic Arthritis and Their Families: Preliminary Results from Interviews
9:00AM-11:00AM
Abstract Number: 2225
Exploring the Relationship between Gout and Diffuse Idiopathic Skeletal Hyperostosis (DISH): An Epidemiologic and Genetic Study
9:00AM-11:00AM
Abstract Number: 2578
Exposure Response Analyses to Describe the Relationship between Ixekizumab Concentrations and Acr Responses in Psoriatic Arthritis Patients
9:00AM-11:00AM
Abstract Number: 2654
Exposure to Air Pollution and the Onset and Progression of Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2142
Exposure to Disease Modifying Antirheumatic Drugs during Pregnancy in Women with Inflammatory Arthritis and the Risk of Serious Maternal Infection: A Population-Based Cohort Study
9:00AM-11:00AM
Abstract Number: 2519
Exposure-Efficacy Analysis in DMARD Inadequate Response Rheumatoid Arthritis Patients Treated with GSK3196165 Along with Methotrexate
9:00AM-11:00AM
Abstract Number: 2049
Expression and Function of a Novel Citrullinated Form of Interleukin 6 in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2029
Extended Phenotypic Immunome Characterization (EPIC): A Web-Based Immune Reference Atlas
9:00AM-11:00AM
Abstract Number: 2753
Extension of Extracranial Vessel Involvement in Patients with Giant Cell Arteritis
9:00AM-11:00AM
Abstract Number: 2366
Facilitating Shared Decision Making in Psoriatic Arthritis: Factors Influencing Patient Preference for Treatment Mode of Administration
9:00AM-11:00AM
Abstract Number: 2285
Factors Associated with Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis
9:00AM-11:00AM
Abstract Number: 2717
Factors Predicting Severe Infections in Patients with Systemic Necrotizing Vasculitides Based on Data from 733 Patients Enrolled in Randomized–Controlled Trials
9:00AM-11:00AM
Abstract Number: 2442
Familial Mediterranean Fever Associated Infertility and Underlying Factors with Fertility
9:00AM-11:00AM
Abstract Number: 2552
Fatigue in Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Early Improvement Is Associated with Week 24 Outcomes in Acr 20, 50, and Health-Related Quality of Life
9:00AM-11:00AM
Abstract Number: 2743
Favorable Efficacy of Rituximab in ANCA-Associated Vasculitis Patients with Excessive B Cell Differentiation
9:00AM-11:00AM
Abstract Number: 2212
Feasibility and Performance of HR-pQCT-Derived Joint Space Width Measurement As Outcome Parameter in Arthropathic Disease – Lessons from Hemochromatosis Arthropathy
9:00AM-11:00AM
Abstract Number: 2493
Features of Disease Severity Associated with Patient Satisfaction with Biologic Treatment: Results from the Abatacept Best Care Real-World Study
9:00AM-11:00AM
Abstract Number: 2025
Fibroblast-like Synoviocytes from Juvenile Idiopathic Arthritis and Controls Influence Expression of Bone Morphogenetic Protein Antagonists in Chondrocytes
9:00AM-11:00AM
Abstract Number: 2374
Flare Warnings: People with Rheumatoid Arthritis’ Perceptions of Their Flares
9:00AM-11:00AM
Abstract Number: 2209
Fluorescence Optical Imaging Xiralite® Is Helpful in the Decision for Rituximab Re-Therapy in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2302
Forearm Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis
9:00AM-11:00AM
Abstract Number: 2318
Fracture Liaison Service in an Open Health System: Outcomes and Challenges
9:00AM-11:00AM
Abstract Number: 2733
From a Myth to a Menace: Increased Disease Severity and Poor Outcomes in an Urban Cohort of African-American Patients with ANCA-Associat­ed Vasculitis
9:00AM-11:00AM
Abstract Number: 2040
Galectin-3 Is a Regulator of 4-1BB/CD137 Activity and Associates with Outcome in Rheumatoid Arthritis.
9:00AM-11:00AM
Abstract Number: 1969
GENE Enhancers Associated with an Increase Risk of Developing JIA Fail to DOWN Regulate RUNX1 after CELL Stimulation
9:00AM-11:00AM
Abstract Number: 1958
Gene Expression Pathways across Multiple Tissues in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Reveal Core Pathways of Disease Pathology
9:00AM-11:00AM
Abstract Number: 2007
Generation of Human Induced Pluripotent Stem Cell Lines from Patients with Hand Osteoarthritis
9:00AM-11:00AM
Abstract Number: 2105
Genetic Analysis of a Drosophila Systemic Lupus Erythematosus Model Reveals Lupus Susceptibility Genes
9:00AM-11:00AM
Abstract Number: 2248
Genetic Variants Identify Interleukin 37 As an Important Anti-Inflammatory Cytokine in Gout in Humans
9:00AM-11:00AM
Abstract Number: 1978
Genome Wide Association Studies in SLE Predict E-Genes and Gene Expression Patterns That Inform Ancestral-Specific Molecular Pathways and Targeted Therapies
9:00AM-11:00AM
Abstract Number: 2061
Genome-Wide DNA Methylation Analysis in Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 2748
Giant Cell Arteritis in Treatment with Tocilizumab. Evolution of Vascular FDG Uptake on PET/CT
9:00AM-11:00AM
Abstract Number: 2744
Giant-Cell Arteritis: Is Glucocorticoid-Sparing Treatment Still Relevant? a Retrospective Study
9:00AM-11:00AM
Abstract Number: 2053
Global Mirna Expression and Transcriptomic Profiling of Monocytes from RA Patients
9:00AM-11:00AM
Abstract Number: 2104
Glomerular and Tubular Transcriptional Profiles Reveal Gene Clusters Specific for Different Stages of Glomerulonephritis in NZM2328 Mice
9:00AM-11:00AM
Abstract Number: 2093
Glucocorticoid-Induced Leucine Zipper (GILZ) Deficiency Worsens Autoimmunity in the Lyn-Deficient Murine Model of Lupus By Disinhibiting the Type I Interferon (IFN) Pathway
9:00AM-11:00AM
Abstract Number: 2092
Glucocorticoid-Induced Leucine Zipper (GILZ) Is a Novel Checkpoint Regulator of Type I Interferon (IFN) Production in SLE
9:00AM-11:00AM
Abstract Number: 2679
Glucocorticoids Withdrawal in Systemic Lupus Erythematosus: Are Remission and Low Disease Activity Reliable Starting Points for Stopping Therapy? a Real-Life Experience
9:00AM-11:00AM
Abstract Number: 2595
Golimumab Improves Socio- and Health Economic Parameters in Patients with RA, Psa and As: Real World-Data from a Non-Interventional Clinical Study in Germany
9:00AM-11:00AM
Abstract Number: 2416
Good Pregnancy and Neonatal Outcomes in Lupus Nephritis Patients with Complete Remission
9:00AM-11:00AM
Abstract Number: 2226
Gout and the Risk of Incident Dementia in the Elderly: A Medicare Claims Study
9:00AM-11:00AM
Abstract Number: 2220
Gout, Flares and Allopurinol Use: A Population Based Study
9:00AM-11:00AM
Abstract Number: 2289
Granulomatous Myositis: Heterogeneity and Response to Treatment
9:00AM-11:00AM
Abstract Number: 2518
GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study
9:00AM-11:00AM
Abstract Number: 2730
Handgrip Strength Predicts the Risk of Bone Fracture and Severe Adverse Events in Patients with Systemic Necrotizing Vasculitis
9:00AM-11:00AM
Abstract Number: 2405
Health-Related Quality of Life, Functioning, and Mental Health of Children with Chronic Non-Infectious Uveitis
9:00AM-11:00AM
Abstract Number: 2507
Healthcare Resource Utilization in Patients with Secondary Sjögren’s Syndrome Associated with RA Compared with Patients with RA in an Insured Population
9:00AM-11:00AM
Abstract Number: 2640
Hematologic Activity in Systemic Lupus Erythematosus: Is Splenectomy Our Best Choice?
9:00AM-11:00AM
Abstract Number: 2161
Hemophagocytic Syndrome in Adults and Association with Rheumatologic Diagnoses: US National Inpatient Trend over Nine Years
9:00AM-11:00AM
Abstract Number: 1995
Heparan Sulfates from Human Osteoarthritic Cartilage Display Increased Sulfation Pattern, Decrease the Protein Binding Capacity to FGF-2 and Increase the Binding to VEGF and Induce Changes of Human Mesenchymal Stem Cell Behavior
9:00AM-11:00AM
Abstract Number: 2767
Herpes Zoster As a Risk Factor for Polymyalgia Rheumatica: A Population-Based Study
9:00AM-11:00AM
Abstract Number: 2451
Herpes Zoster in Rheumatoid Arthritis. Prospective Single Center Study of 390 RA Patients for 5 YEARS
9:00AM-11:00AM
Abstract Number: L08
High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response
9:00AM-11:00AM
Abstract Number: 2273
High Dose Intravenous Methylorednisolone Induces Rapid Improvement in Severe Non-Infectious Uveitis. a Multicenter Study of 120 Patients
9:00AM-11:00AM
Abstract Number: 2692
High Frequency Ultrasound As a Novel Approach to Quantifying the Digital Microangiopathy of Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 2778
High Prevalence of Vascular Surgery and Autoimmune Comorbidity in Takayasu Arteritis
9:00AM-11:00AM
Abstract Number: 2333
High Serum Uric Acid Protects Against Osteoporosis in Postmenopausal Women: Data from the Korean National Health and Nutrition Examination Survey
9:00AM-11:00AM
Abstract Number: 2761
High-Dose Prednisone Use up to 42 Days Prior to Temporal Artery Biopsy (TAB) Did Not Reduce Yield of Positive Biopsy in the Veterans Health Administration (VHA) Database Cohort
9:00AM-11:00AM
Abstract Number: 2240
Hip Involvement in Patients with Gout: Results of an Ultrasound Study
9:00AM-11:00AM
Abstract Number: 1962
HLA Contributions to Risk and Protection for Anti-Centromere Autoantibody-Positive Scleroderma
9:00AM-11:00AM
Abstract Number: 2373
How Do Patients Describe Their “New Normal” in Systemic Lupus Erythematosus? Use of Probabilistic Topic Modelling to Characterize Patients’ Experiences Recorded in an Online Health Community
9:00AM-11:00AM
Abstract Number: 2088
Human TLR8 at the Interface between Innate and Adaptive Immunity in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2102
Hyaluronic Acid Synthesis Inhibition Blocks Nephritis and Extends Lifespan in Mice Prone to Lupus
9:00AM-11:00AM
Abstract Number: 2628
Hydroxychloroquine and Prednisone Have Different Effects on Antiphospholipid Antibodies in SLE, with Hydroxychloroquine Not Reducing IgA Anticardiolipin
9:00AM-11:00AM
Abstract Number: 2668
Hydroxychloroquine and the Risk of Thrombotic Events in Systemic Lupus Erythematosus Patients : A Systematic Review and Meta-Analysis
9:00AM-11:00AM
Abstract Number: 2631
Hydroxychloroquine Blood Levels Are Significantly Associated with Cardiovascular Risk Factors
9:00AM-11:00AM
Abstract Number: 2641
Hydroxychloroquine Could Modulate S100 Proteins Expression, Which Reflect the Activity of Lupus Nephritis or Skin Lesion, in Systemic Lupus Erythematosus Patients with Low Disease Activity
9:00AM-11:00AM
Abstract Number: 2637
Hydroxychloroquine Improves Disease Activity and Allows Reduction of Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2005
Identification of a Human Cartilage Microbial DNA Signature and Characterization of Distinct Microbiome Profiles Associated with Osteoarthritis
9:00AM-11:00AM
Abstract Number: 2090
Identification of a Role for Monocytes in Murine Lupus Associated Diffuse Alveolar Hemorrhage By Mass Cytometry
9:00AM-11:00AM
Abstract Number: 2336
Identification of Osteoporosis As a Reason for Vertebral Fractures in Patients with Rheumatoid Arthritis and Non-Inflammatory Musculoskeletal Diseases – a Comparison between Trabecular Bone Score (TBS) and Bone Mineral Density (BMD)
9:00AM-11:00AM
Abstract Number: 2135
Identification of Psoriatic Arthritis Using an Administrative Claims-Based Algorithm
9:00AM-11:00AM
Abstract Number: 2113
Identification of RNASE2 As a Novel Lupus Candidate Gene
9:00AM-11:00AM
Abstract Number: 2115
Identification of Systemic Lupus Erythematosus Subgroups Using Electronic Health Record and Genetic Databases
9:00AM-11:00AM
Abstract Number: 2735
Identifying ANCA-Associated Vasculitis Cases in Electronic Health Records Using Natural Language Processing
9:00AM-11:00AM
Abstract Number: 2674
Identifying Phenotype Clusters in Systemic Lupus Erythematosus By Damage Cluster
9:00AM-11:00AM
Abstract Number: 2644
Identifying Response for the Systemic Lupus Erythematosus Disease Activity Glucocorticoid Index (SLEDAI-2KG)
9:00AM-11:00AM
Abstract Number: 2112
IFN-Gene Expression Is Elevated in Subacute Cutaneous Lupus Erythematous and DLE and Decreases with Treatment in DLE
9:00AM-11:00AM
Abstract Number: 2111
Ifnβ Affects Osteogenesis-Adipogenesis Axis in SLE Bone Marrow
9:00AM-11:00AM
Abstract Number: 1985
IL-1β Inhibits the Expression of Dickkopf-1, an Antagonist of the Wnt-β-Catenin Signaling Pathway: A Possible Role of Inflammasome in Dysregulation of Endochondral Ossification
9:00AM-11:00AM
Abstract Number: 2052
Immune Therapy of Rheumatoid Arthritis Patients with a Microbiome-Derived, Self/Non-Self Peptide Induces Clinically Relevant Immune Tolerance Pivoting on Immune Checkpoint-Expressing, Therapy-Induced Tregs
9:00AM-11:00AM
Abstract Number: 2042
Immunophenotypic Analysis of Tissue-Resident Memory T Cells in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2541
Impact of 12-Weeks of Upadacitinib Treatment on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic or Biologic Dmards
9:00AM-11:00AM
Abstract Number: 2164
IMPACT of a Systematic Screening of Multimorbidities in Patients with Chronic Inflammatory Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 2534
Impact of Block Switch to Biosimilar Etanercept in Practice, Accross Different Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 2566
Impact of Guselkumab Versus Placebo and Adalimumab on Patient Reported Outcomes in Patients with and without Psoriatic Arthritis in a Phase 3 Pivotal Psoriasis Study
9:00AM-11:00AM
Abstract Number: 2503
Impact of Tobacco Smoking on 1-Year Mortality Following Total Hip and Total Knee Arthroplasty Among Rheumatoid Arthritis Patients – a Danish Cohort Study Using Nationwide Health Care Registers
9:00AM-11:00AM
Abstract Number: 2044
Impaired microRNA Processing in Neutrophils from Rheumatoid Arthritis Patients Confers Their Pathogenic Profile. Modulation By Biological Therapies
9:00AM-11:00AM
Abstract Number: 2309
Implementation of a Primary Prevention, Population-Based Virtual Osteoporosis Clinic Dramatically Increases the Number of Rural Veterans Receiving Osteoporosis Screening and Treatment
9:00AM-11:00AM
Abstract Number: 2304
Implication of Bone Turnover Marker Follow-up during Antiresorptive Therapy in Patients with Active Rheumatoid Arthritis on Immunosuppresssive Agents
9:00AM-11:00AM
Abstract Number: 2294
Improving EULAR/Acr Classification Criteria for Idiopathic Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 2489
In Clinical Practice a Substantial Group of Rheumatoid Arthritis (RA) Patients on Biologic Therapy (bDMARDs) Has Persistent Moderate Disease Activity Despite Treatment Switches That Correlates with Unfavourable Long-Term Outcome
9:00AM-11:00AM
Abstract Number: 2054
In Rheumatoid Arthritis, Changes in Autoantibody Levels Do Not Associate with Treatment Response, but Are a Reflection of Treatment Intensity
9:00AM-11:00AM
Abstract Number: 2307
In the 21st Century: Is Still Rheumatoid Arthritis a Risk Factor for Osteoporotic Fractures?
9:00AM-11:00AM
Abstract Number: 2048
In Vitro Proof-of-Concept of Pathobiology-Guided Therapy in Immune Mediated Inflammatory Arthritis
9:00AM-11:00AM
Abstract Number: 2167
Incidence and Baseline Characteristics of Exacerbation in Patients with Interstitial Pneumonia with Autoimmune Features: A Single Center Large-Scale Cross-Sectional Cohort Study
9:00AM-11:00AM
Abstract Number: 2722
Incidence and Predictors of Severe Infections in ANCA Associated Vasculitis in a Population-Based Cohort – Preliminary Results
9:00AM-11:00AM
Abstract Number: 2390
Incidence of and Risk Factors for Adrenal Suppression Following Ultrasound-Guided Intra-Articular Corticosteroid Injection with Triamcinolone Acetonide in Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 2772
Incidence of Cardiovascular Events in Giant Cell Arteritis: A Matched-Control Study
9:00AM-11:00AM
Abstract Number: 2604
Incidence of Serious Gastrointestinal Events and Inflammatory Bowel Disease Among Tildrakizumab-Treated Patients with Moderate to Severe Plaque Psoriasis: Data from 3 Large Randomized Clinical Trials
9:00AM-11:00AM
Abstract Number: 2452
Incidence Rate and Clinical Characteristics of Herpes Zoster Infection in Korean Patients with Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 2764
Incidence, Characteristics and Management of Giant Cell Arteritis in France: A Study Based on National Health Insurance Claims Data
9:00AM-11:00AM
Abstract Number: 2702
Incidence, Prevalence, Mortality and Comparison of the Acr/EULAR 2013 Classification Criteria with 1980 Criteria in Physician Diagnosed Systemic Sclerosis: Results from a Population Based Cohort (1980-2016)
9:00AM-11:00AM
Abstract Number: 2283
Incidental Steroid Use May Worsen Outcomes in Patients with Heparin Induced Thrombocytopenia in the ICU Setting
9:00AM-11:00AM
Abstract Number: 2255
Increased Cost Burden in an Early Diagnosed Cohort of Uncontrolled Versus Controlled Gout: Analysis of a Large US Payer Database
9:00AM-11:00AM
Abstract Number: 2034
Increased Invasive Capacity and Metabolic Activity in Synovial Fibroblasts from Children with Downs Arthropathy Compared to Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 2696
Increased Mortality in Black and Asian Patients with Systemic Sclerosis in Northern California
9:00AM-11:00AM
Abstract Number: 2691
Increased Plasma Angiopoietin-2 in Systemic Sclerosis: Potential for Use As a Biomarker of Vasculopathy and Fibrosis
9:00AM-11:00AM
Abstract Number: 2729
Increased Risk of Cerebrovascular Accident Among Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Systematic Review and Meta-Analysis of Cohort Studies
9:00AM-11:00AM
Abstract Number: 2145
Increased Risk of Heart Failure with Prolonged Use of Hydroxychloroquine in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2262
Increased Risk of Sarcoidosis Among Patients with Celiac Disease: A Systematic Review and Meta-Analysis
9:00AM-11:00AM
Abstract Number: 2688
Increased Serum Uric Acid Levels Are Associated with a Higher Risk of Digital Ulcers in Patients with Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 2415
Increased Sperm DNA Fragmentation in Male Systemic LUPUS Erythematosus Patients
9:00AM-11:00AM
Abstract Number: 2078
Induction of Netosis in Ankylosing Spondylitis: Association to Disease Pathogenesis and Modulation By Anti-Tnfα Therapy
9:00AM-11:00AM
Abstract Number: 2071
Inflammation at Distant Immunocompetent Sites Combined with a Protocol of Forced Exercise Induces Mild Joint Inflammation
9:00AM-11:00AM
Abstract Number: 2269
Infliximab Therapy in Refractory Retinal Vasculitis of Behçet’s Disease, Short and Long-Term Follow-up. Multicenter Study of 72 Patients
9:00AM-11:00AM
Abstract Number: 2502
Influence of the Treatment with Biologic Agents in the Viremia By the Endogenous Anelovirus Torque Teno Virus in Patients with Chronic Arthritis
9:00AM-11:00AM
Abstract Number: 2059
Inhibition of the Transcription Factor That Drives IL-17 Expression Suppresses Inflammation, Joint Damage, and New Bone Formation in Experimental Spondyloarthritis in HLA-B27 Transgenic Rats
9:00AM-11:00AM
Abstract Number: 2205
Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Measurement of Dissolution of Urate Deposits Associated with Monthly Dosing of a Pegylated Uricase (Pegadricase) with Svp-Rapamycin By Dual Energy Computed Tomography
9:00AM-11:00AM
Abstract Number: 2780
Insufficient Use of Corticosteroids Results in Higher Relapse in Takayasu Arteritis
9:00AM-11:00AM
Abstract Number: 2246
Insulin: Genetic and Physiological Influences on Human Uric Acid Homeostasis
9:00AM-11:00AM
Abstract Number: 2542
Integrated Exposure-Response Analyses for Upadacitinib Efficacy and Effects on Laboratory Parameters in Rheumatoid Arthritis – Analyses of Phase 2b Studies
9:00AM-11:00AM
Abstract Number: 2678
Integrated Safety Profile of Atacicept from All Clinical Studies to Date
9:00AM-11:00AM
Abstract Number: 2224
Interactions between Serum Urate-Associated Genetic Variants and Sex on Gout Risk in a European Population
9:00AM-11:00AM
Abstract Number: 2130
Interferon Induced Gene Transcripts Are Differentially Upregulated in the Kidney of Lupus Nephritis Patients Irrespective of Activity or Damage
9:00AM-11:00AM
Abstract Number: 2114
Interferon Kappa Regulates Apoptotic Response to UVB in Control and Lupus Keratinocytes
9:00AM-11:00AM
Abstract Number: 2685
Interferon-Inducible Gene Expression Kit As a Potential Diagnostic Test for Anifrolumab: Analytical Validation for Use in Clinical Trials
9:00AM-11:00AM
Abstract Number: 2287
Interim Results of an Open-Label Study Assessing Efficacy and Safety of Adrenocorticotropic Hormone Gel for Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
9:00AM-11:00AM
Abstract Number: 2000
Interleukin-1β, Oxidative Stress and Basic Calcium Phosphate Crystals Induce Osteoarthritis-like Changes in Chondrocyte Phenotype By Altering the Expression of PERIOD2, a Core Component of the Chondrocyte Circadian Clock
9:00AM-11:00AM
Abstract Number: 2776
Interleukin-6 Expression in Inflamed and Non-Inflamed Temporal Arteries from Patients with Giant Cell Arteritis
9:00AM-11:00AM
Abstract Number: 2322
Intervals of Bone Mineral Density Measurement during Treatment for Osteoporosis in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2636
Investigating Lupus Nephritis Patient Outcomes Receiving Belatacept Post Renal Transplant Using the UNOS Database
9:00AM-11:00AM
Abstract Number: 2019
Investigating Urine S100A4 and Podocyte Proteins As Biomarkers of Lupus Nephritis Activity
9:00AM-11:00AM
Abstract Number: 2713
Is Effectiveness of Immunosuppression for Interstitial Lung Disease in Systemic Sclerosis (SSc) Modified By Lung Disease Severity or SSc Duration?
9:00AM-11:00AM
Abstract Number: 2782
Is It Necessary to Hold Anticoagulation Prior to Temporal Artery Biopsy?
9:00AM-11:00AM
Abstract Number: 2393
Is Methotrexate-Induced Nausea in Juvenile Idiopathic Arthritis Influenced By Anxiety or Coping Strategies?
9:00AM-11:00AM
Abstract Number: 2555
Ixekizumab Treatment Results in Rapid and Sustained Improvements in the Disease Activity Index for Psoriatic Arthritis (DAPSA) in Patients Naïve to Biologic Dmards or with Previous Inadequate Response to TNF Inhibitors
9:00AM-11:00AM
Abstract Number: 2579
Ixekizumab Treatment Significantly Improves Enthesitis and Dactylitis in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials
9:00AM-11:00AM
Abstract Number: 2515
Joint Damage Progression According to Disease Activity States in Patients with Rheumatoid Arthritis Treated with CT-P10 and Reference Rituximab: Up to 48 Weeks Results from Phase III Study
9:00AM-11:00AM
Abstract Number: 2206
Joint Repair While Initiating Biologic Therapy in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2011
Juvenile Arthritis-Associated Single Nucleotide Polymorphisms Identified on Whole Genome Sequencing Show Enrichment within H3K9me3-Marked Regions
9:00AM-11:00AM
Abstract Number: 2087
Kidney Tissue Damage in Mice with Single and Combined Abnormalities in Complement, Interferon and Apoptotic Cell Clearance
9:00AM-11:00AM
Abstract Number: 2196
Kinetics of Tissue-Specific Distribution of 18f-Fluorodeoxyglucose in Positron Emission Tomography in Large Vessel Vasculitis
9:00AM-11:00AM
Abstract Number: 2055
Laser Capture Microdissection to Interrogate B Cells in RA Synovial Tissue
9:00AM-11:00AM
Abstract Number: 2747
Leflunomide and Methotrexate in Treatment of Giant Cell Arteritis: Comparison of Efficacy, Safety and Drug Survival
9:00AM-11:00AM
Abstract Number: 1973
Leveraging Publicly Available Gene Expression Data and Applying Machine Learning to Identify Novel Biomarkers for Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1970
Linking Genetics to T Cell Phenotype in JIA: Rationale for IL-2 Therapy
9:00AM-11:00AM
Abstract Number: 2447
Liver Enzyme Abnormalities after Tofacitinib Treatment in Patients with Hepatic Steatosis from the Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis Clinical Programs
9:00AM-11:00AM
Abstract Number: 2529
Liver Function Test Levels with Sarilumab Treatment in Phase 3 Trials: Analysis By Baseline Liver Function Test (LFT) Level
9:00AM-11:00AM
Abstract Number: 2234
Liver Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease
9:00AM-11:00AM
Abstract Number: 2290
Long Term Follow-up Results of Myositis Patients Treated with H. P. Acthar Gel
9:00AM-11:00AM
Abstract Number: 2781
Long Term Follow-up Results of Takayasu Arteritis Cohort: A Tertiary-Single Center Study
9:00AM-11:00AM
Abstract Number: 2664
Long-Term Clinical Outcomes in a Cohort of Adults with Childhood-Onset Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2381
Long-Term Disease Control Among Patients with Juvenile Idiopathic Arthritis Receiving Adalimumab (Humira) Treatment for up to Six Years
9:00AM-11:00AM
Abstract Number: 2577
Long-Term Effect of Ixekizumab on Patient-Reported Outcomes in Patients with Psa and Inadequate Response to TNF Inhibitors: 2-Year Follow-up from a Phase 3 Study
9:00AM-11:00AM
Abstract Number: 2575
Long-Term Effects of TNF-Alpha Inhibitors on Bone Mineral Density and the Incidence of Vertebral Fractures in Patients with Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 2271
Long-Term Efficacy and Safety of Adalimumab By Immunosuppressant Use in Patients with Non-Infectious Uveitis
9:00AM-11:00AM
Abstract Number: L13
Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial
9:00AM-11:00AM
Abstract Number: 2606
Long-Term Inhibition of Radiographic Progression with Originator Adalimumab in Patients with Moderate to Severe Psoriatic Arthritis with or without Radiographic Damage at Baseline
9:00AM-11:00AM
Abstract Number: 2516
Long-Term Maintenance of Response in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol
9:00AM-11:00AM
Abstract Number: 2779
Long-Term Outcome and Prognostic Factors after Aortic Valve Surgery Due to Aortic Valve Regurgitation in Patients with Takayasu Arteritis
9:00AM-11:00AM
Abstract Number: 2429
Long-Term Outcome of Children Born to Mothers with Chronic Arthritis and Exposed to TNF-Inhibitors during Pregnancy: A Case-Control Study
9:00AM-11:00AM
Abstract Number: 2261
Long-Term Outcome of Pulmonary Sarcoidosis: A Population-Based Cohort Study from 1976-2013
9:00AM-11:00AM
Abstract Number: 2379
Long-Term Safety of Subcutaneous Tocilizumab Administration in Systemic and Polyarticular Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 2527
Long-Term Safety with Sarilumab Plus Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) and Sarilumab Monotherapy in Rheumatoid Arthritis (RA): An Integrated Analysis with 9,000 Patient-Years (Pt-Yrs) of Follow-up
9:00AM-11:00AM
Abstract Number: 2509
Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years’ Treatment
9:00AM-11:00AM
Abstract Number: 2629
Longitudinal Analysis of Persistent Positivity of Antiphospholipid Antibodies in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2291
Longitudinal Course of the Disease in Anti-Mi2 Patients: More Intense Muscle Weakness, Good Response to Treatment and Progressive Reduction of Autoantibody Titers
9:00AM-11:00AM
Abstract Number: 2584
Low Incidence of Both New-Onset and Flares of Uveitis in Secukinumab-Treated Patients with Ankylosing Spondylitis: Clinical Trial and Post-Marketing Safety Analysis
9:00AM-11:00AM
Abstract Number: 2660
Low-Dose Interleukin-2 Treatment of Refractory Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 2245
Lubricin/Proteoglycan 4 (PRG4) Inhibits NLRP3 Inflammasome Assembly in Monosodium Urate (MSU)-Crystal Induced Arthritis.
9:00AM-11:00AM
Abstract Number: 2214
Lung Involvement in Primary Sjögren’s Syndrome: Spectrum of Pulmonary Abnormalities and Computed Tomography Findings
9:00AM-11:00AM
Abstract Number: 2681
Lupus Primary Care Management Practices
9:00AM-11:00AM
Abstract Number: 2107
Lupus-Prone SLE1.2.3. Mice Exhibit Loss of Thymus-Derived CD4+CD25+Helios+ Tregs
9:00AM-11:00AM
Abstract Number: 1990
Luteolin Modulates Glyco-Lipo-Oxidative Protein Modifications and Inhibits Inflammatory Cytokine Release in Human Osteoarthritic Articular Chondrocytes: Comparison with Colchicine
9:00AM-11:00AM
Abstract Number: 2265
Lymphocyte Immunophenotyping and CD4/CD8 Ratio in Cerebrospinal Fluid for the Diagnosis of Sarcoidosis-Related Uveitis
9:00AM-11:00AM
Abstract Number: 2143
Lymphoproliferative Malignancy in Psoriatic Arthritis and the Role of Systemic Immunosuppressive Therapies
9:00AM-11:00AM
Abstract Number: 2483
Major Secular Trends of Patient Characteristics and Inclusion Criteria in RA Clinical Trials
9:00AM-11:00AM
Abstract Number: 2190
Means of Collaboration between Ophthalmologists, Rheumatologists and Internists in the Management of Non-Infectious Uveitis: A Nationwide Study
9:00AM-11:00AM
Abstract Number: 2282
Measurement of the Pro-Coagulant Activity of Microparticles in Patients with Inflammatory Rheumatic Diseases: Prospective Study
9:00AM-11:00AM
Abstract Number: 1991
Measuring Balance in an Experimental Mouse Model of Osteoarthritis
9:00AM-11:00AM
Abstract Number: 2594
Median Time to Pain Improvement in Patients with Psoriatic Arthritis Treated with Tofacitinib
9:00AM-11:00AM
Abstract Number: 2661
Metformin Combined with Conventional Therapy Increases Absolute Number of Regulatory T Cells in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2264
Methotrexate in the Treatment of Granulomatous Mastitis: A Retrospective Review of 19 Cases
9:00AM-11:00AM
Abstract Number: 2391
Methotrexate Polyglutamates As an Evaluation Tool for Appropriate Dosage of Oral Methotrexate Administration in Pediatric Patients
9:00AM-11:00AM
Abstract Number: 2018
Microenvironment Driven Re-Shaping of Pathogenic T Effector and Regulatory Subset in Active Juvenile Idiopathic Arthritic Patients
9:00AM-11:00AM
Abstract Number: 2074
Micrornas Deregulation in Monocytes and T CD4 Lymphocytes from Patients with Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 2028
Microwave and Magnetic (M2) Myocardial Proteomics in the Mouse Model of Kawasaki Disease Demonstrates Normalization of the Proteome after Interleukin-1 Inhibition, Potential Novel Biomarkers, and Suggests New Insights into Mechanism of Disease
9:00AM-11:00AM
Abstract Number: 2272
Missed Opportunity? Evaluation for Systemic Autoimmune Diseases in Patients with Uveitis May Not be Optimal: 5-Year Analysis of Patients Being Seen in a Tertiary Medical Center
9:00AM-11:00AM
Abstract Number: 2250
Mitigation of Inflammation Induced By Monosodium Urate Crystals in Mice By Treatment with Svp-Rapamycin
9:00AM-11:00AM
Abstract Number: 2134
Modifiable Risk Factors and the Development of Psoriatic Arthritis in People with Psoriasis
9:00AM-11:00AM
Abstract Number: 2043
Monocytes and Macrophages of Patients with Rheumatoid Arthritis Respond to Pathologically Increased Ionized Calcium with Proinflammatory Cytokine Production
9:00AM-11:00AM
Abstract Number: 2235
Monosodium Urate Deposition Distribution in the Knees, Hands, and Feet of Treated Gout Patients: A Dual-Energy CT Study
9:00AM-11:00AM
Abstract Number: 2097
Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease Severity and Alters Immune Cell Subsets in the NZB/W F1 Murine Model of Lupus
9:00AM-11:00AM
Abstract Number: 2136
Mortality Rates and Causes in Psoriatic Arthritis Patients
9:00AM-11:00AM
Abstract Number: 2091
Mucosal-Associated Invariant T (MAIT) Cells As a Potential Therapeutic Target for Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2784
Multi Modal Imaging Algorithm to Improve the Accuracy for the Diagnosis of Giant Cell Arteritis
9:00AM-11:00AM
Abstract Number: 2611
Multidrug Resistant AxSpA: No Advantage of Switching Class in Patients with Inadequate Response to Two Prior TNFi Agents
9:00AM-11:00AM
Abstract Number: 2320
Multimorbidity Is Associated with Hip Fractures in Both Women and Men and across Different Races
9:00AM-11:00AM
Abstract Number: 2033
Multiparameter Mass Cytometry By Time-of-Flight Spectrometry (CyTOF) Phenotyping in Pediatric Localized Scleroderma
9:00AM-11:00AM
Abstract Number: 2006
Murine Ear Wound Cartilage Superhealer Trait Is Associated with Gut Microbiota Changes and Is Transferable to Non-Healer Mice By Gut Microbiome Transplant
9:00AM-11:00AM
Abstract Number: 2260
Musculoskeletal Sarcoidosis: A 15-Year Experience from a Tertiary Care Center in the US
9:00AM-11:00AM
Abstract Number: 1983
Mutations Associated with Clonal Hematopoiesis of Indeterminate Potential Are Found in Peripheral Blood and Synovial Fluid Macrophages from Patients with Rheumatoid and Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 2286
Myositis and Fasciitis By Magnetic Resonance Imaging in Recent-Onset Polymyalgia Rheumatica and Effect of Tocilizumab Therapy
9:00AM-11:00AM
Abstract Number: 2157
Nationwide Estimated Prevalence of SLE: United States Population-Based Study, 2001-2011
9:00AM-11:00AM
Abstract Number: 2441
Needs and Barriers to Pregnancy Counselling in Women with SLE
9:00AM-11:00AM
Abstract Number: 2419
Needs Assessment and Implementation of a Reproductive Health Intention Screen for Women with Systemic Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 2361
Needs, Experiences and Views of People with Rheumatic and Musculoskeletal Diseases about Self-Management Mobile Health Apps: Results of a Mixed Methods Approach
9:00AM-11:00AM
Abstract Number: 2117
Neuropsychiatric Systemic Lupus Erythematosus Is Attenuated By Sphingosine-1-Phosphate Receptor Modulation
9:00AM-11:00AM
Abstract Number: 2095
Neutralizing CXCL13 Attenuates Neuropsychiatric Disease in Lupus-Prone Mice
9:00AM-11:00AM
Abstract Number: 2116
Neutrophil Extracellular Trap Formation Is Dependent on Disease Activity in Systemic Lupus Erythematosus: Determination Using a Flow Cytometry-Based Assay
9:00AM-11:00AM
Abstract Number: 2775
Neutrophil to Lymphocyte Ratio Predicts Glucocorticoid Resistance in Polymyalgia Rheumatica
9:00AM-11:00AM
Abstract Number: L01
New Cardiovascular Events in Patients with Gout Treated with Xanthine-Oxidase Inhibitors: An Inception Cohort Analysis
9:00AM-11:00AM
Abstract Number: 2407
New Onset of Uveitis in Non-Methotrexate Group, Methotrexate Group and Etanercept Group in Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 2014
Next Generation Sequencing Analysis of Familial Haemophagocytic Lymphohistiocytosis (HLH) Related Genes in Macrophage Activation Syndrome (MAS) and Secondary HLH (sHLH)
9:00AM-11:00AM
Abstract Number: 2459
Nivolumab-Induced Synovial Tissue T Cell Infiltration, Sustained PD1 Occupancy and Resolution of Severe Synovitis with Infliximab Therapy
9:00AM-11:00AM
Abstract Number: 2238
Non-Coding Urate-Associated Variants Function in a Conserved Lincrna Regulatory Domain That Alters MAF transcription
9:00AM-11:00AM
Abstract Number: 2601
Nonsteroidal Anti-Inflammatory Drugs Attenuate Active Inflammatory Sacroiliac Joint Lesions in Patients with Early Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 2626
Normalization of CRP Levels and Clinical Response to Ixekizumab in Patients with Psoriatic Arthritis: Results from the Spirit Studies
9:00AM-11:00AM
Abstract Number: 2627
Not All Clinical Responders in SLE Are Equal: Comparison of Subcutaneous Belimumab + Standard of Care Responders to Placebo + Standard of Care Responders
9:00AM-11:00AM
Abstract Number: 2249
Not Just a Swollen Big Toe: Increasing All-Cause Hospitalizations in Patients with Gout in the United States: 1993–2014
9:00AM-11:00AM
Abstract Number: 2682
Novel Antibody Against Commensal Bacterial Antigen in Prediction of the Response of Rituximab in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2296
Novel Classification of Idiopathic Inflammatory Myopathies Based on Distinctive Features and Autoantibodies: Analysis of 67 Korean Patients
9:00AM-11:00AM
Abstract Number: 2208
Novel Fluorescence Optical Imaging Scoring System of Inflammation in the Hand and Wrist Is in Patients with Rheumatoid Arthritis – Agreement with Ultrasonography and Sensitivity to Change
9:00AM-11:00AM
Abstract Number: 2020
Novel Serum Biomarkers Monitor Disease Progression and Response to Change in Corticosteroid Therapy in Children with Juvenile Dermatomyositis
9:00AM-11:00AM
Abstract Number: 2098
NRF2 Downregulates Inflammation and Protects Against Autoimmune Lung Disease in Experimental Lupus
9:00AM-11:00AM
Abstract Number: 2331
Obesity Might Positively Affect TNF Mediated Bone Metabolism in RA Patients
9:00AM-11:00AM
Abstract Number: 2434
Obstetric Outcomes in Women with Takayasu Arteritis: Results from Nationwide Inpatient Sample Database 2003-2011
9:00AM-11:00AM
Abstract Number: 2267
Ocular and Systemic Features in 262 Patients with Systemic Sarcoidosis and Its Correlation with Iwos Criteria
9:00AM-11:00AM
Abstract Number: 2062
Omentin-1: Potential Biomarker of Cardiovascular Risk in Axial Spondyloarthritis? a Serological and Genetic Study
9:00AM-11:00AM
Abstract Number: 2193
Online Direct-to-Patient Recruitment for Systemic Lupus Erythematosus Results in Rapid Enrollment
9:00AM-11:00AM
Abstract Number: 2737
Opportunistic Infections in Medium and Small-Sized Vessel Vasculitis: Based on a Retrospectivestudy on 108 Patients
9:00AM-11:00AM
Abstract Number: 2315
Opportunistic Screening for Osteoporosis Using Thoraco-Abdomino-Pelvic Computed Tomography Assessing the Vertebral Density in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 2705
Optimized Protocol for Extracorporeal Shock Wave Therapy on Digital Ulcers in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 2017
Oral Microbiota in New-Onset Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 1994
Osteoarthritis Severity Is Reduced By Intra-Articular Administration of Hydrogen Sulfide
9:00AM-11:00AM
Abstract Number: 2335
Osteoporotic Fracture Trends in a Population of US Managed Care Enrollees: 2007-2017
9:00AM-11:00AM
Abstract Number: 2440
Outcomes of Pregnancy Complicated By ANCA-Associated Vasculitis: A Retrospective Review
9:00AM-11:00AM
Abstract Number: 2326
Outcomes One Year after Hip Fracture Repair in the Elderly: Does Social Isolation Matter?
9:00AM-11:00AM
Abstract Number: 2172
Overuse of Glucocorticoids in Rheumatoid Arthritis: A National Survey of Primary Care Physicians
9:00AM-11:00AM
Abstract Number: 2077
Pathological Osteogenesis and Inflammation in Experimental Spondyloarthritis Are Associated with Aberrant Type H Blood Vessels and Development of High Endothelial Venules Accompanied By Ectopic Lymphoid Structures in Bone Marrow
9:00AM-11:00AM
Abstract Number: 2723
Patient Experience in ANCA-Associated Vasculitis Evolves over Time from Diagnosis and Both Benefits and Adverse Impacts Are Felt with Current Therapy
9:00AM-11:00AM
Abstract Number: 2368
Patient Preferences for Disease Modifying Anti-Rheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review
9:00AM-11:00AM
Abstract Number: 2687
Patient-Level Evaluation of Components of the American College of Rheumatology Combined Response Index in Systemic Sclerosis (CRISS) Using Patient-Reported Anchors
9:00AM-11:00AM
Abstract Number: 2549
Patient-Reported Benefits of Sarilumab Monotherapy in Adult Patients with Active Rheumatoid Arthritis: Results from an Open-Label Extension Study
9:00AM-11:00AM
Abstract Number: 2480
Patient-Reported Outcome Measures Used in Rheumatoid Arthritis Cohorts and Registries Around the World: An Environmental Scan from the Outcome Measures in Rheumatology Critical Outcomes in Longitudinal Observational Studies Working Group
9:00AM-11:00AM
Abstract Number: 2651
Patients Characteristics and Patters of Treatment in Refractory Systemic Lupus Erythematosus Patients in the Pre-Biologic Period: Data from a Multiethnic, Multinational Latin American Lupus Cohort
9:00AM-11:00AM
Abstract Number: 2369
Patients Preference Goes to MTX Autoinjectors over Prefilled Syringes: Results from a Phase III Trial
9:00AM-11:00AM
Abstract Number: 2030
Patients with Childhood-Onset SLE (cSLE) and Hypertension Have Consistently Higher Serum Concentrations of C3 and C4 Than Those without Hypertension
9:00AM-11:00AM
Abstract Number: 2492
Pattern Shift and Influential Factors in Promoting Treat-to-Target (T2T) for Follow-up RA Patients with a Rheumatologist-Patient Interactive Smart System of Disease Management (SSDM): A Cohort Study from China
9:00AM-11:00AM
Abstract Number: 2613
Patterns of Medication Use in a Validated Cohort of Psoriatic Arthritis (PsA) Patients
9:00AM-11:00AM
Abstract Number: L04
Pediatric Open-Label Clinical Study of Rituximab for the Treatment of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
9:00AM-11:00AM
Abstract Number: 2360
Perceptions of Patients with Rheumatoid Arthritis about Self-Assessment of Disease Activity after Watching an Educational Video: Qualitative Pilot Results from the Auto-DAS in Middle Eastern Arab Countries Study
9:00AM-11:00AM
Abstract Number: 2356
Perceptions, Incentives, and Barriers to Clinical Trial Participation: Qualitative Evaluation of Lupus Patients, Enriched for Minority Participants
9:00AM-11:00AM
Abstract Number: 2694
Performance of Anti-Scl-70 Antibody Testing By Multiple-Bead, Enzyme-Linked Immunosorbent Assay, and Immunodiffusion in a University Setting
9:00AM-11:00AM
Abstract Number: 2297
Performance of the New EULAR/Acr Classification Criteria for Idiopathic Inflammatory Myopathies (IIM) in a Large Monocentric IIM Cohort
9:00AM-11:00AM
Abstract Number: 2432
Peripartum Issues in the Inflammatory Arthritis (IA) Patient: A Survey of the Rapport (Rheumatoid Arthritis Pharmacovigilence Program and Outcomes Research in New Therapies) Registry
9:00AM-11:00AM
Abstract Number: 2305
Peripheral Arterial Disease Is Associated with an Increased Risk of Subsequent Hip Fracture: A Systematic Review and Meta-Analysis of Cohort Studies
9:00AM-11:00AM
Abstract Number: 2732
Peripheral Neuropathy Is More Common in Microscopic Polyangiitis Than in Granulomatosis with Polyangiitis: Data from a Single Tertiary Referral Center
9:00AM-11:00AM
Abstract Number: 2354
Perspectives of Patients with Inflammatory Arthritis Regarding Cardiovascular Risk: A Qualitative Study
9:00AM-11:00AM
Abstract Number: 2338
Pharmacological and Non-Pharmacological Approaches in a Group of Osteoporotic Patients Referring to a Rehabilitation out-Patient Clinic
9:00AM-11:00AM
Abstract Number: 2383
Pharmacovigilance of Biologics for Non-Systemic Juvenile Idiopathic Arthritis By the German Biologics Registry
9:00AM-11:00AM
Abstract Number: 2550
Phase 3 Equira 48 Week Study Results Demonstrated No Impact on Efficacy and Safety When Patients with Moderate-to-Severe Rheumatoid Arthritis Were Switched between Reference Etanercept (ETN) and GP2015, an Etanercept Biosimilar
9:00AM-11:00AM
Abstract Number: 1963
Phenome Wide Association Study of IL6R Variant Identifies Drug Target for Cardiovascular Disease and Inflammation
9:00AM-11:00AM
Abstract Number: 2710
Physical Activity Trackers Work Well As a Monitor of Physical Activity in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 2370
Physician and Patient Preferences for Treating SLE: Insights into the Choice of Intravenous Infusion and Subcutaneous Injection
9:00AM-11:00AM
Abstract Number: 2479
Pilot Study of Characterizing Rheumatoid Arthritis Related Morning Stiffness
9:00AM-11:00AM
Abstract Number: 2080
Plasmatic Glycoprotein and Lipoprotein Nuclear Magnetic Resonance Profiles Associated with Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1971
PLCG2 Variants Influence CVID Susceptibility: Expanding the Spectrum of PLCG2-Associated Immune Dysregulation
9:00AM-11:00AM
Abstract Number: 2125
Pleiotropy of a Positive Antinuclear Antibody (ANA) Test: A Phewas and GWAS Approach
9:00AM-11:00AM
Abstract Number: 2686
Podocyte Foot Process Width Is a Prediction Marker for Complete Renal Remission at 6 and 12 Months after Induction Therapy in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 2179
Poor Rates of Screening for Retinal Toxicity in Patients on Antimalarial Medications: A Population-Based Study
9:00AM-11:00AM
Abstract Number: 2582
Post-Marketing Safety of Secukinumab in Adult Patients with Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Cumulative Analysis across >96,000 Patient-Treatment Years Exposure
9:00AM-11:00AM
Abstract Number: 2690
Potential Markers of Skin Involvement in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 2129
Precipitating Anti-dsDNA Peptide Repertoires in Lupus
9:00AM-11:00AM
Abstract Number: 2580
Predicting Treatment Persistence and Non-Persistence of Newly Initiated TNF Inhibitor Therapy in Ankylosing Spondylitis Patients: A Gender Comparison
9:00AM-11:00AM
Abstract Number: 2195
Predictive Factors of a Positive PET/CT Scan for Vascular Involvement in Patients with Polymyalgia Rheumatica
9:00AM-11:00AM
Abstract Number: 2572
Predictors for Use of Secukinumab 300mg over 150mg in Psoriatic Arthritis: A Meta-Analysis of Four Phase 3 Trials By Machine Learning
9:00AM-11:00AM
Abstract Number: 2247
Predictors of End-Stage Renal Disease (ESRD) in Gout Patients and General Population (GP) Controls – a Role for Interstitial Nephritis, Urate Nephropathy?
9:00AM-11:00AM
Abstract Number: 2458
Predictors of Hypogammaglobulinemia during Rituximab Maintenance Therapy in Rheumatoid Arthritis: A 12-Year Longitudinal Multi-Center Study
9:00AM-11:00AM
Abstract Number: 2323
Predictors of Mortality in Patients with Hip Fragility Fracture
9:00AM-11:00AM
Abstract Number: 2352
Predictors of Patient and Physician Perceptions of Gout Disease Activity
9:00AM-11:00AM
Abstract Number: 2324
Predictors of Refracture in Patients with Hip Fragility Fracture
9:00AM-11:00AM
Abstract Number: 2499
Predictors of Rheumatoid Arthritis Development in Patients with Early Undifferentiated Arthritis: A 2-Years Follow-up Study
9:00AM-11:00AM
Abstract Number: 2621
Predictors of Survival of Adalimumab Treatment in the Management of Ankylosing Spondylitis and Psoriatic Arthritis in Canadian Routine Care
9:00AM-11:00AM
Abstract Number: 2288
Preexisting Anti-Acetylcholine Receptor Autoantibodies and B Cell Lymphopenia Are Associated with the Development of Myositis in Thymoma Patients Treated with Avelumab, an Immune Checkpoint Inhibitor Targeting Programmed Death-Ligand 1
9:00AM-11:00AM
Abstract Number: 2704
Pregnancy in Systemic Sclerosis (SSc): A Systematic Review and Meta-Analysis
9:00AM-11:00AM
Abstract Number: 2430
Pregnancy in Women with Ankylosing Spondylitis Is Not Associated with Poor Obstetric Outcomes: Analysis of Nationwide Inpatient Sample Database 2003-2011
9:00AM-11:00AM
Abstract Number: 2420
Pregnancy Outcome and Perinatal Complications of Neonate Born to Mothers with Juvenile Idiopathic Arthritis in Asia
9:00AM-11:00AM
Abstract Number: 2435
Pregnancy Outcomes Among Women with Rare Autoimmune Diseases
9:00AM-11:00AM
Abstract Number: 2413
Pregnancy Outcomes in Mixed Connective Tissue Disease: Results from a Multicentre Cohort Study
9:00AM-11:00AM
Abstract Number: 2422
Pregnancy Outcomes in Patients with Interstitial Lung Disease Related to Autoimmune Disease and Sarcoidosis
9:00AM-11:00AM
Abstract Number: 2417
Pregnancy Outcomes in Systemic Lupus Erythematous and Pre-Systemic Lupus Erythematous: A Population-Based Cohort Study
9:00AM-11:00AM
Abstract Number: 2433
Pregnancy Outcomes in Undifferentiated Connective Tissue Disease- a Single Academic Center’s Experience
9:00AM-11:00AM
Abstract Number: 2421
Pregnancy Outcomes in Women with Rheumatic Diseases and Thrombophilia Treated in a Multidisciplinary Unit
9:00AM-11:00AM
Abstract Number: 2348
Prescriber Attitudes and Beliefs about Triple Therapy for Patients with Rheumatoid Arthritis: Knowledge Exchange in Internet Forums and Social Media
9:00AM-11:00AM
Abstract Number: 2257
Prevalence and Distinct Clinical Phenotype of Concomitant Sarcoidosis in Other Autoimmune Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 2148
Prevalence and Incidence of FMF in Germany – Results of the First Retrospective Analysis of Representative Claims Data
9:00AM-11:00AM
Abstract Number: 2163
Prevalence and Incidence of Idiopathic Inflammatory Myopathies in Korea:a Nationwide Population-Based Study over 10 Years
9:00AM-11:00AM
Abstract Number: 2449
Prevalence and Risk Factors of Serious Infections in Rheumatoid Arthritis Patients Receiving the Biologic/Targeted Synthetic Dmards: A Propensity Score Analysis from the Hong Kong Biologics Registry
9:00AM-11:00AM
Abstract Number: 2118
Prevalence of Acquired Activated Protein C Resistance and Anti-Protein C Antibodies in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2649
Prevalence of Cancer in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2727
Prevalence of Clinical and Subclinical Ophthalmologic Manifestations in Association with Systemic Symptoms, Disease Activity and Damage in Patients with Granulomatosis with Polyangiitis
9:00AM-11:00AM
Abstract Number: 2232
Prevalence of Gout in the Surviving U.S. Solid Organ Transplant Population
9:00AM-11:00AM
Abstract Number: 2131
Prevalence of Systemic Lupus Erythematosus (SLE) and Associated Comorbidities in the 2011-2015 Medicare Population
9:00AM-11:00AM
Abstract Number: 2237
Prevalence of Urate-Lowering Therapy Use and Target Urate Level Achievement Among Gout Patients in the United States (National Health And Nutrition Examination Survey [NHANES] 2007-2014)
9:00AM-11:00AM
Abstract Number: 2137
Primary Antiphospholipid Syndrome with Vascular Manifestations Is a Rare Disease: A Population-Based, Multi-Source Study Assessing the Prevalence and Incidence in Adults
9:00AM-11:00AM
Abstract Number: 2570
Probability of Achieving Low Disease Activity or Remission in Subjects with Active Psa Treated with Apremilast
9:00AM-11:00AM
Abstract Number: 2186
Process Evaluation of a Culturally-Sensitive, Community Based Self-Management Program for First Nations People with Arthritis and Their Families
9:00AM-11:00AM
Abstract Number: 2695
Progressive Skin Fibrosis, Internal Organ Involvement and All-Cause Mortality in an Early Diffuse Cutaneous Systemic Sclerosis United States Multicenter Registry
9:00AM-11:00AM
Abstract Number: 2466
Prolonged Delay in Presentation to Rheumatologists for Hispanic Patients with Rheumatoid Arthritis Contributes to Later Diagnosis and Treatment
9:00AM-11:00AM
Abstract Number: 2617
Prolonged Effectiveness of a 12 Week Regimen of Biosimilar Adalimumab in Indian (Asian) Patients Suffering from Symptomatic Acute-Chronic Ankylosing Spondylitis (AS)
9:00AM-11:00AM
Abstract Number: 2475
Promis Pain Interference 6b and Fatigue 7a Short Forms and Profile-29 in Rheumatoid Arthritis Patients Treated with TNF Inhibitors
9:00AM-11:00AM
Abstract Number: 2481
Proposal to Re-Evaluate the Definition of Low Disease Activity in Routine Assesment of Patient Index Data 3 (RAPID3) in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 2450
Prosthetic Joint Infection in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2223
Proton Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition (CPPD) in a Population-Based Study
9:00AM-11:00AM
Abstract Number: 2178
Provider Perceptions of Telerheumatology within the Veterans Health Administration: A National Survey Study
9:00AM-11:00AM
Abstract Number: 2404
Quality of Life Assessment in Juvenile Idiopathic Arthritis: A Single Center Assessment
9:00AM-11:00AM
Abstract Number: 2538
Rapamycin Induces Remission in Patients with Newly Diagnosed Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2561
Rapid and Sustained Improvements in Patient-Reported Signs and Symptoms with Ixekizumab in Biologic-Naive and TNF-Inadequate Responder Patients with Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 2523
Rapid Response with Upadacitinib Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Csdmards or Bdmards
9:00AM-11:00AM
Abstract Number: 2467
RAPID3 Is Elevated in 93% of Treatment-Naïve Rheumatoid Arthritis (RA) Patients at Initial Visit Compared to 49% for Erythrocyte Sedimentation Rate (ESR) and 44% for C-Reactive Protein (CRP)
9:00AM-11:00AM
Abstract Number: 2632
Rates and Predictors of Thirty-Day Readmission Among Patients Hospitalized for Systemic Lupus Erythematosus at a Single Tertiary Care Center
9:00AM-11:00AM
Abstract Number: 2314
Ratio of BMI to BMD at Different Sites and Association with Fragility Fractures
9:00AM-11:00AM
Abstract Number: 2357
Reactions to Online Testimonials: A Cluster Analysis of Risk Perception and Decision Making
9:00AM-11:00AM
Abstract Number: 2490
Real World Evidence Describing Infliximab Utilization Patterns in Rheumatoid Arthritis Patients in Community Rheumatology Practices in the United States: Implications for Cost Efficiencies?
9:00AM-11:00AM
Abstract Number: 2658
Real World Medication Use in Incident Systemic Lupus Erythematosus and Lupus Nephritis Patients
9:00AM-11:00AM
Abstract Number: 2138
Real-World Evaluation of Treatment Patterns of Methotrexate Users in Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 2596
Real-World Long-Term Effectiveness of Switching between Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register
9:00AM-11:00AM
Abstract Number: 2486
Real-World Outcomes Associated with Triple Therapy Vs. TNFi Combo Therapy: Results from the Corrona Registry
9:00AM-11:00AM
Abstract Number: 2382
Real-World Safety and Effectiveness of Adalimumab in Patients with Juvenile Idiopathic Arthritis: Results from a Post-Marketing Surveillance in Japan
9:00AM-11:00AM
Abstract Number: 2591
Real-World Use of Secukinumab in Axial Spondyloarthritis: First Year Data from the Czech National Registry
9:00AM-11:00AM
Abstract Number: 2592
Real-World Use of Secukinumab in Psoriatic Arthritis: First Year Data from the Czech National Registry
9:00AM-11:00AM
Abstract Number: 2463
Reducing Time to Treatment in Patients with Early and Uncontrolled RA: Implementation of a Collaborative and Systems-Based Approach to Improve Access to Care
9:00AM-11:00AM
Abstract Number: 2396
Reduction in the Utilization of Prednisone and/or Methotrexate Following the Initiation of Etanercept in Pediatric Patients
9:00AM-11:00AM
Abstract Number: 2274
Refractory and Severe Uveitic Cystoid Macular Edema Improves with Tocilizumab in Different Immune Mediated Diseases
9:00AM-11:00AM
Abstract Number: 2188
Regional Analysis of Impact of Participation in a Patient Support Program on Clinical Outcomes Among Patients with Rheumatoid Arthritis Receiving Adalimumab (Humira)
9:00AM-11:00AM
Abstract Number: 2622
Regional and Temporal Variation in the Baseline Profile of Ankylosing Spondylitis Patients Initiating Adalimumab Following Failure of Non-Biologic Treatment in Canadian Routine Care
9:00AM-11:00AM
Abstract Number: 1984
Regulation of Multiple Differentiation Potential in Mesenchymal Stem Cells Via an Intercellular Ca2+ Signaling Pathway
9:00AM-11:00AM
Abstract Number: 2648
Relationship between Damage and Mortality in Juvenile-Onset Systemic Lupus Erythematosus: Cluster Analyses in a Large Cohort from the Spanish Society of Rheumatology Lupus Registry
9:00AM-11:00AM
Abstract Number: 2170
Relationship between Short- and Long-Term Periods of Self-Reported Physical Activity Patterns in Individuals with SLE
9:00AM-11:00AM
Abstract Number: 2494
Relationship between Specific Joint Involvement and Work/Activity Impairment in Rheumatoid Arthritis Patients: Implications for Clinical Practice
9:00AM-11:00AM
Abstract Number: 2698
Renal Involvement in Mixed Connective Tissue Disease: A Single Center Experience
9:00AM-11:00AM
Abstract Number: 2700
Rescuing Standard Analyses of Immunosuppresive Rescue Therapy in Randomized Controlled Trials: Alternative Approaches in a Scleroderma Clinical Trial
9:00AM-11:00AM
Abstract Number: 1972
Resolving the Synovial Fluid Proteome and Peptidome for Disease-Specific Mediators of Inflammatory Arthritis
9:00AM-11:00AM
Abstract Number: 2085
Response Gene to Complement-32 Promotes Kidney Damage in Immune Complex –Mediated Glomerulonephritis
9:00AM-11:00AM
Abstract Number: 2303
Response Rates for Hip, Femoral Neck, and Lumbar Spine Bone Mineral Density in Patients Treated with Abaloparatide Followed By Alendronate
9:00AM-11:00AM
Abstract Number: 2387
Resurrecting Triamcinolone Hexacetonide (the Steroid Formerly Known as Aristospan®): Efficacy and Safety of a Compounded Preparation of Triamcinolone Hexacetonide for Intra-Articular Injection in Children with Arthritis
9:00AM-11:00AM
Abstract Number: 2543
Retention Rate and Safety Data of Biosimilar CT-P13 in Patients with Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
9:00AM-11:00AM
Abstract Number: 2139
Retrospective Study: Association of Hydroxychloroquine Use and Hemolytic Anemia in Patients with Low Levels of Glucose-6-Phosphate Dehydrogenase (G6PD)
9:00AM-11:00AM
Abstract Number: 2526
Revealing and Addressing Knowledge Gaps Regarding Biosimilars in Rheumatology Practice with Targeted Continuing Education and Patient Surveys
9:00AM-11:00AM
Abstract Number: 2256
Rheumatic Diseases Associated with Neuromyelitis Optica Spectrum Disorders (NMOSD): Prevalence, Clinical, Laboratory and Imaging Characteristics
9:00AM-11:00AM
Abstract Number: 2332
Rheumatoid Arthritis Effect´s on Bone Mass and Muscle
9:00AM-11:00AM
Abstract Number: 2551
Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study
9:00AM-11:00AM
Abstract Number: 1979
Rheumatoid Arthritis-Associated Genetic Alteration Defines a New Promoter for Peptydil Arginine Deiminase 4 Gene
9:00AM-11:00AM
Abstract Number: 2051
Rheumatoid Factor Peptide Expression By Quantitative Proteomics Delineates Responsive and Resistant Clones after Treatment of Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2438
Risk and Severity of Adverse Pregnancy Outcomes in Women with Systemic Sclerosis in Taiwan
9:00AM-11:00AM
Abstract Number: 2358
Risk Factors for Persistent Discordance in Global Assessment of Rheumatoid Arthritis (RA) Disease Activity between RA Patients and Their Physicians: Analysis Based on a Nationwide RA Database (2011 to 2016)
9:00AM-11:00AM
Abstract Number: 2276
Risk of Hemorrhagic Strokes in Patients with Adenosine Deaminase 2 Deficiency
9:00AM-11:00AM
Abstract Number: 2456
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients in Truven Marketscan Data (Jan 2010–Sept 2015) Treated with Biologic or Conventional Dmards
9:00AM-11:00AM
Abstract Number: 2455
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Biologic and Non-Biologic Dmards
9:00AM-11:00AM
Abstract Number: 2742
Rituximab Versus Cyclophosphamide for Vasculitic Neuropathy: A Patient Reported Outcomes Study
9:00AM-11:00AM
Abstract Number: 2073
Role of miRNA-21-5p As a Potential Biomarker for the Inflammation Pathway in Psoriatic Disease and Response to Methotrexate Treatment
9:00AM-11:00AM
Abstract Number: L06
Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards
9:00AM-11:00AM
Abstract Number: 2284
Safety and Efficacy of Lenabasum in Refractory Skin-Predominant Dermatomyositis Subjects Treated on an Open-Label Extension of Trial JBT101-DM-001
9:00AM-11:00AM
Abstract Number: 2565
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
9:00AM-11:00AM
Abstract Number: 2191
Safety of Ultrasound-Guided Injections Using Local Puncture Site Sterility
9:00AM-11:00AM
Abstract Number: 2219
Safety, Pharmacokinetics and Pharmacodynamics of NC-2500, a Novel Xanthine Oxidoreductase Inhibitor, in Healthy Volunteers
9:00AM-11:00AM
Abstract Number: 2535
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CKD-506, a Novel, Histone Deacetylase 6 (HDAC6) Inhibitor, in Healthy Volunteers
9:00AM-11:00AM
Abstract Number: 2539
SB4 Shows Comparable Short-Term Effectiveness to Its Etanercept Originator As First-Line Biologic Treatment for Patients with Rheumatoid Arthritis in Routine Clinical Care
9:00AM-11:00AM
Abstract Number: 2707
Scleroderma Renal Crisis: The Association of High-Dose Steroids and Poor Outcome
9:00AM-11:00AM
Abstract Number: 2766
Seasonal Variation in Incidence of Giant Cell Arteritis: A Population-Based Cohort Study
9:00AM-11:00AM
Abstract Number: 2168
Seasonal Variation in Incidence of Polymyalgia Rheumatica: A Population-Based
9:00AM-11:00AM
Abstract Number: 2556
Secukinumab 150mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with Consistent Safety Profile and High Retention Rate: 4-Year Results from a Phase III Trial
9:00AM-11:00AM
Abstract Number: 2564
Secukinumab Efficacy in Psoriatic Arthritis: Individual Patient Meta-Analysis of Four Phase 3 Trials in 2049 Patients
9:00AM-11:00AM
Abstract Number: 2585
Secukinumab Immunogenicity in Patients with Psoriatic Arthritis and Ankylosing Spondylitis during a 52-Week Treatment Period
9:00AM-11:00AM
Abstract Number: 2562
Secukinumab Improves Grappa-Omeract Core Domains of Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 2386
Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment
9:00AM-11:00AM
Abstract Number: 2583
Secukinumab Provides Early and Sustained Improvements in Health-Related Quality of Life in Patients with Ankylosing Spondylitis: A Pooled Analysis from the Secukinumab Phase 3 Trial Program
9:00AM-11:00AM
Abstract Number: 2553
Secukinumab Provides Early and Sustained Improvements in Health-Related Quality of Life in Patients with Psoriatic Arthritis: Pooled Results from the Secukinumab Phase 3 Trial Program
9:00AM-11:00AM
Abstract Number: 2568
Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial
9:00AM-11:00AM
Abstract Number: 2608
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study
9:00AM-11:00AM
Abstract Number: 2683
Selective Expansion and Targeting of FoxP3+CD127lo Regulatory T Cells By Low-Dose IL-2 Therapy in Active SLE
9:00AM-11:00AM
Abstract Number: 2174
Self-Report of Fracture History Compared to Fracture Codes from an Electronic Health Record Dataset
9:00AM-11:00AM
Abstract Number: 1976
Sequencing of the MHC Region Defines HLA-DQA1 As Driven Risk for Anti-Citrullinated Protein Antibodies (ACPA)-Positive Rheumatoid Arthritis in Han Population
9:00AM-11:00AM
Abstract Number: 2266
Serum 1,25(OH)2 Vitamin D and 25(OH) Vitamin D Ratio for the Diagnosis of Sarcoidosis-Related Uveitis
9:00AM-11:00AM
Abstract Number: 2121
Serum High Type I Interferon Is Associated with Active Proliferative Lupus Nephritis in Lupus Patients Accompanied with High Interferon Signature Gene Expression and Plasmacytoid Dendritic Cell Infiltration in Lupus Nephritis Kidney
9:00AM-11:00AM
Abstract Number: 2066
Serum IL-37 Is an Efficient Biomarker of Disease Activity and Treatment Response in Patients with Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 2046
Serum Immunoglobulin G Targets Citrulline-Containing Immunoglobulin G Peptides in Rheumatoid Arthritis Patients Who Test Positive for Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies
9:00AM-11:00AM
Abstract Number: 2041
Serum Level of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1): A New Biomarker of Disease Activity in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2252
Serum Urate Ant Its Clearance in Patients with Chronic Kidney Disease Under Peritoneal Dialysis
9:00AM-11:00AM
Abstract Number: 2230
Serum Urate Levels in People with Gout on Dialysis – Are We Achieving Treatment Targets?
9:00AM-11:00AM
Abstract Number: 2672
Serum Vitamin D Levels and Its Effect on Disease Activity and Fatigue in Systemic Lupus Erythematosus Patients
9:00AM-11:00AM
Abstract Number: 2726
Severe Infections in Systemic Necrotizing Vasculitis: Incidence and Risk Factors
9:00AM-11:00AM
Abstract Number: 2243
Sex Difference of the Association between Serum Urate and Blood Pressure in Young Adults
9:00AM-11:00AM
Abstract Number: 2495
Sex Differences in the Achievement of Remission in Rheumatoid Arthritis – Choice of Disease Activity Measure Matters
9:00AM-11:00AM
Abstract Number: 2325
Sex Differences in the Association of Frailty and Bone Mineral Density in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2365
Sex, Language and Age of Disease Onset Impact Illness Perceptions Among RA Patients
9:00AM-11:00AM
Abstract Number: 2714
Significance of Anti-Neutrophil Cytoplasmic Antibodies in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 2593
Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis : Results from a Randomized, Double-Blind, Phase III Study
9:00AM-11:00AM
Abstract Number: 2676
SLE Patients with No Organ Damage Might Benefit More from Belimumab Treatment
9:00AM-11:00AM
Abstract Number: 2655
SLE-Key® Ruleout Testing in Support of Patient Triage in the Clinical Rheumatology Setting
9:00AM-11:00AM
Abstract Number: 2667
Sledai and Mex-Sledai Glucocorticoid Indices As Predictors of Damage and Mortality in Multinational Multiethnic Latin American Cohort
9:00AM-11:00AM
Abstract Number: 2643
Sledai-2K Responder Index-50 Is Effective in Demonstrating Partial Response in a Phase 2, Randomized Placebo-Controlled Study of Ustekinumab in Patients with Active Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2156
Smoking Status Predicts Earlier SLICC Damage Index Progression in a Large SLE Cohort
9:00AM-11:00AM
Abstract Number: 2372
Social Media Use for Health-Related Purposes By People with Rheumatic and Musculoskeletal Diseases – Results of a Global Survey
9:00AM-11:00AM
Abstract Number: 2505
Sociodemographic Factors Are Predictors of Poorer Clinical Outcome Trajectories in Early Rheumatoid Arthritis: Results from the Singapore Early Arthritis Cohort
9:00AM-11:00AM
Abstract Number: 2376
Something for Us: Client Perspectives on Lupus Self-Management Programming Using the 5-a Behavior Change Model
9:00AM-11:00AM
Abstract Number: 2187
Specialist Link Telephone Advice Cost Effectively Enhances Rheumatology Patient Care in Alberta, Canada
9:00AM-11:00AM
Abstract Number: 2045
Specific Anti-Citrullinated Protein Antibodies Profiles Are Associated with Rheumatoid Arthritis Related Interstitial Lung Disease
9:00AM-11:00AM
Abstract Number: 2312
Spontaneous Vertebral Fractures after Denosumab Discontinuation
9:00AM-11:00AM
Abstract Number: 1959
Stability of DNA Methylation Signature in Primary RA Synovial Fibroblasts Compared with Cultured Fibroblast-like Synoviocytes
9:00AM-11:00AM
Abstract Number: 2453
Staphylococcus Aureus Carriage Rates Are High in Rheumatoid Arthritis Patients on Biologics
9:00AM-11:00AM
Abstract Number: 2126
STAT4 Activation By Type I Interferons Regulates Pathogenic IL-21 and IFN-γ in Lupus
9:00AM-11:00AM
Abstract Number: 2197
Steroid Bolus Leads to a Negative 18f-FDG PET/CT Scan in Large Vessel Vasculitis. Data from a Multicenter Giant Cell Arteritis Cohort Database
9:00AM-11:00AM
Abstract Number: 2460
Study of Sixteen Cases of Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders Developed in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: L02
Study of Tofacitinib in Refractory Dermatomyositis (STIR): An Open Label Pilot Study in Refractory Dermatomyositis
9:00AM-11:00AM
Abstract Number: 2378
Subcutaneous Abatacept in Patients Aged 2–17 Years with Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months By Juvenile Idiopathic Arthritis Disease Category
9:00AM-11:00AM
Abstract Number: 2293
Subcutaneous Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Analysis of a Monocentric Cohort
9:00AM-11:00AM
Abstract Number: 2299
Subgroup Analysis of the Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 24 Months in Glucocorticoid-Treated Individuals
9:00AM-11:00AM
Abstract Number: 2038
Subgroups By the Peripheral Immunophenotyping and Different Responses to Biological Dmards in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2609
Survival of Disease-Modifying Drugs in Patients with Recent Diagnosis of Psoriatic Arthritis in Daily Clinical Practice
9:00AM-11:00AM
Abstract Number: 2533
Switching Patients with Arthritis from Etanercept (Enbrel) to the Biosimilar Drug, Benepali: A Single- Center Retrospective Observational Study
9:00AM-11:00AM
Abstract Number: 2047
Synovial Fluid Cytokines /Chemokines and Proteins from the Knees of Symptomatic RA and OA Patients Which Correlate with the Magnitude of the Inflammatory Response As Measured By Synovial Fluid WBC Levels
9:00AM-11:00AM
Abstract Number: 2221
Systematic Genetic Analysis of Early-Onset Gout: ABCG2 141K Is the Strongest Predictor
9:00AM-11:00AM
Abstract Number: 2345
Systematic Review of Patient Decision Aids for Chronic Musculoskeletal Pain
9:00AM-11:00AM
Abstract Number: 2359
Systemic Lupus Erythematous Outcome Concerns: Identifying Pain As the Major Discrepancy between Rheumatologists and Patients
9:00AM-11:00AM
Abstract Number: 2739
Systemic Vasculitis: Incidence of Glucocorticoid Related Adverse Events
9:00AM-11:00AM
Abstract Number: 2638
Tacrolimus Use in Hispanic Patients with Refractory Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 2574
Tapering TNF Inhibitors in Axial Spondyloarthritis: Systematicanalysisoftheliteratureandmeta-Analysis
9:00AM-11:00AM
Abstract Number: 2084
Targeting the Voltage-Gated K+ Channels: T Cell Targeted Therapies for Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 2211
Technetium Tc 99m Tilmanocept: A Targeted Immunodiagnostic Radiopharmaceutical for the Assessment of Synovial Macrophage Activity in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2169
Temporal Trends in Mortality in Patients Hospitalized for Cerebrovascular Events with Psoriatic Arthritis: Data from the Healthcare Cost and Utilization Project from 2010-2014
9:00AM-11:00AM
Abstract Number: 2239
Tenocytes Extracted from Rotator Cuff Tendons Are Able to Induce Mineral Deposition in Vitro and Express Genes Related to a Chondrocyte Differentiation
9:00AM-11:00AM
Abstract Number: 2021
Th22 Cells in Peripheral Blood and Synovial Fluid of Patients with Enthesitis Related Arthritis
9:00AM-11:00AM
Abstract Number: 2599
The Agreement between TNFi Treatment Responses and Fatigue Responses Is Weak to Moderate Suggesting Heterogeneity between Experienced Fatigue and Joint Inflammation: A Danish Population-Based Cohort Study
9:00AM-11:00AM
Abstract Number: 2546
The Association between Patient Reported Outcomes and Clinical Measures Among Rheumatoid Arthritis Patients: Analyses Using Phase 3 Clinical Trials of Upadacitinib
9:00AM-11:00AM
Abstract Number: 2306
The Association of Dietary Amino Acids with Incident Hip Fracture, BMD and Body Composition. the Cardiovascular Health Study
9:00AM-11:00AM
Abstract Number: 2176
The Association of Gout with Incident Giant Cell Arteritis in Older Adults
9:00AM-11:00AM
Abstract Number: 2498
The Association of Vitamin D with the Lipid Profile in Rheumatoid Arthritis: An Interplay Among Genetic Polymorphisms, DHCR7 Levels and Seasonality
9:00AM-11:00AM
Abstract Number: 2385
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Updated Report of Baseline Patient Characteristics and Treatment Choices
9:00AM-11:00AM
Abstract Number: 2016
The Chromatin Landscape Around the Juvenile Arthritis-Associated CXCR4 Locus Suggests Regulatory Functions and Genetic Roles in Both Innate and Adaptive Immunity
9:00AM-11:00AM
Abstract Number: 2446
The Combined Use of Folic Acid Influenced the Time until the Development of Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis during Treatment with Methotrexate
9:00AM-11:00AM
Abstract Number: 2089
The Differential Impact of the Abrogation of the Costimulatory Molecule CD137 Ligand on Renal and Cerebral Manifestations in C57BL/6.Faslpr-/- mice
9:00AM-11:00AM
Abstract Number: 1992
The Effect of 4E-BP1 on Osteoarthritis-Related Gene Expression in TGF-β1-Stimulated Chondrocytes
9:00AM-11:00AM
Abstract Number: 2734
The Effect of Age at Diagnosis on Mortality in ANCA-Associated Vasculitides
9:00AM-11:00AM
Abstract Number: 2715
The Effect of an Intensive Controlled 6-Moth Physical-Occupational Therapy Program with Subsequent 6-Month Follow-up Period in Patients with Systemic Sclerosis – Preliminary Data
9:00AM-11:00AM
Abstract Number: 2445
The Effect of Biologic Agents on Hemoglobin Levels of Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2597
The Effect of Biologic Disease-Modifying Antirheumatic Drugs in Patient Reported Outcomes in Axial Spondyloarthritis; A Systematic Literature Review and a Call for Action
9:00AM-11:00AM
Abstract Number: 2573
The Effect of Biologic Disease-Modifying Antirheumatic Drugs in Targeting Disease Remission in Axial Spondyloarthritis: A Systematic Literature Review
9:00AM-11:00AM
Abstract Number: 2770
The Effect of Metabolic Syndrome on Giant Cell Arteritis Treatment
9:00AM-11:00AM
Abstract Number: 2128
The Effect of miRNA-21 Overexpression on the Aberrant T Follicular Helper Cells Differentiation in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2614
The Effect of Secukinumab on the Immunogenicity of Influenza Vaccine in Patients with Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 2616
The Effect of Smoking on Response to Tumor Necrosis Factor-Alpha Inhibitor Treatment in Ankylosing Spondylitis Patients: Results from the Turkbio Registry
9:00AM-11:00AM
Abstract Number: 2615
The Effect of Smoking on Response to Tumour Necrosis Factor-Alpha Inhibitor Treatment in Psoriatic Arthritis Patients: Results from the Turkbio Registry
9:00AM-11:00AM
Abstract Number: 2153
The Effect of Socioeconomic Status on Treatment Outcomes in Lupus Nephritis: Private Versus Public Insurance
9:00AM-11:00AM
Abstract Number: 2401
The Effects of a Gluten-Free Diet in Juvenile Idiopathic Arthritis – a Pilot Study
9:00AM-11:00AM
Abstract Number: 2532
The Efficacy and Drug Survival of the Biosimilar Infliximab (CT–P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results from the Turkbio Registry
9:00AM-11:00AM
Abstract Number: 2313
The Efficacy of Denosumab for Prevention of Osteoporotic Fractures in Patients with Connective Tissue Diseases Receiving Very High Doses of Glucocorticoid
9:00AM-11:00AM
Abstract Number: 2069
The Epigenetic Regulator Sirtuin-1 Modulates T-Helper 17 Cell Differentiation in Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 2414
The Global Antiphospholipid Syndrome Score in Women with Systemic Lupus Erythematosus and Adverse Pregnancy Outcomes
9:00AM-11:00AM
Abstract Number: 2397
The Impact of Adalimumab on Growth in Patients with Pediatric Enthesitis-Related Arthritis
9:00AM-11:00AM
Abstract Number: 2425
The Impact of Biologic Treatment for Rheumatoid Arthritis Patients Who Hope to Conceive
9:00AM-11:00AM
Abstract Number: 2340
The Impact of Chronic Glucocorticoid Use Amongst Patients with Rheumatoid Arthritis: A Qualitative Study
9:00AM-11:00AM
Abstract Number: 2436
The Impact of Different Classes of Lupus Nephritis on Maternal and Fetal Outcomes
9:00AM-11:00AM
Abstract Number: 2472
The Impact of Disease Activity and Patient Reported Outcomes on Grip Force over Time in Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2470
The Impact of Frailty on Changes in Physical Function Among Adults with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2645
The Impact of Metformin on Disease Activity in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2151
The Impact of Obesity on SLE Disease Activity
9:00AM-11:00AM
Abstract Number: 2548
The Impact of Rheumatoid Arthritis on Patient-Reported Outcomes: Comparison between Sarilumab Clinical Trials and Real-World Patient Data
9:00AM-11:00AM
Abstract Number: 2587
The Impact of Tumor Necrosis Factor Inhibitors on Diabetes Mellitus Among Patients with Inflammatory Arthritis
9:00AM-11:00AM
Abstract Number: 2517
The JAK1-Selective Inhibitor Filgotinib Reverses the Disease-Associated Transcriptional Profile Found in the Blood of Patients with Active Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2506
The Joint Disease Burden in Patients with Secondary Sjögren’s Syndrome and RA Compared to Patients with RA Only
9:00AM-11:00AM
Abstract Number: 2012
The Novel G58V Mutation in the TNFRSF1A Gene Identified in a Family with Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS) Decreases the Cell Surface Expression of TNFR1
9:00AM-11:00AM
Abstract Number: 2411
The Ovarian Reserve Measuring the Anti-Müllerian Hormone Is Not Diminished in Patients with Rheumatoid Arthritis Compared to the Healthy Population
9:00AM-11:00AM
Abstract Number: 2339
The Patient’s Perspective of Glucocorticoid Use: A Systematic Literature Review of Quantitative and Qualitative Studies
9:00AM-11:00AM
Abstract Number: 2292
The Predictive Risk Factors for Opportunistic Infection during Immunosuppressive Therapy for Polymyositis/Dermatomyositis
9:00AM-11:00AM
Abstract Number: 2162
The Prevalence, Incidence, and Determinants of Depression and Anxiety in Less Common Systemic Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis
9:00AM-11:00AM
Abstract Number: 2473
The Relation between Inflammatory Joint Activity and Disability Related to the Lower Extremities in Early Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2497
The Relationship between Difficulty Affording Arthritis Medications and Illness Intrusiveness in Rheumatoid Arthritis Patients: A Longitudinal Study
9:00AM-11:00AM
Abstract Number: 2202
The Relationship between Periodontitis and the Treatment Response to Biologics in Rheumatoid Arthritis Patients; A Post-Hoc Analysis Using [18F] Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography
9:00AM-11:00AM
Abstract Number: 2634
The Risk of Hydroxychloroquine Retinopathy in an SLE Cohort: Screening and Prevention in Clinical Practice
9:00AM-11:00AM
Abstract Number: 2444
The Risk of Solid Cancers in Patients with Rheumatoid Arthritis Exposed to Biologic Dmards with/without Prior Cancers
9:00AM-11:00AM
Abstract Number: 2068
The Role of Extracellular Matrix Metalloproteinase Inducer Emmprin in the Pathogenesis of Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 2380
The Safety Profile of Adalimumab across Geographic Regions and Dosing Administrations Among Patients with Juvenile Idiopathic Arthritis Enrolled in a Registry
9:00AM-11:00AM
Abstract Number: 2403
The Therapeutic Alliance Is Associated with a Better Therapeutic Adherence in Children with Juvenile Idiopathic Arthritis: Results of a French Multicenter Study
9:00AM-11:00AM
Abstract Number: 2620
The Treatment Choices and Response for a Psoriatic Arthritis Inception Cohort
9:00AM-11:00AM
Abstract Number: 2165
The Trend of Utilization of Therapeutic Plasmapheresis Among Select Rheumatologic Diseases
9:00AM-11:00AM
Abstract Number: 2482
The Use of Any Conventional Synthetic DMARD Is Associated with Better Indexes of the Physical Component Evaluated By 12-Item Short-Form Health Survey : Analysis of a Cohort of RA Patients
9:00AM-11:00AM
Abstract Number: 2279
Therapeutic Value of Canakinumab in Patients with Yao Syndrome
9:00AM-11:00AM
Abstract Number: 2765
Thyroid Artery Involvement Detected By Colour-Doppler Ultrasonography in an Incipient, Single Centre Giant Cell Arteritis Cohort
9:00AM-11:00AM
Abstract Number: 2625
TNF Inhibitor Reduces ASDAS Faster and More Stable in Ankylosing Spondylitis Patients: Results from a Real World Prospective Cohort Managed By Smart Phone System
9:00AM-11:00AM
Abstract Number: 2327
To Screen or Not to Screen?Dexa Ordering Patterns in SLE Patients Who Take Systemic Glucocorticoids
9:00AM-11:00AM
Abstract Number: 2752
Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 134 Patients of Clinical Practice
9:00AM-11:00AM
Abstract Number: 2758
Tocilizumab Interruption in Patients with Giant Cell Arteritis Achieving the Clinical Remission: Interim Analysis of an Open-Label, 18-Month, Pilot Study
9:00AM-11:00AM
Abstract Number: 2746
Tocilizumab Monotherapy for Large Vessel Vasculitis: Results of 104-Week Treatment of a Prospective, Single-Center, Open Study
9:00AM-11:00AM
Abstract Number: L14
Top-Line Results of a Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of a Reversible B Cell Inhibitor, XmAb®5871, in Systemic Lupus Erythematosus (SLE)
9:00AM-11:00AM
Abstract Number: 2100
Topical Endocannabinoid Administration Protects MRL-Lpr/Lpr Mice from Cutaneous Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2719
Tracking the Risk of Infections in ANCA-Associated Vasculitis: Results from a Scottish Matched-Cohort Study
9:00AM-11:00AM
Abstract Number: 1977
Transcriptional Perturbation of RA-Risk Enhancer By CRISPR-DEADCAS9 Regulates LONG Range GENE Targets
9:00AM-11:00AM
Abstract Number: 1966
Transcriptome and Methylome Integrative Molecular Analysis Uncovers a New Systemic Autoimmune Disease Classification
9:00AM-11:00AM
Abstract Number: 2280
Transcriptomic Analysis of Hidradenitis Suppurativa Skin Demonstrates Dysregulation of Antimicrobial Proteins and Inflammatory Pathways
9:00AM-11:00AM
Abstract Number: 2076
Transmembrane TNF (tmTNF) Transgenic Mice Exhibit Enlarged Lymph Nodes and Elevated Numbers of High Endothelial Cells Associated with Increased Lymphocyte Recruitment
9:00AM-11:00AM
Abstract Number: 2491
Treat-to-Target (T2T) Is Not Enough: Identify Factors Leading to a Mismatch between T2T and HAQ Among RA Patients through Data Mining from Smart System of Disease Management (SSDM)
9:00AM-11:00AM
Abstract Number: 2281
Treatment Choices and Response Rates of SAPHO Syndrome: Single Center Case Series
9:00AM-11:00AM
Abstract Number: 2512
Treatment Continuation on the Etanercept Original in Comparison with a Biosimilar
9:00AM-11:00AM
Abstract Number: 2344
Treatment Modes in Rheumatoid Arthritis: Moving Toward Shared Decision-Making
9:00AM-11:00AM
Abstract Number: 2270
Treatment of Refractory Cystoid Macular Edema to Conventional Immunosuppressive Therapy: Tocilizumab Vs Anti-TNF-Alpha. Multicenter Study of 59 Patients
9:00AM-11:00AM
Abstract Number: 2166
Treatment of Venous Thrombotic Events in Behçet Disease: A Systematic Literature Review
9:00AM-11:00AM
Abstract Number: 2665
Treatment Trends of Systemic Lupus Erythematosus during Early-Years of the Disease
9:00AM-11:00AM
Abstract Number: 2774
Treatment with Methotrexate and Risk of Ischemic Relapses in Patients with Giant Cell Arteritis in Clinical Practice
9:00AM-11:00AM
Abstract Number: L05
Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Reversible Abnormalities of Vascular Function on Cardiac MRI with RA Therapy with Preliminary Suggestion of Greater Improvement with Anti-TNF Compared to MTX/Conventional Therapy – a First, RCT Derived Longitudinal Study
9:00AM-11:00AM
Abstract Number: 2301
Trend of Osteoporosis and Osteoporotic Fragility Fractures Among Select Autoimmune Rheumatologic Diseases: Results from National Inpatient Sample
9:00AM-11:00AM
Abstract Number: 2443
Trends in the Incidence of Lymphomas and Leukemias in Patients with Rheumatoid Arthritis in Spain: An Observational Cohort Study of Hospital Discharges from 1999 to 2015
9:00AM-11:00AM
Abstract Number: 2666
Trends in Treatment of Systemic Lupus Erythematosus and Lupus Nephritis: 2006-2016
9:00AM-11:00AM
Abstract Number: 2395
Tumor Necrosis Factor-α Inhibitor (TNFi)-Induced Psoriasis: Prevalence and Response to Therapy in Patients with Juvenile Idiopathic Arthritis (JIA) in Two Children’s Hospitals
9:00AM-11:00AM
Abstract Number: 2684
Type I IFN, TLR7, MHC Class I, B Cell and OX40 Pathways Suppressed By Anifrolumab (anti-type I IFN receptor) in Moderate to Severe SLE Patients
9:00AM-11:00AM
Abstract Number: 2530
Uncovering Clinicians’ Gaps and Attitudes Toward Biosimilars: Impact of a 2-Phase Educational Program
9:00AM-11:00AM
Abstract Number: 2362
Understanding Patients’ Perceptions of Gout
9:00AM-11:00AM
Abstract Number: 2547
Upadacitinib Monotherapy Improves Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate
9:00AM-11:00AM
Abstract Number: 2254
Update of SEL-212 Phase 2 Clinical Data in Symptomatic Gout Patients: Svp-Rapamycin Combined with Pegadricase Mitigates Immunogenicity and Enables Sustained Reduction of Serum Uric Acid Levels, Low Rate of Gout Flares and Monthly Dosing
9:00AM-11:00AM
Abstract Number: 2218
Use of Anakinra in Hospitalized Patients with Acute Crystalline Arthritis
9:00AM-11:00AM
Abstract Number: 2545
Use of Oral Complementary Medicine in Inflammatory Arthritis: Data from the Australian Rheumatology Association Database (ARAD)
9:00AM-11:00AM
Abstract Number: 2189
Use of Smartphones in Collecting Patient Reported Outcomes (PROs): Feasibility of a Study Nested in a US National Cohort
9:00AM-11:00AM
Abstract Number: 2371
Use of Social Media Among Patients with Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 2213
Usefulness of Shoulder Radiographs to Aid in Determining Need for Advanced Imaging to Detect Operable or Inoperable Full-Thickness Rotator Cuff Tears
9:00AM-11:00AM
Abstract Number: 2192
User Experience with Methotrexate in Managing Inflammatory Arthritis Under the Support of an Interprofessional Arthritis Care Team (UMTX Study)
9:00AM-11:00AM
Abstract Number: 2103
Using a Drosophila Model to Unravel the Genetic Complexity of Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2699
Using ICD-10 Codes to Identify Patients with Systemic Sclerosis in the Electronic Health Record
9:00AM-11:00AM
Abstract Number: 2612
Utility of Infiltration with Steroids in Dactilitis. Is the Infiltration Guided By Ecography Better THAN Conventional?
9:00AM-11:00AM
Abstract Number: 2750
Utility of Methotrexate in Polymyalgia Rheumatica
9:00AM-11:00AM
Abstract Number: 2763
Utility of Serum Free Light Chains, Antiphospholipid Antibodies, and Cytokines in Giant Cell Arteritis
9:00AM-11:00AM
Abstract Number: 2755
Utility of Tocilizumab in Visual Affection of Patients with Giant Cell Arteritis
9:00AM-11:00AM
Abstract Number: 2101
UV-Induced Skin Inflammation Is Exacerbated in Lupus-Prone Ro60 Knockout Female Mice with Interferon Priming
9:00AM-11:00AM
Abstract Number: 2536
Vagus Nerve Stimulation in Patients with Rheumatoid Arthritis: 24 Month Safety and Efficacy
9:00AM-11:00AM
Abstract Number: 2400
Validating and Developing a Selected Questionnaire to Predict Early Diagnosis of Juvenile Idiopathic Arthritis in German Population
9:00AM-11:00AM
Abstract Number: 2728
Validation of the Draft Classification Criteria of Granulomatosis with Polyangiitis (GPA) Amongst Indian Patients with ANCA Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 2471
Validation of the Functional Index for Hand Osteoarthritis (FIHOA) in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2736
Value of Histology for Diagnosis and Classification in ANCA Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 2724
Variable Response to Induction Therapy and Significant Burden of Treatment Adverse Events over the First 12 Months in Incident ANCA-Associated Vasculitis (AAV) Patients – a Study of Routine Clinical Practice in the EU
9:00AM-11:00AM
Abstract Number: 2008
Vascular Adhesion Protein-1 (VAP-1) As Predictor of Radiographic Severity in Symptomatic Knee Osteoarthritis
9:00AM-11:00AM
Abstract Number: 2075
Vascular Endothelial and Inflammatory Differences in Psoriasis and Psoriatic Arthritis Patients
9:00AM-11:00AM
Abstract Number: 2364
Vasculitis Patient Journey: A Scoping Review of Patient Experiences with Vasculitis
9:00AM-11:00AM
Abstract Number: 2721
Venous Thromboembolism in ANCA Associated Vasculitis. a Population-Based Cohort Study from Southern Sweden
9:00AM-11:00AM
Abstract Number: 2337
Vertebral Compression Fractures and Antibodies to Citrullinated Vimentin in Established Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: L07
VIB4920, a Novel, Engineered CD40L Antagonist Decreased Disease Activity and Improved Biomarkers of Immune Activation in Patients with Active Rheumatoid Arthritis in a Phase 1b, Multiple-Ascending Dose Proof-of-Concept Study
9:00AM-11:00AM
Abstract Number: 2454
Virus Reactivation Rate in Rheumatoid Arthritis Using Tofacitinib
9:00AM-11:00AM
Abstract Number: 2330
Vitamin D and Bisphosphonate Therapy in SLE Patients Who Receive Glucocorticoids: Are We Offering the Best Care?
9:00AM-11:00AM
Abstract Number: 2241
What Can Variation in Clinical Practice Teach Us about Treatment Strategies for Patients with Gout?
9:00AM-11:00AM
Abstract Number: 2693
What Is the Effect of Cyclophosphamide Iv Pulse Therapy in Patients with Diffuse Cutaneous Systemic Sclerosis on Skin Involvement: An Observational Study
9:00AM-11:00AM
Abstract Number: 2227
What Should be the Goals of Gout Therapy? a Patient Perspective
9:00AM-11:00AM
Abstract Number: 2375
When Are People Receptive to Self Management Education Information, and What Information Appeals to Them? : An Analysis of Digital Data
9:00AM-11:00AM
Abstract Number: 2477
Which Is the Best Measure for Rheumatoid Arthritis Disease Activity? a Head to Head Comparison of the Six American College of Rheumatology Recommended Disease Activity Measures
9:00AM-11:00AM
Abstract Number: 2027
Whole Exome Trio Sequencing Implicates DOCK2 in Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 2468
Window or No Window? Earlier Is Better When Treating Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2177
Workforce Requirements in Rheumatology: A Systematic Literature Reviewinforming the Development of a Workforce Prediction Risk of Bias Tool and the EULAR Points to Consider
11:00AM-12:30PM
Abstract Number: 2787
−21 HLA-Class I Dimorphism Differentiates Psoriatic Arthritis (PsA) from Psoriasis without Psoriatic Arthritis (PsC)
11:00AM-12:30PM
Abstract Number: 2785
Efficacy and Safety of Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 1-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study
11:00AM-12:30PM
Abstract Number: 2789
Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 28 Weeks: Results from a Phase III Study
11:00AM-12:30PM
Abstract Number: 2786
Prospective Multicenter Validation Study of the Lupus Low Disease Activity State – a Treatment Target for Systemic Lupus Erythematosus
11:00AM-12:30PM
Abstract Number: 2790
Screening of Patients with Adult-Onset Idiopathic Polyarteritis Nodosa for Deficiency of Adenosine Deaminase 2
11:00AM-12:30PM
Abstract Number: 2788
The Effects of Plasma Exchange and Reduced-Dose Glucocorticoids during Remission-Induction for Treatment of Severe ANCA-Associated Vasculitis
2:30PM-4:00PM
Abstract Number: 2803
48-Year Trends in Systemic Sclerosis Mortality in the United States, 1968-2015: Steady Decrease for 15 Years after 33 Years of Continuous Increase
2:30PM-4:00PM
Abstract Number: 2845
A Close Relationship between a Novel Visceral Adiposity Index and Bone Microstructure in Female Early Rheumatoid Arthritis Patients: A 1-Year Follow-up Study By HR-pQCT
2:30PM-4:00PM
Abstract Number: 2844
A Mixed-Methods Feasibility Study Exploring the Cultural Adaptation of Walk with Ease to the United Kingdom
2:30PM-4:00PM
Abstract Number: 2801
A Novel B-Cell-Helper IL-21-Producing CD8+ T Cell Subset Involved in the Pathogenesis of Rheumatoid Arthritis
2:30PM-4:00PM
Abstract Number: 2811
Abaloparatide Effect on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis Aged 80 Years or Older
2:30PM-4:00PM
Abstract Number: 2800
Adenosine 2a Receptor Signals Act to Limit Autoimmune Arthritis By Inhibiting Pathogenic Germinal Center T Follicular Helper (GC-Tfh) Cells
2:30PM-4:00PM
Abstract Number: 2819
Alcohol Consumption and the Risk of Coronary Heart Disease and Mortality in Patients with Rheumatoid Arthritis
2:30PM-4:00PM
Abstract Number: 2841
Apremilast for Behçet’s Syndrome: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study in a Japanese Subgroup
2:30PM-4:00PM
Abstract Number: 2835
Association between Changes in Gene Signature Expression and Disease Activity in Systemic Lupus Erythematosus
2:30PM-4:00PM
Abstract Number: 2805
Association of Dietary Quality Scores and Incident SLE in the Nurses’ Health Studies
2:30PM-4:00PM
Abstract Number: 2807
Association of Exposure to Childhood Abuse with Incident Systemic Lupus Erythematosus in a Longitudinal Cohort of Women
2:30PM-4:00PM
Abstract Number: 2847
Associations between Serum Uric Acid Level and Coronary Artery Disease
2:30PM-4:00PM
Abstract Number: 2817
Cardiovascular Disease Risk with Biologics and Tofacitinib Compared to Conventional Synthetic Dmards in Patients with Rheumatoid Arthritis
2:30PM-4:00PM
Abstract Number: 2815
Cardiovascular Safety – Update from up to 6 Years of Treatment with Baricitinib in Rheumatoid Arthritis Clinical Trials
2:30PM-4:00PM
Abstract Number: 2791
Characterization of Monoclonal Anti-PAD4 Autoantibodies from Rheumatoid Arthritis Patients: Functional Implications for Citrullination and Disease Progression
2:30PM-4:00PM
Abstract Number: 2806
Childhood Physical and Sexual Abuse and Risk of Systemic Lupus Erythematosus Among African American Women
2:30PM-4:00PM
Abstract Number: 2838
Comorbid Vasculitis Among Patients in a National Primary Immunodeficiency Database
2:30PM-4:00PM
Abstract Number: 2823
Comparative Long-Term Effectiveness of Switching to Another Tumour Necrosis Factor Antagonists, Tocilizumab or Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to a First-Line TNF Inhibitor
2:30PM-4:00PM
Abstract Number: 2833
Complement Activation Is a Feature of Diseases in the Lupus Spectrum
2:30PM-4:00PM
Abstract Number: 2816
Development of a Microrna Panel for Predicting Coronary Atherosclerosis in Rheumatoid Arthritis
2:30PM-4:00PM
Abstract Number: 2837
Diminished STAT-3 Phosphorylation and Associated Cell Pathways Characterize MMF-Treated Systemic Lupus Erythematosus Patients
2:30PM-4:00PM
Abstract Number: 2842
Does Leflunomide Have a Role in Giant Cell Arteritis?
2:30PM-4:00PM
Abstract Number: 2821
Dose Tapering and Discontinuation of Biological Therapy in Rheumatoid Arthritis Patients in Routine Care – 2-Year Outcomes and Predictors
2:30PM-4:00PM
Abstract Number: 2826
Emergence of Severe Spondyloarthropathy Related Entheseal Pathology Following Successful Vedolizumab Therapy for Inflammatory Bowel Disease
2:30PM-4:00PM
Abstract Number: 2812
Evaluation of Cortical Microarchitecture, Bone Stiffness and Bone Remodeling in Patients with Atypical Femoral Fracture
2:30PM-4:00PM
Abstract Number: 2798
Expanded T-Cell Clones Are Present in the Synovium before the Clinical Onset of Rheumatoid Arthritis
2:30PM-4:00PM
Abstract Number: 2846
Foot and Lower Limb Characteristics in People with SLE: A Comparison with Age- and Sex-Matched Healthy Control Participants
2:30PM-4:00PM
Abstract Number: 2810
Fracture and Bone Mineral Density Response By Baseline Risk in Patients Treated with Abaloparatide Followed By Alendronate
2:30PM-4:00PM
Abstract Number: 2818
Galectin-3 As a Marker of Subclinical Atherosclerosis, Arterial Stiffness and Myocardial Performance in Patients with Rheumatoid Arthritis
2:30PM-4:00PM
Abstract Number: 2831
High Need for Anti-TNF Therapy after Withdrawal Strategy in Early Peripheral Spondyloarthritis
2:30PM-4:00PM
Abstract Number: 2804
Identifying Lupus Patients in Electronic Health Records: Development and Validation of Machine Learning Algorithms and Application of Rule-Based Algorithms
2:30PM-4:00PM
Abstract Number: 2795
IL-23 Acts through IL-23R+ Tfh cells to Promote Pathogenic IgG Autoantibody Formation in Lupus
2:30PM-4:00PM
Abstract Number: 2843
Leflunomide in Giant Cell Arteritis and Polymyalgia Rheumatica: A Real World Single Centre Experience
2:30PM-4:00PM
Abstract Number: 2836
Measurement of Interferon Alpha Expression Using Multiple Methodologies Identifies a Signature in a Subgroup of Connective Tissue Disease Patients with Haematological Abnormalities
2:30PM-4:00PM
Abstract Number: 2814
Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs
2:30PM-4:00PM
Abstract Number: 2839
Microrna Expression in the Vasculitic Skin Lesions of Adult Patients with IgA Vasculitis
2:30PM-4:00PM
Abstract Number: 2840
MiR-125-b Is a Promising Biomarker for Giant Cell Arteritis in Patients with Negative Temporal Artery Biopsy Examination
2:30PM-4:00PM
Abstract Number: 2793
Molecular Mimicry and Autoimmunity: Anti-P. Gingivalis antibody Response in ACPA-Positive Rheumatoid Arthritis
2:30PM-4:00PM
Abstract Number: 2832
Multiple Subpopulations of Peripheral Lymphocytes Were Absolutely Decreased in SLE Patients with Infection and Restored By Low-Dose IL-2
2:30PM-4:00PM
Abstract Number: 2824
On Tapering Therapy for RA Patients in Clinical Remission; Flare on Csdmards Predicted By Clinical Features and Musculoskeletal Ultrasound, Whereas T-Cell Abnormalities Predictive for b-DMARD Tapering
2:30PM-4:00PM
Abstract Number: 2794
Peptidylarginine Deiminases Are Required for Normal Immunoglobulin G Half-Life
2:30PM-4:00PM
Abstract Number: 2848
Racial Disparities in Utilization of Knee Replacement: Data from the Osteoarthritis Initiative
2:30PM-4:00PM
Abstract Number: 2825
Reduction of Antidrug Antibody Levels after Switching to Rituximab in Patients with Rheumatoid Arthritis with Previous Failure to Infliximab or Adalimumab
2:30PM-4:00PM
Abstract Number: 2797
Regulation of Autoimmune T Cells By the Co-Receptors CD28 and PD-1
2:30PM-4:00PM
Abstract Number: 2827
Remission Targets and Prevention of Subclinical Atherosclerosis in Psoriatic Arthritis- Which Target Should We Choose?
2:30PM-4:00PM
Abstract Number: 2802
Risk of Ischemic Stroke in Veterans with Systemic Sclerosis: A Nationwide Cohort Study
2:30PM-4:00PM
Abstract Number: 2849
Risk of Obstructive Sleep Apnea in Rheumatoid Arthritis
2:30PM-4:00PM
Abstract Number: 2813
Risk of Venous Thromboembolism with Selective Estrogen Receptor Modulators for Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Trials
2:30PM-4:00PM
Abstract Number: 2796
Sex-Based Differences Control ABC Function in Swef-Deficient Mice
2:30PM-4:00PM
Abstract Number: 2822
Should We Prefer Leflunomide to Methotrexate in Combination with Biologics? a Systematic Review and a Meta-Analysis
2:30PM-4:00PM
Abstract Number: 2799
Sjogren’s Syndrome Minor Salivary Gland CD4+ T Cells Associate with Oral Disease Features and Have a T Follicular Helper-like Transcriptional Profile
2:30PM-4:00PM
Abstract Number: 2809
Skeletal Benefit/Risk of Long-Term Denosumab Therapy: A Virtual Twin Analysis of Fractures Prevented to Skeletal Safety Events Observed
2:30PM-4:00PM
Abstract Number: 2820
Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial
2:30PM-4:00PM
Abstract Number: 2830
Synovitis in Psoriatic Arthritis and Seronegative Rheumatoid Arthritis: Differential Histological Features
2:30PM-4:00PM
Abstract Number: 2808
T-Score As an Indicator of Fracture Risk on Therapy: Evidence from Romosozumab Vs Alendronate Treatment in the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk Trial
2:30PM-4:00PM
Abstract Number: 2792
The Effect of B Cell Targeted Therapies on Autoantibodies and Excessive Neutrophil Extracellular Trap Formation in Systemic Lupus Erythematosus
2:30PM-4:00PM
Abstract Number: 2834
The Presence of Anti-Rituximab Antibodies Predicts Infusion-Related Reactions in Patients with Systemic Lupus Erythematosus
2:30PM-4:00PM
Abstract Number: 2829
The Response to TNF-Blockers Treatment of Spa Patients Is Influenced By the Interplay between HLA-B27 and Gut Microbiota Composition at Baseline
2:30PM-4:00PM
Abstract Number: 2828
Utility of Fecal Calprotectin Levels for the Diagnosis of Inflammatory Bowel Disease in Patients with Spondylorarthritis
4:00PM-6:00PM
Abstract Number: L18
A Randomized Controlled 24-Week Trial Evaluating the Safety and Efficacy of Blinded Tapering Versus Continuation of Long-Term Prednisone (5 mg/day) in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab
4:00PM-6:00PM
Abstract Number: L17
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
4:00PM-6:00PM
Abstract Number: L20
Efficacy and Safety of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Hip or Knee
4:00PM-6:00PM
Abstract Number: L16
Intra-Articular TPX-100 in Knee Osteoarthritis: Robust Functional Response at 6 and 12 Months Is Associated with Increased Tibiofemoral Cartilage Thickness
4:00PM-6:00PM
Abstract Number: L15
The Diagnostic Accuracy of PET/CT Scan of the Head, Neck and Thorax Compared with Temporal Artery Biopsy in Patients Newly Suspected of Having GCA
4:00PM-6:00PM
Abstract Number: L19
Transcutaneous Electrical Nerve Stimulation (TENS) Reduces Pain and Fatigue and Improves Disease Impact in Women with Fibromyalgia: A Randomized Controlled Trial
4:30PM-6:00PM
Abstract Number: 2853
A Protective Langerhans Cell-Keratinocyte Axis That Is Dysfunctional in Photosensitivity
4:30PM-6:00PM
Abstract Number: 2857
An Electronic Audit, Reporting, and Data Correction System Improves the Quantity and Quality of Observational Data Collected for US Veterans Enrolled in the Veterans Affairs Rheumatoid Arthritis Registry
4:30PM-6:00PM
Abstract Number: 2866
Biologic Refractory Disease in a Cohort Study of Children and Young People with Juvenile Idiopathic Arthritis from the United Kingdom
4:30PM-6:00PM
Abstract Number: 2865
Canakinumab, on a Reduced Dose or a Prolonged Dose Interval without Concomitant Corticosteroids and Methotrexate, Maintains Efficacy in Systemic Juvenile Idiopathic Arthritis Patients in Clinical Remission
4:30PM-6:00PM
Abstract Number: 2887
Chronic Pain and Assessment of Pain Sensitivity in Patients with Established Axial Spondyloarthritis – a Cross-Sectional Study
4:30PM-6:00PM
Abstract Number: 2861
Clinical Laboratory Telephone Communication Outreach to Rheumatology Patients Improves Guideline-Concordant Timeliness of Monitoring of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
4:30PM-6:00PM
Abstract Number: 2893
Clinical Outcomes and Response to Anti-Thrombotic Treatment Among Patients with Concomitant Lupus Nephritis and Thrombotic Microangiopathy: A Multicenter Cohort Study
4:30PM-6:00PM
Abstract Number: 2874
Comparison of Missing Data Reporting and Handling in Randomized Controlled Trials of Rheumatoid Arthritis Drug Therapy: A Snapshot Ten Years Apart
4:30PM-6:00PM
Abstract Number: 2871
Comprehensive Provider Judgement Is a Significant Determinant of Major Therapeutic Change in Patients with Moderate to Severe Rheumatoid Arthritis
4:30PM-6:00PM
Abstract Number: 2888
Concomitant Csdmards Influence Clinical Response to TNF Inhibitors Only in Overweight Patients with Axial Spondyloarthritis
4:30PM-6:00PM
Abstract Number: 2884
Correlation between Salivary Gland Ultrasonography, Minor Salivary Gland Histhopatology and Sialometry: Towards a Composite Assessment of Salivary Gland Involvement in Primary Sjögren’s Syndrome
4:30PM-6:00PM
Abstract Number: 2860
Disease Activity and Its Measurement in Patients with RA across the U.S.: Data from the Rheumatology Informatics System for Effectiveness (RISE) Registry
4:30PM-6:00PM
Abstract Number: 2856
Do Patients with Moderate or High Disease Activity Escalate RA Therapy According to Treat-to-Target Principles? Results from the Acr’s RISE Registry
4:30PM-6:00PM
Abstract Number: 2859
Do Preventive Cardiology Consults Versus Usual Care Improve Cardiovascular Risk Factor Assessment and Management in Patients with Rheumatoid Arthritis?
4:30PM-6:00PM
Abstract Number: 2890
Effect of Tapering of Tumor Necrosis Factor Inhibitor on Achieving Inactive Disease in Axial Spondyloarthritis Based on the ‘Treat-to-Target’ Strategy: A Nationwide Prospective Cohort Study
4:30PM-6:00PM
Abstract Number: 2895
Effect of Vitamin D on Serum Markers of Bone Turnover in SLE in a Randomized Controlled Trial
4:30PM-6:00PM
Abstract Number: 2867
Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus
4:30PM-6:00PM
Abstract Number: 2891
Eligibility Criteria for TNFi Therapy in Axial Spa: Going Beyond Basdai
4:30PM-6:00PM
Abstract Number: 2852
Excessive Formation of Neutrophil Extracellular Traps: Different Role in the Pathogenesis of ANCA-Associated Vasculitis and Systemic Lupus Erythematosus
4:30PM-6:00PM
Abstract Number: 2855
Expanding the Phenotype: New Variant in the IL1RN-Gene Associated with Late Onset and Atypical Presentation of Dira
4:30PM-6:00PM
Abstract Number: 2885
Expansion of Activated PD-1+ ICOS+ T Follicular and Peripheral Helper Cells in Primary Sjögren’s Syndrome Associates with Abnormalities in B Cell Compartment
4:30PM-6:00PM
Abstract Number: 2858
Gaps in Patient Safety Performance before Treatment with Biologic Disease-Modifying Antirheumatic Drugs or Tofacitinib in a Large Academic Healthcare System
4:30PM-6:00PM
Abstract Number: 2881
How Immunological Profile Drives Clinical Phenotype of Primary Sjögren’s Syndrome at Diagnosis: Analysis of 10.500 Patients (Sjögren Big Data Project)
4:30PM-6:00PM
Abstract Number: 2850
Human Toll-like Receptor 8 Adversely Affects Placental Development and Pregnancy Outcomes in a Mouse Model of Systemic Lupus Erythematosus
4:30PM-6:00PM
Abstract Number: 2897
Hydroxychloroquine Blood Levels Show Significant Trend Test for Risk of Retinopathy
4:30PM-6:00PM
Abstract Number: 2864
Identification of Optimal Subcutaneous Doses of Tocilizumab in Children with Systemic Juvenile Idiopathic Arthritis
4:30PM-6:00PM
Abstract Number: 2875
Identifying Trends in Lines of Therapy Following Initial Biologic Disease-Modifying Antirheumatic Drug in Patients with Rheumatoid Arthritis
4:30PM-6:00PM
Abstract Number: 2869
Incorporation of Patient Reported Outcomes Data in the Care of US Veterans with Rheumatoid Arthritis: A Randomized, Controlled Trial
4:30PM-6:00PM
Abstract Number: 2896
Increased Mortality Among Patients with Systemic Lupus Erythematosus after Hydroxychloroquine Discontinuation
4:30PM-6:00PM
Abstract Number: 2889
Inhibition of Radiographic Progression and Correlation with Changes in Composite Indices of Disease Activity in Patients with Active Psoriatic Arthritis Treated with Intravenous Golimumab, As Measured in a Phase III Trial
4:30PM-6:00PM
Abstract Number: 2863
Long-Term Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant FMF (crFMF), Hids/Mkd and TRAPS: Results from the Pivotal Phase 3 Cluster Trial
4:30PM-6:00PM
Abstract Number: 2862
Magnitude of Response to TNF Inhibitors in Children with Spondyloarthritis and Sacroiliitis
4:30PM-6:00PM
Abstract Number: 2854
Majeed Syndrome Causing LPIN2 mutations May Prevent Bone “Healing” By Rendering M2 Macrophage Proinflammatory
4:30PM-6:00PM
Abstract Number: 2882
Minimal Progression of Disease Manifestation in Patients with Sjögren’s Syndrome Re-Evaluated Multiple Years after Initial Disease Classification
4:30PM-6:00PM
Abstract Number: 2851
NF-Κappa b Signaling in the Myeloid Cell Lineage Drives the Pathogenesis of Immune-Mediated Nephritis
4:30PM-6:00PM
Abstract Number: 2878
Phase II Clinical Trials Systematically Overestimate Treatment Effects of Subsequent Phase III Trials in Rheumatoid Arthritis
4:30PM-6:00PM
Abstract Number: 2879
Plasma IL-23 and IL-25 Predict Response to Anti-TNF-α Therapy in Rheumatoid Arthritis
4:30PM-6:00PM
Abstract Number: 2894
Psychosis in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study
4:30PM-6:00PM
Abstract Number: 2873
Remaining Pain and Widespread, Non-Inflammatory Pain Distribution during the First 12 Months after RA Diagnosis
4:30PM-6:00PM
Abstract Number: 2892
Safety and Immune Response of a Live Attenuated Herpes Zoster Vaccine in Patients with Systemic Lupus Erythematosus (SLE): A Randomized Placebo-Controlled Trial
4:30PM-6:00PM
Abstract Number: 2886
Secukinumab Provides Rapid and Sustained Resolution of Enthesitis in Psoriatic Arthritis Patients: Pooled Analysis of Two Phase 3 Studies
4:30PM-6:00PM
Abstract Number: 2880
Serum Levels of Thymic Stromal Lymphopoietin: A Possible Novel Biomarker in Primary Sjögren’s Syndrome and Related Lymphoproliferation
4:30PM-6:00PM
Abstract Number: 2868
Tender Joint Count May Not Reflect Inflammatory Activity in Established Rheumatoid Arthritis Patients; Results from a Longitudinal Study of Tocilizumab
4:30PM-6:00PM
Abstract Number: 2883
Testing for Anti-Microbial Antibodies with Cross-Reactivity to Human Tissue in Autoimmune Diseases
4:30PM-6:00PM
Abstract Number: 2877
The Comparative Effectiveness of First-Line Tumor Necrosis Factor Inhibitor (TNFi) Compared with Non-TNFi Agents in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
4:30PM-6:00PM
Abstract Number: 2870
Thresholds for Disease Activity Measures DAS28, CDAI, and RAPID3 Do Not Align with Clinical Practice Patterns of Rheumatoid Arthritis (RA) Disease Management Decisions
4:30PM-6:00PM
Abstract Number: 2876
Torque Teno Virus Quantification for Functional Monitoring of Immunomodulation with Biological Compounds in the Treatment of Rheumatoid Arthritis
4:30PM-6:00PM
Abstract Number: 2872
Variation in Predictors of Patient and Physician Defined Flares in Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 2913
A Draft Modified Core Domain Set for Patient-Reported Outcomes (PRO) in Patients with Idiopathic Inflammatory Myopathies (IIM): An Omeract Report
9:00AM-10:30AM
Abstract Number: 2935
A Practical Classification of Systemic Sclerosis Using Subset and Autoantibodies for the Purpose of Early Risk Stratification
9:00AM-10:30AM
Abstract Number: 2908
Agreement between Ultrasound and Whole Body Magnetic Resonance Imaging Assessment of Joint Inflammation and Enthesitis in Rheumatoid Arthritis Patients
9:00AM-10:30AM
Abstract Number: 2919
An Epidemic: Severe Lung Disease in Patients with Systemic Juvenile Idiopathic Arthritis, Risk Factors and Predictors
9:00AM-10:30AM
Abstract Number: 2937
Anti-Vinculin Antibodies in Systemic Sclerosis (SSc): A Potential Biomarker Linking Vascular and Gastrointestinal System Involvement in Two Phenotypically Distinctive SSc Groups
9:00AM-10:30AM
Abstract Number: 2902
Antibodies to PAD4 Drive Monocyte Activation and Differentiation into Osteoclast-like Cells
9:00AM-10:30AM
Abstract Number: 2915
Can Passively-Collected Phone Behavior Determine Rheumatic Disease Activity?
9:00AM-10:30AM
Abstract Number: 2939
Clinical Features Associated with Severe Lower Bowel Involvement in Systemic Sclerosis
9:00AM-10:30AM
Abstract Number: 2907
Comparison of the Joints Ultrasonography in the Patients with Rheumatoid Arthritis Treated By Biological Agents and the Corresponding Synovial Histological Findings
9:00AM-10:30AM
Abstract Number: 2940
Complementary Practices As Alternatives to Pain: Effectiveness of a Pain Management Program for Patients in an Orthopedic Clinic
9:00AM-10:30AM
Abstract Number: 2920
Correlations of Type I Interferon Score and Interferon Induced Chemokines CXCL10 and CXCL9 with Cutaneous and Muscular Disease Activity in Juvenile Dermatomyositis
9:00AM-10:30AM
Abstract Number: 2945
Culturally Enhanced Pain Coping Skills Training for African Americans with Osteoarthritis
9:00AM-10:30AM
Abstract Number: 2910
Development of a Rheumatoid Arthritis Global Outcome Measure to Enable Comparisons of Patient Experiences across Treatment Arms in Randomized Clinical Trials
9:00AM-10:30AM
Abstract Number: 2909
Diagnostic and Prognostic Value of Ultrasound Compared with Plain Radiography in Knee Osteoarthritis
9:00AM-10:30AM
Abstract Number: 2942
Dyadic Study of Partner Social Support for Physical Activity and Its Role in the Initiation and Maintenance of Increased Physical Activity Among Insufficiently Active People with Hip/Knee Osteoarthritis
9:00AM-10:30AM
Abstract Number: 2936
Esophageal Erosion Predicts Progression of Lung Disease in Patients with Systemic Sclerosis
9:00AM-10:30AM
Abstract Number: 2938
Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (ACR CRISS) in a Phase 3 Randomized Controlled Trial
9:00AM-10:30AM
Abstract Number: 2914
Examination of Psychometric Properties of the Patient-Reported Outcomes Measurement Information System Fatigue 4-Item Short Form in Psoriatic Arthritis
9:00AM-10:30AM
Abstract Number: 2925
Fatty Lesions Detected on MRI Scans in Patients with Ankylosing Spondylitis Are Based on the Deposition of Fat in the Vertebral Bone Marrow
9:00AM-10:30AM
Abstract Number: 2943
Helping a Non-Urban Community Walk with Ease: A Feasibility Pilot Study of an Arthritis Activity Intervention
9:00AM-10:30AM
Abstract Number: 2900
Impaired TCR Signaling Paves the Way for Cytokine Hyper-Responsiveness in Arthritogenic T Cells
9:00AM-10:30AM
Abstract Number: 2898
Increased Frequency of Circulating CD4+CXCR5-PD1hi Peripheral Helper T (cTph) Cells in Patients with Seropositive Early Rheumatoid Arthritis (RA)
9:00AM-10:30AM
Abstract Number: 2923
Is All MRI-SIJ Inflammation the Same? Gradient of Structural Damage with Increasing Cumulative Inflammation at the SIJ Quadrant Level in Axial Spondyloarthritis – 5-Year Data from the DESIR Cohort
9:00AM-10:30AM
Abstract Number: 2944
Longitudinal Outcomes and Predictors of E-Learning Effectiveness in Patients with Axial Spondyloarthritis: A Randomized Controlled Trial
9:00AM-10:30AM
Abstract Number: 2912
Lupus Flare Activity from the Patient Perspective
9:00AM-10:30AM
Abstract Number: 2922
Magnetic Resonance Imaging of Sacroiliac Joints in Patients with Osteitis Condensans Ilii Reveals a Typical Pattern of Lesions Relevant for Differential Diagnosis with Axial Spondyloarthritis
9:00AM-10:30AM
Abstract Number: 2931
Missing Outcomes in SLE Clinical Trials: Impact on Estimating Treatment Effects
9:00AM-10:30AM
Abstract Number: 2917
Multiplex Serum Biomarker Analysis before and during Therapy with Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis
9:00AM-10:30AM
Abstract Number: 2934
Myocardial Microscopic Fibrosis Assessed By T1 Mapping Sequences on Cardiac Magnetic Resonance Imaging Predicts Cardiac Events in Systemic Sclerosis: Data from a Prospective Cohort Study on 40 Patients
9:00AM-10:30AM
Abstract Number: 2916
New JADAS10- and cJADAS10-Based Cutoffs for Juvenile Idiopathic Arthritis Disease Activity States: Validation in a Multinational Dataset of 4830 Patients
9:00AM-10:30AM
Abstract Number: 2933
Non-Invasive Tape Sampling Reveals RNA Gene Clusters in Cutaneous Lupus Erythematosus That Discriminate Affected from Unaffected and Healthy Volunteer Skin
9:00AM-10:30AM
Abstract Number: 2911
Patient-Reported Outcomes Measurement Information System (PROMIS®) Global Health Short Form Is Responsive to Patient Reported Changes in SLE Health Status
9:00AM-10:30AM
Abstract Number: 2918
Physical Activity in Canadian Children with Juvenile Idiopathic Arthritis: The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)
9:00AM-10:30AM
Abstract Number: 2930
Prospective Comparison of Remission and Lupus Low Disease Activity State – Effect on Disease Outcomes in Systemic Lupus Erythematosus
9:00AM-10:30AM
Abstract Number: 2941
Reach and Effectiveness of a Health Communications Campaign Promoting Self Management Education: Results of a Pilot Test of the Learn More. Feel Better. Campaign
9:00AM-10:30AM
Abstract Number: 2904
Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients and Healthy Controls
9:00AM-10:30AM
Abstract Number: 2903
Single Cell Association Testing Identifies an Expanded Th1-Skewed Cytotoxic Effector CD4+ T Cell Subset in Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 2924
Spinal Radiographic Progression in Early Axial Spondyloarthritis: 5-Year Data from the DESIR Cohort
9:00AM-10:30AM
Abstract Number: 2901
Sputum Neutrophils from Individuals at-Risk for RA Demonstrate Increased Citrullinated Histone H3 Containing Neutrophil Extracellular Traps That Correlate with Sputum Anti-Cyclic Citrullinated Peptide Antibody Levels
9:00AM-10:30AM
Abstract Number: 2899
Sustained Drug-Free Remission in Early RA Following Methotrexate-Based Strategy: Role of the JAK-STAT Pathway
9:00AM-10:30AM
Abstract Number: 2906
Synovitis Focused Ultrasound in Rheumatoid Arthritis: A Joint Reduction Strategy
9:00AM-10:30AM
Abstract Number: 2932
Systemic Lupus Erythematosus Biomarkers Identified Using Multi-Omic and Artificial Intelligence Analysis through Interrogative Biology
9:00AM-10:30AM
Abstract Number: 2921
The Performance of the Newly Proposed EULAR/Acr Classification Criteria in Juvenile-Onset Systemic Lupus Erythematosus
9:00AM-10:30AM
Abstract Number: 2905
Ultrasound Diagnosis of Large Vessel Inflammation in New-Onset Treatment-Naïve GCA Patients Using Fluorine-18-Fluorodeoxyglucose PET/CT As the Reference Standard – a Prospective Study of 86 Patients Suspected of GCA
9:00AM-10:30AM
Abstract Number: 2928
Validation of New Systemic Lupus Erythematosus Classification Criteria
9:00AM-10:30AM
Abstract Number: 2929
Validation of Remission and Lupus Low Disease Activity State As Predictors of Organ Damage in SLE
9:00AM-10:30AM
Abstract Number: 2927
What Are the Optimal MRI Lesion Cut-Offs That Define Active and Structural Lesions in the Sacroiliac Joint As Being Typical of Axial Spondyloarthritis By Expert Readers?
9:00AM-10:30AM
Abstract Number: 2926
Which MRI Lesions in the Sacroiliac Joint Are Associated with the Diagnosis of Axial Spondyloarthritis after 2 Years Follow up in the Echography in Spondyloarthritis Cohort?
11:00AM-12:30PM
Abstract Number: 2950
10X Genomics-Based Single-Cell RNA-Seq Analysis Identifies a Transcriptional Landscape of Inflammation and Fibrosis in Lupus Nephritis​
11:00AM-12:30PM
Abstract Number: 2985
Achievement of Remission in Two Early Rheumatoid Arthritis Inception Cohorts Implementing Different Treat-to-Target Strategies
11:00AM-12:30PM
Abstract Number: 2949
African American and European American SLE Patients with Variable Disease Activity Reveal Distinct Differences in B Cells and TLR7/8 Pathways
11:00AM-12:30PM
Abstract Number: 2969
Allopurinol Dose Escalation Slows Progression of CT Bone Erosion in People with Gout: Imaging Sub-Study of a Randomized Control Trial
11:00AM-12:30PM
Abstract Number: 2975
Anti-Il-1 Therapies in Patients with Familial Mediterranean Fever Related AA-Amyloidosis
11:00AM-12:30PM
Abstract Number: 2992
Are Specific Vascular Symptoms in Takayasu’s Arteritis Reflective of Vascular Inflammation, Vascular Damage, or Both?
11:00AM-12:30PM
Abstract Number: 2997
Association between Payments By Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology
11:00AM-12:30PM
Abstract Number: 2980
Calcineurin Inhibitor for the Treatment of Myositis-Associated Interstitial Lung Disease: Comparison between Cyclosporine and Tacrolimus
11:00AM-12:30PM
Abstract Number: 2989
Cardiac Involvement in Systemic Vasculitis: A Retrospective Pathological Study
11:00AM-12:30PM
Abstract Number: 2956
Changing Trends and Prescribing Patterns in Opioid-Treated Primary Care Patients with Non-Cancer Pain over a 10-Year Period
11:00AM-12:30PM
Abstract Number: 2988
Characteristics and Outcomes in a Prospective Cohort of Patients with Aortitis Diagnosed Following Surgical Resection
11:00AM-12:30PM
Abstract Number: 2973
Clinical Features and Pulmonary Function Test Findings Associated with Large Airway Disease in Relapsing Polychondritis
11:00AM-12:30PM
Abstract Number: 2994
Costs Associated with Non-Medical Switching from Originator to Biosimilar Etanercept in Patients with Rheumatoid Arthritis in the UK
11:00AM-12:30PM
Abstract Number: 2948
Deconstructing the in Situ Myeloid Cell Microenvironment in Human Lupus Nephritis Tissue
11:00AM-12:30PM
Abstract Number: 2964
Detection of Uric Acid Crystals in the Vasculature of Patients with Gout Using Dual-Energy Computed Tomography
11:00AM-12:30PM
Abstract Number: 2959
Development of a Set of Potentially Preventable Adverse Conditions Specific to Lupus: A Delphi Consensus Study
11:00AM-12:30PM
Abstract Number: 2962
Diagnostic Accuracy of Gout in Electronic Health Records and the Role of Rheumatology Electronic Consults
11:00AM-12:30PM
Abstract Number: 2961
Differences in Healthcare Transition Views, Practices, and Barriers Among North American Pediatric Rheumatology Providers from 2010 to 2018
11:00AM-12:30PM
Abstract Number: 2953
Disappearance of Autoantibodies in RA: Does It Occur with Current Treatment Strategies? a Long-Term Follow-up Study in Patients That Achieved DMARD-Free Sustained Remission
11:00AM-12:30PM
Abstract Number: 2990
Do Polymyalgia Rheumatica Patients Have an Increased Risk of Cardiovascular Events?: A Matched-Control Study
11:00AM-12:30PM
Abstract Number: 2999
Does the Incremental Cost of ACPA-Positive Rheumatoid Arthritis Patients Vary By the Care Pathway They Follow?
11:00AM-12:30PM
Abstract Number: 2960
Evaluation of Performance Measures Reveals Delays and Sub-Optimal Access to Rheumatology Care and Treatment
11:00AM-12:30PM
Abstract Number: 2954
Factors Related to Initiation of TNF Inhibitor Versus Triple Therapy in Rheumatoid Arthritis Patients
11:00AM-12:30PM
Abstract Number: 2995
Healthcare Cost of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis
11:00AM-12:30PM
Abstract Number: 2976
Immune Checkpoint Inhibitor-Associated Myositis: A Characteristic Phenotype with a Poor Outcome Related to Concomitant Myocarditis
11:00AM-12:30PM
Abstract Number: 2963
Improving Clinically Inactive Disease in Patients with Juvenile Idiopathic Arthritis- a Quaternary Center Experience
11:00AM-12:30PM
Abstract Number: 2970
In Idiopathic Retroperitoneal Fibrosis, Persistent FDG PET Uptake Helps Identifying Patients at Risk for Relapse
11:00AM-12:30PM
Abstract Number: 2979
Innovative Approaches for the Assessment of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Ultrasound Evaluation of Pleural Irregularities and Semiquantitative and Quantitative Analysis of Lung CT
11:00AM-12:30PM
Abstract Number: 2977
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Reduces T-Cell Population and Downregulates Type 1 and 2 Interferon Activities in Lesional Dermatomyositis Skin
11:00AM-12:30PM
Abstract Number: 2984
Lifestyle and MTX Use Are the Strongest Predictors of Not Achieving Remission in the First Year of Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort (CATCH)
11:00AM-12:30PM
Abstract Number: 2974
Long-Term Survival in Lung Transplantation for Interstitial Lung Disease Due to Rheumatic Systemic Diseases. Study of 26 Cases of a Single Center
11:00AM-12:30PM
Abstract Number: 2952
Major NSAID Toxicity: Derivation and Internal Validation of a Simple Clinical Risk Score
11:00AM-12:30PM
Abstract Number: 2991
Malignancies In Giant Cell Arteritis- A Population-Based Cohort Study
11:00AM-12:30PM
Abstract Number: 2981
Mitochondrial Extrusion and Autoimmunity in Juvenile Dermatomyositis
11:00AM-12:30PM
Abstract Number: 2958
Multi-Site Study Evaluating Performance on Lupus Nephritis Quality Measures
11:00AM-12:30PM
Abstract Number: 2972
Multicentric Reticulohistiocytosis (1980-2017): A Rare Disease, Commonly Associated with Malignancy and Autoimmunity
11:00AM-12:30PM
Abstract Number: 2982
Normal Mortality of the Cobra Early Rheumatoid Arthritis Trial Cohort after 23 Years Follow up
11:00AM-12:30PM
Abstract Number: 2998
Opioid Use Among SLE Patients and Controls in the Population-Based Michigan Lupus Epidemiology & Surveillance (MILES) Cohort
11:00AM-12:30PM
Abstract Number: 2978
Performance of the 2017 European League Against Rheumatism / American College of Rheumatology (EULAR/ACR) Classification Criteria for Adult Idiopathic Inflammatory Myopathies (IIM) in an Australian Cohort
11:00AM-12:30PM
Abstract Number: 2947
Peripheral Helper T Cells in Systemic Lupus Erythematosus
11:00AM-12:30PM
Abstract Number: 2967
Potent Bifunctional Inhibitors of Xanthine Oxidase and URAT1 Block Fructose-Induced Inflammation Via Increase in AMP Kinase Activity
11:00AM-12:30PM
Abstract Number: 2987
RAPID Remission during the First Year in EARLY ACTIVE Rheumatoid Arthritis Is Associated with Better 5 YEARS Structural Damage Outcomes
11:00AM-12:30PM
Abstract Number: 2955
Risk of Neurological Adverse Events during Tumour Necrosis Factor Inhibitor Treatment for Arthritis: A Population-Based Cohort Study from Danbio and the Danish National Patient Registry
11:00AM-12:30PM
Abstract Number: 2971
Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease: Long Term Outcomes
11:00AM-12:30PM
Abstract Number: 2968
Role of Choline in Gouty Inflammation
11:00AM-12:30PM
Abstract Number: 2957
Socioeconomic Differences in Opioid Use By People with Inflammatory Arthritis
11:00AM-12:30PM
Abstract Number: 2946
T Peripheral Helper Cells Are Expanded in the Circulation of Active SLE Patients and Correlate with CD21low B Cells
11:00AM-12:30PM
Abstract Number: 2965
Targeting Glucose Metabolism in the Murine Air Pouch Model of Acute Gouty Inflammation
11:00AM-12:30PM
Abstract Number: 2983
The Changing Faces of Rheumatoid Arthritis Patients at Presentation: A 20-Year Study
11:00AM-12:30PM
Abstract Number: 2996
The Economic Burden of Systemic Lupus Erythematosus (SLE) within a Medicaid Cohort Stratified By Disease Severity
11:00AM-12:30PM
Abstract Number: 2986
The Impact of Exercise and Clinical Factors on Perceived Cognitive Function in Patients with Rheumatoid Arthritis: Results from a Prospective Cohort Study
11:00AM-12:30PM
Abstract Number: 2966
Ultrasound Shows Rapid Reduction of Uric Load during Treat-to-Target Approach in Gout Patients: Results from a Longitudinal Study
11:00AM-12:30PM
Abstract Number: 2951
Ustekinumab Treatment Response in SLE Is Associated with Changes in Type II but Not Type I Interferons
11:00AM-12:30PM
Abstract Number: 2993
Vascular Involvement in Behcet’s Syndrome May be Associated with Subclinical Atherosclerosis

« View all sessions from this meeting